TW202120487A - Fused heterocyclic compounds and their use as pest control agents - Google Patents

Abstract

The present invention discloses a fused heterocyclic compound of formula (I),

wherein, R¹ , G₁ , G₂ , G₃ , G₄ , A₁ , A₂ , Q, n and Z are as defined in the detailed description. The present invention further discloses methods for their preparation and use of the compounds of formula (I) as a pest control agent.

Description

Condensed heterocyclic compound and its use as pest control agent

The present invention relates to fused heterocyclic compounds. More specifically, the present invention relates to a fused heterocyclic compound of formula (I) and a preparation method thereof. The present invention further relates to the use of the fused heterocyclic compound of formula (I) as a pest control agent.

The currently available modern insecticides and acaricides must meet the requirements of many aspects such as effective amount, residual activity, activity spectrum and effect, and their possible uses. In the past few decades, people have worked hard to develop targeted insecticides that can exert a biochemical mode of action (currently only present in insects or mites) and also show superior properties than known insecticides. .

Heterocyclic compounds with insecticidal activity are known, for example, described in WO2019131575, WO2019131587, WO201913273, WO201908115, WO2018206348, WO2018202494, WO2018197315, WO2018141954, WO2018008727, WO2017055185 and WO2016125621.

However, through long-term use of this insecticide, many pests have acquired resistance, so effective control by existing insecticides and fungicides that have been used for many years has become more and more difficult, and this phenomenon has become increasingly It's getting worse. In addition, some of these existing pesticides are highly toxic or remain in the environment for a long time due to their residual characteristics, which may cause damage to the ecosystem and become an increasingly serious problem.

Therefore, there is a continuing need for new compounds that are more effective, less toxic, safer to the environment, and/or have different modes of action.

In view of the foregoing, the present invention contemplates such compounds that meet or overcome the disadvantages related to the prior art.

Surprisingly, it has been discovered that certain new insecticidal active fused heterocyclic compounds with sulfur-containing substituents have ideal insecticidal properties.

式（I） 其中，R¹ 、G₁ 、G₂ 、G₃ 、G₄ 、A₁ 、A₂ 、Q、n和Z如詳細描述中所定義。Therefore, the present invention provides the fused heterocyclic compound of formula (I) or its agriculturally acceptable salt, isomer/structural isomer, stereoisomer, diastereomer, enantiomer Forms, tautomers, metal complexes, polymorphs or N-oxides.

Formula (I) wherein R ¹ , G ₁ , G ₂ , G ₃ , G ₄ , A ₁ , A ₂ , Q, n, and Z are as defined in the detailed description.

In one embodiment, the present invention provides a method for preparing a compound of formula (I) or an agriculturally acceptable salt thereof.

In another embodiment, the present invention provides a composition for controlling or preventing invertebrate pests, which comprises a biologically effective amount of a compound of formula (I) or an agriculturally acceptable salt, isomer/structure thereof Isomers, stereoisomers, diastereomers, enantiomers, tautomers, metal complexes, polymorphs or N-oxides and at least one selected from surfactants and Other components of the adjuvant.

In another embodiment, the composition further comprises at least one biological agent selected from the group consisting of suicide fungicides, insecticides, nematicides, acaricides, biological pesticides, herbicides, plant growth regulators, antibiotics, fertilizers or nutrients. Active and compatible compounds.

In another embodiment, the present invention provides compounds of formula (I) or agriculturally acceptable salts, isomers/structural isomers, stereoisomers, diastereomers, enantiomers, tautomers Structures, metal complexes, polymorphs or N-oxides, combinations or combinations thereof are used to control invertebrate pests or animal parasites in crops and/or horticultural crops.

In yet another embodiment, the present invention provides a method for controlling invertebrate pests, comprising using a biologically effective amount of a compound of formula (I) or an agriculturally acceptable salt, isomer/structural isomer, stereo Isomers, diastereomers, enantiomers, tautomers, metal complexes, polymorphs or N-oxides, their compositions or combinations contact invertebrate pests, their habitats, and breeding grounds , Food, plant, seed, soil, area, material or environment where invertebrate pests grow or may grow, or material, plant, seed, soil, surface or space where it is desired to be protected from pests or infestations.

Detailed description of the invention definition

The term definitions provided in the present invention are only for illustrative purposes, and in no way limit the scope of the present invention disclosed by the present invention.

As used herein, "include", "include", "have", "have", "characterized by" or any other variations thereof are intended to cover non-exclusive inclusions, unless explicitly indicated. For example, the element table included in the combination, mixture, process, or method is not necessarily limited to these elements, but may include other elements inherent to the combination, mixture, step, or method that are not explicitly listed.

The transition word "consisting of" excludes any unspecified elements, steps or ingredients. If it is in a request (in addition to the miscellaneous items normally associated with it), such a request will contain materials other than those mentioned. When the word "consisting of" appears in a clause in the body of the claim, rather than immediately after the preamble, it only restricts the elements specified in the clause; other factors are not excluded from the entire claim.

The transition term "consisting essentially of" is used to define a composition or method that includes materials, steps, features, ingredients or elements, provided that these additional materials, steps, features, ingredients or elements do not materially affect the protection of the claim The basic elements and novel features of the invention. The term "consisting essentially of" occupies the middle ground between "comprising" and "consisting of".

In addition, unless expressly stated to the contrary, "or" refers to an inclusive "or" rather than an exclusive "or". For example, the condition A "or" B satisfies any one of the following: A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or present), A and B All are true (or exist).

In addition, the indefinite articles "a" and "an" before an element or ingredient of the present invention do not limit the number of instances (ie, the number of occurrences) of the element or ingredient. Therefore, "a" or "an" should be understood to include one or at least one, and the singular word form of an element or component also includes the plural unless the number is clearly singular.

As described in the present invention, the term "invertebrate pests" includes arthropods, gastropods, and nematodes that are economically important pests. The term "arthropod" includes insects, mites, spiders, scorpions, centipedes, millipedes, medicinal insects, and beetles. The term "gastropod" includes snails, slugs and other styloid worms. The term "nematode" refers to living organisms of the phylum Nematode. The term "worm" includes roundworms, canine filarials, phytophagous nematodes, trematodes, acanthocephalans, and tapeworms.

The term "agricultural" refers to the production of crops such as food and fiber, including the cultivation of corn, soybeans and other legumes, rice, grains (such as wheat, oats, barley, rye, rice, corn), green leafy vegetables (such as Lettuce, cabbage and other rape crops), fruit vegetables (such as tomatoes, peppers, eggplants, cruciferous plants and gourds), potatoes, sweet potatoes, grapes, cotton, tree fruits (such as pears and citrus), small fruits (strawberries, Cherries) and other special crops (such as rape, sunflower, olives).

The term "non-agricultural" refers to non-agricultural crops, such as horticultural crops (for example, flower houses, nurseries or ornamental plants that do not grow in the field), residential, agricultural, commercial and industrial structures, turf (for example, turf farms, pastures, golf Fields, lawns, sports fields, etc.), wood products, storage, agroforestry and vegetation management, public health (ie humans) and animal health (such as pets, livestock and poultry and other domesticated animals, wild animals and other non-domesticated animals) applications.

Non-agricultural applications include the protection of animals from invertebrate parasites by administering to the animal to be protected a parasiticidal effective amount (ie, biologically effective) of the compound of the invention (usually in the form of a composition formulated for veterinary use) Infringe. The terms "parasite-killing" and "parasitic pesticidal site" mentioned in the present disclosure and claims refer to the observable effects on invertebrate parasites in order to protect animals from pests. The parasitic insecticidal effect is usually related to reducing the appearance or activity of target invertebrate parasites. This effect on pests includes necrosis, death, growth retardation, reduced mobility or reduced lodging ability on the host animal's body or body, reduced feeding, and inhibition of reproduction. These effects on invertebrate parasites can prevent (including preventing, reducing or eliminating) animals from infestation or infection by parasites.

The compounds of the invention may exist in pure form or as a mixture of different possible isomeric forms, such as stereoisomers or structural isomers. Various stereoisomers including enantiomers, diastereomers, chiral isomers, atropisomers, conformational isomers, rotamers, tautomers, optical isomers , Polymorphs and geometric isomers. Any desired mixtures of these isomers fall within the scope of the claims of the present invention. Those skilled in the art will understand that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to other isomers or when separated from other isomers. In addition, those skilled in the art know processes or methods or techniques for separating, enriching and/or selectively preparing the isomers.

The meanings of various terms used in this description are now explained.

The term "aliphatic compound" or "aliphatic group" as used herein is an organic compound whose carbon atoms are connected in a straight chain, a branched chain, or a non-aromatic ring.

The term "alkyl" (used independently or in compound words such as "alkylsulfide" or "haloalkyl" or -N (alkyl) or alkylcarbonylalkyl or alkylsulfonamide) includes straight chain or Branched C ₁ to C ₂₄ alkyl, preferably C ₁ to C ₁₅ alkyl, preferably C ₁ to C ₁₀ alkyl, more preferably C ₁ to C ₆ alkyl. Non-limiting examples of alkyl groups include methyl, ethyl, propyl, 1-methylethyl, 1-methylethyl, pentyl, 1-methylbutyl, 1-methylbutyl, 2- Methylbutyl, 2-methylpropyl, 1-methylpentyl, 1-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methyl Pentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl , 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methyl Group propyl or different isomers. If the alkyl group is at the end of a compound substituent, for example, in an alkylcycloalkyl group, the part of the initial compound substituent, such as a cycloalkyl group, may be mono- or multiple-substituted by the alkyl group in the same or different ways and independently replace. The same applies to other radicals such as alkenyl, alkyl, hydroxyl, halogen, carbonyl, carbonyloxy and other compound substituents at the end.

The term "alkenyl" (used independently or in compound words) includes linear or C ₂ to C ₂₄ olefins, preferably C ₂ to C ₁₅ olefins, more preferably C ₂ to C ₁₀ olefins, more preferably C ₂ to C ₆ Alkene branching. Non-limiting examples of olefins include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-methyl-1-propenyl, 2-methyl-2-propene Group, 2-methyl-1-butenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-2-butenyl, 3-methyl -3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1-1-dimethyl-2-butenyl, 1,2-dimethyl- 2-propene, 1-ethyl-1-propene, 1-ethyl-2-propene, 1-ethyl-2-pentene, 3-methyl-1-pentene, 2-methyl-1-pentene Ene, 3-methyl-2-pentene, 3-methyl-2-pentene, 3-methyl-3-pentene, 3-methyl-3-pentene, 4-methyl-4-pentene Ene, 3-methyl-4-pentene, 3-methyl-4-pentene, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-Dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-3-butenyl, 2,3-dimethyl- 3-butenyl, 2,3-dimethyl-3-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-3-butenyl, 1- Ethyl-1-butenyl, 1-ethyl-2-butenyl, 2-ethyl-2-butenyl, 2-ethyl-2-butenyl, 2-ethyl-2-butenyl Alkenyl, 2-ethyl-2-butenyl, 2-ethyl-2-butenyl, 1-ethyl-2-butenyl, 1-ethyl-2-methyl-1-propene and l-Ethyl-2-methyl-2-propene and its isomers. Olefins also include polyenes such as 1,2-propadiene and 2,4-hexadiene. Unless there is a clear definition elsewhere, this definition also applies to olefins as part of a composite substituent, such as halogenated olefins.

The term "alkynyl" (used alone or in compound words) includes branched or straight chain C ₂ to C ₂₄ alkynes, preferably C ₂ to C ₁₅ alkynes, more preferably C ₂ to C ₁₀ alkynes, most preferably C ₂ to C ₆ alkynes. Non-limiting examples of alkynes include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl , 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl 3-butynyl, 3-methyl-1-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl -4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4-pentynyl , 4-methyl-1-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, 1,1-dimethyl-3-butynyl , 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-1-butynyl, 1-ethyl-2- Butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1-ethyl-1-methyl-2-propynyl and different isomers. Unless specifically defined elsewhere, the definition also applies to alkynyl groups that are part of a composite substituent, such as haloalkynyl groups and the like. The term "alkynyl" may also include moieties composed of multiple triple bonds, such as 2,5-hexadiynyl.

"Cycloalkyl" refers to an alkyl group that is closed to form a ring. Non-limiting examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Unless specifically defined elsewhere, this definition also applies to cycloalkyl groups that are part of a composite substituent, such as cycloalkylalkyl groups and the like.

"Cycloalkenyl" means an alkenyl group is closed to form a ring, including monocyclic, partially unsaturated hydrocarbon groups. Non-limiting examples include, but are not limited to, cyclopentenyl and cyclohexenyl. Unless specifically defined elsewhere, this definition also applies to cycloalkenyl groups that are part of a composite substituent, such as cycloalkenylalkyl and the like.

"Cycloalkynyl" refers to an alkynyl group closed to form a ring, including monocyclic, partially unsaturated groups. Unless specifically defined elsewhere, this definition also applies to cycloalkynyl groups that are part of a composite substituent, such as cycloalkynylalkyl and the like.

Similar words such as "cycloalkoxy" and "cycloalkenyloxy" have similar definitions. Non-limiting examples of cycloalkoxy groups include cyclopropoxy, cyclopentyloxy and cyclohexyloxy. Unless specifically defined elsewhere, this definition also applies to cycloalkoxy as part of a composite substituent, such as cycloalkoxyalkyl and the like.

"Halogen" (independently or in compound words such as "haloalkyl") includes fluorine, chlorine, bromine or iodine. In addition, when used in compound words such as "haloalkyl", the alkyl group may be partially or completely substituted with halogen atoms, and the halogen atoms may be the same or different. Non-limiting examples of "haloalkyl" include chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl Methyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoro Ethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, Pentafluoroethyl, 1,1,2-difluoroethyl-dichloro-2,2,2-trifluoroethyl and 1,1,1-trifluoroprop-2-yl. Unless specifically defined elsewhere, this definition also applies to haloalkyl as part of a composite substituent, such as haloalkylaminoalkyl and the like.

The definitions of "haloalkenyl" and "haloalkynyl" are similar, except that alkenyl and alkynyl are present as part of the substituent instead of alkyl.

"Haloalkoxy" refers to a straight or branched chain alkoxy group in which some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as described above. Non-limiting examples of halogenated alkoxy groups include chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoro Methoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 1-chloroethoxy, 1-bromoethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2- Difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro- 2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and 1,1,1-trifluoroprop-2-oxy. Unless specifically defined elsewhere, this definition also applies to groups with haloalkoxy as part of a composite substituent, such as haloalkoxyalkyl and the like.

The term "haloalkylthio" refers to straight-chain or branched alkylthio groups in which at least one and at most all hydrogen atoms in these groups can be replaced by halogen atoms as described above. Non-limiting examples of haloalkylthio groups include chloromethylthio, iodomethylthio, bromomethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethyl Sulfuryl, chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethylthio, 1-chloroethylthio, 1-bromoethylthio, 1-fluoroethylthio, 2-fluoroethylthio , 2,2-Difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2-fluoroethylthio, 2-chloro-2,2-difluoroethylthio, 2, 2-Dichloro-2-fluoroethylthio, 2,2,2-trichloroethylthio, pentafluoroethylthio and 1,1,1-trifluoro-2-ylthio. Unless specifically defined elsewhere, this definition also applies to groups with haloalkylthio as part of a composite substituent, such as haloalkylthioalkyl and the like.

Examples of "haloalkylsulfinyl" include CF ₃ S(O), CCl ₃ S(O), CF ₃ CH ₂ S(O). Non-limiting examples of "haloalkylsulfonyl" include CF ₃ S(O) ₂ , CCl ₃ S(O) ₂ , CF ₃ CH ₂ S(O) ₂ and CF ₃ CF ₂ S(O) ₂ .

The term "hydroxy" means -OH, and amino means -NRR, where R can be H or any possible substituent, such as an alkyl group. The carbonyl group represents -C(O)-, the carbonyloxy group represents -OC(O)-, the sulfinyl group represents SO, and the sulfonyl group represents S(O) ₂ .

The term "alkoxy" (used alone or as a compound word) includes C ₁ to C ₂₄ alkoxy, preferably C ₁ to C ₁₅ alkoxy, more preferably C ₁ to C ₁₀ alkoxy, most preferably C ₁ to C ₆ alkoxy. Examples of alkoxy groups include methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1- Dimethylethoxy, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethyl Propoxy, hexyloxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 1-methylpentyloxy, 2-methylpentyloxy, 3-methyl Pentyloxy, 4-methylpentyloxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-di Methylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2- Trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy and 1-ethyl-2-methylpropoxy and different isomers body. Unless specifically defined elsewhere, this definition also applies to alkoxy groups as part of a composite substituent, such as halogenated alkoxy groups, alkynyl alkoxy groups, and the like.

The term "alkoxyalkyl" means that an alkyl group is substituted by an alkoxy group. Non-limiting examples of "alkoxyalkyl" include CH ₃ OCH ₂ , CH ₃ OCH ₂ CH ₂ , CH ₃ CH ₂ OCH ₂ , CH ₃ CH ₂ CH ₂ CH ₂ OCH ₂ and CH ₃ CH ₂ OCH ₂ CH ₂ .

The term "alkoxyalkoxy" means that an alkoxy group is substituted by an alkoxy group.

The term "alkylthio" includes branched or straight chain alkylthio groups, such as methylthio, ethylthio, propylthio, 1-methylthio, butylthio, 1-methylpropylthio , 2-methylpropylthio, 1,1-dimethylethylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 2, 2-Dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 1-methylpentylthio , 2-Methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3- Dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1-ethylbutylthio, 2- Ethylbutylthio, 1,1,2-trimethylpropylthio, 1,2,2-dimethylbutylthio, 2-trimethylpropylthio, 1-ethyl-1-methyl Propylthio and 1-ethyl-2-methylpropylthio and different isomers.

Halocycloalkyl, halocycloalkenyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkyl The definitions of carbonyl, cycloalkylcarbonyl, haloalkoxyalkyl, etc. are similar to the above examples.

The term "alkylthioalkyl" means that an alkyl group is substituted with an alkylthio group. Non-limiting examples of "alkylthioalkyl" include -CH ₂ SCH ₂ , -CH ₂ SCH ₂ CH ₂ , CH ₃ CH ₂ SCH ₂ , CH ₃ CH ₂ CH ₂ CH ₂ SCH ₂ and CH ₃ CH ₂ SCH ₂ CH ₂ . "Alkylthioalkoxy" means that the alkoxy group is substituted with an alkylthio group. "Cycloalkylalkylamino" means that the alkylamino group is substituted with a cycloalkyl group.

The terms alkoxyalkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkylaminoalkyl, cycloalkylaminocarbonyl, etc. are defined in the same way as "alkylthioalkyl" or "cyclic "Alkylalkylamino" is similar.

The term "alkoxycarbonyl" is an alkoxy group bonded to the backbone through a carbonyl group (-CO-). Unless specifically defined elsewhere, this definition also applies to alkoxycarbonyl groups as part of composite substituents, such as cycloalkylalkoxycarbonyl groups and the like.

The term "alkoxycarbonylalkylamino" means that the alkylamino group is substituted by an alkoxycarbonyl group. "Alkylcarbonylalkylamino" means that an alkylamino group is substituted with an alkylcarbonyl group. The definitions of the terms alkylthioalkoxycarbonyl, cycloalkylalkylaminoalkyl, etc. are similar to this.

Non-limiting examples of "alkylsulfinyl" include, but are not limited to, methylsulfinyl, ethylsulfinyl, propylsulfinyl, 1-methylethylsulfinyl, butyl Sulfinyl, 1-methylpropylsulfinyl, 2-methylbutylsulfinyl, 1-methylbutylsulfinyl, 2-methylbutylsulfinyl, 2-Methylbutylsulfinyl, 1-ethylpropylsulfinyl, 1-ethylpropylsulfinyl, 1-2-dimethylpropylsulfinyl, 2-methyl Butyl sulfonate, 3-methyl pentyl sulfonate, 4-methyl pentyl sulfonate, 1,1-dimethyl butyl sulfonate, 1,3-dimethyl butyl sulfonate, 2, 3-dimethyl butyl sulfonate, 3,3-dimethyl butyl sulfonate, 1-ethyl butyl sulfonate, 1,1,2-trimethyl propyl sulfonate, 1-ethyl 1 -Methyl propyl sulfonate and 1-ethyl 2-methyl propyl sulfonate and their isomers. The term "arylsulfinyl" includes Ar-S(O), where Ar can be any carboxyl or heterocyclic ring. Unless specifically defined otherwise, this definition also applies to alkylsulfinyl groups as part of a composite substituent, such as halogenated alkylsulfinyl groups and the like.

Non-limiting examples of "alkylsulfonyl" include, but are not limited to, methylsulfonyl, ethylsulfonyl, propylsulfonyl, 1-methylethylsulfonyl, butylsulfonyl, 1-methylpropylsulfonyl, 2-methylbutylsulfonyl, 1-methylbutylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, 2,2-Methylpropylsulfonyl, 1-ethylpropylsulfonyl, 1-ethylpropylsulfonyl, 1,2-dimethylpropylsulfonyl, 1-methylsulfonyl Acetyl, 2-methylpentylsulfonyl, 3-methylpentylsulfonyl, 4-methylpentylsulfonyl, 1,1-dimethylbutylsulfonyl, 1,2-dimethylbutyl Base sulfo, 2,2-dimethylbutylsulfonyl, 2,3-dimethylbutylsulfonyl, 3,3-dimethylbutylsulfonyl, 1-ethylbutylsulfonyl, 1 , 1,2-Trimethylpropylsulfonyl, 1-ethyl 1-methylpropylsulfonyl, 1-ethyl 2-methylpropylsulfonyl and their isomers. The term "arylsulfonyl" includes Ar-S(O) ₂ , where Ar can be any carboxyl or heterocyclic ring. Unless otherwise defined, this definition also applies to alkylsulfonyl groups as part of a composite substituent, such as alkylsulfonylalkyl groups and the like.

The definitions of terms such as "alkylamino" and "dialkylamino" are similar to the above examples.

The term "carbocyclic" or "carbocyclic" or "carbocyclic" includes "aromatic carbocyclic ring system" and "non-aromatic carbocyclic ring system" or polycyclic or bicyclic (spirocyclic, fused, bridged, Non-fused) ring compounds, where the ring can be aromatic or non-aromatic (where aromatic means conforming to Huckel’s rule, non-aromatic means not meeting Huckel’s rule).

The term "hetero" in connection with the ring refers to a ring in which at least one ring atom is not a carbon atom, which may contain 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, provided that there are no more than 4 in each ring Nitrogen, 2 oxygen and 2 sulfur.

The term "aromatic" means that the Huckel rule is met, and "non-aromatic" means that the Huckel rule is not met.

The term "heterocyclic ring" or "heterocyclic ring" includes "aromatic heterocyclic ring" or "heteroaryl ring system" and "non-aromatic heterocyclic ring system" or polycyclic or bicyclic (spiro, fused, bridged, non-fused Con) cyclic compound, the ring can be aromatic or non-aromatic, wherein the heterocyclic ring contains at least one heteroatom selected from N, O, S(O) _0-2 , and/or the C ring member of the heterocyclic ring can be Replace with C(=O), C(=S), C(=CR*R*) and C=NR* (* represents an integer).

The term "non-aromatic heterocyclic ring" or "non-aromatic heterocyclic ring" refers to a three to fifteen membered (preferably three to twelve membered) saturated or partially saturated or partially containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur Unsaturated heterocycles: monocyclic, bicyclic or tricyclic heterocycles, in addition to carbocyclic members, also contain 1-3 nitrogen atoms and/or one oxygen or sulfur atom or one or two oxygen and/or sulfur atoms; If the ring contains multiple oxygen atoms, they are not directly adjacent; for example (but not limited to) ethylene oxide, azido, oxetanyl, azetidinyl, thietane , 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl , 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 1-pyrazolidinyl, 3-pyrazolidine Group, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5 -Thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1,2,4-oxadiazolidine-3-yl, 1,2,4-oxadiazolidine-5 -Yl, 1,2,4-thiadiazolidine-3-yl, 1,2,4-thiadiazolidine-5-yl, 1,2,4-triazolidine-1-yl, 1,2 ,4-Triazolidine-3-yl, 1,3,4-oxadiazolidine-2-yl, 1,3,4-thiadiazolidine-2-yl, 1,3,4-triazolidine -1-yl, 1,3,4-triazolidine-2-yl, 2,3-dihydrofuran-2-yl, 2,3-dihydrofuran-3-yl, 2,4-dihydrofuran -2-yl, 2,4-dihydrofuran-3-yl, 2,3-dihydrothiophen-2-yl, 2,3-dihydrothiophen-3-yl, 2,4-dihydrothiophen-2 -Yl, 2,4-dihydrothiophen-3-yl, pyrrolinyl, 2-pyrrolin-2-yl, 2-pyrrol-3-yl, 3-pyrrol-2-yl, 3-pyrrol-3-yl Yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2-isoxazolin-4-yl, 3-isoxazolin-3-yl Azolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl , 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3-dihydropyrazole-1 -Yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazole -5-yl, 3,4-dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydro Pyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5 -Dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2 ,3-Dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl , 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazole-3 -Base, 3,4-dihydrooxazol-4-yl, pyridinyl, 2-point divinyl, 3-pyridinyl, 4-pyridinyl, pyrazinyl, morpholinyl, thiomorpholine Group, 1,3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyranyl Azinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, 1,3,5-hexahydrotriazin-2-yl, 1,2,4 -Hexahydrotriazin-3-yl, cycloserine, 2,3,4,5-tetrahydro[1H] azepine-1- or -2- or -3- or -4- or -5- or- 6- or -7-yl, 3,4,5,6-tetrahydro[2H] azepine-2- or -3- or -4- or -5- or -6- or -7-yl, 2 ,3,4,7-Tetrahydro[1H]azepine-1- or -2- or -3- or -4- or -5- or -6- or -7-yl, 2,3,6, 7-Tetrahydro[1H]azepine-1- or -2- or -3- or -4- or -5- or -6- or -7-yl, hexahydroazepine-1- or -2- Or -3- or -4-yl, tetra- and hexahydrooxepenyl, such as 2,3,4,5-tetrahydro[1H]oxepane-2- or -3- or- 4- or -5- or -6- or -7-yl, 2,3,4,7-tetrahydro[1H]oxa-2-one or -3- or -4- or -5- or -6 -Or-7-yl, 2,3,6,7-tetrahydro[1H]oxetan-2-one or -3- or -4- or -5- or -6-or-7-yl, hexahydro Aza-1- or -2-- or -3- or -4-yl, tetra- and hexahydro-1,3-diazepine, tetra- and hexahydro-1,4-diazepine, Tetra- and hexahydro-1,3-oxazepine, tetra- and hexahydro-1,4-oxazepine, tetra- and hexahydro-1,3-dioxepenyl, tetrahydro And hexahydro-1,4-dioxepenyl. Unless specifically defined elsewhere, this definition also applies to heterocycloalkyl as part of a composite substituent, such as heterocyclylalkyl and the like.

The term "heteroaryl" refers to a 5- or 6-membered fully unsaturated monocyclic ring system containing one to four heteroatoms from oxygen, nitrogen and chalcogenide; if the ring contains more than one oxygen atom, they are not directly adjacent ; 5-membered heteroaryl contains one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom: in addition to carbon atoms, five-membered heteroaryl groups can also contain one to four nitrogen atoms or one to three nitrogen atoms and A sulfur or oxygen atom as a ring member, such as (but not limited to) furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, 1, 2 ,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,2,4,4-triazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazole Group, 1,3,4-triazolyl, tetrazolyl; nitrogen-bonded 5-membered heteroaryl containing one to four nitrogen atoms, or benzo-fused nitrogen-bonded containing one to three nitrogen atoms 5-membered heteroaryl group: in addition to carbon atoms, a five-membered heteroaryl group that can contain one to four nitrogen atoms or one to three nitrogen atoms as ring members and two adjacent carbocyclic members or one nitrogen and one Adjacent carbocyclic members can be bridged by a but-1,3-diene-1,4-diyl group, one or two of the carbon atoms can be replaced by nitrogen atoms, and these rings are connected to the backbone through a nitrogen ring member, For example (but not limited to) 1-pyrrolyl, 1-pyrazolyl, 1,2,4-triazol-1-yl, 1-imidazolyl, 1,2,3-triazol-1-yl and 1, 3,4-Triazol-1-yl.

6-membered heteroaryl groups containing 1-4 nitrogen atoms: 6-membered heteroaryl groups, in addition to carbon atoms, can also contain 1-3 and 1-4 nitrogen atoms as ring members, for example (but Not limited to) 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl , 1,3,5-triazin-2-yl, 1,2,4-triazin-3-yl and 1,2,4,5-tetrazin-3-yl; containing one to three nitrogen atoms or one A benzo-fused 5-membered heteroaryl group containing a nitrogen atom and an oxygen or sulfur atom: for example (but not limited to) indol-1-yl, indol-2-yl, indol-3-yl, indole -4-yl, indol-5-yl, indol-6-yl, indol-7-yl, benzimidazol-1-yl, benzimidazol-2-yl, benzimidazol-4-yl, Benzimidazol-5-yl, indazol-1-yl, indazol-3-yl, indazol-4-yl, indazol-5-yl, indazol-6-yl, indazol-7-yl, Indazol-2-yl, 1-benzofuran-2-yl, 1-benzofuran-3-yl, 1-benzofuran-4-yl, 1-benzofuran-5-yl, 1-benzene And furan-6-yl, 1-benzofuran-7-yl, 1-benzothiophen-2-yl, 1-benzothiophen-3-yl group, 1-benzothiophen-4-yl, 1 -Benzothiophen-5-yl, 1-benzothiophen-6-yl, 1-benzothiophen-7-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazole-4 -Yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1,3-benzoxazole-2- Yl, 1,3-benzoxazol-4-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl and 1,3-benzoxazole- 7-yl; benzo-fused 6-membered heteroaryl containing one to three nitrogen atoms: for example (but not limited to) quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, Quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4- Group, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl. Unless specifically defined elsewhere, this definition also applies to heteroaryl groups as part of a composite substituent, such as heteroarylalkyl groups.

The term "trialkylsilyl" includes 3 branched and/or linear alkyl radicals attached to and attached to a silicon atom, such as trimethylsilyl, triethylsilyl and tertiary Butyldimethylsilyl. The "haloalkylsilyl group" means that at least one of the three alkyl groups is partially or completely substituted with a halogen atom, which may be the same or different. "Alkoxytrialkylsilyl" means that at least one of the three alkyl groups is substituted with one or more alkoxy groups which may be the same or different. "Trialkylsilyloxy" means a trialkylsilyl moiety linked by oxygen.

Non-limiting examples of "alkylcarbonyl" include _{C (O) CH 3, C} (O) CH 2 CH 2 CH 3 and _{C (O) CH (CH 3} ) 2. Examples of "alkoxycarbonyl" include CH ₃ OC (=O), CH ₃ CH ₂ OC (=O), CH ₃ CH ₂ CH ₂ OC (=O), (CH ₃ ) ₂ CHOC (=O), and Different butoxy or pentoxycarbonyl isomers. Examples of "alkylaminocarbonyl" include CH ₃ NHC (=O), CH ₃ CH ₂ NHC (=O), CH ₃ CH ₂ CH ₂ NHC (=O), (CH ₃ ) ₂ CHNHC (=O), and Different butylamino- or pentylaminocarbonyl isomers. Examples of "dialkylaminocarbonyl" include (CH ₃ ) ₂ NC(=O), (CH ₃ CH ₂ ) ₂ NC(=O), CH ₃ CH ₂ (CH ₃ )NC(=O), CH ₃ Examples of CH ₂ CH ₂ (CH ₃ )NC(=O) and (CH ₃ ) ₂ CHN(CH ₃ )C(=O) "alkoxyalkylcarbonyl" include CH ₃ OCH ₂ C(=O), CH ₃ OCH ₂ CH ₂ C(=O), CH ₃ CH ₂ OCH ₂ C(=O), CH ₃ CH ₂ CH ₂ CH ₂ OCH ₂ C(=O) and CH ₃ CH ₂ OCH ₂ CH ₂ C( =O). Examples of "alkylthioalkylcarbonyl" include CH ₃ SCH ₂ C(=O), CH ₃ SCH ₂ CH ₂ C(=O), CH ₃ CH ₂ SCH ₂ C(=O), CH ₃ CH ₂ CH ₂ CH ₂ SCH ₂ C(=O) and CH ₃ CH ₂ SCH ₂ CH ₂ C(=O). The definitions of haloalkylsulfonylcarbonyl, alkylsulfonylaminocarbonyl, alkylthioalkoxycarbonyl, alkoxycarbonylalkylamino, etc. are similar to this.

Non-limiting examples of "alkylaminoalkylcarbonyl" include CH ₃ NHCH ₂ C(=O), CH ₃ NHCH ₂ CH ₂ C(=O), CH ₃ CH ₂ NHCH ₂ C(=O), CH ₃ CH ₂ CH ₂ CH ₂ NHCH ₂ C(=O) and CH ₃ CH ₂ NHCH ₂ CH ₂ C(=O).

"Amine" refers to A-R'C = ONR"-B, where R'and R" represent substituents, and A and B represent any group.

"Thioamide" means A-R'C=SNR"-B, where R'and R" represent substituents, and A and B represent any groups.

The total number of carbon atoms in the substituent is represented by _{the prefix "C i} -C _j ", where i and j are the numbers 1-21. For example, C ₁ -C ₃ alkylsulfonyl represents methylsulfonyl to propylsulfonyl; C ₂ alkoxyalkyl represents CH ₃ OCH ₂ ; C ₃ alkoxyalkyl represents, for example, CH3CH(OCH3 ), CH3OCH ₂ CH ₂ or CH ₃ CH ₂ OCH ₂ ; C ₄ alkoxyalkyl means various isomers of alkyl groups substituted with alkoxy groups containing a total of four carbon atoms, examples include CH ₃ CH ₂ CH ₂ OCH ₂ and CH ₃ CH ₂ OCH ₂ CH ₂ . In the above description, when the compound of formula (I) consists of one or more heterocyclic rings, all substituents are connected to these rings through any available carbon or nitrogen by replacing the hydrogen on the carbon or nitrogen.

When a compound is substituted by a substituent with a subscript, the substituent means that the number of the substituent may exceed 1, and the substituent (when they exceed 1) are independently selected from the defined substituents. In addition, when the _{subscript m} in (R) m represents an integer ranging from, for example, 0 to 4, the number of substituents can be selected from an integer between 0 and 4.

When a group contains a substituent that may be hydrogen, then when the substituent is considered to be hydrogen, the group can be considered unsubstituted.

The embodiments herein and their various features and advantageous details will be described with reference to the non-limiting embodiments in the description. To avoid unnecessarily obscuring the embodiments herein, descriptions of known components and processing techniques are omitted. The examples used here are only intended to facilitate understanding of the ways in which the embodiments herein can be practiced, and to further enable those skilled in the art to practice the embodiments herein. Therefore, these embodiments should not be construed as limiting the scope of the embodiments of the present invention.

The description of the specific embodiments will fully reveal the general nature of the embodiments herein, so that others can modify and/or adapt these specific embodiments by applying current knowledge without departing from the general concept. Therefore, this adaptation and modification, It should be understood to have the same meaning and scope as the present invention. It should be understood that the phrases or terms used here are for descriptive purposes and do not impose limitations on the present invention. Therefore, although the embodiments herein are described in the form of preferred embodiments, those skilled in the technology will recognize that the embodiments herein can be practiced with modifications within the spirit and scope of the embodiments described herein.

Any discussion of documents, procedures, materials, devices, articles, etc. contained in this detailed description is only for the purpose of providing the background of the present invention, and should not be regarded as an admission that these matters form part of the prior art basis or are the most important part of this application. General common sense in the field that existed before the previous date.

Although the numerical values mentioned in the description and description/requests may constitute a key part of the present invention, if the deviation follows the same science, any deviation from these numerical values is still within the scope of the present invention. If appropriate, the inventive compounds of the present invention may exist as mixtures of different possible isomeric forms, especially mixtures of stereoisomers, such as E and Z, threo and erythro forms, optical isomers, and tautomers. Body (if appropriate). Any desired mixtures and possible tautomeric forms of E and Z isomers and threo and erythro isomers and optical isomers are within the scope of the present disclosure and claims.

The term "pest" for the purposes of the present invention includes but is not limited to fungi, stramenopiles (Oomycetes), bacteria, nematodes, mites, ticks, insects and rodents.

The term "plant" should be understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants can be plants obtained through conventional breeding and optimization methods or through biotechnology and genetic engineering methods or a combination of these methods, including transgenic plants and plant breeders' rights protected and unprotected plant cultivars.

The term "plants" used for the purpose of the present invention includes trees, shrubs, herbs, grasses, ferns and mosses, which usually grow in the field, absorb water and required substances through their roots, and synthesize the leaves through photosynthesis. The nutrients of living organisms.

Examples of "plants" used for the purpose of the present invention include, but are not limited to, crops such as wheat, rye, barley, triticale, oats or rice; sugar beets; fruits and fruit trees such as pome, stone fruit or soft fruit such as apples, Pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; legumes, such as lentils, peas, alfalfa or soybeans; rape, mustard, olives, sunflowers, coconuts, cocoa beans, castor oil plants , Oil palm, peanuts or soybeans and other oil plants; gourds, such as pumpkin, cucumber or melon; fiber plants, such as cotton, flax, hemp or jute; citrus fruits and citrus trees, such as oranges, lemons, grapefruit or citrus; Any horticultural plant, vegetable, such as spinach, lettuce, asparagus, cabbage, carrot, onion, tomato, potato, gourd or paprika; Laurel plants, such as avocado, cinnamon or camphor; Cucurbitaceae; oily plants; energy and Raw material plants, such as grains, corn, soybeans, other legumes, rapeseed, sugarcane or oil palm; tobacco; nuts; coffee; tea; cocoa; bananas; peppers; grapevines (table grapes and grape juice, grapevines); Hops; turf; sweet leaves (also called stevia); natural rubber plants or ornamental plants and forestry plants, such as flowers, shrubs, broad-leaved trees, or evergreen plants, such as conifers; and plant propagation materials, such as seeds, and crop materials of these plants .

Preferably, plants used for the purpose of the present invention include, but are not limited to, cereals, corn, rice, soybeans and other legumes, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any horticultural plants, Cucurbitaceae, Oily plants, tobacco, coffee, tea, cocoa, beets, sugar cane, cotton, potatoes, tomatoes, onions, peppers and vegetables, ornamental plants, any floral plants and other plants for human and animal use.

The term "plant parts" should be understood to mean all parts and organs of plants above and below the ground. For the purposes of the present invention, the term plant part includes but is not limited to cuttings, leaves, branches, tubers, flowers, seeds, branches, roots, including taproots, lateral roots, root hairs, root tips, root caps, rhizomes, young shoots , Buds, fruits, fruiting bodies, bark, stems, buds, auxiliary buds, meristems, nodes and internodes.

The term "its site" includes the soil, the surrounding environment of the plant or plant part, and the equipment or tools used before, during or after the sowing/planting of the plant or plant part.

The application of the compound of the present invention in the compound or composition of the present invention (consisting of the compound of the present invention and any other compatible compound) on plants or plant materials or their locus includes application by techniques known to those skilled in the art, including But not limited to spraying, coating, dipping, fumigation, dipping, injection and dusting.

The term "application" refers to physical or chemical adhesion to plants or plant parts, including dipping.

式（I） 其中， R¹ 選自C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基和C₃ -C₈ -環烷基-C₁ -C₆ -烷基； Y獨立地選自O和/或NR^y ； R^y 選自氫、氰基、C₁ -C₄ -烷基、C₂ -C₄ -烯基、C₂ -C₄ -炔基、C₁ -C₄ -鹵代烷基、C₂ -C₄ -鹵代烯基、C₃ -C₅ -環烷基和C₃ -C₅ -環烷基-C₁ -C₃ -烷基； Q代表5至10元雜環系統，其可任選地被一個或多個R² 基團取代； R² 選自氫、鹵素、氰基、硝基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、C₁ -C₆ -氰基烷基、OR⁴ 、NR⁵ R⁶ 、CR⁴ =NR⁵ 、C(=O)R⁸ 、S(O)_0-2 R⁷ 、SCN、S(O)_0-1 R⁹ =NR¹⁰ 、N=S(O)_0-1 (R⁹ )₂ 、P(=O)(OR”)₂ 、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基；其中每個R² 可任選地被一個或多個R^2a 基團取代； R^2a 選自鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR⁴ 、NR⁵ R⁶ 、CR⁴ =NR⁵ 、C(=O)R⁸ 、S(O)_0-2 R⁷ 、SCN、S(O)_0-1 R⁹ =NR¹⁰ 、N=S(O)_0-1 (R⁹ )₂ 、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基；或者 兩個R^2a 取代基以及它們所連接的原子或其他選自C、N、O、S的原子，和任選地包括1至3個選自C(=O)、C(=S)、S(O)_0-2 和Si(R”)₂ 的環成員一起可以形成3至7元環，其本身可任選地被一個或多個R^2aa 基團取代； R^2aa 選自鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR⁴ 、NR⁵ R⁶ 、C(=O)R⁸ 、S(O)_0-2 R⁷ 、S(O)_0-1 R⁹ =NR¹⁰ 、N=S(O)_0-1 (R⁹ )₂ 、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基； A₁ 和A₂ 獨立地代表N或CR^A ； R^A 選自氫、鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₃ -C₈ -環烷基、OR”和N(R”)₂ ；其中每個R^A 基團可任選地被一個或多個R^A' 基團取代； R^A' 選自鹵素、氰基、C₃ -C₈ -環烷基、OR”和N(R”)₂ ； Z代表O或S； G₁ 、G₂ 、G₃ 和G₄ 獨立地代表N或CR³ ；其中在環E中同時存在的N不超過兩個； R³ 選自氫、鹵素、氰基、硝基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR⁴ 、NR⁵ R⁶ 、CR⁴ =NR⁵ 、C(=O)R⁸ 、S(O)_0-2 R⁷ 、SCN、S(O)_0-1 R⁹ =NR¹⁰ 、N=S(O)_0-1 (R⁹ )₂ 、P(=O)(OR”)₂ 、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基；其中每個R³ 基團可任選地被一個或多個R^3a 基團取代； R^3a 選自鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR⁴ 、NR⁵ R⁶ 、CR⁴ =NR⁵ 、C(=O)R⁸ 、S(O)_0-2 R⁷ 、S(O)_0-1 R⁹ =NR¹⁰ 、N=S(O)_0-1 (R⁹ )₂ 、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基; R⁴ 選自氫、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、S(O)₂ R⁷ 、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基；其中每個R⁴ 基團可任選地被R^4a 基團取代； R^4a 選自鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR”、NR'R”、S(O)_0-2 R'、C(=O)R'、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基； R⁵ 選自氫、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR⁴ 、NR'R”、S(O)_0-2 R⁷ 、C(=O)R⁸ 、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基；其中每個R⁵⁴ 基團可任選地被R^5a 取代； R^5a 選自鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR”、NR'R”、S(O)_0-2 R'、C(=O)R'、Si(R”)₃ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基； R⁶ 選自氫、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₁ -C₆ -環烷基和C(=O)R⁸ ； R⁷ 選自C₁ -C₆ -烷基, C₂ -C₆ -烯基, C₂ -C₆ -炔基, C₁ -C₆ -鹵代烷基, C₂ -C₆ -鹵代烯基, C₃ -C₈ -環烷基, NR⁵ R⁶ , C₆ -C₁₀ -芳基, C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基；其中每個R⁷ 基團可任選地被一個或多個R^7a 基團取代； R^7a 選自鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR”、NR'R”、S(O)_0-2 R'、C(=O)R'、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基； R⁸ 選自氫、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR⁴ 、NR⁵ R⁶ 、N=S(O)_0-1 (R⁹ )₂ 、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基；其中每個R⁸ 可任選地被一個或多個R^8a 基團取代； R^8a 選自鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、OR”、NR'R”、S(O)_0-2 R'、C(=O)R'、C₆ -C₁₀ -芳基、C₇ -C₁₄ -芳烷基和C₃ -C₁₀ -雜環基； R⁹ 選自C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基和C(=O)R⁸ ； R¹⁰ 選自氫、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₁ -C₆ -鹵代烷基、C₂ -C₆ -鹵代烯基、C₃ -C₈ -環烷基、Si(R”)₃ 、S(O)_0-2 R⁷ 和C(=O)R⁸ ； 或者兩個R⁹ 取代基以及它們所連接的原子或其他選自C、N、O，和任選地包括C(=O)取代基的原子一起可以形成4至7元環，其本身可任選地被一個或多個鹵素、氰基、C₁ -C₆ -烷基、C₁ -C₆ -鹵代烷基或C₁ -C₆ -烷氧基基團取代； 或者R⁹ 和R¹⁰ 取代基以及它們所連接的原子或其他選自C、N、O，和任選地包括C(=O)取代基的原子一起可以形成4至7元環，其本身可任選地被一個或多個鹵素、氰基、C₁ -C₆ -烷基、C₁ -C₆ -鹵代烷基或C₁ -C₆ -烷氧基基團取代； R'選自氫、鹵素、氰基、C₁ -C₆ -烷基、C₂ -C₆ -烯基、C₂ -C₆ -炔基、C₃ -C₈ -環烷基、OR”、N(R”)₂ 、S(O)_0-2 R”、C(=O)R”、C(=O)OR”和C(=O)N(R”)₂ ； R”選自氫、C₁ -C₆ -烷基、C₂ -C₆ -烯基和C₂ -C₆ -炔基和C₃ -C₈ -環烷基；其中每個R”基團可任選地被鹵素取代； 每個R¹ 至R¹⁰ 、R^A 、R^2a 、R^2aa 、R^3a 、R^4a 、R^5a 、R^7a 和R^8a 可任選地被一個或多個選自X、CN、R'、OR”、SR'、N(R')₂ 、COOR”和CON(R')₂ 的基團取代； “n”為0〜2的整數； 或其農業上可接受的鹽、異構體/結構異構體、立體異構體、非對映異構體、對映異構體、互變異構體、多晶型物、金屬絡合物、N-氧化物或S-氧化物。In one embodiment, the present invention provides a compound of formula (I),

Formula (I) wherein, R ^{1 is} selected from C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -Haloalkenyl, C ₃ -C ₈ -cycloalkyl and C ₃ -C ₈ -cycloalkyl-C ₁ -C ₆ -alkyl; Y is independently selected from O and/or NR ^y ; R ^y Selected from hydrogen, cyano, C ₁ -C ₄ -alkyl, C ₂ -C ₄ -alkenyl, C ₂ -C ₄ -alkynyl, C ₁ -C ₄ -haloalkyl, C ₂ -C _{4 -halo} Alkenyl, C ₃ -C ₅ -cycloalkyl and C ₃ -C ₅ -cycloalkyl-C ₁ -C ₃ -alkyl; Q represents a 5- to 10-membered heterocyclic ring system, which may optionally be Or multiple R ² groups; R ^{2 is} selected from hydrogen, halogen, cyano, nitro, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, C ₁ -C ₆ -cyanoalkyl, OR ⁴ , NR ⁵ R ⁶ , CR ⁴ =NR ⁵ , C(=O)R ⁸ , S(O) _0-2 R ⁷ , SCN, S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , P(=O)(OR”) ₂ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclic group; Wherein each R ² may be optionally substituted by one or more R ^2a groups; R ^{2a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C _2- C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , CR ⁴ =NR ⁵ , C(=O)R ⁸ , S(O) _0-2 R ⁷ , SCN, S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , Si( R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; or two R ^2a substituents and the atoms to which they are connected or other options Atoms from C, N, O, S, and optionally including 1 to 3 rings selected from C(=O), C(=S), S(O) _0-2 and Si(R”) ₂ The members together can form a 3 to 7 membered ring, which itself can be optionally substituted by one or more R ^2aa groups; R ^{2aa is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , C(=O) R ⁸ , S(O) _0-2 R ⁷ , S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , Si( R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; A ₁ and A ₂ independently represent N or CR ^A ; R ^{A is} selected From hydrogen, halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₃ -C _8- cycloalkyl, oR "and N (R") _2; wherein each R ^a groups may be optionally substituted with one or more R ^{a 'substituent} group; R ^a' is selected from halo, cyano, C ₃ - C ₈ -Cycloalkyl, OR” and N(R”) ₂ ; Z represents O or S; G ₁ , G ₂ , G ₃ and G ₄ independently represent N or CR ³ ; where both exist in ring E N does not exceed two; R ^{3 is} selected from hydrogen, halogen, cyano, nitro, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C _1- C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , CR ⁴ =NR ⁵ , C(=O)R ⁸ , S (O) _0-2 R ⁷ , SCN, S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , P(=O)(OR”) ₂ , Si(R") ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl, and C ₃ -C ₁₀ -heterocyclic group; wherein each R ³ group can be optionally replaced by one or Multiple R ^3a groups are substituted; R ^{3a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C _6- Haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , CR ⁴ =NR ⁵ , C(=O)R ⁸ , S(O) _0-2 R ⁷ , S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; R ^{4 is} selected from hydrogen, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, S( O) ₂ R ⁷ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl, and C ₃ -C ₁₀ -heterocyclic group; wherein each R ⁴ group can Optionally substituted by the R ^4a group; R ^{4a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR", NR'R", S(O) _0-2 R', C(=O)R ', Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclic group; R ^{5 is} selected from hydrogen, C ₁ -C _6- Alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl , OR ⁴ , NR'R”, S(O) _0-2 R ⁷ , C(=O)R ⁸ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aryl Alkyl and C ₃ -C ₁₀ -heterocyclyl; wherein each R ⁵⁴ group may be optionally ^{substituted by R 5a} ; R ^{5a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C _2- C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR", NR' R”, S(O) _0-2 R', C(=O)R', Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C _3- C ₁₀ -heterocyclyl; R ^{6 is} selected from hydrogen, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₁ -C ₆ -cycloalkyl and C(=O)R ⁸ ; R ^{7 is} selected from C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, NR ⁵ R ⁶ , C ₆ -C _10- Aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; wherein each R ⁷ group can be optionally taken by one or more R ^7a groups R ^{7a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C _2- C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR", NR'R", S(O) _0-2 R', C(=O)R', C ₆ -C _10- Aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; R ^{8 is} selected from hydrogen, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C _2- C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , N=S(O) _0-1 (R ⁹ ) ₂ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl, and C ₃ -C ₁₀ -heterocyclyl; wherein each R ⁸ may optionally be one or Multiple R ^8a groups are substituted; R ^{8a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C _6- Haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR", NR'R", S(O) _0-2 R', C(=O)R', C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; R ^{9 is} selected from C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl , C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl and C(=O)R ⁸ ; R ¹⁰ Selected from hydrogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C _{6 -halo} Alkenyl, C ₃ -C ₈ -cycloalkyl, Si(R”) ₃ , S(O) _0-2 R ⁷ and C(=O)R ⁸ ; or two R ⁹ substituents and their connection The atoms or other atoms selected from C, N, O, and optionally including C(=O) substituents together can form a 4 to 7-membered ring, which itself can be optionally substituted by one or more halogens, cyano groups , C ₁ -C ₆ -alkyl, C ₁ -C ₆ -haloalkyl or C ₁ -C ₆ -alkoxy group substitution; or R ⁹ and R ¹⁰ substituents and their attached atoms or other selected C, N, O, and atoms optionally including C(=0) substituents together can form a 4- to 7-membered ring, which itself may be optionally substituted by one or more halogen, cyano, C ₁ -C ₆ -Alkyl, C ₁ -C ₆ -halo Substituted alkyl or C ₁ -C ₆ -alkoxy group; R'is selected from hydrogen, halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₃ -C ₈ -cycloalkyl, OR”, N(R”) ₂ , S(O) _0-2 R”, C(=O)R”, C(=O)OR” And C(=O)N(R”) ₂ ; R” is selected from hydrogen, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl and C ₂ -C ₆ -alkynyl and C ₃ -C ₈ - cycloalkyl; wherein each R "group may optionally be substituted by halogen; each R ¹ to ^{R 10, R A, R 2a} , R 2aa, R 3a, R 4a, R 5a, R 7a , and R ^8a may be optionally substituted with one or more groups selected from X, CN, R', OR", SR', N(R') ₂ , COOR" and CON(R') ₂ ; "n" It is an integer from 0 to 2; or its agriculturally acceptable salts, isomers/structural isomers, stereoisomers, diastereomers, enantiomers, tautomers, polymorphs Type, metal complex, N-oxide or S-oxide.

式（IA）In another embodiment, the compound of formula (I) is represented by the compound of formula (IA);

Formula (IA)

式（IB）In another embodiment, the compound of formula (I) is represented by the compound of formula (IB);

Formula (IB)

其中，#表示與DE環的連接點，

表示與-S(Y)_n R¹ 基團的連接點，並且Q環可任選被一個或多個R² 基團取代； 其中每個脂族基團可以任選地被一個或多個R^2a 基團取代，並且R² 的環狀基團可以任選地被一個或多個R^2b 基團取代； “n”為0〜2的整數。In one embodiment, the Q ring is selected from formulas Q1 to Q14;

Among them, # represents the connection point with the DE ring,

Represents the point of attachment to the -S(Y) _n R ¹ group, and the Q ring may be optionally substituted by one or more R ² groups; wherein each aliphatic group may be optionally substituted by one or more R ^{The 2a} group is substituted, and ^{the cyclic group of R 2} may be optionally substituted with one or more R ^2b groups; "n" is an integer from 0 to 2.

In one embodiment, preferred R ² substituents are selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, C ₁ -C ₆ -cyanoalkyl, OR ⁴ , NR ⁵ R ⁶ , S(O) _{0 -2} R ⁷ , S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , P(=O)(OR”) ₂ , Si(R”) ₃ , Phenyl, benzyl, phenoxy and C ₃ -C ₆ -heterocyclyl;

其中，＃表示與Q環的連接點。In another embodiment, the DE ring is selected from formulas DE-a to DE-c; wherein G ₁ , G ₂ , G ₃ and G ₄ independently represent N or CR ³ ; A ₁ and A ₂ independently represent N or CR ^A ; where there are no more than two N simultaneously existing in ring E;

Among them, # indicates the connection point with the Q ring.

其中，#表示與Q環的連接點，並且DE環可任選被一個或多個R³ 和R^A 基團取代。In a preferred embodiment, the DE ring is selected from formulas DE1 to DE16;

Wherein # denotes the point of attachment of the Q ring, and the ring may DE optionally substituted with one or more substituents R ³ and R ^A groups.

In one embodiment, preferred R ³ substituents are selected from halogen, cyano, C ₁ -C ₆ -haloalkyl, C ₃ -C ₈ -cycloalkyl, OC ₁ -C ₆ -haloalkyl, S(Y ) _0-2 -C ₁ -C ₆ -(halo)alkyl.

In one embodiment, in particular, the compound of formula (I) is selected from 2-(3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H )-Ketone; 2-(3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-bromo-3-(ethyl) Sulfuryl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl) -6-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(6-chloro-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl) Phthalazine-1(2H)-one; 2-(5-(3,5-dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl) Phthalazine-1(2H)-one; 2-(5-(3,5-difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl) Phthaloazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl) Yl)phthalazine-1(2H)-one; 2-(3-(ethylthio)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1 (2H)-ketone; 2-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(3-(Ethylsulfonyl)-6-(1H-1,2,4-triazol-1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine -1(2H)-one; 2-(3-(ethylsulfonyl)-6-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine-2 -Base)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(3-(trifluoromethyl)-1H-pyridine Azol-1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(3-( Trifluoromethyl)-1H-1,2,4-triazol-1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3 -(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(ethyl) Thio)-6'-fluoro-[3,3'-dipyridyl]-6-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl Sulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5 -(Ethylsulfonyl)-6'-fluoro-[3,3'-dipyridine]-6-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 7- (5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7- ( 3-(Ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(6-chloro- 3-(Ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethyl) Sulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7 -(3-(Ethylsulfonyl)-5-(3-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2 ,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-3-(trifluoromethyl) )Pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridine- 2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4- Fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7- (3-(Ethylsulfonyl)-6-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H )-Ketone; 7-(3-(ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2 ,3-d]pyridazine-8(7H)-one; 4-(5-(ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3 -d]Pyridazine-7(8H)-yl)pyridin-3-yl)benzonitrile; 7-(3-(ethylsulfonyl)-6-(4-(trifluoromethoxy)phenyl )Pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5- Phenylpyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(5-(3,5-difluorophenyl) )-3-(Ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(5- (3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H )-Ketone; 7-(3-(ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-3-(trifluoro Methyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-6-(3-(trifluoromethyl)phenyl)pyridine -2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(6-(3,5-dichlorophenyl)-3 - (Ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 3-(3-(ethylsulfon) (Pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)pyridin-2-yl)-7- (Trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylthio)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl) ) Quinazolin-4(3H)-one; 7-(3-(ethylsulfonyl)-6-(3-methyl-1H-1,2,4-triazol-1-yl)pyridine- 2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-6-(3- Fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 4- (5-(Ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine-2- Group) benzonitrile; 7-(3-(ethylsulfonyl)-6-(4-fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoro Methyl)pyrido[2,3-d]pyridazine-8(7H)-one; 3-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoro Methyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl) Quinazolin-4(3H)-one; 3-(5-(3,5-dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl ) Quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)quine Oxazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-phenylpyridin-2-yl)-6-(trifluoromethyl)quinazoline-4(3H) -Ketone; 3-(3-(ethylsulfonyl)-5-(4-methoxyphenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline-4(3H) -Ketone; 3-(3-(ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline-4 (3H)-one; 7-(3-(ethylsulfonyl)-6-phenylpyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine- 8(7H)-ketone; 7-(3-(ethylsulfonyl)-5-(2-fluoro-4-(trifluoromethoxy)phenyl)pyridin-2-yl)-3-( Trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(5-(2,2-difluorobenzo[d][1,3] dioxane Penten-5-yl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one ; 7-(6 -(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8( 7H)-ketone; 7-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-3- (Trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 3-(3-(ethylsulfonyl)-5-(3-(trifluoromethoxy) Phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 4-(5-(ethylsulfonyl)-6-(4-oxo- 6-(Trifluoromethyl)quinazolin-3(4H)-yl)pyridin-3-yl)benzonitrile; 3-(3-(ethylsulfonyl)-5-(4-(trifluoro) Methoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(3,5-difluorophenyl)-3 -(Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(4-chlorophenyl)-3-( Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(3- (Trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5- (2-Fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(3 -Chloro-4-(trifluoromethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(Ethylsulfonyl)-5-(2-fluoro-4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazole Lin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(4-fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-6- (Trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(2-fluoro-5-(trifluoromethoxy)phenyl) Pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 2-(3-(ethylsulfonyl)-5-(4-fluoro-3-( (Trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4 -Fluoro-3-methoxyphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2,4-difluorobenzene) Yl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)- 5-(4-Fluoro-3-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-chlorobenzene) Yl)-3-(ethylsulfonyl)pyridine -2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-6 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(4-fluorophenyl)pyridin-2-yl)-6-(tris Fluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine- 2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(4-(trifluoromethoxy)phenyl )Pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylsulfonyl)-5-(4-(1,1,2 ,2-Tetrafluoroethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 2-(6-(4-chlorophenyl) -3-(Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2-chloro-4-fluorophenyl) )-3-(Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5 -(3,4,5-Trifluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) -5-(4-Fluoro-2-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-chloro-3- (Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(4- Fluoro-2-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-(2-chloro-4-fluorophenyl) )-3-(Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6 -(3,4,5-trifluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-bromo-3-(ethyl) Sulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(5-(3,5-dichlorophenyl)-3-(ethyl) Sulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(4-fluorobenzene) Yl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(4-(trifluoromethyl) (Oxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 2-(3-(ethylsulfonyl)-5-(4- Fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(4-fluorophenyl) )Pyridin-2-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-one; 2-(6-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl Yl)phthalazine-1(2H)-one; 3-(5-(3,5-difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl Yl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridin-2-yl)-7- (Trifluoromethyl)quinazoline-4(3H)-one; 4-(5-(ethylsulfonyl)-6-(4-oxo-7-(trifluoromethyl)quinazoline- 3(4H)-yl)pyridin-3-yl)benzonitrile; 3-(3-(ethylsulfonyl)-5-(4-methoxyphenyl)pyridin-2-yl)-7- (Trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(tris Fluoromethyl)quinazolin-4(3H)-one; 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl Yl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2 -(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 3-(3- (Ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3- (3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quine Oxazolin-4(3H)-one; 2-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridine-2- Group)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoro) Ethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4- (Trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6- (4-(Trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(5-(4-bromophenyl) -3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5 -(3-Fluoro-4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3- (Ethylsulfonyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazoline-4( 3H)-ketone; 3-(5-bromo-3 -(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4(3H)-one; 3-(5-(4-chloro Phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4(3H)-one; 3-(3 -(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4(3H)-one ; 3-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl Yl)pyrido[3,2-d]pyrimidin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridine- 2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4(3H)-one; 2-(3-(ethylsulfonyl)-5-(4-( Perfluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,5-difluorophenyl)- 3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,5-dichlorophenyl)- 3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-( 4-(Perfluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-thione; 2-(3-(ethylsulfonyl) -5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-thione; 2-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(3-(Ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone; 4-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) Benzonitrile; 2-(3-(ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-one; 2-(5-(3,4-difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-one; 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 1 -(4-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)phenyl) Cyclopropane-1-carbonitrile; 2-(5-(4-(difluoromethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1 (2H)-ketone; 2-(5-(ethylsulfonyl)-6'-fluoro-[3,3'-dipyridyl]-6-yl)-7-(trifluoromethyl)phthalazine -1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-thione; 2-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine -1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(methylthio)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl )Phthalazine-1(2H)-one; 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-thione; 2-(5-(3,4-dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(5-(3-chloro-5-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridine-2- Yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(trifluoromethoxy) )Phenyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-( 4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-thione; 5-(ethylsulfonyl)-6-(1-oxo- 7-(Trifluoromethyl)phthalazine-2(1H)-yl)nicotinonitrile; 2-(5-(3,5-dichlorophenyl)-3-(ethylsulfonyl)pyridine-2- Yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridine- 2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,5-difluorophenyl)-3-(ethylsulfon) (Pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-chloro-3-fluorophenyl)- 3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2-chloro-5-(trifluoromethyl) Yl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-chloro-5-(5-( Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazin-2(1H)-yl)pyridin-3-yl)benzonitrile; 2-(3-(ethyl) Sulfonyl)-5-(2-fluoro- 5-(Trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-chloro-2-fluoro) Phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-bromophenyl) -3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonyl)-6 -(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2-methylpropionate; 2-(4-(5 -(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)phenoxy)-2,2- Difluoro-N,N-dimethylacetamide; 2-(3-(ethylsulfonyl)-5-(3,3,3-trifluoropropyl-1-en-2-yl)pyridine -2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(2,2,3,3 ,3-Pentafluoropropoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2,2-difluorobenzene) And [d][1,3]dioxol-5-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-one; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl )Oxy)acetonitrile; 2-(3-(ethylsulfonyl)-5-(1,1,2,3,3,3-hexafluoropropoxy)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-hydroxyphenyl)pyridin-2-yl)-7-(trifluoromethyl) )Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-hydroxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(5-(2-chloro-4-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -Ketone; 2-(3-(Ethylsulfonyl)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one; 5'-(ethylsulfonyl)-6'-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)- Group)-[2,3'-dipyridine]-5-carbonitrile; 2-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine- 2(1H)-yl)pyridin-3-yl)pyrimidine-5-carbonitrile; 2-(3-(ethylsulfonyl)-5-(2,2,2-trifluoroethoxy)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2,2,3,3,3-penta Fluoropropoxy)pyridin-2-yl) -7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-fluorophenyl)pyridin-2-yl)-7- (Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazole -5-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(pyrimidine-5- Yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-methylpyridin-2-yl) -7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((methylthio)methoxy)pyridin-2-yl) -7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(cyclopropylmethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one; 3-(5-bromo-3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)benzo[d ][1,2,3]triazine-4(3H)-one; 3-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzene And [d][1,2,3]triazine-4(3H)-one; 2-(5-((dimethyl((oxo)-l6-sulfinyl)amino)-3-( Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((methyl Sulfonyl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(4-(ethylsulfonyl)-6-(3 -(Trifluoromethyl)phenyl)pyridazin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5 -(Oxetan-3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonyl) Yl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2-methylpropanamide; 2-(3 -(Ethylsulfonyl)-6-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-ketone; 2-(5-((diethyl((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(5'-(ethylsulfonyl)-4-(trifluoromethyl)-[2,3'-dipyridine]- 6'-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5'-(ethylsulfonyl)-5-(trifluoromethyl)-[2, 3'-Dipyridine]-6'-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3-(benzyloxy)cyclobutoxy)- 3-(Ethylsulfonyl)pyridine Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3-chloro-4-fluorophenyl)-3-(ethylsulfonyl) )Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridine- 2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-(3-(ethylsulfonyl)-5- (2-Methoxypyrimidin-5-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(ethylsulfonyl)- 6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)acetonitrile; 2-(5-bromo-3-(ethylthio)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl )Pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(3-(ethylsulfonyl) -5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3 ] Triazine-4(3H)-one; 3-(3-(ethylthio)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d ][1,2,3]Triazine-4(3H)-one; 3-(5-(4-chlorophenyl)-3-(ethylthio)pyridin-2-yl)-6-(trifluoro Methyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-(5-(2-bromo-1,1,2,2-tetrafluoroethoxy)- 3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylthio)-5-(4- (Trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 3-( 5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4 (3H)-one; 3-(5-(3,5-dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d ][1,2,3]triazine-4(3H)-one; 3-(5-(3,5-difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)- 6-(Trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(5-(3-chloro-5-fluorophenyl)-3-( (Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(3-(ethyl) Sulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine- 4(3H)-ketone; 2-(5-((4 ,4-Difluorobut-3-en-1-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(3-(ethylthio)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)-7- (Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-1H-pyrazol-4-yl)pyridine-2- Group)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-fluoro-5-(trifluoromethyl) Phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 1-(5-(ethylsulfonyl)-6-(1-oxo-7 -(Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane-1-carbonitrile; 2-(3-(ethylsulfonyl)-5-(4-( Methylsulfonyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylthio)-5-(4- Fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; (5-(ethylsulfonyl)-6-(1-oxo-7- (Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) ethyl phosphonate; 2-(5-(dimethylphosphoryl)-3-(ethylsulfonyl) Yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonylimino)-5-(4-(1, 1,2,2-Tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonate) Yl)-5-((S-methylsulfonylimino)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3 -(Ethylsulfonylimino)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3- (Ethylsulfonyl)-5-(1,1,2,2-tetrafluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(Ethylsulfonyl)-5-(3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylsulfonyl)-5-hydroxypyridin-2-yl)-6-(trifluoromethyl)benzo[d] [1,2,3]Triazine-4(3H)-one; 3-(3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1, 2,3]Triazine-4(3H)-one; 3-(3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2 ,3]Triazine-4 (3H)-ketone; 3-(5-((diethyl((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-6- (Trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-(3-(ethylsulfonyl)-5-(ethylthio)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-fluorophenyl)-3-(N-methylethylsulfonylimide) )Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; (5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoro) Methyl)phthalazine-2(1H)-yl)pyridin-3-yl)tert-butyl carbamate; 2-(5-((ethyl(methyl)((oxo)-l6-sulfinyl) )Amino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(5-((ethyl(isopropyl) ((Oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1, 2,3]Triazine-4(3H)-one; 5-(ethylsulfonyl)-6-(4-oxo-6-(trifluoromethyl)benzo[d][1,2, 3] Triazine-3(4H)-yl)pyridin-3-yl dimethylsulfamate; 2-((5-(ethylsulfonyl)-6-(4-oxo-6-(three Fluoromethyl)benzo[d][1,2,3]triazine-3(4H)-yl)pyridin-3-yl)oxy)acetonitrile; 3-(3-(ethylsulfonyl)-5 -(2,2,2-Trifluoroethoxy)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one ; 3-(5-(Cyclopropylmethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3 ]Triazine-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(methoxymethoxy)pyridin-2-yl)-6-(trifluoromethyl)benzene And [d][1,2,3]triazine-4(3H)-one; 3-(5-(difluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)- 6-(Trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-((5-(ethylsulfonyl)-6-(4-oxy Subo-6-(trifluoromethyl)benzo[d][1,2,3]triazine-3(4H)-yl)pyridin-3-yl)oxy)-2-methylpropanamide; 2 -(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-2-methylpropane Nitrile; 5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl dimethylsulfamate; 2-(5-Amino-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-chloro-3- (Ethyl Sulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(1H-1,2 ,4-Triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5- ((4-oxoanion-1,4l6-xanthene-4-yl subunit)amino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2 -(6-Bromo-3-(ethylthio)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-( 5-(Difluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 1-cyano-N -(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane-1-methyl Amide; 2-(3-(Ethylsulfonyl)-6-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((2,2,2-trifluoroethyl)thio)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3,5-bis(ethylsulfonyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; 2-(5-((1,1-difluoroethyl)thio)-3-(ethylsulfonyl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(ethylsulfonylimino)-3-(ethylsulfonyl)pyridin-2-yl)-7- (Trifluoromethyl)phthalazine-1(2H)-one; 2-(5-((1,1-difluoroethyl)sulfonyl)-3-(ethylsulfonyl)pyridine-2- Group)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-(dimethylphosphoryl)phenyl)-3-(ethylsulfonyl) Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(three Fluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropanecarboxamide; 2-((5-(ethylsulfonyl)-6-(1-oxo-7- (Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2-methylpropionitrile; 2-(3-(ethylsulfonyl)-5-isopropoxy Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((1,1,1-tri Fluoro-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) Yl)-5-(trifluoromethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)- 5-( 1-oxyanion group-4,5-dihydro-3H-1l6-isothiazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2 -(3-(Ethylsulfonyl)-5-((3-hydroxy-1-oxytetrahydro-1l6-thiophen-1-ylylene)amino)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((4-oxoanion-1,4l6-xanthene-4-yl subunit) Amino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 4-(5-(ethylsulfonyl)-6-(1-oxo-7- (Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)benzenesulfonyl fluoride; 2-(5-(4-(dimethylphosphoryl)phenyl)-3-( Ethylsulfonylimino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 5'-(ethylsulfonylimino)-6'-(1- Oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)-[3,3'-dipyridine]-6-sulfonyl fluoride; 5-(ethylsulfonyl)-6- (1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3-sulfonyl fluoride; 2-(5-(4-(1,1-difluoroethyl) Phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) -5-(1-(trifluoromethyl)cyclopropyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfon) (Actyl)-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one ; 2-(3-(Ethylsulfonyl)-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)pyridin-2-yl )-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-isobutyl-1H-pyrazol-4-yl )Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-methoxy-1- Methyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(1'-(difluoromethyl)- 5-(Ethylsulfonyl)-6'-oxo-1',6'-dihydro-[3,3'-dipyridine]-6-yl)-7-(trifluoromethyl)phthalazine -1(2H)-one; 2-(3-(ethylsulfonyl)-5-isopropylpyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one ; 2-(5-(3,5-dimethylisoxazol-4-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridine-2 -Yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonylimino)-5-(3-(1, 1,2,2-Tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 4-(5-(ethylsulfonyl) Yl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)phenylsulfur fluoride; 2-(3-(ethylsulfon Amino)-5-((1,1,1-trifluoro-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-one; 2-((5-(ethylsulfonylimino)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine -3-yl)oxy)-2-methylpropionitrile; 2-(3-(ethylsulfonyl)-5-((methylsulfinyl)methoxy)pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2,2,3,3-tetrafluoropropoxy)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1,1,2-trifluoro-2- (Trifluoromethoxy)ethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5 -(2,2,3,4,4,4-hexafluorobutoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3- (Ethylsulfonyl)-5-(2,2,3,3,3-pentafluoropropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(5-(2,2-Difluoro-2-(trifluoromethoxy)ethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)- Yl)pyridin-3-yl)-2,2-difluorocyclopropane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoro Methyl)phthalazine-2(1H)-yl)pyridin-3-yl)-2,2-dimethylcyclopropane-1-carboxamide; N-(5-(ethylsulfonyl)-6 -(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-fluorocyclopropane-1-carboxamide; N-(5-( Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methylcyclopropane-1-methyl Amide; N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-N -Methylcyclobutane carboxamide; 1 -Cyano-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) ring Propane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3 -Yl)-3,3-dimethylcyclobutane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl) Phthalazine-2(1H)-yl)pyridin-3-yl)-3,3-difluorocyclobutane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1 -Oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclobutanecarboxamide; N-(5-(ethylsulfonyl)-6- (1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methylcyclobutane-1-carboxamide; N-(5- (Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-3-methylcyclobutane-1 -Formamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) -3-oxocyclobutane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H) )-Yl)pyridin-3-yl)cyclopentanecarboxamide; 1-cyano-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl) )Phthalazine-2(1H)-yl)pyridin-3-yl)cyclopentane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7- (Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methylcyclopentane-1-carboxamide; N-(5-(ethylsulfonyl)- 6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclohexanecarboxamide; N-(5-(ethylsulfonyl) )-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-4-methylcyclohexane-1-carboxamide; N -(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-4,4-bis Fluorocyclohexane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl) Pyridin-3-yl)azetidine-3-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine- 2(1H)-yl)pyridin-3-yl)-1-methylazetidine-3-carboxamide; 1-ethyl-N-(5-(ethylsulfonyl)-6- (1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)azetidine-3-carboxamide; N-(5-(ethyl Sulfonyl)-6-(1-oxo-7-(three Fluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxetane e-3-formamide; 3-ethyl-N-(5-(ethylsulfonyl) -6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxetane e-3-formamide; N-(5 -(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methylpyrrolidine-3 -Formamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) Tetrahydrofuran-3-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3 -Yl)piperidine-4-methylamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl) )Pyridin-3-yl)-1-methylpiperidine-4-methamide; 1-ethyl-N-(5-(ethylsulfonyl)-6-(1-oxo-7-( Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)piperidine-4-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo) -7-(Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)tetrahydro-2H-pyran-4-carboxamide; N-(5-(ethylsulfonyl) )-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-4-fluorotetrahydro-2H-pyran-4-methan Amine; 2-(7-Bromo-3-(ethylsulfonyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(3-(Ethylsulfonyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-one; 2-(3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1 ,2-a]pyridin-7-yl)acetonitrile; 3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazole And [1,2-a]pyridine-7-carbonitrile; 2-(3-(ethylsulfonyl)-7-methoxyimidazo[1,2-a]pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; 1-(3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)- Yl)imidazo[1,2-a]pyridin-7-yl)cyclopropane-1-carbonitrile; 2-(3-(ethylsulfonyl)-7-(2,2,2-trifluoroethane Yl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-bromo-3-(ethylsulfonyl) Yl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6 -(Trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 3-(ethylsulfonyl) -2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine-6-carbonitrile; 2-(3-(ethyl Sulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridin-6-yl)acetonitrile; 2 -(3-(Ethylsulfonyl)-7-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-one; 2-(3-(ethylsulfonyl)-7-(methylamino)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl) ) Phthalazine-1(2H)-one; 7-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridine-2 -Yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(3-( 1,1,2,2-Tetrafluoroethoxy)phenyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one ; 7-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3 -d]Pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-2-(trifluoromethyl) Pyrido[2,3-d]pyridazine-8(7H)-one; 5-(ethylsulfonyl)-6-(8-oxo-2-(trifluoromethyl)pyrido[2, 3-d]pyridazine-7(8H)-yl)nicotinonitrile; 2-(5-(ethylsulfonyl)-6-(8-oxo-2-(trifluoromethyl)pyrido[2 ,3-d]pyridazine-7(8H)-yl)pyridin-3-yl)acetonitrile; 1-(5-(ethylsulfonyl)-6-(8-oxo-2-(trifluoromethyl) Yl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridin-3-yl)cyclopropane-1-carbonitrile; 2-((5-(ethylsulfonyl)-6 -(8-oxo-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridin-3-yl)oxy)-2-methylpropionitrile; 7-(5-(Difluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-8 (7H)-ketone; 2-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-(perfluoroethyl)phthalazine-1(2H)- Ketone; 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(perfluoroethyl)phthalazine-1(2H)-one ; 2-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(perfluoroethyl Yl)phthalazine-1(2H)-one; 5-(ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H)-yl)nicotinonitrile ; 2-(5-(Ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H)-yl)pyridin-3-yl)acetonitrile; 1- (5-(Ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane-1-carbonitrile ; 5-(Ethylsulfonyl)-6-(1-oxo-7-((trifluoromethyl)sulfonyl)phthalazine-2(1H)-yl)nicotinonitrile; 2-(3- (Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-((trifluoromethyl)sulfonyl)phthalazine-1(2H)-one; 2-(3 -(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-((trifluoromethyl)sulfonyl)phthalazine-1(2H)-one; 1- (5-(Ethylsulfonyl)-6-(1-oxo-7-((trifluoromethyl)sulfonyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane -1-carbonitrile; 7-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3- d]Pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridine- 2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4- (Trifluoromethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 2-(5-( Ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridin-3-yl)acetonitrile; 1-(5-(Ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine- 3-yl)cyclopropane-1-carbonitrile; 7-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido [2,3-d]Pyridazine-8(7H)-one; 2-(3-(ethylsulfonyl)-5-(ethylthio)pyridin-2-yl)-7-(trifluoromethyl Yl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((2-(trifluoromethyl)cyclopropyl)methoxy)pyridin-2-yl )-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-methoxyazetidine-1-yl) )Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((1-methyl heterocyclo Butan-3-yl) Oxygen)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1H-1,2,4 -Triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2H -1,2,3-Triazol-2-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) )-5-(3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H )-Ketone; 2-(3-(ethylsulfonyl)-5-(4-(2-hydroxy-2-methylpropyl)-1H-1,2,3-triazol-1-yl) Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-(trifluoromethyl)- 1H-pyrazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-( 3-Methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 2- (5-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(2,2,2-trifluoro Ethoxy)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(2,2, 3,3,3-Pentafluoropropoxy)phthalazine-1(2H)-one; 1-(3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl) )Phthalazine-2(1H)-yl)imidazo[1,2-a]pyrimidin-7-yl)cyclopropane-1-carbonitrile; 2-(3-(ethylsulfonyl)-6-methan Glycine imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-(ethylsulfonyl)-2- (Trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 5-(ethylsulfonyl) -6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[2,1-b]thiazole-2-carbonitrile; 1-(3-(ethyl Sulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyrimidin-6-yl)cyclopropane- 1-carbonitrile; 1-(3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyrazolo[1, 5-a]pyridin-5-yl)cyclopropane-1-carbonitrile; 2-(2-(ethylsulfonyl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl )- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-1-methyl-6-(trifluoromethoxy)-1H-indole -2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoro) Methyl)phthalazine-2(1H)-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)acetonitrile; 2-(5-(ethylsulfonyl)-1-methyl -1H-pyrazolo[3,4-b]pyridin-6-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(7-cyclopropyl-2-( Ethylsulfonyl)imidazo[1,2-a]pyrimidin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) Yl)imidazo[1,2-a]pyrazin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)imidazole And [1,2-b]pyridazin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(bromodifluoromethoxy)-3- (Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(pyridine- 3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(pyridine-2 -Yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-((5-bromopyridin-2-yl)oxy)- 3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-( Pyrimidine-2-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(( 1-Methyl-1H-pyrazol-3-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,3 -Difluorocyclobutoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2 ,2-Difluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 2-(5-( (1,3-Difluoropropan-2-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one ; 2-(3-(Ethylsulfonyl)-5-(neopentyloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 1- (((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)methyl) Cyclopropane-1-carbonitrile; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine- 3 -Yl)oxy)propionitrile; 2-(3-(ethylsulfonyl)-5-((1-fluoro-2-methylpropan-2-yl)oxy)pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-methoxypyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2-fluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine -3-yl)oxy)-2-(methylthio)acetonitrile; 2-(5-((2,2-difluorocyclopropyl)methoxy)-3-(ethylsulfonyl)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 4-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoro) Methyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)butyronitrile; 2-(5-(cyclobutylmethoxy)-3-(ethylsulfonyl)pyridin-2-yl )-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2,2-difluoropropoxy)-3-(ethylsulfonyl)pyridine-2- Yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-fluoroethoxy)pyridin-2-yl) -7-(trifluoromethyl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalein Azin-2(1H)-yl)pyridin-3-yl)oxy)-N,N-dimethyl-2-(methylthio)acetamide; 2-ethyl-2-((5-(ethyl Sulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)butyronitrile; 2-(3-(ethyl) Sulfonyl)-5-isobutoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)- 5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2-bromo- 1,1-Difluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5- ((3-Cyclopropylisoxazol-5-yl)methoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H )-Ketone; 2-(3-(ethylsulfonyl)-5-(3-methoxycyclobutoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone; 5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl difluoromethanesulfonate Ester; 3-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy )Cyclobutane-1-carbonitrile ; 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl fluoromethanesulfonate; 3- ((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-3-methyl Butyronitrile; 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yltrifluoromethanesulfonic acid Ester; 2-(3-(Ethylsulfonyl)-5-((1-methoxy-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H) -Yl)pyridin-3-yl)oxy)-N,N,2-trimethylpropionamide; 2-(3-(ethylsulfonyl)-5-((3-methyloxetan Alk-3-yl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; (E)-2-(3-(ethylsulfonyl) )-5-(2-(methylimino)propoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-5-((trimethylsilyl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-5-(2-oxypropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfon) ((2-methyl-3-oxobutan-2-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(5-(allyloxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2- (3-(Ethylsulfonyl)-5-propoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-ethoxy- 3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-( Methoxymethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-cyclobutyl-3-(ethylsulfonyl) Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2,2-difluorocyclopropyl)-3-(ethylsulfonyl) )Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2-methyloxetan Alk-2-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-methyl) Thioetanyl-3-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(1,1-dioxanion) Thietidine 2-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 6-((5-(ethyl Sulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)nicotinonitrile; 2-(3-(ethyl) Sulfonyl)-5-(thietanyl-3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 2-(5 -((1,1-Dioxanethioetanyl-3-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(5-((1,1-dioxanylthietane-3-yl)methyl)-3-(ethylsulfonyl)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 7-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl) -2-(Trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 2-(3-(N-methylethylsulfonylimino)-5-( 3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3- (N-Methylethylsulfonylimido)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl Yl)phthalazine-1(2H)-one; N-(ethyl((oxo)(2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)- 5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-3-yl)-16-sulfinyl)cyanamide; 2-(3-(N-ethyl Ethylsulfonylimino)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-one; 2-(6-bromo-3-(ethylsulfonylimino)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(6-bromo-3-(N-methylethylsulfonylimino)imidazo[1,2-a]pyridin-2-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-one; 1-(3-(ethylsulfonylimino)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2 (1H)-yl)imidazo[1,2-a]pyridin-6-yl)cyclopropane-1-carbonitrile; 3-(ethylsulfonylimino)-2-(1-oxo-7 -(Trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine-6-carbonitrile; 2-(6-(cyclopropylamino)-3-(ethyl Sulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one and N-(5-(ethylsulfonyl)-6-(1-oxo- 7-(Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-2-yl)cyclopropanecarboxamide.

The compounds of the present invention may exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. Those skilled in the art will understand that one stereoisomer can be more active and/or can exhibit beneficial effect. In addition, the skilled person knows how to separate, enrich and/or selectively prepare the stereoisomers. The compound of the present invention may exist in the form of a mixture of stereoisomers, individual stereoisomers, or in an optically active form.

Where the compound of formula (I) is a cation or is capable of forming a cation, the anionic portion of the salt may be inorganic or organic. Alternatively, where the compound of formula I is an anion or is capable of forming an anion, the cationic portion of the salt may be inorganic or organic. Examples of the inorganic anion portion of the salt include, but are not limited to, chloride, bromide, iodide, fluoride, sulfate, phosphate, nitrate, nitrite, bicarbonate, and bisulfate. Examples of the organic anion portion of the salt include (but are not limited to) formate, alkanoate, carbonate, acetate, trifluoroacetate, trichloroacetate, propionate, glycolate, thiocyanate , Lactate, succinate, malate, citrate, benzoate, cinnamate, oxalate, alkyl sulfate, alkyl sulfonate, aryl sulfonate, aryl disulfonate Acid salts, alkyl phosphonates, aryl phosphonates, aryl diphosphonates, p-toluene sulfonate and salicylate. Examples of the inorganic cation portion of the salt include, but are not limited to, alkali metals and alkaline earth metals. Examples of the organic cationic portion of the salt include, but are not limited to, pyridine, methylamine, imidazole, benzimidazole, piperidine, phosphazene, tetramethylammonium, tetrabutylammonium, choline, and trimethylamine.

The most common metal ions in the metal complexes of the compound of formula I are: the ions of the elements of the second main group, especially calcium and magnesium; the third and fourth main groups, especially aluminum, tin and lead; and the first From the first to the eighth transition group, especially chromium, manganese, iron, cobalt, nickel, copper, zinc, etc. It is preferably an element of the fourth period and a metal ion of the first to eighth transition group. Here, metals can exist in various valence states that they can assume.

In another embodiment, the present invention provides compounds of formula I, agriculturally acceptable salts, metal complexes, structural isomers, stereoisomers, diastereomers, enantiomers, hand Isomers, atropisomers, conformational isomers, rotamers, tautomers, optical isomers, polymorphs, geometric isomers or their N-oxides and their excipients Forms, inert carriers, or any other basic ingredients (such as surfactants, additives, solid diluents and liquid diluents).

The compound of formula I (including all its stereoisomers, N-oxides and salts) may generally exist in more than one form. Therefore, Formula I includes all crystalline and non-crystalline forms of the compound represented by Formula I. Amorphous forms include solid (such as wax and glue) embodiments as well as liquid (such as solution and melt) embodiments. The crystalline form includes an embodiment that substantially represents a single crystal form and an embodiment that represents a mixture of polymorphs (ie, different crystal forms). The term "polymorph" is a specific crystalline form-a chemical compound can crystallize in different crystalline forms that have different molecular arrangements and/or structures in the crystal lattice. Although polymorphs can have the same chemical composition, they can also be in composition due to the presence or absence of co-crystal water or other molecules (these co-crystal water or other molecules can be weakly or strongly combined in the crystal lattice). different. There are differences in the chemical, physical and biological properties of crystal forms, such as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspension, dissolution rate, and bioavailability. Those skilled in the art will understand that the polymorphic form of the compound represented by formula I can show beneficial effects relative to another polymorphic form or a mixture of polymorphic forms of the same compound represented by formula I (for example, suitable for preparing useful Formulations, improved biological performance). The preparation and isolation of specific polymorphs of the compound represented by Formula I can be achieved by methods known to those skilled in the art, including, for example, selecting a solvent for crystallization at a suitable temperature.

式（I）In one embodiment, the present invention provides a method of preparing a compound of formula (I) or an agriculturally acceptable salt.

Formula (I)

The compounds of the present invention defined by formula (I) and/or table (I) can be prepared in a known manner according to various methods described in schemes 1-6. The compounds of the present invention can be prepared according to the following scheme, in which unless otherwise specified, the definition of each variable is the same as that made for the compound of formula (I).

According to the features of the present invention, the compound of formula (I) (wherein all the substituents are as defined above) can be given in Scheme-1, Scheme-2, Scheme 3, Scheme-4, Scheme-5 and Scheme-6 or examples. The method of preparation. Representative steps are shown below, but the present disclosure should not be construed as limiting the scope of the manner in which the compound of formula (I) can be obtained in the present invention.

According to Scheme-1, the present invention provides a carboxylic acid derivative of formula (2) (wherein DE ring, G ₁ , G ₂ , G ₃ , G ₄ , R ₁ , R ₂ and n are as defined above, A ₁ is N, A ₂ is CR ^A (where R ^A is hydrogen and Z is oxygen)) A method for preparing the compound of formula (I). L and L'are leaving groups such as halide, sulfonate and sulfonate. Non-limiting examples of leaving groups are fluorine, chlorine, bromine, iodine, methylsulfonyl, tosylate, tosylate, triflate, and the like.

The carboxyl group of the compound of formula (2) can be converted into a more reactive functional group, such as acid chloride, mixed anhydride, acyl azide, N-acyl benzotriazole, active ester, or peptide coupling agent such as N, N'- Dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), bis(2-oxo-3-oxazolidinyl) Phosphinyl chloride (BOP-Cl) is transformed by in-situ activation. Then react with diisopropylamine in a solvent such as dichloromethane, dichloroethane, N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, acetonitrile or their mixtures to obtain the formula ( 3) Compound. Organic non-nucleophilic bases can be used, such as triethylamine, ethyldiisopropylamine, pyridine, N-methylpyrrolidine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The reaction temperature may preferably be in the range of about 0°C to about 150°C.

The compound of formula (3) can be used as a potential carboxylic acid in the ortho-metallation reaction of step 2. N of formula (3) thus obtained, N- diisopropyl-benzamide derivatives can be prepared by -50 ^o C to -78 ^o C in a solvent such as diethyl ether, tetrahydrofuran and the non-nucleophilic hindered dialkyl Lithium amide bases such as lithium diisopropylamide (LDA), lithium 2,2,6,6-tetramethylpiperidine (LiTMP), lithium bis(trimethylsilyl)amide (LTSA) or n-butyl lithium With N,N,N',N'-tetramethylene diamine (TMEDA) for formylation reaction, then use N,N-dimethylformamide, N-methylformanilide, comin reagent Or N-formylpiperidine can be quenched to obtain the compound of formula (4).

The acid-catalyzed cyclization reaction of the compound of formula (4) can be carried out by refluxing in pure hydrochloric acid or a mixture of hydrochloric acid and acetic acid for 10 to 24 hours to obtain the compound of formula (5).

Alternatively, the formula (5) compound may be by about -50 to about -78 ^o C ^o C is performed at a temperature in a halogen solvent such as ether, tetrahydrofuran and the like using an alkyl lithium reagent - metal exchange reaction, followed by an electrophile ( For example, N,N-dimethylformamide, N-methylformanilide, Comin reagent or N-formyl piperidine) are prepared by intramolecular quenching.

The methods generally known in the art can be used, such as the method disclosed in "Synthetic Science" (2004, 16, 315-372), European Patent Application No. 634404, and the hydrazine derivative of formula (7) is used to further treat formula (5). ) Compound to obtain the compound of formula (8). The reaction is usually carried out in a protic solvent such as water, methanol, ethanol, isopropanol, n-butanol, isoamyl alcohol, carboxylic acid (such as acetic acid, formic acid, or propionic acid), a suitable mixture of the above solvents, and a mixture with water (such as aqueous ethanol). ). When the hydrazine of formula (7) is used in the form of a salt (for example, hydrochloride), the reaction can usually be carried out in the presence of a base such as triethylamine, sodium acetate or potassium carbonate. The reaction can be carried out at about 0°C to about 150°C for about 1 to 48 hours. The preparation of the compound of formula (7) has been described in the document WO2018008727.

The compound of formula (8) can be conveniently coupled with boronic acid or the borate compound of formula (9) or the compound of formula (10) under standard Suzuki cross-coupling conditions or Buchwald-Hartwig cross-coupling conditions, respectively, to obtain Compound of formula (I). The Suzuki cross-coupling reaction can be carried out in a suitable solvent (such as tetrahydrofuran, N,N'-dimethylformamide (DMF), 1,2-dimethoxyethane, 1,4-dioxane) or solvent system (For example, mixtures of tetrahydrofuran (THF)/water, 1,2-dimethoxyethane/water, 1,4-dioxane/water, etc.) are passed through a palladium-based catalyst (including but not limited to 1,1'- Bis(diphenylphosphino)ferrocene]dichloropalladium(II) or tetrakis(triphenylphosphine)palladium(0) to catalyze). This reaction is usually carried out in the presence of a base such as potassium carbonate, cesium carbonate, or potassium phosphate. The reaction temperature may preferably be in the range of ambient temperature (20°C) to the boiling point of the reaction mixture. This method of obtaining the compound of formula (I) is described in the literature (for example, "Review of the Chemical Society" 2014, 43, 412-443 or WO2014070978). The Buchwald-Hartwig cross-coupling conditions are well known to those skilled in the art, and many changes have been made in the literature (for example, in "Organic Synthesis" (Elsevier Press, 2005, p. 70) the strategic applications and citations of naming reactions References) have descriptions and have been reviewed and approved. Generally, the reaction is carried out in a solvent or solvent mixture (such as toluene) in the presence of a base (such as cesium carbonate or sodium tert-butoxide) and catalyzed by a palladium-based catalyst (such as palladium acetate). The reaction is preferably carried out in an inert atmosphere. Next, in the presence of a suitable chelating phosphine such as 2,2'-bis(diphenylphosphino)-1,1'-binapthyl (BINAP) or Xantphos. The reaction temperature may preferably be in the range of ambient temperature (20°C) to the boiling point of the reaction mixture in the process of preparing the compound of formula (I).

In one embodiment, the compound of formula (I) can be prepared according to Scheme 2 as described below, wherein the DE ring, G ₁ , G ₂ , G ₃ , G ₄ , R ₁ , R ₂ and n are as defined above, A ₁ is N and A ₂ is CR ^A (wherein R ^A is hydrogen, Z is oxygen). L and L ¹ are leaving groups such as halide, sulfonate and sulfonate. Non-limiting examples of leaving groups are fluorine, chlorine, bromine, iodine, methylsulfonyl, tosylate, tosylate, triflate and the like.

The compound of formula (5) can be treated with hydrazine hydrate to obtain the compound of formula (11) using methods generally known in the art and the method described in step 4 of Scheme 1.

The compound of formula (8) can be prepared in the presence of a suitable base such as organic bases, alkali metal carbonates, alkali metal hydrides, etc., in a suitable solvent (such as ethers, aromatic hydrocarbons, nitriles, aprotic polar solvents and mixtures thereof ) Is prepared by reacting a compound of formula (11) with a compound of formula (12). The reaction can be carried out at a temperature of about 50°C to about 150°C, and the reaction time is about 1 to 48 hours. Suitable metal catalysts and ligands can also be used in this reaction. Suitable metal catalysts may include copper(I) iodide, copper(I) bromide, copper(I) chloride, copper(I) oxide, copper(I) triflate, benzene complex, tetrakis(acetonitrile) ) Copper (I) hexafluorophosphate, copper (I) thiophene-2-carboxylate, etc.; bis(cyclooctadiene) nickel (0), nickel catalysts, such as nickel chloride (II), palladium acetate (II), Tetrakis(triphenylphosphine)palladium(0). Suitable ligands may include triphenylphosphine, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, ferrocene, 2-dicyclohexylphosphino-2', 4',6'-triisopropylbiphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 2-aminoethanol, 8-hydroxyquinoline, 1,10-phenanthrene Pyroline, trans-1,2-cyclohexanediamine, trans-N,N'-dimethylcyclohexane-1,2-diamine and N,N'-dimethylethylenediamine, etc. Preferably, the reaction temperature is from ambient temperature (20°C) to the boiling point of the reaction mixture.

The compound of formula (12) can be synthesized according to the method described in Chinese Journal of Organic Chemistry (68(12), 4918, 2003) or WO 2013/086397.

The compound of formula (8) can be converted to the compound of formula (I) according to the method described in step 5 of general scheme-1.

Scheme 3 describes the preparation of the compound of formula (I), wherein the DE ring, G ₁ , G ₂ , G ₃ , G ₄ , R ₁ , R ₂ and n are as defined above. A ₁ is N and A ₂ is CR ^A, wherein R ^A is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, Z is oxygen. L and L ¹ are leaving groups such as halide, sulfonate and sulfonate. Non-limiting examples of leaving groups are fluorine, chlorine, bromine, iodine, methylsulfonyl, tosylate, tosylate, triflate and the like.

The acyl-substituted phenol compound of formula (13) can be converted into the N-carbonyl hydrazone of formula (14) by reacting with a suitable carbamate in a suitable solvent such as ethanol, methanol, and n-propanol. The reaction temperature is preferably in the range of about 0°C to about 150°C.

Step 2 is by using lead(IV) acetate in solvents such as tetrahydrofuran and 1,4-dioxane or [bis(acetoxy)iodide] in solvents such as dichloromethane or chloroform at 0°C to 25°C The N-carbonyl hydrazone of formula (14) is oxidized with benzene to prepare the diacyl derivative of formula (15).

The method known in the art and the method described in step 4 of Scheme 1 can be used to treat the diacyl derivative of formula (15) with hydrazine hydrate to obtain the compound of formula (11a).

The compound of formula (11a) can be converted into the compound of formula (I) according to the methods described in the second and third steps of Scheme 2.

In another embodiment, the compound of formula (I) of the present invention can be prepared according to the method described in Scheme-4, wherein the rings DE, G ₁ , G ₂ , G ₃ , G ₄ , R ₁ , R ₂ and n as defined above, and A ₂ is N; A ₁ is CR ^A (wherein R ^A is hydrogen, Z is oxygen). L is a leaving group such as halide, sulfonate and sulfonate. Non-limiting examples of leaving groups are fluorine, chlorine, bromine, iodine, methylsulfonyl, tosylate, tosylate, triflate and the like.

The compound of the formula (21) can be prepared from the compound of the formula (16) (wherein R represents a hydrogen atom or a lower alkyl group) and formamide (18) or formamidine (19) and their salts and other formamide equivalents. In one example (wherein R is a hydrogen atom), the reaction can be achieved by combining the compound of formula (16) with a The amides are mixed to obtain the compound of formula (21). In another example (wherein R is an alkyl group), the reaction can be achieved by combining the compound of formula (16) with the solvent at a temperature ranging from 50°C to the boiling point of the solvent in the presence or absence of acid Formamidine acetate is mixed to obtain a compound of formula (21).

The compound of formula (21) can also be prepared by using the compound of formula (17) and the orthoformate of formula (20) (R' represents a lower alkyl group) in the presence or absence of a solvent (such as acetic anhydride). The reaction temperature may preferably be from ambient temperature (20°C) to the boiling point of the reaction mixture.

The compound of formula (I) can be prepared from compound (22) according to the methods described in step 2 and step 3 of Scheme 2.

In one embodiment, the compound of formula (I) can be prepared according to the method described in Scheme-5, wherein DE ring, G ₁ , G ₂ , G ₃ , G ₄ , A ₁ , A ₂ , R ₁ , R ₂ And n are as defined above, and Z is a sulfur atom.

The compound of formula (I) (where Z=S) can be passed through the method described in step 5 of Scheme 1, usually at ^{a temperature of 50 to 160 o} C in a solvent (such as N,N-dimethylformamide or toluene) The compound of formula (23) (Z=O) is reacted with a suitable reagent (such as Lawson's reagent) that can transfer sulfur atoms to obtain the compound of formula (24), which is then further converted into The compound of formula (I) is prepared. Such transformations are well known to those skilled in the art, and are described in "Tetrahedron" (2007, 63, 11862) or US20120309796, for example.

Alternatively, as shown in Scheme 6, the compound of formula (I) can be prepared according to the methods described in steps 2 and 3 of scheme 2, wherein L', A ₁ , A ₂ , G ₁ -G ₄ , Z, R ¹ , R ² and Q are as defined above. Compound 25 can be synthesized according to the method described in Step 1 or Step 1 of Scheme 4 or Step 1 of Scheme 2.

As shown in Scheme 7, the present invention provides a method for preparing a compound of formula (I) by using an anthranilic acid derivative of formula (27), wherein DE ring, G ₁ , G ₂ , G ₃ , G ₄ , R ₁ , R ₂ and n are as defined above, A ₁ is N, A ₂ is N, and Z is oxygen. L is a leaving group. Non-limiting examples of leaving groups are fluorine, chlorine, bromine, iodine, methylsulfonyl, tosylate, tosylate, triflate and the like.

The compound of formula (28) can be used in a suitable aprotic solvent (such as tetrahydrofuran, 1,4-dioxane, dichloromethane, dichloroethane), using reagents such as triphosgene, phosgene, and the corresponding o-aminobenzene Formic acid (27) derivatives were prepared. The compound of formula (29) can be prepared by using an organic base (such as triethylamine, diisopropylethylamine) or an inorganic base (such as potassium tert-butoxide) in a suitable solvent (such as tetrahydrofuran, 1,4-dioxane, etc.) , Sodium tert-butoxide), prepared by treating a compound of formula (28) with an amine of formula (32).

The compound of formula (30) can be prepared from the compound of formula (29) by using a diazotizing reagent (such as sodium nitrite, tert-butyl nitrite) under acidic conditions (such as 6N hydrochloric acid). Then in the temperature range of 0 ℃ to the boiling point of the solvent, in the presence of a suitable inorganic base (such as sodium hydride, potassium carbonate, potassium tert-butoxide, sodium tert-butoxide) in a suitable solvent (such as N,N-dimethyl The compound of formula (30) is reacted with the corresponding alkyl mercaptan in methyl formamide, N,N-dimethylacetamide, tetrahydrofuran, acetonitrile) to obtain the compound of formula (30-a).

The compound of formula (31) can be prepared with the compound of formula 30 or (30-a) according to the method described in "Acta Organic Chemistry" (68(12), 4918, 2003) or WO 2013/086397.

The compound of formula (31) can be converted to the compound of formula (I) according to the method described in step 5 of general scheme-1.

The compound of formula (23) (wherein L is chlorine, bromine or iodine) can be treated with organometallic substances (such as butyl lithium or organomagnesium compounds), and then with borate compound B(X) ₃ (where X is C _1- C ₆ alkyl group) to obtain the compound of formula (33). This reaction is preferably carried out in an anhydrous aprotic solvent such as tetrahydrofuran at -78°C to 25°C. According to the properties of the borate and the subsequent processing conditions, the compound of formula (33) can be separated into boric acid (where BX ₂ is -B(OH) ₂ ) or dialkyl borate.

）。該反應可以在非質子溶劑中，在鹼，優選弱鹼（如乙酸鉀）和催化劑（如[1,1'-雙（二苯基膦基）二茂鐵]二氯鈀（II）或Pd (dppf)Cl₂ ）存在下進行。反應優選在80℃至溶劑沸點的溫度下進行。Alternatively, the pinacol borate functional group can be introduced into the compound of formula (23) (where L is chlorine, bromine, iodine or trifluoromethane) through a palladium catalyzed reaction using bipinacol diborane (B2Pin2) as a reagent. Sulfonate). This reaction produces a cyclic borate compound of formula (33) (where BX ₂ is

). The reaction can be carried out in an aprotic solvent, in a base, preferably a weak base (such as potassium acetate) and a catalyst (such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)) or Pd (dppf)Cl ₂ ) in the presence of. The reaction is preferably carried out at a temperature from 80°C to the boiling point of the solvent.

By treating with an oxidizing agent (preferably hydrogen peroxide or urea complex) in a preferred solvent (such as tetrahydrofuran), the compound of formula (33) can be converted into the compound of formula (34).

Subsequently, in the presence of a base (such as sodium hydride, potassium carbonate or cesium carbonate) in an inert solvent (such as tetrahydrofuran, N,N-dimethylformamide or acetonitrile), the general formula is RX _a (where X _a The compound of formula (34) is treated with an alkylating agent preferably Br, I or triflate) to obtain a compound of general formula (I).

Alternatively, it can be used in the range of 20°C to 120°C in hydroxide salts (such as cesium hydroxide, sodium hydroxide or potassium hydroxide), palladium sources (such as Pd(dba) ₂ ) and phosphine ligands (such as tBu -XPhos (CAS 564483-19-8)) and the compound of formula ROH, in a solvent such as 1,4-dioxane or tetrahydrofuran, the compound of formula (23) is subjected to palladium-catalyzed hydroxylation and converted to formula ( 34) The compound.

According to the method described in Step 5 of Scheme 1, under conventional reaction conditions, using tert-butyl carbamate as the amine ligand, the compound of formula (23) can be subjected to palladium-catalyzed Buchwald-Hartwig cross-coupling to convert it to formula ( 35) The compound. Then follow standard methods under acidic conditions (using hydrochloric acid, trifluoroacetic acid, acetic acid or Lewis acid (such as zinc bromide), tin chloride, etc.); in one or more solvents (such as dichloromethane, tetrahydrofuran, methanol, water, The protected amino group in the compound of formula (35), such as tert-butyl carbamate, is partially deprotected in toluene, 1,4-dioxane or a mixture thereof, to obtain a compound of formula (36).

It can be used in one or more solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran or mixtures thereof with a base (such as cesium carbonate, potassium carbonate, sodium carbonate, etc.) and formula R ^{The 2-} L compound alkylates the compound of formula (35) to obtain the compound of formula (35a). Then, the compound of formula (35a) can be deprotected according to the method described in step 3 of Scheme-9 under standard conditions to obtain the compound of formula (36a).

The compound of formula (36a) can be further alkylated according to the method described in step 2 of Scheme 9 under general reaction conditions to obtain the compound of formula (I).

Finally, it can be used in amide coupling conditions (using carboxylic acid chloride or using peptide coupling agents such as bis(2-oxo-3-oxazolidinyl) phosphinyl chloride, N,N'-dicyclohexylcarbodiimide Amine, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium 3-oxide hexafluorophosphate in-situ activated carboxylic acid), in a solvent such as dichloromethane, dichloroethane, N,N-dimethylformamide, N,N -Dimethylacetamide, tetrahydrofuran, acetonitrile or their mixtures are used in formula (36) or formula (36a) to obtain the compound of formula (I). Organic non-nucleophilic bases (eg triethylamine, ethyldiisopropylamine, pyridine, N-methylpyrrolidine, 1,8-diazabicyclo[5.4.0]undecyl-7-ene) Can be used for this step. The reaction is preferably carried out at a temperature of about 0°C to about 150°C.

The compound of formula (I), its stereoisomers, salts and N-oxides and precursors in the synthesis process can be prepared by the above-mentioned methods. If the individual compounds cannot be prepared by the above-mentioned route, they can be prepared by derivatization of other compounds (I) or corresponding precursors or by conventional changes to the synthetic route. For example, in individual cases, certain compounds of formula (I) can be conveniently derived from other compounds of formula (I) through derivatization reactions (such as ester hydrolysis, amidation, esterification, ether cleavage, olefination, reduction, oxidation, etc.) ) Or through conventional changes to the synthetic route.

The reaction mixture is processed as usual, such as mixing with water, separating the phases, and chromatographic purification of the crude product (if appropriate). Some intermediates and final products are obtained in the form of colorless or slightly brown viscous oils, which need to be purified or volatile components removed under reduced pressure and moderately high temperatures. If the intermediates and final products are obtained in solid form, they can also be purified by recrystallization or digestion.

If a certain compound (I) cannot be obtained through the above-mentioned route, they can be prepared by derivatizing other compounds (I). However, if the synthesis produces a mixture of isomers, separation is usually not necessary, because in some cases, a single isomer can be used during post-treatment or during application (for example, under the action of light, acid or base). ) Mutual transformation. Such transformation can also be carried out after use (for example in treated plants or in harmful fungi to be controlled).

In one embodiment, the present invention provides a composition for controlling or preventing invertebrate pests. The composition contains a biologically effective amount of the compound of formula (I) or its agriculturally acceptable salt, isomer/structural isomer, stereoisomer, diastereomer, enantiomer, mutual Mutants, metal complexes, polymorphs or N-oxides, and at least one other component selected from surfactants and auxiliary agents.

In another embodiment, the composition additionally comprises at least one biological agent selected from the group consisting of suicide fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers or nutrients. .

In another embodiment, the compound of formula (I) or its N-oxides and salts provided by the present invention are conventional agrochemical compositions, such as solutions, emulsions, suspensions, powders, powders, pastes, granules, Compressed preparations, capsules and mixtures thereof. Examples of composition types are suspensions (e.g. SC, OD, FS), emulsifiable concentrates (e.g. EC), emulsions (e.g. EW, EO, ES, ME), capsules (e.g. CS, ZC), pastes, tablets Formulations, wettable powders or powders (such as WP, SP, WS, DP, DS), compressed formulations (such as BR, TB, DT), granules (such as WG, SG, GR, FG, GG, MG), insecticides Products (such as LN), and gel formulations used to treat plant propagation materials such as seeds (such as GF). These and other composition types are defined in "Pesticide Formulation Types and International Coding System" (Technical Monograph No. 2.61h Edition. May 2008. International Crop Life Association).

The composition is prepared in a known manner, and the preparation method is described in, for example, Mollet and Grube mann, "Formulation Technology", Wiley VCH Press, Weinheim, 2001; or Knowles (Knowles ), described in "New Development of Crop Protection Product Formulations" (Agrow Reports DS243, T&F lnforma, London, 2005).

Suitable auxiliary agents include solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetting agents, adjuvants, solubilizers, penetration enhancers, protective colloids, binders, thickeners, and humectants , Insect repellent, attractant, feeding stimulant, compatibilizer, fungicide, anti-freezing agent, defoamer, coloring agent, viscosity increasing agent and adhesive.

Suitable solvents and liquid carriers are water and organic solvents, such as medium to high boiling point mineral oil fractions, such as kerosene, diesel; vegetable oil or animal oil; aliphatic, cyclic and aromatic hydrocarbons, such as toluene, paraffin, tetralin, Alkylated naphthalene; alcohols, such as ethanol, propanol, butanol, benzyl alcohol, cyclohexanol; ethylene glycol; DMSO; ketones, such as cyclohexanone; esters, such as lactic acid, carbonate, fatty acid ester , Γ-butyrolactone; fatty acid; phosphonate; amine; amides, such as N-methylpyrrolidone, fatty acid dimethyl amide; and mixtures thereof.

Suitable solid carriers or fillers include mineral earths, for example, silicate, silica gel, talc, kaolin, limestone, lime, chalk, clay, dolomite, diatomaceous earth, bentonite, calcium sulfate, magnesium sulfate, magnesium oxide; polysaccharides, For example, cellulose, starch; fertilizers, such as ammonium sulfate, ammonium phosphate, ammonium nitrate, urea; products of plant origin, such as grain flour, bark powder, wood flour, nut shell powder and mixtures thereof.

Suitable surfactants are surface-active compounds such as anionic, cationic, nonionic and amphoteric surfactants, block polymers, polyelectrolytes and mixtures thereof. These surfactants can be used as emulsifiers, dispersants, solubilizers, wetting agents, penetration enhancers, protective colloids or adjuvants. Examples of surfactants are listed in McCutcheon, Volume 1: Emulsifiers and Detergents, "McCutcheon's Directories", Gran Rock City, USA, 2008 (International or North American Edition) .

Suitable anionic surfactants are alkali metal, alkaline earth metal or ammonium salts of sulfonates, sulfates, phosphates, carboxylates and mixtures thereof. Examples of sulfonates are alkyl aryl sulfonates, diphenyl sulfonates, α-olefin sulfonates, lignosulfonates, sulfonates of fatty acids and oils, and ethoxylated alkyl phenols. Sulfonate, sulfonate of alkoxylated arylphenol, sulfonate of condensed naphthalene, dodecyl and tridecylbenzene sulfonate, naphthalene sulfonate and alkyl naphthalene, sulfosuccinic acid Salt or sulfosuccinate. Examples of sulfates are the sulfates of fatty acids and oils, ethoxylated alkylphenols, alcohols, ethoxylated alcohols or fatty acid esters. Examples of phosphate esters are phosphate esters. Examples of carboxylates are alkyl carboxylates and carboxylated alcohol or alkylphenol ethoxylates.

Suitable nonionic surfactants are alkoxylates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants, and mixtures thereof. Examples of alkoxylates include 1 to 50 equivalents of alkoxylated alcohols, alkylphenols, amines, amines, arylphenols, fatty acids or fatty acid ester compounds. Ethylene oxide and/or propylene oxide can be used for alkoxylation, preferably ethylene oxide. Examples of N-substituted fatty acid amides are fatty acid glucosamines or fatty acid alkanol amides. Examples of esters are fatty acid esters, glycerides or monoglycerides. Examples of sugar-based surfactants are sorbitan, ethoxylated sorbitan, sucrose and glucose esters or alkyl polyglucosides. Examples of polymeric surfactants are homopolymers or copolymers of vinylpyrrolidone, vinyl alcohol or vinyl acetate.

Suitable cationic surfactants are quaternary ammonium surfactants, such as quaternary ammonium compounds having one or two hydrophobic groups, or salts of long-chain primary amines. Suitable amphoteric surfactants are alkyl betaine and imidazoline. Suitable block polymers include AB or ABA type block polymers containing polyethylene oxide and polypropylene oxide blocks, or ABC type block polymers containing alkanol, polyethylene oxide and polypropylene oxide. Segment polymer. Suitable polyelectrolytes are polyacids or polyols. Examples of polyacids are alkali salts of polyacrylic acid or polyacid comb polymers. Examples of polybases are polyvinylamine or polyvinylamine.

Suitable adjuvants are compounds that have little insecticidal activity by themselves and can improve the biological properties of the compound of formula (I) on the target. Examples are surfactants, mineral or vegetable oils and other additives. Other examples are listed in Knowles' "Adjuvants and Additives" (Agrow report DS256, T&F lnforma UK, 2006, Chapter 5).

Suitable thickeners are polysaccharides (such as xanthan gum, carboxymethyl cellulose), inorganic clays (organically modified or unmodified), polycarboxylates and silicates. Suitable bactericides are bronopol and isothiazolinone derivatives, such as alkyl isothiazolinones and benzisothiazolinones. Suitable antifreeze agents are ethylene glycol, propylene glycol, urea and glycerin. Suitable defoamers are silicones, long-chain alcohols and fatty acid salts. Suitable coloring agents (such as red, blue or green) are low water-soluble pigments and water-soluble dyes. Examples are inorganic colorants (such as iron oxide, titanium oxide, iron hexacyanoferrate) and organic colorants (such as alizarin-, azo- and phthalocyanine colorants). Suitable tackifiers or binders are polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol, polyacrylates, biological or synthetic waxes and cellulose ethers.

Examples of composition types and their preparation are: i) Water-soluble concentrates (SL, LS) The compound of formula (I) with a weight ratio of 10-60% and a wetting agent (such as alcohol alkoxylate) with a weight ratio of 5-15% are dissolved in water and/or a water-soluble solvent with a weight ratio of 100% ( For example, alcohol). The active substance dissolves when diluted with water. ii) Dispersible concentrate (DC) The compound of formula (I) with a weight ratio of 5-25% and a dispersant (such as polyvinylpyrrolidone) with a weight ratio of 1-10% are dissolved in an organic solvent (such as cyclohexanone) with a weight ratio of 100%. Dilution with water gives a dispersible concentrate. iii) Emulsifiable concentrate (EC) The compound of formula (I) with a weight ratio of 15-70% and an emulsifier (such as calcium dodecylbenzene sulfonate and castor oil ethoxylate) with a weight ratio of 5-10% are dissolved in a weight ratio of 100% In water-insoluble organic solvents (such as aromatic hydrocarbon carbon). Dilution with water gives an emulsion. iv) Emulsion (EW, EO, ES) The compound of formula (I) with a weight ratio of 5-40% and an emulsifier (such as calcium dodecylbenzene sulfonate and castor oil ethoxylate) with a weight ratio of 1-10% are dissolved in a weight ratio of 20- 40% in water-insoluble organic solvents (such as aromatic hydrocarbons). The mixture is dissolved in water with a weight ratio of 100% by an emulsifier to prepare a homogeneous emulsion. Dilution with water gives an emulsion. v) Suspension (SC, OD, FS) In a stirred ball mill, pulverize the compound of formula (I) with a weight ratio of 20-60%, and add a dispersant and a wetting agent (such as sodium lignosulfonate and alcohol ethoxylate) with a weight ratio of 2-10%. , A thickener (for example, xanthan gum) with a weight ratio of 0.1-2% and water with a weight ratio of 100% to obtain a fine active substance suspension. Dilution with water gives a stable suspension of the active substance. For FS-type compositions, a binder (such as polyvinyl alcohol) is added up to 40% by weight. vi) Water-dispersible particles and water-soluble particles (WG, SG) Crush the compound of formula (I) with a weight ratio of 50-80%, add a dispersant and a wetting agent (such as sodium lignosulfonate and alcohol ethoxylate) with a weight ratio of 100%, and pass technical tools (such as Extrusion, spray tower, fluidized bed) are prepared as water-dispersible or water-soluble particles. Dilution with water can obtain a stable dispersion or solution with active substances. vii) Water-dispersible powder and water-soluble powder (WP, SP, WS) Grind the compound of formula (I) with a weight ratio of 50-80% in a rotor-stator mill and add a dispersant (such as sodium lignosulfonate) with a weight ratio of 1-5% at a weight ratio of 1-3% The wetting agent (such as alcohol ethoxylate) and the weight ratio of 100% solid carrier (such as silicone). Dilution with water gives a stable dispersion or solution with active substance. viii) Gel (GW, GF) In a stirred ball mill, crush the compound of formula (I) with a weight ratio of 5-25%, add a dispersant (such as sodium lignosulfonate) with a weight ratio of 3-10%, and a thickener with a weight ratio of 1-5% (Such as carboxymethyl cellulose) and 100% water by weight to obtain a fine suspension of active substance. Dilution with water gives a stable suspension of active substance. ix) Microemulsion (ME) Add the compound of formula (I) with a weight ratio of 5-20% to an organic solvent mixture (such as fatty acid dimethylamide and cyclohexanone) with a weight ratio of 5-30%, and the surface with a weight ratio of 10-25% Mixtures of active agents (such as alcohol ethoxylates and arylphenol ethoxylates), and 100% water by weight. The mixture was stirred for 1 hour, and a thermodynamically stable microemulsion was spontaneously produced. x) Microcapsule (CS) It contains 5-50% by weight of the compound of formula (I), 0-40% by weight of water-insoluble organic solvents (such as aromatic hydrocarbons), and 2-15% by weight of acrylic monomers (such as methacrylic acid). The oil phase of methyl ester, methacrylic acid and di- or triacrylate) is dispersed in an aqueous solution of protective colloid (such as polyvinyl alcohol). Free radical polymerization forms poly(meth)acrylate microcapsules. Alternatively, the compound of formula (I) according to the present invention in a weight ratio of 5-50%, a water-insoluble organic solvent (such as aromatic hydrocarbon) and an isocyanate monomer (such as diphenylmethane) in a weight ratio of 0-40% The oil phase of 4,4'-diisocyanate is dispersed in an aqueous solution of protective colloid (such as polyvinyl alcohol). Polyamines (such as hexamethylphenylenediamine) are added to form polyurea microcapsules. The amount of monomer accounts for 1-10% by weight. The wt% is the percentage of the total weight of the microcapsule composition. xi) Dustable powder (DP, DS) The compound of formula (I) with a weight ratio of 1-10% is finely ground and mixed with a solid carrier (for example, finely divided kaolin) with a weight ratio of 100%. xii) Granules (GR, FG) The compound of formula (I) in a weight ratio of 0.5-30% is finely ground and mixed with a solid carrier (such as silicate) in a weight ratio of 100%. Granulation is achieved through extrusion processing, spray drying or fluidized bed. xiii) Ultra low volume liquid (UL) The compound of formula (I) with a weight ratio of 1-50% is dissolved in an organic solvent (for example, aromatic hydrocarbon) with a weight ratio of 100%. The compositions of i) to xiii) may optionally contain other adjuvants, such as a biocide at a weight ratio of 0.1-1%, an antifreeze at a weight ratio of 5-15%, and a defoamer at a weight ratio of 0.1-1% The weight ratio of agent to coloring agent is 0.1-1%.

In another embodiment of the present invention, there is provided an agrochemical composition of formula (I), which comprises 0.01 to 95% by weight, preferably 0.1 to 90%, more preferably 1 to 70%, especially 10% Up to 60% of active substances. And 60% by weight of active substance. The use purity of the active material is 90% to 100%, preferably 95% to 100% (according to the NMR spectrum).

When processing plant propagation materials (especially seeds), seed treatment solutions (LS), suspension emulsions (SE), flowable concentrates (FS), dry treatment powders (DS), and water dispersible powders for slurry treatment (WS) are often used Water-soluble powders (SS), emulsions (ES), emulsifiable concentrates (EC) and gels (GF) are commonly used. After a two to ten-fold dilution, the composition produces an active substance concentration in a ready-to-use formulation of 0.01 to 60% by weight, preferably 0.1 to 40%. Application can be carried out before or during sowing.

The methods for applying the compound of formula (I) and the composition thereof to plant propagation materials (especially seeds) include dressing, coating, granulation, dusting and soaking, and furrow application methods. Preferably, the compound of formula (I) or its composition is applied to the plant propagation material by methods that do not induce germination, such as seed dressing, granulation, coating, and dusting.

When used for plant protection, the amount of active substance applied is 0.001 to 2 kg per hectare, preferably 0.005 to 2 kg per hectare, more preferably 0.05 to 0.9 kg per hectare (especially 0.1 to 0.75 kg per hectare, depending on the desired effect). kilogram).

When treating plant propagation materials such as seeds, for example, by dusting, coating or soaking seeds, the amount of active substance is 0.1 to 1000 g, preferably 1 to 500 g, per 100 kg of plant propagation material (usually preferably seeds), and more It is preferably 1 to 100 grams, most preferably 5 to 100 grams.

When used for the protection of materials or storage, the amount of active substance applied depends on the type of application and the desired effect. The amount usually used to protect the material is 0.001 g to 2 kg, preferably 0.005 g to 1 kg of active substance per cubic meter of treated material.

Various types of oils, wetting agents, adjuvants, fertilizers or micronutrients and other pesticides (such as herbicides, insecticides, fungicides, growth regulators, safeners, biological insecticides) can be added to the active substance or Include them in the composition as a premix or, if appropriate, add before use (can mix). These agents can be mixed in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:1 according to the composition of the present invention.

Various types of oils, wetting agents, adjuvants, fertilizers or micronutrients and other pesticides (such as herbicides, insecticides, fungicides, growth regulators, safeners, biological insecticides) can be added to the active substance or Include them in the composition as a premix or, if appropriate, add before use (can mix). These agents can be mixed in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:1 according to the composition of the present invention.

In one embodiment, the individual components of the composition according to the present invention, such as part of the reagent or part of the binary or ternary mixture, can be stored by the user in a spray tank or any other kind of container for application (such as a seed processor drum). , Seed granulation machinery, knapsack sprayer), and can choose to add other auxiliary agents.

Therefore, the compounds and compositions of the present invention can be used to protect field crops from phytophagous invertebrate pests in agriculture, and can be used to protect other horticultural crops and plants from phytophagous invertebrates in non-agriculture. Infestation by pests. This utility includes the protection of crops and other plants (ie, agronomic and non-agronomic) that contain genetic material introduced through genetic engineering (ie, transgene) or modified by mutagenesis to provide beneficial traits.

The compounds of the present invention have favorable metabolic and/or soil residue patterns, and exhibit the activity of controlling a series of agronomic and non-agronomic invertebrate pests. The compounds of the present invention are valuable preventive and/or therapeutic active ingredients in the field of pest control (even if the application rate is low), and can be used to target insecticide-resistant pests such as insects and mites. In addition, warm-blooded animals, fish and plants can tolerate them well.

In the context of the present invention, "invertebrate pest control" refers to inhibiting the growth (including death) of invertebrate pests, significantly reducing their eating or other damage or destruction caused by them. In the present invention, the term "invertebrate pests" includes arthropods, gastropods, and nematodes that are economically important as pests. The term "arthropod" includes insects, mites, spiders, scorpions, centipedes, millipedes, coccidioides, and syngas.

The term "gastropod" includes snails, slugs, and other columnar gastropods. The term "nematode" includes all worms, such as roundworms, heartworms and phytophagous nematodes, flukes, acanthocephalans and tapeworms. Those skilled in the art will recognize that not all compounds are equally effective against all pests.

The compounds of the present invention show activity against pests of economically important agronomy, forests, greenhouses, nurseries, ornamental plants, food and fiber, public and animal health, household and commercial structures, households and stored products. These include lepidopteran larvae, such as armyworms in the Noctuidae family, cutworms, bentworms (such as autumn armyworm), beet armyworm, black armyworm, cabbage, tobacco armyworm; borers from the family Pyrididae, sheath moths, Netting caterpillars, cone nematodes, leaf rollers, leaf worms (such as European corn borer, orange borer, corn root earthworms, turf earthworms; leafhoppers, tobacco caterpillars, seed worms and fruit worms ( Such as codling moth), grape berry moth, oriental fruit moth; and many other economically important lepidopteran insects (such as diamondback moth, pink bollworm, gypsy moth); cockroach nymphs and adults include cockroaches (such as oriental cockroach) , Asian cockroaches, German cockroaches, brown cockroaches, American cockroaches, brown cockroaches, Madeira cockroaches); leaf sheath larvae and coleoptera adult insects include weevil (such as cotton boll Weevil, rice weevil, granary weevil, rice weevil); flea beetle, cucumber beetle, root beetle, leaf beetle, potato beetle and Liriomyza in crustaceans (e.g. Colorado potato beetle, western corn root Beetles); beetles and other beetles from the family Scarabidae (e.g. Japanese beetles and European beetles); carpet beetles from the Dermatodidae; golden needle beetles from the Clickworm family; bark beetles from the Beetles family and from the Pedidae The flour beetle. In addition, it also includes: Dermatoptera adults and larvae, including ground centipedes from the Glycidae family (e.g. European coccinea, black earwig); Hemiptera and Homoptera adults and nymphs, such as Miliidae Plant insects from the family Cicadaceae, leafhoppers from the Cicada family, Rice planthoppers from the Cicada family and Planthopper family, Grasshoppers from the Cicada family, Psyllids from the Psyllidae family, and Whitefly family Whiteflies, aphids from Aphididae, Phylloxera from Phylloxera, mealybugs from Mealcoccidae, scales from Coccidae, Scutellaidae and Coccididae, lace insects from Dictyidae family, from Stink bugs from the family Pyrididae, flatworms and other seed insects from the Pyrididae family, squash insects from the Mycoididae family, pumpkin insects from the Pyrididae family, red bed bugs and dirty cotton worms from the Rhododidae family. Also included are ticks. Adults and larvae of mites (mites), such as spider mites and red mites of the Tetranychus family. (e.g. European red mites, two-spotted spider mites, McDaniel mites, and flat mites of the family Tetranychus (such as citrus mites) )), rust disease and bud mites in the mites family, and other spider mites and mites that have important effects on human and animal health, namely dust mites of the epidermidaceae, egg mites of the ecdysidae, and grain mites of the mites , Ticks arranged in the order of the Ixodes family, such as the deer tick (Ixodes scapularis), the Australian paralysis tick (Ixodes scapularis), the American dog tick (Dermots variabilis), the lone star tick (American soft tick), and the scabies mite Scabies and mites of the family, Scabidae and Scabidae; Adult and immature species of Orthoptera, including locusts, locusts and crickets, such as migratory grasshoppers (such as Schistosoma black bass), American grasshoppers (such as Schistosoma americana), Desert locusts, migratory locusts, house crickets, moles; Diptera adults and larvae, including leaf flies, midges, fruit flies, glass flies, soil maggots, house flies (e.g. house flies, small house flies (e.g. ), stable flies (such as stinging flies), face flies, horned flies, blow flies and other muscle-like flies pests, horse flies (such as worms), bovine grubs, deer flies, and axolotl (such as the genus Sheep Stinging Flies) And other Brachycercaria, mosquitoes (such as Aedes, Anopheles, Culex), black flies (such as Axolotl, Axolotl), biting mosquitoes, sand flies, scissors insects and other nematodes; Adults of the Thysanidae And larvae, including onion thrips and other foliar thrips; Hymenoptera pests include ants (such as red carpenter ants, black carpenter ants, pharaoh ants, small fire ants, fire ants, red imported fire ants, Argentine ants, crazy Ants, road ants, cornfield ants, smell ants), bees (including carpenter bees), wasps, yellow jackets and wasps; isoptera insect pests, including eastern subterranean termites, western subterranean termites, Taiwan subterranean termites, and West Indian dry wood Termites and other economically important termites; Thysanidae pests such as whitebait and silverfish; Trichophagous pests, including head lice, body lice, chicken body lice, dog bite lice, hairy lice, sheep body lice, and short Nose bull lice, proboscis bull lice, and other sucking and chewing parasitic lice that attack humans and animals; Phleadian insect pests include Eastern rat fleas, cat fleas, dog fleas, hen fleas, sticky fleas, human fleas and other tormenting mammals And bird fleas. Other covered arthropod pests include: arachnid spiders, such as brown recluse spiders and black widow spiders, and scorpid centipedes, such as house centipedes. The activity also includes members of the classes Nematodes, Cephalopods, Flukes, and Acanthocephalus, including economically important members of Strongyloides, Ascarididae, Acerococcus, Microcephalus, Trichocera, and Sclerotium, such as but not Limited to economically important agricultural pests (such as root-knot nematodes in the genus Root-knot nematodes, spot nematodes in the genus Brachytematia, and short root-knot nematodes in the genus Trichoderma, etc.) and animal and human health pests (that is, all economically Important trematodes, tapeworms and roundworms, such as strong linear worms in horses, Toxoplasma canis in dogs, Haematocodon contortus in sheep, Heartworms in dogs, Gymnocephalum in horses, ruminants Fasciola hepatica and so on.

The compounds of the present invention show particularly high activity against lepidopteran pests. These pests include cotton leaf moth (cotton leaf insect), fruit tree yellow roller moth (fruit leaf roller), European leaf roller moth and other yellow leaf moths, two Chinese rice borer (rice stem borer), rice leaf roller (rice stem borer), corn root grass borer, blue grass earthworm, codling moth, spiny cotton bollworm, spotted cotton bollworm, American cotton bollworm, corn earworm, tobacco armyworm , Turf earthworm, grape berry moth, pink bollworm, citrus, big white butterfly, small white butterfly, diamondback moth, beet armyworm, prodenia litura (tobacco armyworm, tufted caterpillar), autumn armyworm, cabbage armyworm and Tomato leaf miner.

The compounds of the present invention also have commercially significant activities against members of the order Homoptera. These include pea aphids, cowpea aphids, black bean aphids, cotton aphids, melon aphids, apple aphids, spiraea aphids, caterpillar yellow aphids, strawberry aphids, Russian wheat aphids, rose apple aphids, wool apple aphids, peach aphids, grain aphids, potato aphids, green peach aphids, green peach aphids, lettuce aphids, phylloxera and gall aphids, corn leaf aphids, bird cherry oat aphids, green Aphid, Piper aphid, Alfalfa aphid, tea aphid, black citrus aphid) and brown citrus aphid; Aphid genus; Phylloxera; American walnut phylloxera; Whitefly (Whitefly, Sweet potato whitefly), crop-like Silver leaf whitefly (silver leaf whitefly), citrus whitefly and greenhouse whitefly; potato leafhopper, smaller brown planthopper, aster leafhopper, green leafhopper, rice leafhopper, brown planthopper, corn planthopper, white back Planthoppers, rice planthoppers, white apple leafhoppers, grape leafhoppers; clustered cicadas; wheatgrass (cotton pad scale), chlorpyrifos (San Jose scale); citrus phytophthora (citrus whitefly); false Coccus (other whitefly complexes); Gibberella (pear psyllids), persimmon psyllids.

These compounds are also active against members of the order Hemiptera, which include green bugs, pumpkin bugs, long bug nymphs, cotton edge bugs, tomato bugs, cotton worms, eucalyptus brown bugs (brown bugs), eucalyptus brown spotted liriomycetes (single Spot bugs), Staphylococcus (seed insect complex), Pine seed insects, Liriomyza eucalyptus, color-changing plant insects, Nezha virus Linnaeus (southern green bug), American beetles (rice bug), Large milkweed insects, cotton fleas.

Other insect orders that can be controlled by the compounds of the present invention include Thysanoptera (e.g., Western flower thrips, citrus thrips, soybean thistle, and onion thrips; and Coleoptera (e.g., Colorado potato beetle, Mexican bean beetle and belonging to the golden needle insect , Or nematodes of the genus Fluke).

In particular, the compounds of formula (I), their N-oxides, their isomers, their polymorphs and their salts are particularly suitable for effectively fighting against the following pests: Insects from the Lepidoptera (Lepidoptera), For example, small cutworm, yellow cutworm, cotton leaf moth, Lidou armyworm, silver moth of the silver moth family, silver moth, pine looper, fir leaf roller, tobacco moth, winter foot moth, two-spotted borer , Spruce leaf roller moth, Fir-colored roller moth, Mythimna separata, Codling moth, European pine caterpillar, Cucumber silk borer, Southwestern corn borer, cotton spotted moth, Emerald spodoptera, South American corn seedling moth, Grape and apple leaf roller moth, spotted armyworm, wax moth, small leaf roller moth, pear coreworm, cotton bollworm, cotton bollworm, corn earworm, cabbage borer, American white moth, apple nest moth, tomato stem wheat Moth, Hemlock Geometrid, Beet Armyworm, Coffee Leaf Miner, Swirl Leaf Miner, Golden Leaf Miner, Grape Moth, Grass Borer, Yellow Spot Borer, Gypsy Moth, Hooded Crane, Peach Leaf Miner, Running Dog Moth, Cabbage Noctuidae, Pseudosciaena chinensis, European corn borer, Spodoptera exigua, Cotton red bollworm, Spodoptera exigua, Cyclopus spp, potato tuber moth, Citrus leaf miner, Pieris rapae, Alfalfa green armyworm, Plutella xylostella , Soybean Spodoptera, Pinus sylvestris, Chilo suppressalis, Scrotal Flea, Wheat Moth, Grape Spodoptera, Spodoptera frugiperda, Spodoptera litura, Spodoptera exigua, Beet Armyworm, Pine Row Moth, Quercus Green roll moth, Fennel armyworm, and Canadian goldenrod small roll moth; and beetles (Coleoptera), such as pear chitin, straight click beetle, dark click beetle, June beetle, fennel, cotton boll weevil, apple Flower elephant, Syrphididae, Brassica oleracea, Toxicola vulgaris, Broad bean weevil, Pea weevil, European lentil weevil, Pear leaf weevil, Beet tortoise shell, Phaseolus vulgaris, Golden beetle, Cabbage seed turtle weevil, cabbage seed turtle weevil, beet shin beetle, tobacco golden needle beetle, cypress mudworm, longhorn leaf beetle, leaf beetle, cucumber beetle, South American leaf beetle, corn root beetle, Mexican bean scoop Insects, tobacco jump beetles, elephant variants, pine weevil, leaf weevil, leaf weevil, spruce bark beetle, lema hawkmoth, black horned mud beetle, potato beetle, beet knock beetle, rice water weevil, canola beetle , Gill beetle, big chestnut beetle, rice minus worm, black grape ear weevil, leaf weevil, rape gold-headed beetle, leaf-eating beetle, garden beetle beetle, light-footed beetle, yellow striped beetle Aegilops, Japanese beetle, and valley weevil; flies, mosquitoes (Diptera), such as Aedes aegypti, Aedes albopictus, Aedes albopictus, An. flies, Anopheles quinquefolius, Anopheles catharticus, White devil Anopheles, Anopheles gambiae, Anopheles panbos, Anopheles albopictus, Anopheles minor, Anopheles tetragonata, Blow-headed blowfly, Mediterranean fruit fly, Golden maggot, Anopheles ancient human, Anopheles maculatus, Anopheles platypus, Silica beetle, Anopheles atlanticus, Triatomine anthropophagus, Sorghum gall midge, Human skin fly, Culex pilaris, Culex pipiens pipiens, Culex pipiens rubrum, Culex quinquefasciatus, Culex tarsalis, Culex purple, Black tail Cymbidium, cucurbita, olive fruit fly, rape leaf gall midge, onion fly, wheat field fly, gray ground fly, cabbage field fly, human skin fly, summer toilet fly, geometrid, gastrointestinal fly , Tsetse fly, Glossy fly, Tsetse fly, Tsetse genus, Parasitic tsetse fly, Western horned fly, Liriomyza, Species, Glossy flies, Liriomyza todii, Liriomyza sativae, Liriomyza trilobata, Lucilia brasiliensis, Lucilia sericata, Lucilia sericata, Manglietia, Hessian gall midge, Autumn housefly, Housefly, Rot fly, Oestrus , Gramineae, Swedish wheat stalk fly, Hydrangea sylvatica, Rot fly, Turnip fly, Grass species fly, Silver-footed sandfly, Colombian scale mosquito, Carrot stalk fly, Scale mosquito, Protosimum, Cherry ring Real rope, apple fruit fly, red-tailed Sarcophaga, Sarcophaga, Gadfly, Sting Fly, Gadfly, North American Black Fly, Horse Fly, Gadfly, Crane, and Swamp Crane; Termite (Isoptera), For example, heterotermites, North American white ants, Southern white ants, Southern European reticulated white ants, Santer white ants, Taiwanese white ants; cockroaches (Blatidae), such as German cockroaches, Asian cockroaches, American cockroaches, Japanese cockroaches, Brown cockroach, black-breasted cockroach, Australian cockroach, and oriental cockroach; ants, bees, wasps, leaf bees (Hymenoptera) such as cabbage bees, tropical leaf-cutting ants, big-headed leaf-cutting ants, leaf-cutting ants , Texas leaf-cutting ants, ant, black ants, yellow house ants, fire ants, red fire ants, black fire ants, red harvest ants, harvester ants, big-headed ants, tasmania, bumblebees, Yellow spotted wasp, Pennsylvanian cockroach, yellow-side wasp, long-legged wasp, Florida ant, and Argentine ant; crickets, grasshoppers, locusts (Orthoptera), such as house cricket, European mole cricket, Oriental migratory locust, double Grasshopper, red-footed black locust, Mexican black locust, blood black locust, Rocky mountain locust, red-winged locust, American desert locust, desert locust, Moroccan halodendron, Gard locust, Indian locust, Italian locust , Australian plague, and brown migratory locust; Arachnid, such as black widow spiders and human arachnid spiders; Fleas (Sylla), such as cat ctenops, dog fleas, squirrel fleas, itchy fleas, skin diving Fleas, and disease-bearing fleas, silverfish (Thysanoptera), such as small fish, centipedes (centipedes), such as feeding ants, polypods (Dipoda), such as earwigs (Dermoptera) ), for example, centipede, lice (Coleoptera), such as human head lice, human lice, human pubic lice, bovine blood wind, blood lice, bovine jaw lice, cattle feather lice and buffalo blind lice; Collembola ), such as the genus Acanthopanax.

They are also suitable for controlling nematodes: plant parasitic nematodes such as root knot nematode, northern root knot nematode, southern root knot nematode, Java root knot nematode and other root knot nematodes; cyst forming nematode, potato golden nematode and other nematode species; oat spores Cyst nematode, soybean cyst nematode, sugar beet cyst nematode, clover cyst nematode, and other heteroderma Spiny nematode species; Bursaphelenchus xylophilus, Bursaphelenchus xylophilus, and other pine wood nematodes; Ring nematodes, Ringworm species, Microcircle nematode species, Rotifer species, Central ring nematode species; Stem and bulb nematodes, Ditylenchus sweetpotato, scale Ditylenchus corms and other Ditylenchus species; Trypanosoma, Trypanosoma species; Helix nematode, Banana spiral nematode, and other Helix nematode species; Sheath and sheath nematodes, Coleoptile nematode species and Hemicyclic nematode species; Hypotomyza species; Spear Nematodes, Spike nematodes; Pseudoroot nematode, Pearl nematode species; Needle nematodes, Elongated long needle nematodes, and other long needle nematode species; Spotted nematodes, Unselected short needle nematodes, Punctured short needle nematodes, bent needle nematodes, short needle nematodes, and other short needle nematodes Nematode species; burrowing nematode, banana perforation nematode, and other perforating nematode species; kidney-shaped nematodes, spiral nematodes and spiral nematode species; Scutellaria species; Scutellaria species; Scutellaria spp., Trichocarhinia cartilaginous and other Trichodonta species, and prickly-like species Dwarf nematodes, Clayton dwarf nematodes, reciprocal dwarf nematodes and other dwarf nematode species; Citrus nematodes, piercing nematode species; Dagger nematodes, sword nematode species; and other plant parasitic nematode species.

The compounds of formula (I) and their salts can also be used to control arachnids (Arachnida), such as mites (Acarina), such as cryptorhynchus, Ixodes and scabies species, such as American flower tick, Acarina Eye tick, Persian sharp tick, ringed cattle tick, micro tick, Dermatophaga forest, Hyalopsis longiborus, Ixodes vulgaris, Ixodes light red tick, Ornithodoros africa, and wall worms, Spiny dermatoglyphus, sheep Itch mites, additional Rhipicephalus ticks, Rhizophora valgus, scabies, and mites of the family mites, such as apple spiny rust mites, citrus rust mites and citrus gall mites; Tarsus mites, such as polyphagous tarsus mites; Tetranychus family, such as purplish red short hair mites; Tetranychus family, such as cinnabarinus spider mite, Kanzawa's spider mite, Pacific spider mite, cotton spider mite and two-spotted spider mite, apple panonychus mite, panonychus mites and grass mites Claw mite.

In another embodiment of the present invention, the compound of formula (I) can be used to control insects selected from sucking or piercing insects, for example from Thysanoptera, Diptera and Hemiptera, especially the following species: Thysanoptera: Blattella fuschia, Blattella occipitalis, Blattella nigra, Lemon yellow thrips, Rice blast thrips, Palm thrips and thrips; Diptera: For example, Aedes aegypti, Aedes albopictus, Aedes albopictus, Anopheles quinquefolius, Anopheles vulgaris, Anopheles albopictus, Anopheles gambiae, Anopheles panax, Anopheles leucocephalus, small Anopheles, Anopheles tetragonus, Blowfly, Mediterranean fruit fly, Anopheles maggot, Anopheles ancient, Anopheles maculatus, Chafer, Anopheles siella, Anopheles anthropophagus, Anopheles anthropophagus, Sorghum gall midge, human Skin flies, Culex pipiens, Culex pipiens, Culex black-bearded, Culex pipiens fatigue, Culex tarsalis, Culex purple, black-tailed mosquito, fruit fly, olive fruit fly, rape leaf gall midge, green onion Flies, wheat field flies, gray field flies, cabbage field flies, human skin skin flies, summer toilet flies, geometridae, gastrointestinal flies, tsetse flies, tsetse flies, tsetse flies, parasitic tsetse flies , Western horn fly, Liriomyza, Species, Liriomyza, Liriomyza todii, Liriomyza sativae, Liriomyza triloba, Lucilia brazilian, Lucilia sericata, Lucilia sericata, Manna, Hessian Gall Mosquitoes, autumn house flies, house flies, rotting flies, oestrus, gramineus, swedish wheat stalk flies, hydrangea springni, rotting flies, turnip flies, grass species, silver-footed sandflies, Colombian scales Mosquitoes, carrot stalk flies, scale mosquitoes, original gnats, cherry stalks, apple fruit flies, red-tailed Sarcophaga, Sarcophaga, gnats, stinging flies, gadfly, North American black horsefly, horsefly, and horsefly, large Mosquitoes and marsh crane mosquitoes; Hemiptera, especially aphids: aphid, larch aphid, natto aphid, broad bean aphid, fujian aphid, apple aphid, cotton aphid, sphaeranthus vulgaris, carex aphid, leaf roller tooth, pipe pea aphid , Aphid spp., Aphid spp., Aphid plum, Aphid prunus, Brachyura aphid, Aphid locust, Aphid aphid, Aphid aphid, Aphid spp, Aphid spp, Spondylococcal tooth, cloud Cunninghamia lanceolata, round-tailed aphid, plantain aphid, potato green leafhopper, big-tailed ivory, hyperurophis, tube aphid, potato tube aphid, tube worm tooth, vetch aphid, color aphid, wheat Aphids without nets, Aphids on winter onion, Aphids, Aphids, Nilaparvata lugens, Lean worm teeth, Sugarcane planthoppers, Aphids, Apple psyllids, Psylla pears , Corn Aphid, Rice Wheat Aphid, Round Tail Aphid, Wheat Aphid, Schizophyllum, Pipe Aphid, Greenhouse Whitefly, Citrus Aphid and Grape Phylloxera.

In one embodiment, the present invention provides a compound comprising a biologically effective amount of formula (I) and at least one additional selected suicide fungicide, insecticide, nematicide, acaricide, bioinsecticide, herbicide, plant Growth regulators, antibiotics, fungicides, insecticides, nematicides, acaricides, bioinsecticides, herbicides, plant growth regulators, antibiotics, fertilizers and nutrients reported in WO2016156129 and WO2017153200 and at least one of these substances Inventive combinations of compounds of formula (I) should be included herein as non-limiting examples. A combination of fertilizers and nutrients with bioactive compatible compounds. The compound used in the composition and the compound combined with the compound of formula (I) are also referred to as active compatible compounds.

Known and reported fungicides, insecticides, nematicides, acaricides, bioinsecticides, herbicides, plant growth regulators, antibiotics and nutrients can be combined with at least one compound of formula (I) of the present disclosure combination. For example, the fungicides, insecticides, nematicides, acaricides, bioinsecticides, herbicides, plant growth regulators, antibiotics, fertilizers, and nutrients disclosed and reported in WO2016156129 and WO2017153200 can be combined with at least one of the present disclosure. A combination of compounds of formula (I).

In particular, the compound of the present invention can be mixed with at least one other biologically active compatible compound to form a multi-component pesticide, providing a wider range of agricultural applications. The compounds include, but are not limited to, insecticides, fungicides, nematicides, fungicides, acaricides, growth regulators such as rooting stimulants, chemical sterilization agents, chemical information elements, repellents, attractants, information Vegetarian, feeding stimulants, other biologically active compounds or insect pathogenic bacteria, viruses or fungi.

WO2019072906A1 (pages 27 to 37) discloses examples of such biologically active compounds or reagents/formulations that can be combined/formulated with the compound of formula (I) of the present invention.

In one embodiment, the biological agents used for mixing with the compounds of the present invention include Bacillus thuringiensis, Bacillus thuringiensis delta endotoxin, and naturally-occurring and genetically modified viral insecticides, including members of the baculoviridae family and insect fungi .

In some cases, the combination with other invertebrate pest control compounds or agents with similar control profiles but different modes of action is particularly beneficial for resistance management. Therefore, the composition of the present invention may further comprise at least one additional biologically effective amount of an invertebrate pest control compound or an agent having a similar control spectrum but a different mode of action. Contacting plants or plant sites genetically modified with a biologically effective amount of the compounds of the present invention to express plant protection compounds (for example, proteins) can also provide a broader spectrum of plant protection and facilitate resistance management.

In one embodiment of the present invention, the biologically effective amount of the compound of formula (I) in the composition is 0.1% to 99%, preferably 5% to 50% of the total weight of the composition.

The present invention also relates to a method for combating insects and mite pests, the method comprising contacting invertebrate pests, their habitats, breeding grounds, food, plants, seeds, soil, and invertebrate pests with a biologically effective amount of the compound or composition of the present invention. The area, material, or environment where vertebrate pests grow or are likely to grow, or materials, plants, seeds, and soil that are desired to be protected from pests or infestations.

The control of invertebrate pests is achieved by applying one or more compounds of the present invention in an effective amount to the pest environment, including agronomic and/or agronomically infested sites, areas to be protected or directly on the pests to be controlled And the protection of agronomy, horticulture and special crops, and the realization of animal and human health. Therefore, the present invention further includes methods for controlling leaf and soil-inverted invertebrates and protecting agronomic and/or non-agricultural crops, including contacting the invertebrates or their environment with a biologically effective amount of one or more compounds of the present invention, or containing at least A composition of such a compound or a composition comprising at least one such compound and an effective amount of at least one additional biologically active compound or agent. The preferred contact method is spraying. Alternatively, the granular composition containing the compound of the present invention can be applied to plant leaves or soil. The compound of the present invention is effectively delivered by plant ingestion by contacting the plant with a composition containing the compound of the present invention, the composition is applied to the soil as a soil soaking agent of a liquid formulation, a granular formulation, treatment or dipping in a nursery box. Other methods of contact include direct and residual spray, air spray, seed coat, microencapsulation, systemic ingestion, bait, ear tag, bolus, spray, fumigant, aerosol, dust and many other methods to apply the compound of the present invention Or composition.

The compounds of the present invention can be incorporated into baits favored by invertebrates or in devices such as traps. Granules or baits containing 0.01-5% active ingredient, 0.05-10% moisturizer and 40-99% plant powder, especially lethal by ingestion rather than by direct contact with the active ingredient dose, can be effective at very low application rates Control soil insects. The compound of the present invention can be administered in its pure form, but the most commonly used application is a formulation containing one or more compounds with suitable carriers, diluents and surfactants, and it may also be combined with food, depending on the intended end use . A preferred method of application includes spraying an aqueous dispersion of the compound or a refined oil solution. Combinations with spray oils, spray oil concentrations, coating patches, adjuvants, other solvents, and synergists (such as piperonyl butoxide) can often improve compound efficacy.

The application rate required for effective control (ie, the "biologically effective amount") will depend on such things as the type of invertebrate to be controlled, the life cycle of the pest, its life stage, its size, location, season, host crop or animal, and food intake. Behavior, mating behavior, environmental humidity, temperature, etc. Under normal circumstances, an application rate of about 0.01 to 2 kg of active ingredients per hectare is sufficient to control pests in agro-ecosystems, but some hectares may only require 0.0001 kg, or as much as 8 kg. For non-agricultural purposes, the effective utilization rate ranges from about 1.0 to 50 mg/m², but it may only be 0.1 mg/m², and up to 150 mg/m² may be required. Those skilled in the art can easily determine the biologically effective amount required to control the level of invertebrate pests.

Animal pests (ie insects, spiders and nematodes), plants, soil or water that can grow plants by application methods known in the art, and compounds of formula (I) and their N-oxides and salts or compositions containing them contact. Therefore, "contact" includes direct contact (applying the compound/composition directly to animal pests or plants that are usually applied to the leaves, stems or roots of plants) and indirect contact (applying the compound/composition to the locus of animal pests or plants ).

The compounds of the present invention or insecticidal compositions containing them can be used to protect growing plants and crops from animal pests (especially insects, acarids, etc.) by contacting plants/crops with an insecticidal effective amount of at least one compound of the present invention. Or spider) infestation or infestation. The term "crops" refers to crops that are growing and harvested.

In one embodiment, the present invention provides a method for protecting crops from attack or infestation by invertebrate pests. The method includes combining the crop with a biologically effective amount of the compound or composition, isomer, or polymorph of the present invention. , N-oxide or its salt contact.

The compound of the present invention can be used as it is or in the form of a composition using an insecticidal effective amount of the active compound to treat insects or plants, plant propagation materials, such as seeds, soil, surfaces, materials, or spaces, to protect them from insecticidal attack. Application can be carried out before and after infection of plants, plant propagation material, such as insect seeds, soil, surface, material or between before and after infection.

In one embodiment, the present invention provides a method of protecting seeds from soil insects and protecting seedlings from soil and leaf insects’ roots and shoots. The method includes contacting the present invention with seeds before sowing and/or after germination. The compound or its composition, the N-oxide or its salt contacts the seed.

In addition, the present invention relates to a method for treating or protecting an animal from infestation or infection by parasites. The method includes oral, topical or parenteral administration or administering to the animal a biologically effective amount of the compound or composition, isomer, or polymorph of the present invention. Type, N-oxide or veterinary acceptable salt.

For the treatment of crop plants in agricultural or horticultural crops, the application rate (effective dose applied) of the compound of the present invention may be in the range of 1 g to 5000 /ha, preferably 25 g to 600 g / hectare, more preferably 50 g to 500 g per hectare .

The compounds and compositions of the present invention are particularly suitable for controlling various insects on various cultivated plants, such as cereals, root crops, oil crops, vegetables, spices, ornamental plants, such as durum wheat and other wheat seeds, barley, oats, black Wheat, corn (forage corn and sugar corn/sweet corn), soybeans, oil crops, cruciferous plants, cotton, sunflower, banana, rice, rape, turnip rape, sugar beet, fodder beet, eggplant, potato, grass, lawn , Turf, fodder grass, tomato, leeks, pumpkin/pumpkin, cabbage, iceberg lettuce, pepper, cucumber, melon, brassica, cantaloupe, beans, peas, garlic, onion, carrot, potato and other tuber plants, sugar cane, Tobacco, grapes, petunia, geranium/geranium, pansies and impatiens.

In particular, the compounds or compositions of the present invention can be used to protect crops, such as cereals, corn, rice, soybeans and other legumes, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any horticultural plants, gourds Family, oily plants, tobacco, coffee, tea, cocoa, sugar beet, sugar cane, cotton, potato, tomato, onion, pepper and other vegetables and ornamental plants.

The compounds of the present invention are effective both through contact (through soil, grass, walls, bed nets, carpets, plant parts or animal parts) and ingestion (bait or plant parts).

The compounds of the present invention can also be used for non-crop insects and mite pests, such as ants, termites, wasps, flies, mosquitoes, crickets or cockroaches. In order to combat the non-crop pests, the compounds of the present invention are preferably used in bait compositions.

The bait can be a liquid, solid or semi-solid preparation (eg gel). The solid bait can be formed into various shapes and forms suitable for the respective application, such as granules, blocks, rods, discs. The liquid bait can be filled into various devices to ensure proper application, such as open containers, spray devices, droplet sources, or evaporation sources. Gels can be based on water-based or oily bases, and can be formulated into specific necessities in terms of viscosity, moisturizing or aging properties.

The bait used in the composition is a product that is sufficient to attract insects such as ants, termites, wasps, flies, mosquitoes, crickets, or cockroaches to eat it. The attraction can be manipulated through the use of feeding stimulants or sex pheromone. For example, it can be, but not limited to, animal and/or vegetable protein (meat, fish meal, insect parts, egg yolk), fat and oil of animal and/or vegetable origin, or mono-, oligosaccharide polyorganic sugars, oligomeric organic Sugars, especially sucrose, lactose, fructose, dextrose, glucose, starch, pectin or even molasses or honey select food stimulants. Fresh or rotten parts of fruits, crops, plants, animals, insects or specific parts thereof can also be used as feeding stimulants. It is known that sex pheromone is more insect-specific. Specific pheromones are described in the literature and are known to those skilled in the art.

When used in a bait composition, the typical content of the active ingredient is 0.001% to 15% by weight, ideally 0.001% to 5% by weight.

The preparation of the compound of the present invention as a spray (such as a spray can), an oil spray or a pump spray is very suitable for non-professional users to control pests such as flies, fleas, ticks, mosquitoes or cockroaches. The spray formulation is preferably composed of active compounds, solvents such as lower alcohols (such as methanol, ethanol, propanol, butanol), ketones (such as acetone, methyl ethyl ketone), with a boiling range of about 50-250°C paraffin hydrocarbons ( Such as kerosene), dimethylformamide, N-methylpyrrolidone, dimethyl sulfide, aromatic hydrocarbons such as toluene, xylene, water, and auxiliary agents such as emulsifiers such as sorbitol monooleate, Oleoyl ethoxylates, with 3-7 moles of ethylene oxide, fatty alcohol ethoxylates, perfume oils, etc. as ether oils, esters of medium fatty acids and lower alcohols, aromatic compounds, stabilizers if appropriate Such as sodium benzoate, amphoteric surfactants, lower epoxides, triethyl orthoformate, if necessary, propellants such as propane, butane, nitrogen, compressed air, dimethyl ether, carbon dioxide, nitroxide or these gases Mixture composition.

The difference between the spray formula and the spray formula is that no propellant is used. In the spray composition, the active ingredient accounts for 0.001 to 80% of the total weight, preferably 0.01 to 50%, most preferably 0.01 to 15%.

The compounds of the present invention and their respective compositions can also be used in mosquito coils and fumigation coils, cigarette cases, evaporator plates or long-term sprayers, as well as moth paper, moth pads or other heat-independent evaporator systems.

The method of using the compound of formula (I) and their respective compositions to control infectious diseases spread by insects (such as malaria, dengue fever and yellow fever, lymphatic filariasis and leishmaniasis) also includes surface treatment of cabins and houses, air Spraying and impregnation of curtains, tents, clothing, mosquito nets, fly traps, etc. The insecticidal composition for fibers, fabrics, knitwear, nonwoven fabrics, mesh materials or foils and tarpaulins preferably contains a mixture containing an insecticide, an optional insect repellent and at least one binder. Suitable insect repellents are, for example, N,N-diethyl-m-toluamide (DEET), N,N-diethylphenylacetamide (DEPA), 1-(3-cyclohexane-1- -Carbonyl)-2-methylpiperidine, (2-hydroxymethylcyclohexyl) lactone, 2-ethyl-1,3-hexanol and alcohol, methyl dodecamide (MNDA), one kind Pyrethroids for insect control, such as (+/-)-3-allyl-2-methyl-4-oxocyclopentan-2-(+)-enyl-(+)-trans -Chrysanthemum mosquito ester, an insect repellent derived from or the same as plant extracts, such as limonene, eugenol, and crude plant extracts such as Vitex simplicifolia and lemongrass. Suitable binders are selected from, for example, polymers and copolymers of vinyl esters of aliphatic acids (such as vinyl acetate and vinyl versatate), alcoholic acrylic and methacrylic esters, such as butyl acrylate, 2-ethyl acrylate Hexyl acrylate, and methyl acrylate, mono- and diethylenically unsaturated hydrocarbons such as styrene and aliphatic dienes such as butadiene.

Generally, curtains and mosquito nets are impregnated by dipping textile materials into insecticide emulsions or dispersions or spraying them on the net.

The compounds of the present invention and their compositions can be used to protect wooden materials, such as trees, board fences, sleepers, etc., and buildings, such as houses, outbuildings, factories, and building materials, furniture, leather, fibers, vinyl products, and wires And cables are protected from ants and/or termites, and used to control ants and termites causing damage to crops or humans (for example, when pests invade houses and public facilities). The compound of the present invention is not only applied to the surrounding soil surface or the soil under the floor to protect wood materials, but also can be applied to such as underfloor concrete, niche pillars, beams, plywood, furniture, etc., wood products such as particle board, half board Etc. and vinyl products such as coated wires, vinyl sheets, insulating materials such as styrene foam, etc. on the surface.

The compound of the present invention is used to prevent and control ants from harming crops or humans, applied to crops or surrounding soil, or directly applied to ant nests and the like.

Seed treatment

The present invention still further relates to seeds containing the compound of the present invention, in particular, the content thereof is about 0.0001% to about 1% of the weight of the seed before treatment.

The compound of the present invention can also be used to treat seeds to protect seeds from insect pests, especially soil living insects and mites, and the roots and shoots of the resulting plants can resist soil pests and leaf insects.

The compounds of the present invention are particularly useful for protecting seeds from soil pests, as well as protecting plant roots and shoots from soil pests and leaf insects. It can be preferably used to protect the roots and shoots of plants. It is more preferred to protect the branches of the resulting plant from piercing and sucking insects, and most preferred is to protect it from aphids, leafhoppers, thrips and whiteflies.

Therefore, the present invention includes methods for protecting seeds from insects (especially soil insects), and protecting seedling roots and shoots from insects (especially soil and leaf insects), the method comprising before sowing and/or at After accelerating germination, the compound of the invention is brought into contact with the seed. In this method, it is particularly preferred to protect the roots and branches of the plants therein, more preferably to protect the branches of the plants from piercing and sucking by insects, and the most preferred method is to protect the branches of the plants from aphids.

The term "seed" includes various seeds and plant propagules, including but not limited to real seeds, seed pieces, suckers, bulbs, bulbs, fruits, tubers, grains, cuttings, cut branches, etc., and in a preferred embodiment refers to The real seed.

The term seed treatment includes all suitable seed treatment techniques known in the art, such as seed dressing, seed coating, seed dusting, seed soaking and seed granulation.

The invention also includes seeds coated with or containing active compounds. The seeds can be coated with a seed coating composition containing the compound of the present invention. For example, there are seed coating compositions reported in EP3165092, EP3158864, WO2016198644, WO2016039623, WO2015192923, CA2940002, US2006150489, US2004237395, WO2011028115, EP2229808, WO2007067042, EP1795071, EP1273219, WO200178507, EP1247436, NL1012918, and CA2083415.

The term "coated and/or containing" generally means that the active ingredient is mostly on the surface of the reproductive product when applied, although more or less of the ingredient can penetrate into the reproductive product, depending on the method of application. When the propagation product is (re)planted, it can absorb the active ingredients.

Suitable seeds are grains, root crops, oil crops, vegetables, spices, seeds of ornamental plants, such as durum wheat seeds and other wheat, barley, oats, rye, corn (forage corn and sugar corn/sweet corn fields), Soybeans, oil crops, cruciferous plants, cotton, sunflower, banana, rice, rapeseed, turnip rape, sugar beet, fodder beet, eggplant, potato, grass, lawn, turf, fodder grass, tomato, leeks, pumpkin/pumpkin, cabbage , Iceberg lettuce, pepper, cucumber, melon, Brassica, melon, beans, peas, garlic, onion, carrot, tubers such as potatoes, sugar cane, tobacco, grapes, petunia, geranium, pansies and impatiens.

In addition, the compounds of the present invention can be used to treat plant seeds that are tolerant to herbicides or fungicides or insecticides due to breeding (including genetic engineering methods).

For example, the compounds of the invention can be used to treat the seeds of plants that are resistant to herbicides other than sulfonylurea, imidazolinone, glufosinate-ammonium or glyphosate-isopropylammonium and similar active substances (see For example, EP242236, EP242246) (WO92/00377) (EP257993, US5013659) or genetically modified crop plants (such as cotton) have the ability to produce Bacillus thuringiensis toxin (Bt toxin), which makes plants resistant to certain pests (EP142924 , EP193259).

In addition, the compounds of the present invention can be used to treat seeds from plants that have modified characteristics compared to existing plant compositions-they can be produced, for example, by traditional breeding methods and/or mutants or by recombinant procedures. For example, there have been many cases describing crop plants that are recombinantly modified in order to modify the starch synthesized in plants (such as WO92/1376, WO92/14827, WO91/19806) or genetically modified crop plants with modified fatty acid compositions (WO91/ 13972).

The application of the compound of the present invention to treat seeds is carried out by spraying or dusting the seeds before sowing the plants and before the emergence of the plants.

Compositions that are particularly useful for seed treatment include, for example: A. Soluble concentrates (SL, LS) B. Emulsion (EW, EO, ES) C. Suspending agent (SC, OD, FS) D. Water-dispersible particles and water-soluble particles (WG, SG) E. Water-dispersible powder and water-soluble powder (WP, SP, WS) F. Gel formulation (GF) G. Powder that can be dusted (DP, DS) Conventional seed treatment formulations include, for example, flowable concentrate FS, solution LS, powder DS for drying treatment, water-dispersible powder WS for slurry treatment, water-soluble powder SS and emulsion ES and EC, and gel formulations GF. These formulations can be applied to diluted or undiluted seeds. The application to the seeds is carried out before sowing, either directly on the seeds or after pre-germination of the seeds.

In one embodiment, the FS formulation is used for seed treatment. In particular, the FS formulation may contain 1-800g/l active ingredient, 1-200g/l surfactant, 0-200g/l antifreeze, 0-400g/l binder, 0-200g/l pigment and at most 1 liter Solvent (preferably water).

In particular, the FS preparation of the compound of the present invention used for seed treatment usually contains 0.1 to 80% (1 to 800 g / l) of active ingredient in a weight ratio of 0.1 to 20% (1 to 200 g / l) of at least A surfactant with a weight ratio of 0.05 to 5% of wetting agent and 0.5 to 15% (up to 20%) of dispersant, 5 to 20% of antifreeze, and a weight ratio of from 0 to 15% (for example, 1 to 15 %) of pigments and/or dyes, 0 to 40% by weight (for example, 1 to 40%) of binder (adhesive/adhesive), optionally with a weight ratio of up to 5% (for example, 0.1 to 5%) Thickener, optional defoamer with a weight ratio of 0.1 to 2%, and optional preservatives (such as biocides, antioxidants, etc.), for example, with a weight ratio of 0.01 to 1%, plus filler/ The carrier constitutes 100% by weight.

The seed treatment formulation may additionally contain a binder and a coloring agent.

Binders can be added to improve the adhesion of the active material to the seed after treatment. Suitable binders are homopolymers and copolymers from alkylene oxides, such as ethylene oxide or propylene oxide, polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone and its copolymers, ethylene-vinyl acetate Copolymers, acrylic acid homopolymers and copolymers, polyvinylamines, polyvinylamides and polyvinylpyrimidines, polysaccharides such as cellulose, infills and starches, polyolefin homopolymers and copolymers such as olefin/maleic anhydride copolymers, Polyurethane, polyester, polystyrene homopolymer and copolymer.

Optionally, coloring agents may also be included in the formulation. Suitable coloring agents or dyes for seed treatment preparations are Rhodamine B, CI, Pigment Red 112, CI, Solvent Red 1, Pigment Blue 15:4, Pigment Blue 15:3, Pigment Blue 15:2, Pigment Blue 15 :1, Pigment Blue 80, Pigment Yellow 1, Pigment Yellow 13, Pigment Red 112, Pigment Red 48:2, Pigment Red 48:1, Pigment Red 57:1, Pigment Red 53:1, Pigment Orange 43, Pigment Orange 34 , Pigment Orange 5, Pigment Green 36, Pigment Green 7, Pigment White 6, Pigment Brown 25, Basic Violet 10, Basic Violet 49, Acid Red 51, Acid Red 52, Acid Red 14, Acid Blue 9, Acid Yellow 23 , Basic Red 10, Basic Red 108.

Examples of gelling agents are carrageenan (Satiagel®)

In seed treatment, the application rate of the compound of the present invention is usually 0.1 g to 10 kg per 100 kg of seeds, preferably 1 g to 5 kg per 100 kg of seeds, more preferably 1 g to 1000 g per 100 kg of seeds (especially 1 g to 200 g per 100 kg of seeds). Therefore, the present invention also provides seeds comprising a compound of formula (I) or an agriculturally useful salt of I as defined herein. The amount of compound I or its agriculturally acceptable salt is usually 0.1 g to 10 kg per 100 kg of seeds, preferably 1 g to 5 kg per 100 kg of seeds (especially 1 g to 1000 g per 100 kg of seeds). For certain crops such as lettuce, the application rate can be higher.

Animal health

The present invention also provides agricultural and/or veterinary compositions comprising at least one compound of the present invention.

The present invention further relates to the use of the compound, N-oxide or veterinarily acceptable salt or the composition of the present invention in the preparation of a medicament for treating or protecting animals from infestation or infection by insects and mites or parasites.

The compounds of formula (I), their N-oxides and/or veterinarily acceptable salts are particularly suitable for use against parasites in animals.

Therefore, an object of the present invention is to provide a new method for controlling parasites in animals. Another object of the present invention is to provide safer animal insecticides. Another object of the present invention is to provide animal insecticides that can be used in lower doses than existing insecticides. Another object of the present invention is to provide insecticides for animals to provide long-term residual control of parasites.

The present invention also relates to a composition containing at least one compound of formula (I), an N-oxide or a veterinarily acceptable salt and an acceptable carrier in an effective amount of parasiticidal, which is used to combat parasites in animals.

The present invention also provides a method of treating, controlling, preventing and protecting animals from parasitic infections and infections, the method comprising oral, topical or parenteral administration or administration of a parasiticidal effective amount of the compound of the present invention or a composition containing it .

The present invention also provides a method for preparing a composition for treating, controlling, preventing or protecting animals from infestation or infection by parasites (the composition contains a parasiticidal effective amount of the compound of the present invention or a composition containing it).

The activity of the compounds against agricultural pests does not indicate that they are suitable for controlling endoparasites in animals and ectoparasites on the body surface, low non-emetic doses required for oral administration, metabolic compatibility with animals, low toxicity and safety operating.

Surprisingly, it has now been found that the compounds of the present invention are suitable for combating endoparasites in animals and ectoparasites on the body surface.

The compound of the present invention and the composition containing the compound are suitable for controlling and preventing infestation and infection to animals, including warm-blooded animals (including humans) and fish. They are suitable for the control and prevention of mammals (such as cattle, sheep, pigs, camels, deer, horses, pigs, poultry, rabbits, goats, dogs and cats, buffalo, donkeys, deer and reindeer), fur animals (such as mink, Infestation and infection of chinchillas and raccoons, birds such as hens, geese, turkeys and ducks, and fish (such as fresh and saltwater fish such as trout, carp and eel).

The compound of the present invention and the composition containing the compound are suitable for controlling and preventing infestation and infection of domestic animals (such as dogs or cats).

Pests that infest warm-blooded animals and fish include, but are not limited to, lice, biting lice, ticks, nose flies, sheep ticks, biting flies, flies, flies, fly larvae, chiggers, mosquitoes, mosquitoes, and fleas.

The compound of the present invention and the composition containing the compound are suitable for systemic and/or non-systemic control of ectoparasites and/or endoparasites. They can effectively resist all or some stages of development.

The compounds of the invention are particularly useful for combating ectoparasites.

The compounds of the present invention are particularly suitable for combating parasites of the following orders and species: fleas (Hipoptera), such as cat head fleas, round head bugs, clawed frogs, bugs, cockroaches, such as German cockroaches, Blattella gracilis, American cockroach, Japanese cockroach, brown cockroach, etc., American cockroach, Australian cockroach, Oriental cockroach, flies, mosquitoes (Diptera), such as Aedes aegypti, Aedes albopictus, Aedes, A. mexicanus , Anopheles pentaphyllum, Anopheles crucian, Anopheles gambiae, Anopheles panbos, Anopheles albopictus, Anopheles mini, Fourspots, Red-headed blowfly, Big-headed golden flies, Corrupted cone flies, Central spotted fly, Plague fly, Atlantic fly, Trypanosoma anthropophagus, Human skin fly, Culex pipiens, Culex black beard, Culex pipiens vulgaris, Culex tarsalis, the vector of Kachi Valley virus, Cyperus black tail, human Skin skin flies, summer toilet flies, gastrointestinal flies, tsetse flies, tsetse flies, parasitic tsetse flies, western horned flies, Liriomyza, sclerotia, Lucilia sericata, Lucilia sericata, Manna, housefly, Rot fly, sheep fly, foot sandfly, Colombian scale mosquito, scale mosquito, protognathus, red-tailed sarcophagus, Sarcophagus, gnat, gnat fly, gadfly, black horsefly, horsefly, and horsefly, Louses (Epidoptera), such as human head lice, human lice, human pubic lice, bovine blood wind, blood louse, bovine jaw lice, cattle feather lice, chicken feather lice, and buffalo blind lice. Ticks and parasitic mites (Paramites): Ticks (True ticks), such as Ixodes scapularis, Ixodes pertussis, Ixodes pacificum, Dermacentor angifera, Dermacentor variabilis, American flower tick, Amnioticus Newts, Ornithology ticks, and parasitic mites (Mesophaga suborder), such as Avian spiny mites Burrito and Dermatophagocarpus, Radix mites, Acaroid mites, e.g. Acarina spp, Acarina spp, Sarcophagous mites, Sores Acarina, Demodex, Chigger, Shovel, Acaroid, Tyrophagous, Xylophilus, Dermatophagidae, Pterodactylus, Itchy mites, Foot mites, Ear mites, Scabies Acarina, Acarina, Acarina, and Bedbugs (Heteroptera): Temperate bed bugs, tropical bed bugs, assassin bugs, Trinops, long red assassin bugs, pantoris and wheel bugs, lice Orders, such as Pteridae, Trichosanthes, Human Psylidae, and Tubelouses, Trichophagous orders (Lepidoptera suborders), such as Trichosanthes, Brachychidae, Duck louse, Bovine louse, Wei The genus Nicotiana, the spp. and the spp.

Nematodes:

Ironworms and Trichinella diseases (Capillary tube), such as Trichinellaceae (Trichoderma), Trichinella, Capillaria, Microbes, for example, Microcaria, Strongyloides, Thick crabs, Cymbidium Nematodes, such as Strongyloides, Ancylostoma, Ancylostoma, Ancylostoma (Duodenum), Haemonchus contortus, Oersted, Coopera, Nematodes, Dictyocaulis, Cupmouth Genus, Nodular Nematodes, Crown Nematodes, Panhead nematodes, Chabot Nematodes, Crown Cysts, Tracheal Pterodactylidae, Ancylostoma, Benthos, Globosporus, Bankou Nematodes, Hippocampus Strongyloides, strongyloides cat, and nematode nematodes, intestinal roundworms (Ascarididae), such as roundworms, Ascaris suum, Ascaris gallisepticum, Paraworms equine, Intestinal roundworms (pinworms), Toxoplasma canis , Toxoplasma lionii, Steinella, and horse pinworms, Camelids, such as Dracunculiasis, Trichocerca, such as Sucking Nematodes, Wu Tse Nematodes, Bruegrass, Onchocerca, Heartworm genus, Acanthopanax genus, Celiac filarial genus, Silkworm genus, Pennisetum genus, and Nematode genus, spiny headed worms (Acanthocephalus), such as Acanthocephalum, Swine giant snout Acanthocepha and Uncariacephala, Planaria (Platyma): Flukes (Flames), such as Chinese snails, Fasciola grandis, Paragonimus, Dichaenia, Ginger brachia, Clonorchis sinensis, Schistosoma, Trichomonas, Pteranodon, Paragonimus, and Ceratops, especially the subclass Polynodular tapeworms (taenia), For example, the genus Schistocephala, the genus Echinococcus, the genus Dippia canis, the genus Polycephalus, the genus Hymenocystis, the genus Taenia, the genus Midge, the genus Moniz, and the genus Gymnocephalus.

The compounds of formula (I) and compositions containing them are particularly suitable for controlling pests of the orders Diptera, Siphonaptera and True ticks.

In one embodiment, the present invention provides the use of the compound of formula (I) and the composition thereof against mosquitoes.

In one embodiment, the present invention provides the use of the compound of formula (I) and the composition thereof against flies.

In one embodiment, the present invention provides the use of the compound of formula (I) and the composition thereof against fleas.

The use of the compounds of the present invention and their compositions for combating ticks is another embodiment of the present invention.

The compounds of the present invention are also particularly suitable for combating endoparasites (nematodes, spiny head worms and planarians).

In one embodiment, the administration of the compounds of the invention can be done prophylactically and therapeutically.

In another embodiment, the administration of the compound of the present invention can be carried out directly or in the form of a suitable formulation orally, topical/dermal or parenteral.

For oral administration to warm-blooded animals, the compounds of the present invention can be formulated into animal feed, animal feed premixes, animal feed concentrates, pills, solutions, pastes, suspensions, infusions, gels, tablets, and pellets. And capsules. In addition, the compounds of the present invention can be administered to animals in their drinking water. For oral administration, the selected dose should provide animals with the compound of the present invention from 0.01 mg/kg to 100 mg/kg × animal body weight per day, preferably 0.5 mg/kg to 100 mg/kg × animal body weight per day.

Alternatively, the compounds of the invention can be administered to animals parenterally, for example by intracavity, intramuscular, intravenous or subcutaneous injection. The compound of the present invention can be dispersed or dissolved in a physiologically acceptable carrier for subcutaneous injection. Alternatively, the compounds of the invention can be formulated as implants for subcutaneous administration. In addition, the compounds of the present invention can be administered to animals transdermally. For parenteral administration, the selected dose should provide the animal with the compound of the present invention from 0.01 mg/kg to 100 mg/kg × animal body weight per day.

The compounds of the present invention can also be topically applied to animals in the form of impregnants, powders, powders, collars, medals, sprays, shampoos, drops and splashes and ointments or oil-in-water agents. For topical application, dipping and spraying usually contain 0.5 ppm to 5,000 ppm, preferably 1 ppm to 3,000 ppm of the compound of the invention. In addition, the compounds of the present invention can be formulated as ear tags for animals (particularly quadrupeds such as cows and sheep).

Suitable formulations are: solutions, such as oral solutions, concentrates for oral administration after dilution, solutions for skin or body cavity, pouring formulations, gels, emulsions and suspensions for oral or skin administration, semi- Solid preparations, preparations in which the active compound is processed in an ointment base or a water-in-oil or water-in-oil emulsion base, solid preparations (such as powders, premixes or concentrates, granules, pellets, tablets, boluses, capsules, aerosols) And inhalants, shaped products containing active compounds).

Compositions suitable for injection are prepared by dissolving the active ingredient in a suitable solvent and optionally adding other ingredients such as acids, bases, buffer salts, preservatives and solubilizers. Solvent filtration and sterilization.

Suitable solvents include physiologically tolerable solvents (such as water), alkanols (such as ethanol, butanol, benzyl alcohol, glycerin, propylene glycol, polyethylene glycol, N-methylpyrrolidone, 2-pyrrolidone and mixtures thereof) ).

The active compound may optionally be dissolved in a physiologically tolerable vegetable oil or synthetic oil suitable for injection.

Suitable solubilizers are solvents that promote the dissolution of the active compound in the main solvent or prevent its precipitation. For example, polyvinylpyrrolidone, polyvinyl alcohol, polyoxyethylated castor oil, and polyoxyethylated sorbitan ester.

Suitable preservatives are benzyl alcohol, trichlorobutanol, parabens and n-butanol.

The oral solution is administered directly. After pre-diluted to use concentration, the concentrate is administered orally. Oral solutions and concentrates are prepared according to the prior art and the method for preparing injection solutions as described above, without aseptic operation.

The method for skin application is to drip, smear, rub, sprinkle or spray on the solution.

The solution for the skin is prepared according to the prior art and according to the method for preparing an injection solution as described above, and does not require aseptic operation.

Other suitable solvents are polypropylene glycol, phenethyl alcohol, phenoxyethanol, esters such as ethyl acetate or butyl acetate, benzyl benzoate, ethers such as alkyl glycol ethers, such as dipropylene glycol monomethyl ether, Ketones such as acetone, methyl ethyl ketone, etc., aromatic hydrocarbons, vegetable and synthetic oils, dimethylformamide, dimethylacetamide, reducing diols, acetone glycidyl, propylene carbonate, and mixtures thereof.

It may be beneficial to add thickeners during the preparation process. Suitable thickeners include inorganic thickeners (such as bentonite, colloidal silicic acid, aluminum monostearate), organic thickeners (such as cellulose derivatives, polyvinyl alcohol and its copolymers, acrylates and methacrylic acid). ester).

The gel is applied to the skin or applied to the skin or introduced into the body cavity. The gel is prepared by adding enough thickener to a solution prepared according to the method of preparing an injection solution to produce a transparent material with an ointment-like consistency. The thickeners used are those listed above.

The pour-on preparation is poured or sprayed onto a limited area of the skin, and the active compound penetrates the skin and acts on the whole body. Pouring formulations are prepared by dissolving, suspending or emulsifying the active compound in a suitable skin compatible solvent or solvent mixture. If appropriate, other additives such as coloring agents, bioabsorption promoting substances, antioxidants, light stabilizers, and adhesives can be added.

Suitable solvents are: water, alkanol, glycol, polyethylene glycol, polypropylene glycol, glycerin, aryl alcohol such as benzyl alcohol, phenylethanol, phenoxyethanol, esters such as ethyl acetate, butyl acetate , Benzyl benzoate, ketones such as alkylene glycol ether, diethylene glycol monobutyl ether, acetone, methyl ethyl ketone, cyclic carbonate such as propylene carbonate, aromatic and/or fatty Group hydrocarbons and other ethers such as alkylene glycol ethers, vegetable oils or synthetic oils, DMF, dimethylacetamide, n-alkylpyrrolidone, such as methylpyrrolidone, n-butylpyrrolidone or N-octylpyrrolidone, N-methylpyrrolidone, 2-pyrrolidone, 2,2-dimethyl-4-oxo-methylene-1,3-dioxolane and glycerol formal.

Suitable coloring agents are all coloring agents that are allowed to be used on animals and can be dissolved or suspended.

Suitable absorption promoting substances include: dimethyl sulfide, coating oils, such as isopropyl myristate, dipropylene glycol nonanoate, silicone oil and its copolymers with polyethers, fatty acid esters, triglycerides, fatty alcohols Wait.

Suitable antioxidants are sulfites or metabisulfites, such as potassium metabisulfite, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, tocopherol and the like.

Suitable light stabilizers include ortho-phthalic acid and the like. Suitable binders include cellulose derivatives, starch derivatives, polyacrylates, natural polymers such as alginate, gelatin and the like. Emulsion can be administered orally, skin or injection. The emulsion may be of the water-in-oil type or the oil-in-water type.

They are by dissolving the active compound in the hydrophobic or hydrophilic phase, with the help of suitable emulsifiers and other suitable additives (such as coloring agents, absorption promoting substances, preservatives, antioxidants, light stabilizers, viscosity-increasing substances) It is prepared by homogenizing it with the solvent of the other phase.

Suitable hydrophobic phases (oils) are:

Liquid paraffin, silicone oil, natural vegetable oils, such as sesame oil, almond oil, castor oil, synthetic triglycerides, such as caprylic/capric triglycerides, triglyceride mixtures, vegetable fatty acids _{with chain lengths of C 1} -C _{12 or others} Special selection of natural fatty acids, partial glycerides of saturated or unsaturated fatty acids, monoglycerides and diglycerides that may also contain hydroxyl, Cs-do fatty acids, fatty acid esters such as ethyl stearate, di-n-adipate Butyl ester, hexyl laurate, dipropylene glycol nonanoate, _{saturated fatty alcohol with ester chain length C 16} -C ₁₈ , isopropyl myristate, isopropyl palmitate, chain length C ₁₂ -C ₁₈ Caprylic acid/capric acid ester of saturated fatty alcohol, isopropyl stearate, oleyl oleate, decyl oleate, medium-chain long-chain branched fatty acid, ethyl oleate, ethyl lactate, waxy fatty acid ester, such as Synthetic duck tailbone gland fat and fat, dibutyl phthalate, diisopropyl adipate, and ester mixtures related to the latter, fatty alcohols such as isotridecanol, 2-octyldodecanol, Cetyl stearyl alcohol, oleyl alcohol, and fatty acids such as oleic acid and mixtures thereof. Suitable hydrophilic phases are: water, alcohols such as propylene glycol, glycerin, sorbitol and mixtures thereof.

Suitable emulsifiers are nonionic surfactants, such as polyethoxylated castor oil, polyethoxylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate , Polyoxyethylene stearate, or alkylphenol polyethylene glycol ether; amphoteric surfactants, such as disodium N-lauryl-p-iminodipropionate or lecithin.

Suitable anionic surfactants include sodium lauryl sulfate, fatty alcohol ether sulfate, mono/dialkyl polyglycol ether orthophosphate monoethanolamine salt; suitable cationic surfactant is cetyl tris Methyl ammonium chloride and so on.

Suitable other additives are substances that enhance viscosity and stabilize emulsions, such as carboxymethyl cellulose, methyl cellulose and other cellulose and starch derivatives, polyacrylates, alginates, gelatin, gum arabic, polyvinylpyrrolidone , Polyvinyl alcohol, methyl vinyl ether and maleic anhydride copolymer, polyethylene glycol, wax, colloidal silicic acid or a mixture of these substances.

The suspension can be administered orally or topically/cutaneously. They are prepared by suspending the active compound in a suspending agent, if appropriate, adding other auxiliary agents such as wetting agents, coloring agents, bioabsorption promoting substances, preservatives, antioxidants, and light stabilizers.

Liquid suspending agents are homogeneous solvents and solvent mixtures.

Suitable wetting agents (dispersants) are the emulsifiers listed above.

Other additives that may be mentioned are also given above.

Semi-solid preparations can be administered orally or topically/cutaneously. They differ from the above-mentioned suspensions and emulsions only in their higher viscosity.

The preparation of solid preparations is to mix the active compound with suitable excipients (adding adjuvants if appropriate), and then prepare the desired form.

Suitable excipients are all physiologically tolerable solid inert substances, including inorganic and organic substances. Inorganic substances include sodium chloride, carbonates such as calcium carbonate, bicarbonate, aluminum oxide, titanium oxide, silicic acid, clay soil, precipitated or colloidal silica or phosphate. Organic substances include sugar, cellulose, food and baby food (such as milk powder, animal meal, cereal powder and chips, starch) and so on.

Suitable adjuvants are the preservatives, antioxidants, and/or coloring agents mentioned above.

Other suitable additives are lubricants and glidants, such as magnesium stearate, stearic acid, talc, bentonite, disintegration promoting substances such as starch or cross-linked polyvinylpyrrolidone, binders such as starch, gelatin or linear poly Vinylpyrrolidone, and dry binders such as microcrystalline cellulose.

Generally speaking, the "effective amount of parasiticide" refers to the effect of achieving an observable effect on growth (including necrosis, death, arrest, prevention, removal, destruction or other ways to reduce the occurrence and activity of the target organism). The amount of active ingredient required. The effective amount of parasiticide can vary according to the various compounds/compositions used in the present invention. The composition of the effective amount of parasiticide will also vary according to the main conditions, such as the desired parasitic effect and duration, target species, method of application, and the like. The compositions useful in the present invention generally contain about 0.001-95% of the compound of the present invention.

Generally, it is advantageous to administer the compound of the present invention in a total amount of 0.5 mg/kg to 100 mg/kg per day, preferably 1 mg/kg to 50 mg/kg per day. The ready-to-use preparation contains a compound that acts on parasites (preferably ectoparasites) in a concentration range of 10 ppm to 80% of the total weight, preferably 0.1 to 65% of the total weight, more preferably 1 to 50% of the total weight , Most preferably 5-40% of the total weight. The preparation is diluted before use and contains a compound that acts on ectoparasites at a concentration of 0.5-90% by weight, preferably 1-50% by weight. In addition, the concentration of the compound preparation of the present invention against endoparasites ranges from 10 ppm to 2% of the total weight, preferably 0.05 to 0.9% of the total weight, very particularly preferably 0.005 to 0.25% of the total weight.

In one embodiment, the composition comprising the compound of the invention is administered transdermally/topically.

In another embodiment, the topical application is in the form of shaped articles containing the compound, such as collars, wearing badges, ear tags, bandages, and adhesive strips and sheets that are fixed to body parts.

It is generally advantageous to administer the solid formulation of the compound of the present invention in an application amount of 10 mg/kg to 300 mg/kg, preferably 20 mg/kg to 200 mg/kg, and most preferably 25 mg/kg to 160 mg/kg in one cycle (three weeks).

Use thermoplastics and flexible plastics as well as elastomers and thermoplastic elastomers to prepare molded products. Suitable plastics and elastomers are polyethylene resins, polyurethanes, polyacrylates, epoxy resins, cellulose, cellulose derivatives, polyamides and polyesters, which are fully compatible with the compounds of the present invention. For example, WO2003/086075 gives a detailed list of plastics and elastomers and the preparation methods of molded products.

The crop is responding:

The compounds of the present invention not only effectively control insects and mite pests, but also show positive crop responses, such as plant growth enhancing effects, such as enhanced root growth, enhanced drought tolerance, high salt, high temperature, cold, frost or light Irradiation, improved flowering, increased nutrient utilization (such as improved nitrogen assimilation), improved plant product quality, increased tillers, increased resistance to fungi, insects, pests, etc., thereby increasing yield.

Chemical examples:

The following examples illustrate the methods and methods for preparing the compounds of the present invention, and include the best mode contemplated by the inventors to implement the present invention, but do not impose any limitation on the present invention.

Example 1: 2-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(three Synthesis of fluoromethyl phthalazine-1(2H)-one (Compound No. 103): a) Step 1 : 3- hydroxy -6-( trifluoromethyl ) isobenzofuran -1(3H) -one : At -78°C, add 2-bromo-5-(trifluoromethyl)benzoic acid (7.0 g, 26.0 mmol) to a stirred solution of n-butyllithium (21.86 mL, 54.6 mmol) in tetrahydrofuran (50 mL) ) The tetrahydrofuran solution, the addition time is more than 15 minutes. The reaction was stirred while maintaining the temperature at -78°C for 1 hour. Anhydrous N,N-dimethylformamide (20.2 mL, 260.0 mmol) was added to the resulting reaction mixture, and the reaction mixture was stirred for 6 hours while the reaction was warmed to 25°C. After the reaction was completed, the reaction mixture was cooled to 0° C., and the reaction mixture was quenched by the dropwise addition of 2N sodium hydroxide (15 mL). The reaction mixture was extracted twice with ethyl acetate (50 mL). The aqueous layer was separated, and 10N hydrochloric acid was carefully added to neutralize it until pH-4, and then extracted twice with ethyl acetate (100 mL). The mixed ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain crude 3-hydroxy-6-(trifluoromethyl)isobenzofuran-1(3H)-one (2.4g, 11.00 mmol, 42% yield), which can be used in the next step without further purification. ESI MS (m/z) 217.00 (MH) ⁺ . b) Step 2 : 2-(5- Bromo- 3-( ethylsulfonyl ) pyridin -2- yl) -7-( trifluoromethyl ) phthalazine -1(2H) -one: To 3- Hydroxy-6-(trifluoromethyl)isobenzofuran-1(3H)-one (1.3 g, 5.96 mmol) in acetic acid (20 mL) was added to a stirred solution of 5-bromo-3-(ethylsulfonyl) )-2-hydrazinepyridine hydrochloride (1.67 g, 5.96 mmol) [prepared according to the procedure described in ((WO2018/008727))]. The reaction mixture was heated at 115°C for 2 hours. After the reaction was completed, the reaction mixture was cooled to 25°C, diluted with water (100 mL), and extracted twice with ethyl acetate (100 mL). The mixed ethyl acetate layer was washed with brine (100 mL) and water (100 mL), dried over anhydrous sodium sulfate and concentrated to obtain a crude product, which was passed through silica gel column chromatography (using 40% ethyl acetate in hexane as washing Removal) purification to obtain 2-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (880 mg, 1.9 mmol, 32% yield). ¹ H-NMR (400 MHz, DMSO- d6 ) δ 9.19 (d, J = 2.4 Hz, 1H), 8.80 (d, J = 2.4 Hz, 1H), 8.76 (s, 1H), 8.52 (d, J = 0.9 Hz, 1H), 8.42 (dd, J = 8.3, 1.8 Hz, 1H), 8.33 (d, J = 8.6 Hz, 1H), 3.47 (q, J = 7.4 Hz, 2H), 1.14 (t, J = 7.5 Hz, 3H) ); ESI-MS (m/z) 463.55 (MH)+. c) Step 3 : 2-(3-( Ethylsulfonyl )-5-(4-(1,1,2,2- tetrafluoroethoxy ) phenyl ) pyridin -2- yl) -7 -( Trifluoromethyl ) phthalazine -1(2H) -one: to 2-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Oxazine-1(2H)-one (150 mg, 0.32 mmol) and (4-(1,1,2,2-tetrafluoroethoxy)phenyl)boronic acid (93.0 mg, 0.39 mmol) in 1,4- To a stirred solution of dioxane (2 mL) and water (0.5 mL) was added sodium acetate (80 mg, 0.974 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium dichloride ( II) Dichloromethane adduct (26.5 mg, 0.032 mmol). The reaction mixture was subjected to 3 vacuum/nitrogen cycles and heated at 110°C for 1 hour. After the reaction was completed, the reaction mixture was diluted with ethyl acetate (50 mL) and water (10 mL). Separate, dry with anhydrous sodium sulfate, and concentrate under reduced pressure to obtain the crude product, which is purified by silica gel column chromatography (using 60% ethyl acetate in hexane as the eluent) to obtain 2-(3-(benzene) Formaldehyde))-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)phenyl-2-yl)-7-(trifluoromethyl)benzoic acid-1(2H)- Ketone 2-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl Base) phthalazine-1(2H)-one (80 mg, 0.14 mmol, 42% yield), as a solid. ¹ H-NMR (400 MHz, DMSO- d6 ) δ 9.32 (d, J = 2.4 Hz, 1H), 8.75-8.78 (m, 2H), 8.54 (s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.07 (dd, J = 6.7, 2.1 Hz, 2H), 7.51 (d, J = 8.9 Hz, 2H), 6.74-7.00 (m, 1H ), 3.50 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 576.05 (MH) ⁺ .

Example 2: 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one( Compound No. 15) Synthesis: a) Step 1 : N,N -Diisopropyl- 4-( trifluoromethyl ) benzamide: To 4-(trifluoromethyl)benzoic acid at 0℃ To a stirred solution of (10.00 g, 52.6 mmol) of anhydrous dichloroethane (80 mL) and anhydrous N,N-dimethylformamide (0.4 mL, 5.26 mmol) was added oxalyl chloride (9.21 mL, 105.0 mmol). The reaction was stirred at 25°C for 2 hours and then concentrated under reduced pressure. The obtained residue was dissolved in anhydrous dichloroethane (60 mL), and then xylylamine (18.74 mL, 131.0 mmol) was added dropwise at 0°C. The reaction mixture was stirred at 25°C for 4 hours. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure. The obtained residue was treated with 1N hydrochloric acid, and extracted twice with dichloromethane (200 mL). The mixed dichloromethane layer was washed with water (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel flash column chromatography (using 40% ethyl acetate in hexane as the eluent) to obtain N,N-diisopropyl-4-(trifluoromethyl)benzamide (12.0 g, 43.9 mmol, 83% yield). ¹ H-NMR (400 MHz, DMSO- d6 ) δ 7.78 (d, J = 8.1 Hz, 2H), 7.50 (d, J = 8.1 Hz, 2H), 3.53-3.60 (m, 2H), 1.47 (d, J = 27.4 Hz, 6H), 1.14 (d, J = 34.0 Hz, 6H); ESI MS (m/z) 274.0 (MH)+. b) Step 2 : 2- Methyl- N,N -diisopropyl- 4-( trifluoromethyl ) benzamide: To N,N-diisopropyl-4 at -78℃ -(Trifluoromethyl)benzamide (5.0 g, 18.29 mmol) in anhydrous tetrahydrofuran (60 mL) was added to a stirred solution of n-butyl lithium (24.0 mL, 38.4 mmol). After stirring at this temperature for 1 hour, anhydrous N,N-dimethylformamide (3.54 mL, 45.7 mmol) was added in batches, while the reaction temperature was gradually raised to 25° C. within 1 hour. The reaction mixture was cooled to 0° C., a saturated solution of ammonium chloride was added dropwise to quench the reaction mixture, and it was diluted with water (100 mL). The reaction mixture was extracted twice with ethyl acetate (100 mL). The combined ethyl acetate layer was washed with water (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel flash chromatography (using 30% ethyl acetate in hexane as the eluent) to give 2-methanyl-N,N-diisopropyl-4-(trifluoromethyl)benzyl Amide (4.9 g, 16.26 mmol, 89% yield). ¹ H-NMR (400 MHz, DMSO- d6 ) δ 10.03 (d, J = 1.5 Hz, 1H), 8.32 (s, 1H), 8.08 (d, J = 7.3 Hz, 1H), 7.51-7.60 (m, 1H), 3.60 (m, 1H), 3.40 (m, 1H), 1.47 (d, J = 27.4 Hz, 6H), 1.14 (d, J = 34.0 Hz, 6H); ESI MS (m/z) 302.20 ( MH) ⁺ . c) Step 3 : 3- Hydroxy -5-( trifluoromethyl ) isobenzofuran -1(3H) -one: To 2-formyl-N, N-diisopropyl-4-(trifluoromethyl) To a stirred solution of methyl)benzamide (10.0 g, 33.2 mmol) in acetic acid (50 mL) was added 6N hydrochloric acid (30.2 mL). The reaction mixture was heated to 110°C for 40 hours. After the reaction was completed, the reaction mixture was cooled to 0°C and quenched by the dropwise addition of 10% sodium hydroxide (pH 8-9). The reaction mixture was extracted with ethyl acetate (100 mL), and the resulting aqueous layer was acidified (pH 3-4) with 10% hydrochloric acid, and then extracted with ethyl acetate (200 mL). The ethyl acetate layer was washed with water (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 3-hydroxy-5-(trifluoromethyl)isobenzofuran-1(3H)-one (2.7 g , 12.38 mmol, 37% yield), it can be used in the next step without further purification. ¹ H-NMR (400 MHz, DMSO- d6 ) δ 8.38 (d, J = 8.3 Hz, 1H), 8.00-8.10 (m, 3H), 6.74 (d, J = 8.3 Hz, 1H); ESI MS (m /z) 217.15 (MH) ⁺ . d) Step 4 : 2-(5- Bromo- 3-( ethylsulfonyl ) pyridin -2- yl) -6-( trifluoromethyl ) phthalazine -1(2H) -one: To 3- Hydroxy-5-(trifluoromethyl)isobenzofuran-1(3H)-one (1.5 g, 6.88 mmol) in acetic acid (20 mL) was added to a stirred solution of 5-bromo-3-(ethylsulfonyl) )-2-hydrazinepyridine hydrochloride (1.93 g, 6.88 mmol) [prepared according to the procedure described in (WO2018008727)]. The reaction mixture was heated at 115°C for 2 hours. After the reaction was completed, the reaction mixture was raised to 25°C, diluted with water (100 mL), and extracted twice with ethyl acetate (100 mL). The mixed ethyl acetate layer was washed with brine (100 mL), dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was purified by silica gel column chromatography (using 40% ethyl acetate in hexane as the eluent) to obtain 2-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one (2.50 g, 5.41 mmol, 79% yield rate). ¹ H-NMR (400 MHz, DMSO- d6 ) δ 9.20 (d, J = 2.4 Hz, 1H), 8.81 (d, J = 2.2 Hz, 1H), 8.75 (d, J = 0.5 Hz, 1H), 8.60 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.28 (dd, J = 8.7, 1.6 Hz, 1H), 3.48 (q, J = 7.4 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H); ESI MS (m /z) 462.0, 464.0 [(MH) + Br ^{79, 81} ]. e) Step 5 : 2-(3-( Ethylsulfonyl )-5-(4- fluorophenyl ) pyridin -2- yl) -6-( trifluoromethyl ) phthalazine -1(2H) - one: to a 2- (5-bromo-3- (sulfo acyl-ethyl) pyridin-2-yl) -6- (trifluoromethyl) phthalazine -1 (2H) - one (200 mg, 0.43 mmol ) And (4-fluorophenyl)boronic acid (72.6 mg, 0.52 mmol) in 1,4-dioxane (5 mL) and water (1 mL) were added to a stirred solution of sodium acetate (106 mg, 1.30 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane adduct (31.0 mg, 0.043 mmol), the reaction mixture was subjected to 3 vacuum/nitrogen cycles to make It was completely deoxygenated and then heated to 110°C for 1 hour. After the reaction was completed, the reaction mixture was diluted with ethyl acetate (50 mL) and water (10 mL). The ethyl acetate layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (using 50% ethyl acetate in hexane as the eluent) to obtain 2-(3- (Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one (138 mg, 0.29 mmol, 67% Yield), as a solid. ¹ H-NMR (400 MHz, DMSO- d6 ) δ 9.29 (d, J = 2.2 Hz, 1H), 8.71-8.74 (m, 2H), 8.59 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.26-8.28 (m, 1H), 8.01-8.04 (m, 2H), 7.42-7.47 (m, 2H), 3.49 (q, J = 7.4 Hz, 2H), 1.16 (t, J = 7.3 Hz , 3H); ESI MS (m/z) 477.9 (MH) ⁺ .

Example 3: 3-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one Synthesis of (Compound No. 87): a) Step 1 : 3-(5- Bromo- 3-( ethylsulfonyl ) pyridin -2- yl) -7-( trifluoromethyl ) quinazoline- 4 (3H) -one: To 7-(trifluoromethyl)quinazolin-4(3H)-one (1.6 g, 7.47 mmol) [according to "Organic Express" (18(11), 2580-2583; 2016) Prepared by the method described in] and 5-bromo-3-(ethylsulfonyl)-2-fluoropyridine (2.60 g, 9.71 mmol) [prepared according to the method described in WO2018008727] adding carbonic acid to the stirred suspension Cesium (2.92 g, 8.97 mmol), and the reaction mixture was irradiated in a microwave at 80°C for 1 hour. After the reaction was completed, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (200 mL). The ethyl acetate layer was separated, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (using 60% ethyl acetate in hexane as the eluent) to obtain 3-(5- Bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one (645 mg, 1.34 mmol, 19% yield). ¹ H-NMR (400 MHz, DMSO- d6 ) δ 9.22 (dd, J = 8.8, 6.4 Hz, 1H), 8.86-8.93 (m, 1H), 8.63 (t, J = 6.4 Hz, 1H), 8.36- 8.48 (m, 1H), 8.13 (s, 1H), 7.94 (dd, J = 8.4, 1.6 Hz, 1H), 3.38-3.62 (m, 2H), 1.14-1.20 (t, J = 7.3 Hz, 3H) ; ESI MS (m/z) 461.55, 463.55 [(MH)+ Br ^{79, 81} ]. b) Step 2 : 3-(3-( Ethylsulfonyl )-5-(4- fluorophenyl ) pyridin -2- yl) -7-( trifluoromethyl ) quinazoline- 4(3H ) -One: To 3-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one (150.0 mg, 0.325 mmol) and (4-fluorophenyl)boronic acid (45.4 mg, 0.33 mmol) in 1,4-dioxane (2.5 mL) and water (0.3 mL) were stirred with sodium acetate (133.0 mg, 1.62 mmol) And 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane adduct (24.0mg, 0.03mmol), the reaction mixture was subjected to 3 vacuum/nitrogen cycles to make It was completely deoxygenated and then heated at 110°C for 1 hour. After the completion of the reaction, the reaction mixture was diluted with water (10 mL), extracted with ethyl acetate (50 mL), the ethyl acetate layer was separated, dried over anhydrous sodium sulfate and concentrated at 90°C. The crude product was obtained under reduced pressure and purified by silica gel column chromatography (using 50% ethyl acetate in hexane as the eluent) to obtain 3-(3-(ethylsulfonyl)-5-(4- Fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one (115.0 mg, 0.24 mmol, 74% yield). ¹ H-NMR (400 MHz, DMSO- d6 ) δ 9.35 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 2.2 Hz, 1H), 8.69 (s, 1H), 8.43 (d, J = 8.3 Hz, 1H), 8.15 (s, 1H), 8.02-8.06 (m, 2H), 7.96 (dd, J = 8.4, 1.6 Hz, 1H), 7.42-7.48 (m, 2H), 3.42-3.59 (m , 2H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 477.95 (MH)+.

Example 4: 2-(3-(Ethylsulfonyl)-5-(1,1,2,2-tetrafluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine Synthesis of -1( 2H)-one (Compound No. 210): a) Step 1 : (5-( Ethylsulfonyl )-6-(1- oxo- 7-( trifluoromethyl ) phthalazine) -2(1H) -yl ) pyridin- 3 -yl ) boronic acid: to 2-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-ketone (500 mg, 1.08 mmol) in 1,4-dioxane (10 mL) stirred solution was added potassium acetate (212 mg, 2.16 mmol) and pinacol diborate (549 mg, 2.16 mmol). The reaction mixture was completely deoxygenated by vacuum/nitrogen cycles three times, and then 1,1'-bis(diphenylphosphino)ferrocene dichloropalladium(II) dichloromethane adduct (88 mg, 0.11 mmol) was added. The reaction was heated at 90°C for 4 hours. After the reaction was completed, the reaction mixture was cooled to 25°C, diluted with water (20 mL), and extracted with ethyl acetate (50 mL). The ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to obtain the crude compound (5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)) -Yl)pyridin-3-yl)boronic acid (350 mg, 0.82 mmol, 76% yield), which can be used in the next step without further purification. ESI-MS (M/Z) 427.70 (MH) ⁺ . b) Step 2 : 2-(3-( Ethylsulfonyl )-5- hydroxypyridin -2- yl) -7-( trifluoromethyl ) phthalazine -1(2H) -one to (5- (Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)boronic acid (200 mg, 0.47 mmol) in tetrahydrofuran (5 mL) Add hydrogen peroxide (1.196 ml, 11.71 mmol) to the stirred solution. The reaction mixture was stirred at 25°C for 16 hours. After completion, the reaction mixture was quenched with saturated sodium thiosulfate (10 mL) and extracted with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel flash column chromatography (using 80% dichloromethane in methanol as the eluent) to obtain 2-(3-(ethylsulfonyl)-5-hydroxypyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one (110 mg, 0.23 mmol, 59% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 11.36 (s, 1H), 8.70 (s, 1H), 8.50 (s, 1H), 8.45 (d, J = 2.8 Hz, 1H), 8.39 (d, J = 8.3 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 2.8 Hz, 1H), 3.37 (q, J = 6.8 Hz, 2H), 1.06-1.13 (m, 4H); ESI MS (m/z) 399.95 (MH) ⁺ . c) Step 3 : 2-(5-(2- Bromo -1,1,2,2- tetrafluoroethoxy )-3-( ethylsulfonyl ) pyridin -2- yl) -7-( Trifluoromethyl ) phthalazine -1(2H) -one : at 25°C, in a nitrogen atmosphere to 2-(3-(ethylsulfonyl)-5-hydroxypyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one (0.5g, 1.25 mmol) in N,N-dimethylformamide (20 mL) was added to a stirred solution of cesium carbonate (0.612 g, 1.88 mmol) , And then the reaction mixture was stirred for 5 minutes. Then 1,2-dibromo-1,1,2,2-tetrafluoroethane (0.23 mL, 1.88 mmol) was added to the reaction mixture at 25°C, and the reaction was stirred at 25°C for 16 hours. After the reaction was over, the reaction was quenched by adding water (15 mL). The reaction mixture was extracted twice with ethyl acetate (50 mL), the combined organic layer was dried over sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was passed through silica gel column chromatography (using ethyl acetate in hexane as the washing Liquid removal) purification to obtain 2-(5-(2-bromo-1,1,2,2-tetrafluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-one (0.31 g, 0.54 mmol, 43% yield), as a solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 9.17 (d, J = 2.7 Hz, 1H), 8.78 (d, J = 0.5 Hz, 1H), 8.59 (d, J = 2.7 Hz, 1H), 8.52 (s, 1H), 8.43 (dd, J = 8.3, 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 3.51 (q, J = 7.4 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 579.90 (MH) ⁺ . d) Step 4 : 2-(3-( Ethylsulfonyl )-5-(1,1,2,2- tetrafluoroethoxy ) pyridin -2- yl) -7-( trifluoromethyl ) Phthalazine- 1( 2H) -one: at 25°C to 2-(5-(2-bromo-1,1,2,2-tetrafluoroethoxy)-3-(ethylsulfonyl )Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (200 mg, 0.35 mmol) in acetic acid (5 mL) was added to a stirred solution of zinc powder (45.2 mg, 0.69 mmol) ). The reaction mixture was heated at 120°C for 6 hours. After completion, the reaction was quenched by adding water (15 mL), and the reaction mixture was extracted twice with ethyl acetate (50 mL), the mixed organic layer was dried over sodium sulfate, and filtered And concentrated to obtain the crude product. It was purified by silica gel column chromatography (using ethyl acetate in hexane as the eluent) to obtain 2-(3-(ethylsulfonyl)-5-(1,1,2,2-tetrafluoro) Ethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (100 mg, 0.20 mmol, 58% yield), as a solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 9.10 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 0.6 Hz, 1H), 8.53 (d, J = 2.4 Hz, 2H), 8.43 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 6.98 (tt, J = 51.6, 3.0 Hz, 1H), 3.49 (q, J = 7.3 Hz, 2H) , 1.14 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 500.00 (MH) ⁺ .

Example 5: 2-(3-(Ethylsulfonyl)-5-(3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7 Synthesis of -(trifluoromethyl)phthalazine-1(2H)-one (Compound No. 211): a) Step 1 : 2-(3-( Ethylsulfonyl )-5-(3 -methyl) -5-( trifluoromethyl )-1H- pyrazol- 1 -yl ) pyridin -2- yl) -7-( trifluoromethyl ) phthalazine -1(2H) -one: To 2-(5- Bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (600 mg, 1.29 mmol) and 3-methyl-5- To a stirred solution of (trifluoromethyl)-1H-pyrazole (292 mg, 1.95 mmol) in N,N-dimethylformamide (10 mL) was added copper(I) iodide (74.2 mg, 0.39 mmol) , N,N'-dimethylethylenediamine (68.7mg, 0.78mmol) and potassium carbonate (269mg, 1.95mmol), and the resulting mixture was stirred at 130°C for 5 hours. After the reaction was completed, the reaction mixture was cooled to 25°C, water (20 mL) was added to quench the reaction, the reaction mixture was extracted twice with ethyl acetate (50 mL), the mixed organic layer was dried with sodium sulfate, filtered, and reduced Concentrate under pressure to obtain a crude product. The crude product was purified by silica gel flash chromatography (using 30% ethyl acetate in hexane as the eluent) to obtain 2-(3-(ethylsulfonyl)-5-(3-methyl-5- (Trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (51 mg, 0.09 mmol, 7.0% yield Rate), as a solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 9.32 (d, J = 2.4 Hz, 1H), 8.80 (d, J = 2.4 Hz, 2H), 8.55 (s, 1H), 8.43 (dd, J = 8.3, 1.7 Hz, 1H), 8.35 (d, J = 8.1 Hz, 1H), 6.94 (s, 1H), 3.50 (q, J = 7.4 Hz, 2H), 2.55 (s, 3H), 1.17 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 532.00 (MH) ⁺ .

Example 6: 2-(5-(Dimethylphosphoryl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one Synthesis of (Compound No. 206): a) Step 1 : 2-(5-( Dimethylphosphoryl )-3-( ethylsulfonyl ) pyridin -2- yl) -7-( trifluoromethyl) Yl ) phthalazine -1(2H) -one: to 2-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein at 25°C Dimethylphosphine oxide (51.0 mg, 0.65 mmol) was added to a stirred solution of azin-1(2H)-one (300 mg, 0.65 mmol) in 1,4-dioxane (5 mL). Then add tris(dibenzylideneacetone)dipalladium(0) (36.0 mg, 0.04 mmol), 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (18.8 mg, 0.03 mmol) and triethylamine (0.12 ml, 0.85 mmol), and the reaction was heated at 110°C for 24 hours. After the completion of the reaction, the reaction mixture was diluted with water, extracted with ethyl acetate (50 mL), the ethyl acetate was dried over sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by preparative high performance liquid chromatography to obtain 2 -(5-(Dimethylphosphoryl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (150 mg, 0.33 mmol, 50.0% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 9.32 (dd, J = 5.4, 2.0 Hz, 1H), 8.83 (dd, J = 10.0, 2.0 Hz, 1H), 8.78 (d, J = 0.5 Hz, 1H), 8.53 (s, 1H), 8.43 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 3.46 (q, J = 7.4 Hz, 2H), 1.90 ( s, 3H), 1.87 (s, 3H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 460 (MH) ⁺ .

Example 7: 2-(5-((Dimethyl((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoro Synthesis of methyl)phthalazine-1(2H)-one (Compound No. 171): a) Step 1 : 2-(5-(( Dimethyl ( (oxo) -l6 - sulfinyl) amino) ) -3-( ethylsulfonyl ) pyridin -2- yl) -7-( trifluoromethyl ) phthalazine -1(2H) -one: to 2-(5-bromo-3-(ethylsulfonyl) (Pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one (300 mg, 0.65 mmol) in toluene (6 mL) was added to the stirred solution of iminodimethyl- l6-sulfaketone (121 mg, 1.29 mmol), tripotassium hydrogen phosphate (276 mg, 1.29 mmol) and 2-dicyclohexylphosphino-2',4',6'-triisopropyl bisphenyl (62.0 mg, 0.13 mmol). The reaction mixture was completely deoxygenated by vacuum/nitrogen cycle 3 times within 15-20 minutes, and then tris(dibenzylideneacetone)dipalladium(0) (59.4 mg, 0.06 mmol) was added. The reaction mixture was heated at 110°C for 2 hours. After the reaction was completed, the reaction mixture was filtered through a bed of celite, washed with ethyl acetate (30 mL), the organic solvent was washed with brine, dried over sodium sulfate, filtered and concentrated to give Crude product. The crude product was purified by silica gel flash column chromatography (using 60% ethyl acetate in hexane as the eluent) to obtain 2-(5-((dimethyl((oxo)-l6-ylidene)) Sulfonyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (190 mg, 0.40 mmol, 62% yield Rate). ¹ H-NMR (400 MHz, DMSO-D6) δ 8.70 (s, 1H), 8.50 (s, 1H), 8.44 (d, J = 2.7 Hz, 1H), 8.39 (dd, J = 8.4, 1.8 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 7.88 (d, J = 2.7 Hz, 1H), 3.41-3.46 (m, 6H), 3.36 (q, J = 7.2 Hz, 2H) , 1.12 (t, J = 7.5 Hz, 3H) ESI MS (m/z); 474.95 (MH) ⁺ .

Example 8: 2-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)acetonitrile ( Compound No. 184): a) Step 1 : 2-(6- Chloro -5-( ethylthio ) pyridin- 3 -yl ) acetonitrile: To 5-bromo-2-chloro-3-(ethylthio) ) To a stirred solution of pyridine (3.0 g, 11.88 mmol) and trimethylsilylacetonitrile (3.25 mL, 23.76 mmol) in N,N-dimethylformamide (15 mL) was added zinc fluoride (737 mg, 7.13 mmol) And 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (687mg, 1.19mmol). The reaction mixture was completely deoxygenated by vacuum/nitrogen cycling three times within 15-20 minutes, and then tris(dibenzylideneacetone)dipalladium(0) (544 mg, 0.59 mmol) was added. The reaction mixture was heated at 110°C for 5 hours. After the reaction was completed, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (50 mL). The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure to give 2-(6-chloro-5-(ethylthio)pyridin-3-yl)acetonitrile (1.9 g, 8.93 mmol, 75% yield) as a solid . ¹ H-NMR (400 MHz, CHLOROFORM-D) δ 8.08 (q, J = 0.7 Hz, 1H), 7.48 (d, J = 2.4 Hz, 1H), 3.76 (d, J = 0.7 Hz, 2H), 3.00 (q, J = 7.4 Hz, 2H), 1.42 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 212.65 (MH) ⁺ . b) Step 2 : 2-(6- Chloro -5-( ethylsulfonyl ) pyridin- 3 -yl ) acetonitrile: to 2-(6-chloro-5-(ethylthio) at 0°C To a stirred solution of pyridin-3-yl)acetonitrile (0.60 g, 2.82 mmol) in dichloromethane (20 mL) was added m-chloroperbenzoic acid (1.0 g, 5.92 mmol). The reaction mixture was stirred at 25°C for 12 hours. After the reaction was completed, the reaction mixture was diluted with water and extracted with dichloromethane (50 mL). The organic layer was washed with 1N sodium hydroxide solution, dried over sodium sulfate, filtered and evaporated under reduced pressure to obtain a crude product. The crude product was purified by silica gel flash column chromatography (using ethyl acetate in hexane as the eluent) to obtain 2-(6-chloro-5-(ethylsulfonyl)pyridin-3-yl)acetonitrile ( 0.35 g, 1.43 mmol, 51% yield); ESI MS (m/z) 244.70 (MH) ⁺ . c) Step 3 : 2-(5-( Ethylsulfonyl )-6- hydrazinopyridin- 3 -yl ) acetonitrile: To 2-(6-chloro-5-(ethylsulfonyl) at 25°C To a stirred solution of pyridin-3-yl)acetonitrile (250 mg, 1.02 mmol) in ethanol (5 mL) was added hydrazine hydrate (0.4 mL, 5.11 mmol), and the reaction mixture was heated at 90°C for 16 hours. After the reaction was completed, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (50 mL). The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure to give 2-(5-(ethylsulfonyl)-6-hydrazinopyridin-3-yl)acetonitrile (210 mg, 0.87 mmol, 86% yield) Rate), as a solid. ESI MS (m/z) 241.00 (MH) ⁺ . d) Step 4 : 2-(5-( Ethylsulfonyl )-6-(1- oxo- 7-( trifluoromethyl ) phthalazine -2(1H) -yl ) pyridin- 3 -yl ) Acetonitrile: To the stirred solution of 3-hydroxy-6-(trifluoromethyl)isobenzofuran-1(3H)-one (250 mg, 1.146 mmol) in acetic acid (10 mL) was added 2-(5-( Ethylsulfonyl)-6-hydrazinopyridin-3-yl)acetonitrile (275 mg, 1.15 mmol), and the reaction mixture was heated at 115°C for 2 hours. After the reaction was completed, water (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (70 mL). The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated to obtain a crude product, which was purified by silica gel flash chromatography (using 40% ethyl acetate in hexane as the eluent) to give 2-(5-( Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)acetonitrile (190 mg, 0.45 mmol, 39% yield rate). ¹ H-NMR (400 MHz, DMSO-D6) δ 8.98 (d, J = 2.2 Hz, 1H), 8.76 (d, J = 0.5 Hz, 1H), 8.58 (d, J = 2.2 Hz, 1H), 8.52 (s, 1H), 8.42 (dd, J = 8.3, 1.7 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 4.38 (s, 2H), 3.36-3.43 (m, 2H), 1.13 ( t, J = 7.3 Hz, 3H) ESI MS (m/z) 423 (MH) ⁺ .

Example 9: 1-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane Synthesis of -1-carbonitrile (Compound No. 202): a) Step 1 : 1-(6- Chloro -5-( ethylthio ) pyridin- 3 -yl ) cyclopropane- 1 -carbonitrile: at 0°C To a stirred solution of 2-(6-chloro-5-(ethylthio)pyridin-3-yl)acetonitrile (0.5g, 2.35 mmol) in tetrahydrofuran (10 mL) was added 1,2-dibromoethane (0.3 mL, 3.06 mmol). Then sodium hydride (0.2 g, 8.23 mmol) was added to the reaction mixture at 0°C, and the reaction was stirred at 25°C for 3 hours. After the reaction was completed, the reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (75 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure to obtain a crude product. The crude product was purified by silica gel flash chromatography (using ethyl acetate in hexane as the eluent) to obtain 1-(6-chloro-5-(ethylthio)pyridin-3-yl)cyclopropane-1- Formonitrile (350 mg, 1.47 mmol, 62% yield) as a solid. ESI MS (m/z) 238.80 (MH) ⁺ . b) Step 2 : 1-(6- Chloro -5-( ethylsulfonyl ) pyridin- 3 -yl ) cyclopropane- 1 -carbonitrile: to 1-(6-chloro-5- (Ethylthio)pyridin-3-yl)cyclopropane-1-carbonitrile (350 mg, 1.47 mmol) in dichloromethane (10 mL) was added to a stirred solution of m-chloroperbenzoic acid (531 mg, 3.08 mmol), and The reaction mixture was stirred at 25°C for 12 hours. After the reaction was completed, the reaction mixture was diluted with 1N sodium hydroxide (10 mL) solution and extracted with dichloromethane (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to obtain a crude product. The crude product was purified by silica gel flash chromatography (using ethyl acetate in hexane as the eluent) to obtain 1-(6-chloro-5-(ethylsulfonyl)pyridin-3-yl)cyclopropane-1 -Formonitrile (250 mg, 0.92 mmol, 63.0% yield) as a solid. ESI MS (m/z) 270.85 (MH) ⁺ . c) Step 3 : 1-(5-( Ethylsulfonyl )-6- hydrazinopyridin- 3 -yl ) cyclopropane- 1 -carbonitrile: To 1-(6-chloro-5 -(Ethylsulfonyl)pyridin-3-yl)cyclopropane-1-carbonitrile (250 mg, 0.92 mmol) in ethanol (5 mL) was added to a stirred solution of hydrazine hydrate (0.35 mL, 4.62 mmol). The reaction mixture was heated at 90°C for 16 hours. After the reaction was completed, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to give 1-(5-(ethylsulfonyl)-6-hydrazinopyridin-3-yl)cyclopropane-1-carbonitrile (210 mg, 0.8 mmol, 85% yield), as a solid. ESI MS (m/z): 264.95 (MH) ^- . d) Step 4 : 1-(5-( Ethylsulfonyl )-6-(1- oxo- 7-( trifluoromethyl ) phthalazine -2(1H) -yl ) pyridin- 3 -yl ) Cyclopropane- 1 -carbonitrile: Add 3-hydroxy-6-(trifluoromethyl)isobenzofuran-1(3H)-one (250 mg, 1.15 mmol) in a stirred solution of acetic acid (10 mL) 1-(5-(Ethylsulfonyl)-6-hydrazinopyridin-3-yl)cyclopropane-1-carbonitrile (305 mg, 1.15 mmol), and then the reaction mixture was heated at 115°C for 2 hours. After the reaction was completed, the reaction was quenched with water (10 mL), and the reaction mixture was extracted with ethyl acetate (75 mL). The organic layer was washed with brine, dried over sodium sulfate and evaporated under reduced pressure to obtain the crude product, which was purified by silica gel flash chromatography (using 40% ethyl acetate in hexane as the eluent) to obtain 1-(5- (Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane-1-carbonitrile (190 mg , 0.42 mmol, 37.0% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 8.93 (d, J = 2.4 Hz, 1H), 8.75 (d, J = 0.5 Hz, 1H), 8.51 (s , 1H), 8.40-8.42 (m, 2H), 8.33 (d, J = 8.3 Hz, 1H), 3.44 (q, J = 7.4 Hz, 2H), 1.95-1.99 (m, 2H), 1.88-1.93 ( m, 2H), 1.12-1.16 (t, 3H); ESI MS (m/z) 449.05 (MH) ⁺ .

Example 10: 1-cyano-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3 Synthesis of -yl)cyclopropane-1-methanamide (Compound No. 236): a) Step 1 : (5-( Ethylsulfonyl )-6-(1- oxo- 7-( trifluoromethyl) yl) phthalazine -2 (1H) - yl) pyridin-3-yl) carbamate: to a solution of 2- (5-bromo-3- (sulfo acyl-ethyl) pyridin-2-yl) -7- (Trifluoromethyl)phthalazine-1(2H)-one (1.5 g, 3.25 mmol) in 1,4-dioxane (15 mL) stirred solution (1.5 g, 3.25 mmol) was added tert-butyl carbamate (0.5 g, 4.22 mmol), 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (0.2 g, 0.32 mmol), cesium carbonate (1.56 g, 4.87 mmol) and three (Dibenzylideneacetone)dipalladium(0) (0.3 g, 0.32 mmol), and the reaction mixture was heated at 110°C for 5 hours. After the completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted twice with ethyl acetate (50 mL). The combined organic layer was washed with brine, dried over sodium sulfate, and evaporated to obtain a crude product, which was purified by silica gel flash chromatography (using ethyl acetate in hexane as the eluent) to obtain (5-(ethyl) Sulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) tert-butyl carbamate (1 g, 2.01 mmol, 62 % Yield), as a solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 10.30 (s, 1H), 8.87 (d, J = 2.4 Hz, 1H), 8.72 (d, J = 0.5 Hz, 1H), 8.68 (d, J = 2.4 Hz, 1H), 8.51 (s, 1H), 8.40 (dd, J = 8.3, 1.5 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 3.35 (q, J = 7.3 Hz, 2H) , 1.52 (s, 9H), 1.12 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 499 (MH) ⁺ . b) Step 2 : 2-(5 -Amino- 3-( ethylsulfonyl ) pyridin -2- yl) -7-( trifluoromethyl ) phthalazine -1(2H) -one: at 0°C Downward tert-butyl (5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)carbamate Trifluoroacetic acid (2.0 mL, 26.5 mmol) was added to a stirred solution of (1.1 g, 2.21 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at 25°C for 4 hours. After the reaction was completed, the reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed with brine, dried over sodium sulfate, and evaporated to obtain a crude product, which was purified by silica gel flash chromatography (using ethyl acetate in hexane as the eluent) to obtain 2-(5-amino-3- (Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (0.5 g, 1.25 mmol, 57% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 8.66 (s, 1H), 8.49 (d, J = 0.9 Hz, 1H), 8.37 (dd, J = 8.4, 1.7 Hz, 1H), 8.29 (d, J = 8.3 Hz, 1H), 8.12-8.14 (m, 1H), 7.57 (d, J = 2.8 Hz, 1H), 6.31 (d, J = 16.2 Hz, 2H), 3.21-3.29 (q, J = 7.3 Hz, 2H), 1.09 (t, J = 7.6 Hz, 3H); ESI MS (m/z) 399.00 (MH) ⁺ . c) Step 3 : 1- cyano -N-(5-( ethylsulfonyl )-6-(1- oxo- 7-( trifluoromethyl ) phthalazine -2(1H) -yl ) (Pyridin- 3 -yl ) cyclopropane- 1 -carboxamide: to 1-cyanocyclopropane-1-carboxylic acid (42 mg, 0.38 mmol) and 2-(5-amino-3-( Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one (200 mg, 0.50 mmol) in dichloromethane (5 mL) was added to the stirring solution Tolylethylamine (0.17 mL, 1.01 mmol) and hexafluorophosphate (382 mg, 1.004 mmol), the reaction mixture was stirred at 25°C for 16 hours. After the reaction was completed, the reaction mixture was diluted with water (10 mL) and extracted twice with dichloromethane (50 mL). Dry with sodium sulfate, filter and concentrate to obtain the crude product, which was purified by silica gel flash chromatography (using ethyl acetate in hexane as the eluent) to obtain 1-cyano-N-(5-(ethylsulfonate) Amino)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane-1-carboxamide (100 mg, 0.20 mmol , 41% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 10.80 (s, 1H), 9.16 (d, J = 2.4 Hz, 1H), 8.79 (d, J = 2.8 Hz, 1H), 8.74 (s, 1H) , 8.52 (s, 1H), 8.41 (dd, J = 8.3, 1.8 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 3.37 (q, J = 7.3 Hz, 2H), 1.79 (d, J = 4.3 Hz, 4H), 1.13 (t, J = 7.5 Hz, 3H); ESI MS (m/z). 492.00(MH) ⁺ .

Example 11: 2-(3-(Ethylsulfonylimino)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7- Synthesis of (trifluoromethyl)phthalazine-1(2H)-one (Compound No. 207): a) Step 1 : 5- Bromo- 3-( ethylthio )-2- hydrazinepyridine hydrochloride: in To a stirred solution of 5-bromo-2-chloro-3-(ethylthio)pyridine (2.5 g, 9.90 mmol) in ethanol (20 mL) at 25°C was added hydrazine hydrate (3.70 mL, 49.5 mmol). The reaction mixture was heated at 90°C for 60 hours. After completion, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give 5-bromo-3-(ethylthio)-2-hydrazinepyridine hydrochloride (2.1 g, 8.46 mmol, 85% yield) as an oil . ESI MS (m/z) 247.90 (MH) ⁺ . b) Step 2 : 2-(5- Bromo- 3-( ethylthio ) pyridin -2- yl) -7-( trifluoromethyl ) phthalazin -1(2H) -one: to 3-hydroxy- To a stirred solution of 6-(trifluoromethyl)isobenzofuran-1(3H)-one (2.0 g, 9.27 mmol) in acetic acid (25 mL) was added 5-bromo-3-(ethylthio)-2- Hydrazine pyridine hydrochloride (1.0 g, 4.03 mmol), and the reaction mixture was heated at 115°C for 2 hours. After the reaction was completed, the reaction was quenched with water (20 mL), and the reaction mixture was extracted with ethyl acetate (150 mL). The organic layer was washed with brine, dried over sodium sulfate and evaporated to obtain the crude product, which was purified by silica gel flash chromatography (using 30% ethyl acetate in hexane as the eluent) to obtain 2-(5-bromo-3) -(Ethylthio)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (1.1 g, 2.56 mmol, 63% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 8.75 (d, J = 0.5 Hz, 1H), 8.55 (d, J = 2.0 Hz, 1H), 8.52 (s, 1H), 8.40 (dd, J = 8.2, 1.6 Hz, 1H), 8.29-8.32 (m, 2H), 3.06 (q, J = 7.3 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 431.85 ( MH) ⁺ . c) Step 3 : 2-(3-( Ethylthio )-5-(4-(1,1,2,2- tetrafluoroethoxy ) phenyl ) pyridin -2- yl) -7-( Trifluoromethyl ) phthalazine -1(2H) -one: To 2-(5-bromo-3-(ethylthio)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone (400 mg, 0.93 mmol) in a mixture of 1,4-dioxane (5 mL) and water (1 mL) was added to the stirred solution of 3,3,4,4-tetramethyl-1-( 4-(1,1,2,2-tetrafluoroethoxy)phenyl)borane (353 mg, 1.12 mmol), potassium carbonate (321 mg, 2.32 mmol) and 1,1'-bis(diphenyl) Phosphine) ferrocene-palladium(II) dichloride dichloromethane complex (76 mg, 0.09 mmol). The reaction mixture was completely deoxygenated by a vacuum/nitrogen cycle 3 times, and the reaction was heated at 110°C for 3 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate (50 mL) and water (10 mL). The ethyl acetate layer was separated, dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (using 40% ethyl acetate in hexane as the eluent) to obtain 2-(3-( Ethylthio)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -Ketone (270 mg, 0.49 mmol, 53% yield), as a solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 8.76 (s, 1H), 8.71 (d, J = 2.1 Hz, 1H), 8.54 (s, 1H), 8.41 (dd, J = 8.3, 1.5 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 8.25 (d, J = 2.1 Hz, 1H), 7.96-7.99 (m, 2H), 7.46 (d, J = 8.6 Hz, 2H), 6.72- 6.99 (m, 1H), 3.12 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 544.05 (MH) ⁺ . d) Step 4 : 2-(3-( Ethylsulfonylimino )-5-(4-(1,1,2,2- tetrafluoroethoxy ) phenyl ) pyridin -2- yl) -7-( Trifluoromethyl ) phthalazine -1(2H) -one: to 2-(3-(ethylthio)-5-(4-(1,1,2,2-tetrafluoroethoxy) )Phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (250 mg, 0.46 mmol) in methanol (5 mL) was added to a stirred solution of iodophenyl diacetate (370 mg, 1.15 mmol) and ammonium carbamate (71.8 mg, 0.92 mmol). The mixture was stirred at 25°C for 5 hours. After the reaction was completed, water (20 mL) was added, and the reaction mixture was extracted twice with ethyl acetate (75 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel flash chromatography (using 60% ethyl acetate in hexane as the eluent) to obtain 2-(3-(ethylsulfonylimino)-5-(4-(1, 1,2,2-Tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (140mg, 0.24 mmol, 53.0% yield) , Is a solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 9.23 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.69 (d, J = 2.1 Hz, 1H), 8.52 (s, 1H) , 8.40 (dd, J = 8.3, 1.8 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 8.01-8.04 (m, 2H), 7.51 (d, J = 8.9 Hz, 2H), 6.86 ( tt, J = 52.0, 2.9 Hz, 1H), 4.61 (d, J = 38.8 Hz, 1H), 3.27 (q, J = 6.7 Hz, 2H), 1.12 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 575.10 (MH) ⁺ .

Example 12: 3-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6(trifluoromethyl)benzo[d][1,2,3 ] Triazine-4(3H)-one (Compound No. 182): a) Step 1 : 6-( Trifluoromethyl )-2H- benzo [d][1,3] oxazine -2, 4(1H) -Diketone: To a stirred solution of 2-amino-5-(trifluoromethyl)benzoic acid (500mg, 2.44mmol) in tetrahydrofuran (7mL) at 0°C was added triphosgene (247mg, 0.83 mmol) in tetrahydrofuran (2mL). The reaction mixture was stirred at 25°C for 4 hours. After the reaction was completed, the reaction mixture was diluted with water (20 mL) and extracted twice with ethyl acetate (50 mL). The mixed ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to obtain 6-(trifluoromethyl)-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (500 mg, 2.16 mmol, 89% yield). ¹ H-NMR (400 MHz, DMSO-d6) δ 12.08 (s, 1H), 8.13 (t, J = 0.7 Hz, 1H), 8.05-8.08 (m, 1H), 7.31 (d, J = 8.8 Hz, 1H); ESI MS (m/z) 229.85 (MH) ^- . b) Step 2 : 2 -Amino -N-(5- bromo- 3- fluoropyridin -2- yl) -5-( trifluoromethyl ) benzamide: To potassium tert-butoxide (3.40 g, 30.3 Add 5-bromo-3-fluoropyridin-2-amine (2.60 g, 13.63 mmol) to a suspension of tetrahydrofuran (70 mL) in tetrahydrofuran (70 mL). The reaction mixture was stirred at 25°C for 10 minutes, and then 6-(trifluoromethyl)-2H-benzo[d] [1,3]oxazine-2,4(1H)-dione ( 3.5 g, 15.14 mmol). The reaction was then stirred at 25°C for an additional hour. After the reaction was completed, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (200 mL). The ethyl acetate layer was separated, dried over sodium sulfate and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (using ethyl acetate in hexane as the eluent) to obtain 2-amino-N-( 5-Bromo-3-fluoropyridin-2-yl)-5-(trifluoromethyl)benzamide (2.8 g, 7.40 mmol, 48.9% yield). ¹ H-NMR (400 MHz, DMSO-d6) δ 10.86 (s, 1H), 8.47-8.47 (m, 1H), 8.25 (dd, J = 9.4, 2.1 Hz, 1H), 8.12 (d, J = 1.0 Hz, 1H), 7.50 (dd, J = 8.9, 1.8 Hz, 1H), 7.19 (s, 2H), 6.89 (d, J = 8.6 Hz, 1H), ESI MS (m/z) 377.90 (MH) ⁺ . c) Step 3 : 3-(5- Bromo- 3- fluoropyridin -2- yl) -6-( trifluoromethyl ) benzo [d][1,2,3] triazine -4(3H) - one: to a solution of 2-amino-0 ℃ -N- (5- bromo-3-fluoropyridin-2-yl) -5- (trifluoromethyl) benzoyl-amine (2.8 g, 7.40 mmol) in 6N A solution of sodium nitrite (0.8g, 11.11mmol) in water (4mL) was added dropwise to a stirred solution of hydrochloric acid (12ml), and the reaction was stirred at 25°C for 1 hour. After the reaction was completed, the mixture was basified with saturated sodium bicarbonate solution and extracted with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain a crude product, which was purified by flash chromatography to obtain 3-(5-bromo-3-fluoropyridin-2-yl)-6-(trifluoromethyl) Yl)benzo[d][1,2,3]triazine-4(3H)-one (2.4 g, 6.17 mmol, 83% yield), as a solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 8.81-8.81 (m, 1H), 8.67 (dd, J = 8.8, 2.0 Hz, 1H), 8.56-8.59 (m, 2H), 8.53 (dd, J = 8.7, 1.8 Hz, 1H); ESI MS (m/z) 390.90 (MH) ⁺ . d) Step 4: 3- (5-bromo-3- (ethylthio) pyridin-2-yl) -6- (trifluoromethyl) benzo [d] [1,2,3] triazin - 4(3H) -ketone: To a stirred suspension of sodium hydride (34.5 mg, 0.86 mmol) in N,N-dimethylformamide (5 mL) was added ethyl mercaptan (0.1 mL, 0.86 mmol) at 0°C. The reaction mixture was stirred at the same temperature for 15 minutes. Subsequently, 3-(5-bromo-3-fluoropyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one ( A solution of 280 mg, 0.72 mmol) in N,N-dimethylformamide (2 mL) was added dropwise to the above reaction mixture, and the reaction was stirred at 0°C for 30 minutes. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (40 mL). The ethyl acetate layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was passed through silica gel column chromatography (using ethyl acetate in The solution in alkane is used as the eluent) to obtain 3-(5-bromo-3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1, 2 ,3] Triazine-4(3H)-one (240 mg, 0.56 mmol, 77% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 8.66 (d, J = 2.1 Hz, 1H), 8.58 (d, J = 8.3 Hz, 2H), 8.54 (dd, J = 8.6, 1.8 Hz, 1H) , 8.41 (d, J = 2.1 Hz, 1H), 3.10 (q, J = 7.3 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 432.85 (MH) ⁺ . e) Step 5 : 3-(5- Bromo- 3-( ethylsulfonyl ) pyridin -2- yl) -6-( trifluoromethyl ) benzo [d][1,2,3] tri Azin -4(3H) -one: To 3-(5-bromo-3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][ To a stirred solution of 1,2,3]triazine-4(3H)-one (120 mg, 0.28 mmol) in dichloromethane (10 mL) was added m-chloroperbenzoic acid (176 mg, 0.61 mmol). The reaction mixture was stirred at 25°C for 12 hours. After the reaction, the reaction mixture was diluted with dichloromethane (40 mL), and washed with saturated sodium bicarbonate solution (10 mL) and saturated sodium thiosulfate solution (10 mL) successively. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (using ethyl acetate in hexane as the eluent) to obtain 3-(5-bromo-3- (Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one (93 mg, 0.20 mmol, 72% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 9.28 (d, J = 2.4 Hz, 1H), 8.94 (d, J = 2.2 Hz, 1H), 8.60 (d, J = 8.1 Hz, 2H), 8.55 (dd, J = 8.6, 2.0 Hz, 1H), 3.47 (q, J = 7.4 Hz, 2H), 1.13 (t, J = 7.4 Hz, 3H); ESI MS (m/z) 464.85 (MH) ⁺ . f) Step 6 : 3-(3-( Ethylsulfonyl )-5-(4- fluorophenyl ) pyridin -2- yl) -6( trifluoromethyl ) benzo [d][1, 2,3] Triazine -4(3H) -one: To 3-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d ][1,2,3]triazine-4(3H)-one (400 mg, 0.86 mmol) and (4-fluorophenyl)boronic acid (181 mg, 1.29 mmol) in 1,4-dioxane (6 Add sodium acetate (133.0mg, 1.62mmol) and 1,1′-bis(diphenylphosphino)ferrocene-palladium dichloride (II) dichloride to the stirred solution of a mixture of mL) and water (1 mL) Methane adduct (63.2mg, 0.08mmol). The reaction mixture was vacuum/nitrogen looped 3 times to completely deoxygenate, and then heated at 110°C for 10 hours. After the reaction, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain a crude product, which was purified by reverse-phase preparative high performance liquid chromatography (using an aqueous solution of acetonitrile as an eluent) to obtain 3-(3-( Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H) -Ketone (75 mg, 0.16 mmol, 18% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 9.39 (d, J = 2.4 Hz, 1H), 8.84 (d, J = 2.2 Hz, 1H), 8.60-8.62 (m, 2H), 8.56 (dd, J = 8.7, 1.8 Hz, 1H), 8.05-8.10 (m, 2H), 7.43-7.49 (m, 2H), 3.51 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H ); ESI MS (m/z) 478.95 (MH) ⁺ .

Example 13: 2-(4-(Ethylsulfonyl)-6-(3-(trifluoromethyl)phenyl)pyridazin-3-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-Kone: Synthesis of (Compound No. 173): a) Step 1 : Synthesis of 3- chloro -6-(3-( trifluoromethyl ) phenyl ) pyridazine: To 3,6-dichloro To a stirred solution of pyridazine (5.0 g, 33.2 mmol) in 1,4-dioxane (45 mL) and water (5.00 ml) was added potassium carbonate (11.48 g, 83.0 mmol) and (3-(trifluoromethyl) ) Phenyl)boronic acid (5.05 g, 26.6 mmol). The reaction mixture was completely deoxygenated by vacuum/nitrogen cycle 3 times, and then [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.35g, 1.66mmol) was added. The reaction mixture was heated at 90°C for 2 hours. After the reaction was completed, water (50 mL) was added to the reaction mixture, and it was extracted with ethyl acetate (150 mL). The ethyl acetate layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel flash column chromatography (using 20% ethyl acetate in hexane as the eluent) to give 3-chloro-6-(3-(trifluoromethyl)phenyl)pyridazine (5.0 g, 19.33 mmol, 58% yield), as a white solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 8.43-8.49 (m, 2H), 8.06-8.10 (m, 1H), 8.03 (d, J = 4.0 Hz, 1H), 7.91-7.95 (m, 1H) ), 7.79-7.86 (m, 1H); ESI-MS (M/Z) 259.00 (MH) ⁺ . b) Step 2 : Synthesis of 6-(3-( trifluoromethyl ) phenyl ) pyridazin -3(2H) -one: Add 3-chloro-6-(3-(trifluoromethyl)phenyl ) A solution of pyridazine (5.0 g, 19.33 mmol) in acetic acid (45 mL) was heated at 115°C for 12 hours. After the reaction was completed, the reaction mixture was cooled to 25°C, and the acetic acid was removed under vacuum pressure. Ice-cold water (50 mL) was added to the residue, and the solid thus separated was filtered and dried in vacuo to obtain 6-(3 (trifluoromethyl)phenyl)pyridazine-3(2H)-one (3.5 g, 14.57) mmol, 75% yield), a white solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 13.1 (s, 1H), 8.13-8.17 (m, 3H), 7.79 (d, J = 7.6 Hz, 1H), 7.72 (t, J = 8.1 Hz, 1H), 7.02 (d, J = 10.1 Hz, 1H); ESI-MS (M/Z) 241.05 (MH) ⁺ . c) Step 3 : 4- Bromo -6-(3-( trifluoromethyl ) phenyl ) pyridazine -3(2H) -one: To 6-(3-(trifluoromethyl) at 25°C )Phenyl)pyridazine-3(2H)-one (3.5 g, 14.57 mmol) in water (87.5 ml) was stirred with potassium acetate (2.15 g, 21.86 mmol) and potassium bromide (5.20 g, 43.7 mmol) . Then bromine (2.3 mL, 43.7 mmol) was added dropwise to the reaction mixture at 0°C, and the reaction was heated at 100°C for 12 hours. After the reaction was completed, the reaction mixture was quenched by adding saturated sodium sulfite solution (50 mL) at 0°C, and then extracted with ethyl acetate (150 mL). The ethyl acetate layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel flash column chromatography (using 25% ethyl acetate in hexane as the eluent) to give 4-bromo-6-(3-(trifluoromethyl)phenyl)pyridazine-3( 2H)-ketone (4.0 g, 12.54 mmol, 86% yield), a white solid substance. ¹ H-NMR (400 MHz, DMSO-D6) δ 13.67 (s, 1H), 8.77 (s, 1H), 8.19-8.22 (m, 2H), 7.81 (d, J = 7.6 Hz, 1H), 7.72 ( t, J = 7.8 Hz, 1H); ESI MS (m/z) 316.85, 318.85 [(MH) ⁺ Br ^{79, 81} ]. d) Step 4 : 4-( Ethylthio )-6-(3-( trifluoromethyl ) phenyl ) pyridazine -3(2H) -one: At 0℃, add ethanethiol (1.1mL , 15.04mmol) of N,N-dimethylformamide (10mL) was added sodium hydride (0.5g, 12.54mmol) into the stirring solution, and the reaction was stirred for 15 minutes. Then add 4-bromo-6-(3-(trifluoromethyl)phenyl)pyridazine-3(2H)-one (4.0 g, 12.54 mmol) in N,N-dimethylformamide ( 10 mL), the reaction was stirred at 25°C for 16 hours. After the completion of the reaction, the reaction mixture was cooled to 0°C, and the reaction was quenched by the dropwise addition of water (20 mL) and diluted with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel flash column chromatography (using 25% ethyl acetate in hexane as the eluent) to obtain 4-(ethylthio)-6-(3-(trifluoromethyl)phenyl) Pyridazine-3(2H)-one (2.0 g, 6.66 mmol, 53% yield) as a white solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 13.27 (s, 1H), 8.20-8.23 (m, 2H), 7.79-7.81 (m, 1H), 7.72 (t, J = 7.7 Hz, 1H), 7.65 (s, 1H), 3.10 (q, J = 7.3 Hz, 2H), 1.32 (t, J = 7.3 Hz, 3H); ESI-MS (M/Z) 301.00 (MH) ⁺ . e) Step 5 : 3- Chloro- 4-( ethylthio )-6-(3-( trifluoromethyl ) phenyl ) pyridazine: Add 4-(ethylthio)-6-(3-( A stirred solution of trifluoromethyl)phenyl)pyridazine-3(2H)-one (2.0 g, 6.66 mmol) in phosphorus oxychloride (6.5 mL, 69.9 mmol) was heated at 110°C for 4 hours. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure. The resulting solid residue was carefully treated by dropwise addition of saturated sodium bicarbonate solution (25 mL) and extracted twice with ethyl acetate (150 mL). The combined ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel flash column chromatography (using 15% ethyl acetate in hexane as the eluent) to obtain 3-chloro-4-(ethylthio)-6-(3-(trifluoromethyl)benzene Pyridazine (2.0 g, 6.27 mmol, 94% yield) as a white solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 8.45-8.47 (m, 2H), 8.06 (s, 1H), 7.92 (dd, J = 8.4, 0.6 Hz, 1H), 7.81 (t, J = 7.8 Hz, 1H), 3.34 (t, J = 7.3 Hz, 2H), 1.36 (t, J = 7.3 Hz, 3H); ESI-MS (M/Z) 318.90 (MH) ⁺ . f) Step 6 : 3- chloro- 4-( ethylsulfonyl )-6-(3-( trifluoromethyl ) phenyl ) pyridazine: to 3-chloro-4-(ethyl Sulfuryl)-6-(3-(trifluoromethyl)phenyl)pyridazine (2.0 g, 6.27 mmol) in dichloromethane (20 mL) was added to a stirred solution of 3-chloroperoxybenzoic acid (5.4 g, 18.82 mmol). The reaction was stirred at 25°C for 16 hours. After the reaction was completed, the reaction mixture was quenched by dropwise addition of saturated sodium bicarbonate solution (10 mL), and extracted with dichloromethane (100 mL). The organic layer was concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel flash column chromatography (using 10% ethyl acetate in hexane) as the eluent to obtain 3-chloro-4-(ethylsulfonyl)-6-(3-(trifluoromethyl) (Yl)phenyl)pyridazine (2.0 g, 5.70 mmol, 91% yield) as a white solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 8.70 (s, 1H), 8.54 (t, J = 7.6 Hz, 2H), 7.99 (dd, J = 7.8, 0.7 Hz, 1H), 7.83-7.89 ( m, 1H), 3.69 (q, J = 7.4 Hz, 2H), 1.21-1.27 (m, 3H); ESI-MS (M/Z) 350.95 (MH) ⁺ . g) Step 7 : 2-(4-( Ethylsulfonyl )-6-(3-( trifluoromethyl ) phenyl ) pyridazin- 3 -yl )-7-( trifluoromethyl ) phthalein Azin -1(2H) -one: To 7-(trifluoromethyl)phthalazine-1(2H)-one (0.120 g, 0.56 mmol) in N,N-dimethylformamide (10 Add potassium carbonate (0.116 g, 0.84 mmol) to the stirring solution in mL), and stir the reaction for 5 minutes. Then 3-chloro-4-(ethylsulfonyl)-6-(3-(trifluoromethyl)phenyl)pyridazine (0.24 g, 0.67 mmol) was added to the reaction mixture, and the reaction was carried out at 25°C. Stir for 16 hours. After the reaction was completed, the reaction mixture was diluted with cold water (5 mL) and extracted with ethyl acetate (50 mL). The ethyl acetate layer was dried with sodium sulfate and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel flash column chromatography (using 20% ethyl acetate in hexane as the eluent) to obtain 2-(4-(ethylsulfonyl)-6-(3-(trifluoromethyl) (Phenyl)phenyl)pyridazin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (135 mg, 0.25 mmol, 46% yield), as an off-white solid. ¹ H-NMR (400 MHz, DMSO-D6) δ 9.09 (d, J = 19.6 Hz, 1H), 8.89 (d, J = 0.6 Hz, 1H), 8.58-8.71 (m, 3H), 8.48 (dd, J = 8.3, 1.5 Hz, 1H), 8.39 (d, J = 8.3 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.92 (t, J = 7.8 Hz, 1H), 3.75 (q, J = 7.2 Hz, 2H), 1.22 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 528.85 (MH) ⁺ .

Example 14: 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1( Synthesis of 2H)-one (Compound No. 131): a) Step 1 : 2-(5- Bromo- 3-( ethylsulfonyl ) pyridin -2- yl) -4 -methyl -7-( 三fluoro-methyl) phthalazin--1 (2H) - one to a solution of 2-acetyl-5- (trifluoromethyl) benzoic acid (200 mg, 0.86 mmol) in acetic acid (6 mL) was added 5-bromo - 3-(Ethylsulfonyl)-2-hydrazinepyridine hydrochloride (265 mg, 0.95 mmol) [prepared according to the procedure described in (WO2018008727)]. The reaction mixture was heated at 120°C for 4 hours. After the reaction was completed, the reaction mixture was cooled to 25°C, diluted with water (50 mL), and extracted twice with ethyl acetate (100 mL). The mixed ethyl acetate layer was washed with brine (50 mL), dried over sodium sulfate and concentrated to obtain the crude product, which was purified by silica gel column chromatography (using 40% ethyl acetate in hexane as the eluent) to obtain 2-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one (200 mg, 0.42 mmol, 49% yield); ¹ H-NMR (400 MHz, DMSO-D6) δ 9.17 (s, 1H), 8.77 (s, 1H), 8.53 (s, 1H), 8.41 (d, J = 8.9 Hz , 1H), 8.31 (d, J = 8.9 Hz, 1H), 3.44-3.52 (m, 2H), 2.64 (s, 3H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z ) 475.55, 477.65 [(MH) ⁺ Br ^{79, 81} ]. b) Step 2 : 2-(3-( Ethylsulfonyl )-5-(4- fluorophenyl ) pyridin -2- yl) -4 -methyl -7-( trifluoromethyl ) phthalazine -1(2H) -one: To 2-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1( Add 2H)-ketone (160 mg, 0.34 mmol) and (4-fluorophenyl)boronic acid (70.5 mg, 0.50 mmol) to a stirred solution of 1,4-dioxane (6 mL) and water (1.5 mL) Potassium bicarbonate (116 mg, 0.84 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane adduct (27.4 mg, 0.034 mmol). The reaction mixture was vacuum/nitrogen looped three times to completely deoxygenate, and then heated at 110°C for 3 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate (50 mL) and water (10 mL), and the ethyl acetate was separated. The layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was obtained, which was purified by silica gel column chromatography (using 40% ethyl acetate in hexane as the eluent) to obtain 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl) )Pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one (120 mg, 0.24 mmol, 72.7% yield); ¹ H-NMR (400 MHz , DMSO-D6) δ 9.28 (d, J = 2.1 Hz, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.55 (s, 1H), 8.41 (dd, J = 8.6, 1.8 Hz, 1H) , 8.32 (d, J = 8.3 Hz, 1H), 8.02 (dd, J = 8.6, 5.5 Hz, 2H), 7.44 (t, J = 8.7 Hz, 2H), 3.47-3.52 (m, 2H), 2.66 ( s, 3H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 492.10 (MH) ⁺ .

Example 15: 2-(6-Bromo-3-(ethylthio)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one Synthesis of (Compound No. 234): a) Step 1 : 2-(6- Bromo- 3 -nitroimidazo [1,2-a] pyridin -2- yl) -7-( trifluoromethyl ) phthalein Azin -1(2H) -one: To 7-(trifluoromethyl)phthalazine-1(2H)-one (2.5 g, 11.67 mmol) in N,N-dimethylformamide (20 mL) stirred solution Add cesium carbonate (7.6 g, 23.35 mmol) and 6-bromo-2-chloro-3-nitroimidazo[1,2-a]pyridine (3.20 g, 11.67 mmol). The reaction mixture was stirred at 25°C for 5 hours. After the reaction was completed, water (50 mL) was added to the reaction mixture, and then extracted twice with ethyl acetate (100 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated to obtain the crude product, which was purified by silica gel flash chromatography (using ethyl acetate in hexane as the eluent) to obtain 2-(6-bromo-3-nitro Imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (3.1 g, 6.83 mmol, 58% yield), as a solid. ESI MS (m/z) 455.80 (MH) ⁺ . b) Step 2 : 2-(3- Amino -6- bromoimidazo [1,2-a] pyridin -2- yl) -7-( trifluoromethyl ) phthalazine -1(2H) -one: To 2-(6-bromo-3-nitroimidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (5 g, 11.01 mmol) of acetic acid (100 mL) was added to the stirring suspension of iron powder (3.07g, 55.0mmol), the reaction mixture was heated at 90 ℃ for 6 hours, after the completion of the reaction, the reaction mixture was filtered through diatomaceous earth, with ethyl acetate ( 150mL), and the ethyl acetate layer was washed with water (50mL) and saturated sodium carbonate solution. The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure to obtain 2-(3-amino-6-bromoimidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalein Ozin-1(2H)-one (3.4 g, 8.02 mmol, 73% yield). ESI MS (m/z) 425.85 (MH) ⁺ . c) Step 3 : 2-(6- Bromo- 3-( ethylthio ) imidazo [1,2-a] pyridin -2- yl) -7-( trifluoromethyl ) phthalazine -1(2H ) -Ketone: Add tert-butyl nitrite (0.05 mL, 0.71 mmol) dropwise to a stirred solution of diethyl disulfide (0.1 mL, 0.57 mmol) in acetonitrile (5 mL) at 25°C, and place the resulting mixture in Stir at the same temperature for 30 minutes. Subsequently, 2-(3-amino-6-bromoimidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (200 mg, 0.47 mmol) was added dropwise, and the reaction mixture was stirred at 25° C. for 4 hours. After the reaction was completed, the reaction mixture was diluted with water (30 mL) and extracted twice with ethyl acetate (50 mL). Dry over sodium sulfate, filter and evaporate under reduced pressure to obtain the crude product, which was purified by silica gel flash chromatography (using ethyl acetate in hexane as the eluent) to obtain 2-(6-bromo-3-(ethyl) Thio)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (110 mg, 0.23 mmol, 50% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 8.86 (q, J = 0.8 Hz, 1H), 8.76 (d, J = 8.9 Hz, 1H), 8.54 (s, 1H), 8.41 (dd, J = 8.4, 2.0 Hz, 1H), 8.31 (d, J = 8.6 Hz, 1H), 7.71-7.75 (m, 1H), 7.64-7.68 (m, 1H), 2.74 (q, J = 7.3 Hz, 2H), 1.05 (t, J = 24.7, 7.1 Hz, 3H); ESI MS (m/z) 468.90 (MH) ⁺ .

Example 16: 2-(3-(Ethylsulfonyl)-6-(1H-1,2,4-triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Synthesis of azin-1(2H)-one (Compound No. 232): a) Step 1 : 2-(6- Chloro- 3-( ethylsulfonyl ) pyridin -2- yl) -7-( trifluoro Methyl ) phthalazine -1(2H) -one: To 3-hydroxy-6-(trifluoromethyl)isobenzofuran-1(3H)-one (200 mg, 0.92 mmol) in acetic acid (5 mL) 5-chloro-3-(ethylsulfonyl)-2-hydrazinepyridine hydrochloride (216 mg, 0.92 mmol) was added to the stirred solution. The reaction mixture was heated at 115°C for 2 hours. After the reaction was completed, the reaction mixture was cooled to 25°C, diluted with water (20 mL), and then extracted twice with ethyl acetate (50 mL). The mixed ethyl acetate layer was washed with brine (20 mL) and water (20 mL), dried over sodium sulfate and concentrated to obtain a crude product, which was subjected to silica gel column chromatography (using 30% ethyl acetate in hexane as the elution Reagent) to obtain 2-(5-chloro-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (135 mg, 0.323 mmol, 35% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 9.11 (d, J = 2.4 Hz, 1H), 8.76 (d, J = 0.5 Hz, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.52 (d, J = 1.2 Hz, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 3.46 (q, J = 7.4 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 418.05(MH) ⁺ . b) Step 2 : 2-(3-( Ethylsulfonyl )-6-(1H-1,2,4- triazol- 1 -yl ) pyridin -2- yl) -7-( trifluoromethyl yl) phthalazine -1 (2H) - one: to a 2- (6-chloro-3- (sulfo acyl-ethyl) pyridin-2-yl) -7- (trifluoromethyl) phthalazine -1 (2H )-Ketone (150 mg, 0.36 mmol) in N,N-dimethylformamide (5 mL) was added cesium carbonate (292 mg, 0.89 mmol) and 1H-1,2,4-triazole (37.2 mg, 0.540 mmol). The reaction was stirred at 25°C for 5 hours. After the reaction was completed, water (50 mL) was added to the reaction mixture and extracted twice with ethyl acetate (100 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel flash chromatography (using ethyl acetate in hexane as the eluent) to obtain 2-(3-(ethylsulfonyl)-6-(1H-1,2,4-triazole) -1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one (135 mg, 0.30 mmol, 83% yield). ¹ H-NMR (400 MHz, DMSO-D6) δ 9.44 (s, 1H), 8.80-8.82 (m, 2H), 8.54 (d, J = 0.9 Hz, 1H), 8.44 (dd, J = 7.9, 1.8 Hz, 2H), 8.33-8.37 (m, 2H), 3.41-3.46 (q, 2H), 1.15 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 450.95 (MH) ⁺ .

The following compounds (Table 1) are obtained by using suitable starting materials and following the similar methods described in Schemes 1-9 or Examples 1-16. Table-1 Item No. Compound name analyze data 1 2-(3-(Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.02 (dd, J = 4.9, 1.7 Hz, 1H), 8.74 (s, 1H), 8.61 (dd, J = 7.8, 1.7 Hz, 2H), 8.51 (d , J = 8.3 Hz, 1H), 8.28 (dd, J = 8.3, 1.5 Hz, 1H), 7.90-7.99 (m, 1H), 3.40 (q, J = 7.4 Hz, 2H), 1.13 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 384.1 (MH)+. 2 2-(3-(Ethylthio)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.69 (d, J = 7.8 Hz, 1H), 8.55 (s, 1H), 8.49 (d, J = 8.3 Hz, 1H), 8.41 (dd, J = 4.6 , 1.5 Hz, 1H), 8.23 (dd, J = 8.4, 1.6 Hz, 1H), 8.03-8.08 (m, 1H), 7.58 (dd, J = 8.1, 4.6 Hz, 1H), 2.96 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 352.1 (MH)+ 3 2-(5-Bromo-3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.74 (d, J = 0.7 Hz, 1H), 8.57 (t, J = 2.4 Hz, 2H), 8.52 (d, J = 8.3 Hz, 1H), 8.30 ( d, J = 2.2 Hz, 1H), 8.27 (dd, J = 8.6, 1.5 Hz, 1H), 3.08 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 430, 432 [(MH)+ Br79, 81]. 4 2-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.20 (d, J = 2.4 Hz, 1H), 8.81 (d, J = 2.2 Hz, 1H), 8.75 (d, J = 0.5 Hz, 1H), 8.60 ( s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.28 (dd, J = 8.7, 1.6 Hz, 1H), 3.48 (q, J = 7.4 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 462.0, 464.0 [(MH)+ Br79, 81]. 5 2-(6-Chloro-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.76 (d, J = 2.4 Hz, 1H), 8.60-8.65 (m, 2H), 8.51 (d, J = 8.3 Hz, 1H), 8.28-8.32 (m , 1H), 8.12-8.14 (m, 1H), 3.43 (q, J = 7.4 Hz, 2H), 1.13-1.24 (t, J = 7.4 Hz, 3H); ESI MS (m/z) 417.85 (MH) +. 6 2-(5-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.4 Hz, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.61 (m, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.29 (dd, J = 8.7, 1.6 Hz, 1H), 8.14 (d, J = 2.0 Hz, 2H), 7.82 (t, J = 1.8 Hz, 1H), 3.53 (q, J = 7.4 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 527.9, 529.9 [(MH)+ Cl35, 37]. 7 2-(5-(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.4 Hz, 1H), 8.83 (d, J = 2.2 Hz, 1H), 8.76 (d, J = 0.5 Hz, 1H), 8.61 ( s, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.29 (dd, J = 8.3, 1.5 Hz, 1H), 7.83-7.88 (m, 2H), 7.47 (tt, J = 9.3, 2.3 Hz , 1H), 3.53 (q, J = 7.4 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 496.10 (MH)+. 8 2-(3-(Ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 2.4 Hz, 1H), 8.83 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.62 (s, 1H), 8.54 (d, J = 8.3 Hz, 1H), 8.29 (d, J = 6.8 Hz, 1H), 8.22 (d, J = 8.3 Hz, 2H), 7.98 (d, J = 8.1 Hz, 2H), ), 3.50 (q, J = 7.4 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 527.95 (MH)+. 9 2-(3-(Ethylthio)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6DMSO-d6) δ 8.86 (q, J = 1.0 Hz, 1H), 8.78 (d, J = 0.5 Hz, 1H), 8.60 (s, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.41 (d, J = 1.7 Hz, 1H), 8.29 (dd, J = 8.3, 1.5 Hz, 1H), 3.15 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 420 (MH)+ 10 2-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.51 (q, J = 1.1 Hz, 1H), 8.94-8.95 (m, 1H), 8.79 (d, J = 0.5 Hz, 1H), 8.62 (s, 1H ), 8.53 (d, J = 8.3 Hz, 1H), 8.30 (dd, J = 8.3, 1.5 Hz, 1H), 3.55 (q, J = 7.4 Hz, 2H), 1.18 (t, J = 7.5 Hz, 3H ); ESI MS (m/z) 451.95 (MH)+. 11 2-(3-(Ethylsulfonyl)-6-(1H-1,2,4-triazol-1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1 (2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.47 (d, J = 1.0 Hz, 1H), 8.83 (d, J = 8.6 Hz, 1H), 8.80 (d, J = 2.0 Hz, 1H), 8.62 ( d, J = 4.6 Hz, 1H), 8.54 (d, J = 8.3 Hz, 1H), 8.47 (d, J = 1.2 Hz, 1H), 8.34-8.37 (m, 1H), 8.29-8.32 (m, 1H) ), 3.45 (q, J = 7.4 Hz, 2H), 1.15 (t, J = 7.4 Hz, 3H); ESI MS (m/z) 451.15 (MH)+. 12 2-(3-(Ethylsulfonyl)-6-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-6-(three Fluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.77-8.79 (m, 2H), 8.61 (s, 1H), 8.55 (d, J = 8.3 Hz, 1H), 8.36 (d, J = 8.6 Hz, 1H ), 8.30 (d, J = 8.3 Hz, 1H), 6.94 (s, 1H), 3.49 (q, J = 7.4 Hz, 2H), 2.62 (s, 3H), 1.19 (t, J = 7.3 Hz, 3H ); ESI MS (m/z) 531.95 (MH)+. 13 2-(3-(Ethylsulfonyl)-6-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalein Oxazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.83 (q, J = 1.2 Hz, 1H), 8.74-8.76 (m, 2H), 8.58 (s, 1H), 8.49 (d, J = 8.3 Hz, 1H) ), 8.39 (d, J = 8.6 Hz, 1H), 8.26 (dd, J = 8.3, 1.5 Hz, 1H), 7.12 (d, J = 2.8 Hz, 1H), 3.40 (q, J = 7.4 Hz, 2H ), 1.12 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 518.15 (MH)+. 14 2-(3-(Ethylsulfonyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)pyridin-2-yl)-6-( Trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.78 (d, J = 0.7 Hz, 1H), 8.89 (d, J = 8.6 Hz, 1H), 8.81 (s, 1H), 8.63 (s, 1H), 8.54 (d, J = 8.3 Hz, 1H), 8.43 (d, J = 8.6 Hz, 1H), 8.30-8.32 (m, 1H), 3.48 (q, J = 7.4 Hz, 2H), 1.16-1.24 (t , J = 7.4 Hz, 3H); ESI MS (m/z) 519.1 (MH)+. 15 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 2.2 Hz, 1H), 8.71-8.74 (m, 2H), 8.59 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H) ), 8.26-8.28 (m, 1H), 8.01-8.04 (m, 2H), 7.42-7.47 (m, 2H), 3.49 (q, J = 7.4 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 477.9 (MH)+. 16 2-(5-(Ethylthio)-6'-fluoro-[3,3'-dipyridine]-6-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.77 (d, J = 2.8 Hz, 1H), 8.76 (d, J = 2.1 Hz, 1H), 8.74 (s, 1H), 8.57 (s, 1H), 8.52 (td, J = 8.0, 3.0 Hz, 2H), 8.31 (d, J = 2.1 Hz, 1H), 8.26 (dd, J = 8.6, 1.5 Hz, 1H), 7.40 (dd, J = 8.6, 2.8 Hz , 1H), 3.12 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.3 Hz,, 3H); ESI MS (m/z) 447.1 (MH)+ 17 2-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 2.1 Hz, 1H), 8.72-8.73 (m, 2H), 8.57 (s, 1H), 8.48 (d, J = 8.3 Hz, 1H) ), 8.24 (dd, J = 8.5, 1.3 Hz, 1H), 8.05-8.09 (m, 2H), 7.57 (d, J = 7.9 Hz, 2H), 3.46 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 544.2(MH)+. 18 2-(5-(Ethylsulfonyl)-6'-fluoro-[3,3'-dipyridine]-6-yl)-6-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.83 (d, J = 2.1 Hz, 1H), 8.75 ( s, 1H), 8.50-8.63 (m, 3H), 8.27 (dd, J = 8.6, 1.5 Hz, 1H), 7.43 (td, J = 8.9, 2.6 Hz, 1H), 3.49 (q, J = 7.4 Hz , 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 479.0 (MH)+. 19 7-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.53 (d, J = 2.2 Hz, 1H), 9.22 (d, J = 2.1 Hz, 1H), 9.09 (d, J = 1.5 Hz, 1H), 8.83 ( d, J = 2.2 Hz, 1H), 8.75 (s, 1H), 3.45-3.51 (q, J = 7.4 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 462.7, 464.7 [(MH)+ Br79, 81]. 20 7-(3-(Ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.53 (d, J = 1.7 Hz, 1H), 9.10 (t, J = 1.1 Hz, 1H), 9.03 (dd, J = 4.9, 1.7 Hz, 1H), 8.74 (s, 1H), 8.62 (dd, J = 7.8, 1.7 Hz, 1H), 7.99 (dd, J = 7.9, 4.8 Hz, 1H), 3.40 (q, J = 7.4 Hz, 2H), 1.14 (t , J = 7.3 Hz, 3H); ESI MS (m/z) 384.8 (MH)+. twenty one 7-(6-Chloro-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (dd, J = 2.2, 0.5 Hz, 1H), 9.10 (q, J = 1.0 Hz, 1H), 8.76 (s, 1H), 8.66 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 8.3 Hz, 1H), 3.44 (q, J = 7.4 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 419.1 (MH)+. twenty two 7-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8 (7H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (d, J = 2.2 Hz, 1H), 9.32-9.35 (m, 1H), 9.11 (t, J = 1.1 Hz, 1H), 8.75 (t, J = 2.1 Hz, 2H), 8.03-8.07 (m, 2H), 7.44-7.50 (m, 2H), 3.52 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 479.5 (MH)+. twenty three 7-(3-(Ethylsulfonyl)-5-(3-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[ 2,3-d)pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (d, J = 2.2 Hz, 1H), 9.43 (d, J = 2.4 Hz, 1H), 9.11 (d, J = 1.5 Hz, 1H), 8.90 ( d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.27 (d, J = 12.0 Hz, 1H), 8.01-8.07 (m, 2H), 3.5 (q, J = 7.3 Hz, 2H), 1.20 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 547 (MH)+ twenty four 7-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8( 7H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.55 (d, J = 2.2 Hz, 1H), 9.52 (d, J = 4.6 Hz, 1H), 9.11 (s, 1H), 8.97 (d, J = 2.4 Hz, 1H), 8.79 (d, J = 1.7 Hz, 1H), 3.56 (q, J = 7.4 Hz, 2H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 452.8 ( MH)+. 25 7-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3- d)Pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.52 (d, J = 1.8 Hz, 1H), 9.34 (d, J = 2.4 Hz, 1H), 9.09 (d, J = 1.5 Hz, 1H), 8.77 ( d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.10 (dt, J = 9.4, 2.5 Hz, 2H), 7.60 (d, J = 7.9 Hz, 2H), 3.50 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 545.2 (MH)+. 26 7-(3-(Ethylsulfonyl)-5-(4-fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[ 2,3-d)pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.52 (d, J = 1.8 Hz, 1H), 9.37 (d, J = 2.4 Hz, 1H), 9.09 (d, J = 1.5 Hz, 1H), 8.86 ( d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.34-8.39 (m, 2H), 7.74-7.79 (m, 1H), 3.46-3.53 (q, J = 7.6 Hz 2H), 1.17 ( t, J = 7.3 Hz, 3H); ESI MS (m/z) 546.9 (MH)+. 27 7-(3-(Ethylsulfonyl)-6-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8 (7H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.52 (d, J = 2.1 Hz, 1H), 9.09 (t, J = 1.1 Hz, 1H), 8.75 (s, 1H), 8.63 (t, J = 4.1 Hz, 1H), 8.51 (d, J = 8.6 Hz, 1H), 8.23-8.28 (m, 2H), 7.37-7.43 (m, 2H), 3.41 (q, J = 7.3 Hz, 2H), 1.16 (t , J = 7.3 Hz, 3H); ESI MS (m/z) 479.0 (MH)+. 28 7-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d ]Pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.52 (d, J = 2.2 Hz, 1H), 9.39-9.40 (m, 1H), 9.09 (s, 1H), 8.86-8.86 (m, 1H), 8.75 (d, J = 1.0 Hz, 1H), 8.35 (d, J = 4.6 Hz, 1H), 8.26-8.29 (m, 1H), 7.80-7.93 (m, 2H), 3.52 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 529.2 (MH)+. 29 4-(5-(Ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine- 3-yl)benzonitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (d, J = 1.6 Hz, 1H), 9.41 (d, J = 2.4 Hz, 1H), 9.11 (d, J = 1.6 Hz, 1H), 8.86 ( d, J = 2.0 Hz, 1H), 8.77 (s, 1H), 8.20-8.23 (m, 2H), 8.09-8.12 (m, 2H), 3.53 (q, J = 7.3 Hz, 2H), 1.19 (t , J = 7.2 Hz, 3H); ESI MS (m/z) 485.8 (MH)+. 30 7-(3-(Ethylsulfonyl)-6-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3- d)Pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (d, J = 1.6 Hz, 1H), 9.11 (t, J = 1.1 Hz, 1H), 8.78 (s, 1H), 8.69 (d, J = 8.3 Hz, 1H), 8.57 (d, J = 8.6 Hz, 1H), 8.33 (dt, J = 9.5, 2.6 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 3.45 (q, J = 7.4 Hz, 2H), 1.18 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 545.0 (MH)+. 31 7-(3-(Ethylsulfonyl)-5-phenylpyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (d, J = 1.7 Hz, 1H), 9.34 (d, J = 2.4 Hz, 1H), 9.11 (d, J = 1.5 Hz, 1H), 8.76 ( t, J = 2.1 Hz, 2H), 7.97-7.99 (m, 2H), 7.57-7.65 (m, 3H), 3.52 (q, J = 7.3 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H ); ESI MS (m/z) 461.0 (MH)+. 32 7-(5-(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridine Oxazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (s, 1H), 9.39 (d, J = 2.4 Hz, 1H), 9.11 (s, 1H), 8.85 (d, J = 2.0 Hz, 1H), 8.76 (s, 1H), 7.85 (d, J = 6.8 Hz, 2H), 7.46 (t, J = 9.2 Hz, 1H), 3.53 (q, J = 7.3 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 497.0 (MH)+. 33 7-(5-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridine Oxazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (d, J = 2.0 Hz, 1H), 9.40 (d, J = 2.2 Hz, 1H), 9.11 (d, J = 1.6 Hz, 1H), 8.87 ( d, J = 2.3 Hz, 1H), 8.76 (s, 1H), 8.15 (d, J = 1.6 Hz, 2H), 7.82 (t, J = 2.0 Hz, 1H), 3.54 (q, J = 7.3 Hz, 2H), 1.20 (t, J = 7.2 Hz, 3H); ESI MS (m/z) 529.0, 531.0 [(MH)+ Cl35, 37]. 34 7-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-3-(trifluoromethyl)pyridine And [2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.56 (d, J = 2.4 Hz, 1H), 9.52 (d, J = 1.8 Hz, 1H), 9.09 (d, J = 1.8 Hz, 2H), 8.94 ( d, J = 2.1 Hz, 1H), 8.76 (s, 1H), 7.24 (d, J = 2.8 Hz, 1H), 3.51 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.6 Hz, 3H); ESI MS (m/z) 519.0 (MH)+. 35 7-(3-(Ethylsulfonyl)-6-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d ]Pyridazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.41 (d, J = 1.7 Hz, 1H), 8.58 (d, J = 8.1 Hz, 1H), 8.47-8.49 (m, 2H), 8.40 (s, 1H) ), 8.29 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 8.1 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 3.46 (q, J = 7.4 Hz, 2H), 1.38 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 528.8 (MH)+. 36 7-(6-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridine Oxazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.38 (d, J = 1.8 Hz, 1H), 8.54 (d, J = 8.3 Hz, 1H), 8.46 (d, J = 1.2 Hz, 1H), 8.45 ( s, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.98 (d, J = 1.8 Hz, 2H), 7.49-7.52 (m, 1H), 3.43 (q, J = 7.4 Hz, 2H), 1.35 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 528.9 ,530.9[(MH)+ Cl35, 37] 37 3-(3-(Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.04-9.08 (m, 1H), 8.71 (s, 1H), 8.65 (dd, J = 8.1, 1.7 Hz, 1H), 8.42-8.50 (m, 1H) , 8.17-8.30 (m, 1H), 7.97-8.04 (m, 2H), 3.36-3.46 (m, 2H), 1.18 (t ,J = 7.3 Hz,, 3H); ESI MS (m/z) 384 ( MH)+ 38 3-(3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.05 (dd, J = 4.9, 1.7 Hz, 1H), 8.68 (s, 1H), 8.65 (dd, J = 8.1, 1.7 Hz, 1H), 8.43 (d , J = 8.3 Hz, 1H), 8.17 (s, 1H), 8.02 (dd, J = 7.9, 4.8 Hz, 1H), 7.97 (dd, J = 8.4, 1.6 Hz, 1H), 3.36 3.38 (m, 2H ), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 383.6 (MH)+ 39 3-(3-(ethylthio)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.67-8.69 (m, 2H), 8.14 (s, 1H), 8.00-8.07 (m, 2H), 7.91-7.95 (m, 1H), 2.95-3.10 ( m, 2H), 1.33 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 420 (MH)+ 40 7-(3-(Ethylsulfonyl)-6-(3-methyl-1H-1,2,4-triazol-1-yl)pyridin-2-yl)-3-(trifluoromethyl )Pyrido[2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.37 (d, J = 1.5 Hz, 1H), 9.00 (s, 1H), 8.60 (dd, J = 8.6, 2.4 Hz, 1H), 8.41-8.45 (m , 2H), 8.20 (d, J = 8.6 Hz, 1H), 3.40 (q, J = 7.4 Hz, 2H), 2.52 (s, 3H), 1.33 (t, J = 7.3 Hz, 3H); ESI MS ( m/z) 465.8 (MH)+. 41 7-(3-(Ethylsulfonyl)-6-(3-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[ 2,3-d)pyridazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.41 (d, J = 1.7 Hz, 1H), 8.60 (d, J = 8.3 Hz, 1H), 8.48-8.50 (m, 2H), 8.16 (d, J = 8.1 Hz, 1H), 7.99 (t, J = 8.0 Hz, 2H), 7.78 (t, J = 7.7 Hz, 1H), 3.47 (q, J = 7.4 Hz, 2H), 1.38 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 547.0 (MH)+. 42 4-(5-(Ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine- 2-base) benzonitrile 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.38 (d, J = 1.2 Hz, 1H), 8.57 (d, J = 8.3 Hz, 1H), 8.45 (d, J = 9.8 Hz, 2H), 8.21 ( d, J = 8.3 Hz, 2H), 8.15 (d, J = 8.3 Hz, 1H), 7.81 (d, J = 8.3 Hz, 2H), 3.44 (q, J = 7.4 Hz, 2H), 1.35 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 485.8 (MH)+. 43 7-(3-(Ethylsulfonyl)-6-(4-fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[ 2,3-d)pyridazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.38 (d, J = 1.5 Hz, 1H), 8.55 (d, J = 8.3 Hz, 1H), 8.45-8.47 (m, 2H), 8.39 (dd, J = 6.7, 1.8 Hz, 1H), 8.27-8.31 (m, 1H), 8.11 (d, J = 8.3 Hz, 1H), 7.35 (t, J = 9.2 Hz, 1H), 3.43 (q, J = 7.4 Hz , 2H), 1.35 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 546.8 (MH)+. 44 3-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.98 (d, J = 2.4 Hz, 1H), 8.64 (d, J = 2.4 Hz, 1H), 8.63 (q, J = 0.7 Hz, 1H), 8.13 ( t, J = 6.1 Hz, 1H), 8.07 (dd, J = 8.6, 1.7 Hz, 1H), 7.96 (d, J = 8.6 Hz, 1H), 3.35-3.46 (m, 2H), 1.40 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 461.95, 463.95 [(MH)+ Br79, 81]. 45 3-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.55 (q, J = 1.1 Hz, 1H), 9.02-9.02 (m, 1H), 8.70 (s, 1H), 8.48 (q, J = 0.7 Hz, 1H ), 8.30 (dd, J = 8.7, 2.1 Hz, 1H), 8.04 (d, J = 8.6 Hz, 1H), 3.47-3.61 (m, 2H), 1.20 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 451.8 (MH)+. 46 3-(5-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.45 (d, J = 2.4 Hz, 1H), 8.93 (d, J = 2.2 Hz, 1H), 8.73 (s, 1H), 8.48 (t, J = 1.1 Hz, 1H), 8.29 (dd, J = 8.6, 2.0 Hz, 1H), 8.16 (d, J = 2.0 Hz, 2H), 8.04 (t, J = 4.3 Hz, 1H), 7.83 (t, J = 1.8 Hz, 1H), 3.48-3.62 (m, 2H), 1.18-1.24 (t,J=7.3Hz, 3H); ESI MS (m/z) 528.00, 530.00 [(MH)+ Cl35, 37]. 47 3-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.1 Hz, 1H), 8.78 (d, J = 2.1 Hz, 1H), 8.72 (s, 1H), 8.46 (d, J = 2.1 Hz, 1H), 8.27 (dd, J = 8.6, 2.1 Hz, 1H), 8.01-8.06 (m, 3H), 7.43-7.48 (m, 2H), 3.42-3.59 (m, 2H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 477.7 (MH)+. 48 3-(3-(Ethylsulfonyl)-5-phenylpyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 2.1 Hz, 1H), 8.73 (s, 1H), 8.46 (d, J = 2.1 Hz, 1H), 8.27 (dd, J = 8.9, 2.1 Hz, 1H), 8.02 (d, J = 8.6 Hz, 1H), 7.96-7.98 (m, 2H), 7.54-7.64 (m, 3H), 3.43 -3.60 (m, 2H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 459.75 (MH)+. 49 3-(3-(Ethylsulfonyl)-5-(4-methoxyphenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 2.4 Hz, 1H), 8.74 (t, J = 2.4 Hz, 2H), 8.48 (d, J = 2.2 Hz, 1H), 8.29 ( dd, J = 8.7, 2.1 Hz, 1H), 8.04 (d, J = 8.6 Hz, 1H), 7.94-7.97 (m, 2H), 7.18 (dd, J = 6.8, 2.0 Hz, 2H), 3.87 (s , 3H), 3.43-3.60 (m, 2H), 1.2 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 490.00 (MH)+. 50 3-(3-(Ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline-4(3H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.45 (d, J = 2.2 Hz, 1H), 8.90 (d, J = 2.2 Hz, 1H), 8.75 (s, 1H), 8.48 (s, 1H), 8.29 (dd, J = 8.6, 2.2 Hz, 1H), 8.23 (d, J = 8.1 Hz, 2H), 8.04 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 8.3 Hz, 2H), 3.46-3.59 (m, 2H), 1.21 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 527.85 (MH)+. 51 7-(3-(Ethylsulfonyl)-6-phenylpyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.37 (d, J = 1.5 Hz, 1H), 8.49 (d, J = 8.3 Hz, 1H), 8.44 (d, J = 7.0 Hz, 2H), 8.07- 8.11 (m, 3H), 7.47-7.52 (m, 3H), 3.43 (q, J = 7.4 Hz, 2H), 1.35 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 461.2 (MH )+. 52 7-(3-(Ethylsulfonyl)-5-(2-fluoro-4-(trifluoromethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido [2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.38 (d, J = 1.5 Hz, 1H), 9.06 (q, J = 1.1 Hz, 1H), 8.61 (q, J = 1.1 Hz, 1H), 8.45- 8.46 (m, 2H), 7.61 (t, J = 8.6 Hz, 1H), 7.19-7.24 (m, 2H), 3.48 (q, J = 7.3 Hz, 2H), 1.36 (t, J = 7.2 Hz, 3H ); ESI MS (m/z) 563.1 (MH)+. 53 7-(5-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-3-(ethylsulfonyl)pyridin-2-yl)- 3-(Trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.38 (s, 1H), 9.05 (d, J = 2.1 Hz, 1H), 8.55 (d, J = 2.1 Hz, 1H), 8.45 (d, J = 4.3 Hz, 2H), 7.40-7.42 (m, 2H), 7.28 (s, 1H), 3.47 (q, J = 7.4 Hz, 2H), 1.37 (t, J = 7.3 Hz, 3H); ESI MS (m/ z) 540.9 (MH)+. 54 7-(6-(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridine Oxazine-8(7H)-one 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.38 (d, J = 1.5 Hz, 1H), 8.54 (t, J = 4.1 Hz, 1H), 8.46 (d, J = 1.2 Hz, 1H), 8.44 ( s, 1H), 8.07 (d, J = 8.3 Hz, 1H), 7.61-7.67 (m, 2H), 6.93-7.00 (m, 1H), 3.44 (q, J = 7.3 Hz, 2H), 1.35 (t , J = 7.3 Hz, 3H); ESI MS (m/z) 497.0 (MH)+. 55 7-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl )Pyrido[2,3-d]pyridazine-8(7H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (d, J = 2.2 Hz, 1H), 9.35 (d, J = 2.4 Hz, 1H), 9.11 (d, J = 1.6 Hz, 1H), 8.79 ( d, J = 2.4 Hz, 1H), 8.76 (s, 1H), 8.09 (dd, J = 6.6, 2.2 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 6.88 (tt, J = 52.0 , 2.9 Hz, 1H), 3.52 (q, J = 7.3 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 577.0 (MH)+. 56 3-(3-(Ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline-4(3H )-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.46-9.47 (m, 1H), 8.94 (q, J = 1.1 Hz, 1H), 8.74 (d, J = 1.0 Hz, 1H), 8.48 (d, J = 4.4 Hz, 1H), 8.38 (d, J = 4.9 Hz, 1H), 8.28-8.32 (m, 2H), 8.04 (dd, J = 8.6, 2.4 Hz, 1H), 7.93-7.96 (m, 1H) , 7.84-7.89 (m, 1H), 3.73 (q, J = 7.4 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H) 57 4-(5-(Ethylsulfonyl)-6-(4-oxo-6-(trifluoromethyl)quinazolin-3(4H)-yl)pyridin-3-yl)benzonitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.45 (d, J = 2.2 Hz, 1H), 8.91 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.48 (q, J = 0.7 Hz, 1H), 8.29 (dd, J = 8.7, 2.1 Hz, 1H), 8.22 (dd, J = 6.8, 2.0 Hz, 2H), 8.11 (dd, J = 6.6, 2.0 Hz, 2H), 8.04 (d , J = 8.6 Hz, 1H), 3.46-3.63 (m, 2H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 485.05 (MH)+. 58 3-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline-4(3H )-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (t, J = 2.2 Hz, 1H), 8.84 (d, J = 2.2 Hz, 1H), 8.74 (s, 1H), 8.49 (d, J = 7.1 Hz, 1H), 8.29 (dd, J = 8.7, 2.1 Hz, 1H), 8.12-8.15 (m, 2H), 8.04 (d, J = 8.6 Hz, 1H), 7.62-7.66 (m, 2H), 3.53 (q, J = 7.3 Hz, 3H), 1.20 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 544.05 (MH)+. 59 3-(5-(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.45 (t, J = 2.1 Hz, 1H), 8.90 (d, J = 2.2 Hz, 1H), 8.74 (d, J = 1.7 Hz, 1H), 8.47 ( d, J = 1.7 Hz, 1H), 8.29 (dd, J = 8.6, 2.2 Hz, 1H), 8.04 (d, J = 8.6 Hz, 1H), 7.85-7.89 (m, 2H), 7.48 (tt, J = 9.3, 2.2 Hz, 1H), 3.55 (q, J = 7.3 Hz, 2H), 1.21 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 496.05 (MH)+. 60 3-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 2.2 Hz, 1H), 8.83 (t, J = 2.6 Hz, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.48 ( d, J = 5.4 Hz, 1H), 8.27-8.30 (m, 1H), 8.03-8.05 (m, 3H), 7.68-7.71 (m, 2H), 3.53 (q, J = 7.2 Hz, 2H), 1.20 (t, J = 7.2 Hz, 3H); ESI MS (m/z) 493.95 (MH)+. 61 3-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline-4(3H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.46 (t, J = 2.1 Hz, 1H), 8.94 (t, J = 2.2 Hz, 1H), 8.74 (d, J = 2.0 Hz, 1H), 8.49 ( d, J = 5.1 Hz, 1H), 8.38 (d, J = 4.9 Hz, 1H), 8.28-8.32 (m, 2H), 8.04 (d, J = 8.6 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.86 (t, J = 7.7 Hz, 1H), 3.47-3.64 (m, 2H), 1.22 (t, J = 7.4 Hz, 3H); ESI MS (m/z) 528.00 (MH)+ . 62 3-(3-(Ethylsulfonyl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline -4(3H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.30 (t, J = 1.7 Hz, 1H), 8.84 (d, J = 0.9 Hz, 1H), 8.76 (s, 1H), 8.46 (s, 1H), 8.28 (dd, J = 8.6, 2.1 Hz, 1H), 8.10 (t, J = 7.9 Hz, 1H), 7.99-8.04 (m, 2H), 7.84 (d, J = 8.3 Hz, 1H), 3.40-3.53 (m, 2H), 1.18 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 546.05 (MH)+. 63 3-(5-(3-chloro-4-(trifluoromethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline- 4(3H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 2.1 Hz, 1H), 8.92 (d, J = 2.4 Hz, 1H), 8.65-8.69 (m, 1H), 8.43 (t, J = 1.1 Hz, 1H), 8.38 (d, J = 2.1 Hz, 1H), 8.25 (td, J = 8.9, 2.1 Hz, 2H), 7.99 (d, J = 8.6 Hz, 1H), 7.94 (d, J = 8.6 Hz, 1H), 3.42-3.58 (m, 2H), 1.15-1.22 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 561.70 (MH)+. 64 3-(3-(Ethylsulfonyl)-5-(2-fluoro-4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazole Lin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.22-9.26 (m, 1H), 8.79 (t, J = 1.1 Hz, 1H), 8.76 (s, 1H), 8.46 (d, J = 1.8 Hz, 1H ), 8.28 (dd, J = 8.6, 2.1 Hz, 1H), 7.99-8.03 (m, 2H), 7.71 (dd, J = 10.9, 1.7 Hz, 1H), 7.50 (d, J = 8.9 Hz, 1H) , 3.41-3.53 (m, 2H), 1.11-1.19(t, J = 7.4 Hz, 3H); ESI MS (m/z) 561.75 (MH)+. 65 3-(3-(Ethylsulfonyl)-5-(4-fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline -4(3H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.43 (d, J = 2.1 Hz, 1H), 8.92 (d, J = 2.4 Hz, 1H), 8.71 (s, 1H), 8.46 (d, J = 1.8 Hz, 1H), 8.34-8.39 (m, 2H), 8.27 (dd, J = 8.9, 2.1 Hz, 1H), 8.02 (d, J = 8.6 Hz, 1H), 7.75-7.80 (m, 1H), 3.44 -3.60 (m, 2H), 1.16-1.21( t, J = 7.5 Hz, 3H); ESI MS (m/z) 543.95 (MH)+. 66 3-(3-(Ethylsulfonyl)-5-(2-fluoro-5-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazole Lin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.27 (t, J = 1.8 Hz, 1H), 8.81 (t, J = 1.1 Hz, 1H), 8.75 (s, 1H), 8.46-8.48 (m, 1H ), 8.28 (dd, J = 8.6, 2.1 Hz, 1H), 7.99-8.03 (m, 2H), 7.61-7.65 (m, 2H), 3.40-3.56 (m, 2H), 1.11-1.20 (t, J = 7.4 Hz, 3H); ESI MS (m/z) 561.70 (MH)+. 67 2-(3-(Ethylsulfonyl)-5-(4-fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine- 1(2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.2 Hz, 1H), 8.86 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.61 (s, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.35-8.40 (m, 2H), 8.29 (dd, J = 8.6, 1.7 Hz, 1H), 7.76-7.80 (m, 1H), 3.52 (q, J = 7.3 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 545.7 (MH)+. 68 2-(3-(Ethylsulfonyl)-5-(4-fluoro-3-methoxyphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H )-ketone 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.07 (d, J = 2.4 Hz, 1H), 8.65 (d, J = 8.1 Hz, 1H), 8.60 (d, J = 2.3 Hz, 1H), 8.42 ( s, 1H), 8.12 (s, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.29 (d, J = 3.2 Hz, 1H), 7.23-7.25 (m, 2H), 4.03 (s, 3H ), 3.43 (q, J = 7.4 Hz, 2H), 1.37 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 507.7 (MH)+. 69 2-(5-(2,4-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.18 (q, J = 1.2 Hz, 1H), 8.75 (s, 1H), 8.68 (q, J = 1.1 Hz, 1H), 8.60 (s, 1H), 8.52 (d, J = 8.6 Hz, 1H), 8.27 (dd, J = 8.6, 1.5 Hz, 1H), 7.94 (td, J = 8.9, 6.4 Hz, 1H), 7.52-7.58 (m, 1H), 7.36 (td, J = 8.6, 2.1 Hz, 1H), 3.46 (q, J = 7.6 Hz, 2H), 1.15 (t, J = 7.6 Hz, 3H); ESI MS (m/z) 495.7 (MH)+. 70 2-(3-(Ethylsulfonyl)-5-(4-fluoro-3-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.59 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.27 (dd, J = 8.6, 1.5 Hz, 1H), 7.93 (dd, J = 7.2, 2.0 Hz, 1H), 7.81-7.85 (m, 1H), 7.37 (t, J = 9.0 Hz, 1H), 3.48 (q, J = 7.3 Hz, 2H), 2.36 (d, J = 1.5 Hz, 3H), 1.16 (t, J = 7.5 Hz, 3H); ESI MS ( m/z) 491.7 (MH)+. 71 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazin-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 2.1 Hz, 1H), 8.74 (d, J = 2.4 Hz, 2H), 8.59 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.27 (dd, J = 8.6, 1.5 Hz, 1H), 7.99-8.02 (m, 2H), 7.67 (dd, J = 6.7, 2.1 Hz, 2H), 3.49 (q, J = 7.7 Hz , 2H), 1.16 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 493.7 (MH)+. 72 2-(5-Cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.76 (d, J = 2.2 Hz, 1H), 8.71 (s, 1H), 8.58 (s, 1H), 8.50 (d, J = 8.3 Hz, 1H), 8.26 (dd, J = 8.4, 1.6 Hz, 1H), 8.17 (d, J = 2.2 Hz, 1H), 3.39 (q, J = 7.4 Hz, 2H), 2.24-2.31 (m, 1H), 1.17-1.22 (m, 2H), 1.13 (t, J = 7.5 Hz, 3H), 1.00-1.04 (m, 2H); ESI MS (m/z) 424.0 (MH)+. 73 2-(3-(Ethylsulfonyl)-6-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.75 (s, 1H), 8.60-8.62 (m, 2H), 8.50 (dd, J = 8.3, 5.5 Hz, 2H), 8.23-8.28 (m, 3H) , 7.36-7.42 (m, 2H), 3.41 (q, J = 7.3 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 477.7 (MH)+. 74 2-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalein Oxazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.55 (d, J = 2.8 Hz, 1H), 9.09 (t, J = 1.4 Hz, 1H), 8.93 (d, J = 2.8 Hz, 1H), 8.76 ( s, 1H), 8.60 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.28 (dd, J = 8.6, 1.5 Hz, 1H), 7.24 (d, J = 2.8 Hz, 1H), 3.50 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 517.7 (MH)+. 75 2-(3-(Ethylsulfonyl)-6-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.67 (d, J = 8.3 Hz, 1H), 8.61 (s, 1H), 8.54 (t, J = 8.7 Hz, 2H), 8.28-8.35 (m, 3H), 7.56-7.58 (m, 2H), 3.44 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 544.1 (MH)+. 76 3-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl )Quazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 2.2 Hz, 1H), 8.83 (d, J = 2.2 Hz, 1H), 8.74 (s, 1H), 8.48 (d, J = 2.2 Hz, 1H), 8.28-8.31 (m, 1H), 8.09-8.11 (m, 2H), 8.05 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.6 Hz, 2H), 7.04-6.72 (m, 1H), 3.53 (dd, J = 16.7, 7.5 Hz, 2H), 1.20 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 576.05 (MH)+. 77 2-(6-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.61-8.70 (m, 2H), 8.53 (q, J = 4.2 Hz, 2H), 8.29 (dd, J = 8.4, 1.6 Hz , 1H), 8.23 (dd, J = 6.8, 2.0 Hz, 2H), 7.65 (dd, J = 6.8, 2.0 Hz, 2H), 3.43 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 494.0 (MH)+. 78 2-(5-(2-Chloro-4-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.10 (d, J = 2.2 Hz, 1H), 8.78 (s, 1H), 8.65 (d, J = 2.2 Hz, 1H), 8.62 (s, 1H), 8.54 (d, J = 8.3 Hz, 1H), 8.29 (dd, J = 8.4, 1.6 Hz, 1H), 7.84 (dd, J = 8.8, 6.1 Hz, 1H), 7.76 (dd, J = 8.9, 2.6 Hz , 1H), 7.47-7.52 (m, 1H), 3.48 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.2 Hz, 3H); ESI MS (m/z) 511.9 (MH)+. 79 2-(3-(Ethylsulfonyl)-5-(3,4,5-trifluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 2.1 Hz, 1H), 8.81 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.59 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.27 (dd, J = 8.3, 1.5 Hz, 1H), 8.10 (dd, J = 9.3, 6.6 Hz, 2H), 3.50 (q, J = 7.6 Hz, 2H ), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 513.7 (MH)+. 80 2-(3-(Ethylsulfonyl)-5-(4-fluoro-2-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.03 (d, J = 2.2 Hz, 1H), 8.77 (s, 1H), 8.62 (s, 1H), 8.52-8.55 (m, 2H), 8.28-8.30 (m, 1H), 7.56 (dd, J = 8.4, 6.0 Hz, 1H), 7.33 (dd, J = 10.0, 2.4 Hz, 1H), 7.25 (td, J = 8.7, 2.8 Hz, 1H), 3.49 ( q, J = 7.4 Hz, 2H), 2.36 (s, 3H), 1.17 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 491.8 (MH)+. 81 2-(6-Chloro-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.62 (d, J = 8.6 Hz, 1H), 8.52 (s, 1H), 8.42 (dd, J = 8.3, 1.8 Hz, 1H ), 8.34 (d, J = 8.3 Hz, 1H), 8.12 (d, J = 8.3 Hz, 1H), 3.42 (q, J = 7.4 Hz, 2H), 1.13 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 418.0 (MH)+. 82 2-(3-(Ethylsulfonyl)-6-(4-fluoro-2-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.74 (s, 1H), 8.62 (d, J = 8.3 Hz, 1H), 8.58 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.26 (dd, J = 8.4, 1.7 Hz, 1H), 8.09 (d, J = 8.3 Hz, 1H), 7.62 (dd, J = 8.6, 6.1 Hz, 1H), 7.18-7.25 (m, 2H), 3.45 (q, J = 7.3 Hz, 2H), 2.40 (s, 3H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 491.7 (MH)+. 83 2-(6-(2-Chloro-4-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.75 (s, 1H), 8.68 (d, J = 7.9 Hz, 1H), 8.59 (s, 1H), 8.50 (d, J = 8.6 Hz, 1H), 8.24-8.28 (m, 2H), 7.76 (dd, J = 8.9, 6.1 Hz, 1H), 7.68 (dd, J = 8.9, 2.4 Hz, 1H), 7.41 (td, J = 8.5, 2.5 Hz, 1H) , 3.45 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 511.7 (MH)+. 84 2-(3-(Ethylsulfonyl)-6-(3,4,5-trifluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.69 (d, J = 8.3 Hz, 1H), 8.60 (t, J = 4.3 Hz, 2H), 8.51 (d, J = 8.3 Hz, 1H), 8.27 (dd, J = 8.6, 1.5 Hz, 1H), 8.17 (dd, J = 9.2, 6.7 Hz, 2H), 3.43 (q, J = 7.3 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 513.7 (MH)+. 85 2-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.19 (d, J = 2.4 Hz, 1H), 8.80 (d, J = 2.4 Hz, 1H), 8.76 (s, 1H), 8.52 (d, J = 0.9 Hz, 1H), 8.42 (dd, J = 8.3, 1.8 Hz, 1H), 8.33 (d, J = 8.6 Hz, 1H), 3.47 (q, J = 7.4 Hz, 2H), 1.14 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 461.55, 463.55 [(MH)+ Br79, 81]. 86 3-(5-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.44 (d, J = 2.4 Hz, 1H), 8.91 (d, J = 2.4 Hz, 1H), 8.68 (s, 1H), 8.42 (d, J = 8.3 Hz, 1H), 8.15 (t, J = 2.1 Hz, 3H), 7.96 (dd, J = 8.5, 1.6 Hz, 1H), 7.82 (t, J = 1.8 Hz, 1H), 3.53 (q, J = 7.2 Hz, 2H), 1.14-1.22 (t, J = 7.4 Hz, 3H); ESI MS (m/z) 528.05, 530.05 [(MH)+ Cl35, 37]. 87 3-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 2.2 Hz, 1H), 8.69 (s, 1H), 8.43 (d, J = 8.3 Hz, 1H), 8.15 (s, 1H), 8.02-8.06 (m, 2H), 7.96 (dd, J = 8.4, 1.6 Hz, 1H), 7.42-7.48 (m, 2H), 3.42-3.59 (m, 2H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 477.95 (MH)+. 88 3-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazoline-4(3H )-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 2.4 Hz, 1H), 8.84 (d, J = 2.4 Hz, 1H), 8.71 (s, 1H), 8.45 (d, J = 8.3 Hz, 1H), 8.17 (s, 1H), 8.11-8.15 (m, 2H), 7.98 (dd, J = 8.3, 1.7 Hz, 1H), 7.63 (d, J = 7.8 Hz, 2H), 3.52 (q , J = 7.5 Hz, 2H), 1.20 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 544.10 (MH)+. 89 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.72 (d, J = 2.1 Hz, 1H), 8.54 (s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.01-8.05 (m, 2H), 7.44 (t, J = 8.9 Hz, 2H), 3.50 (q , J = 7.4 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 477.7 (MH)+. 90 2-(3-(Ethylsulfonyl)-6-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.62 (d, J = 8.3 Hz, 1H), 8.54 (s, 1H), 8.50 (d, J = 8.6 Hz, 1H), 8.42 (dd, J = 8.4, 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.23-8.27 (m, 2H), 7.36-7.42 (m, 2H), 3.42 (q, J = 7.4 Hz, 2H), 1.16 (t, J = 7.4 Hz, 3H); ESI MS (m/z) 477.9 (MH)+. 91 2-(6-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.66 (d, J = 8.3 Hz, 1H), 8.54 (d, J = 8.6 Hz, 2H), 8.44 (dd, J = 8.3 , 1.7 Hz, 1H), 8.36 (d, J = 8.3 Hz, 1H), 8.23 (dt, J = 9.1, 2.3 Hz, 2H), 7.63-7.68 (m, 2H), 3.44 (q, J = 7.3 Hz , 2H), 1.17 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 493.9(MH)+. 92 3-(5-(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.43 (d, J = 2.1 Hz, 1H), 8.88 (d, J = 2.4 Hz, 1H), 8.69 (s, 1H), 8.42 (d, J = 8.3 Hz, 1H), 8.16 (s, 1H), 7.96 (dd, J = 8.6, 1.5 Hz, 1H), 7.86 (dd, J = 8.7, 2.0 Hz, 2H), 7.44-7.49 (m, 1H), 3.53 (q, J = 7.3 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 496.05 MH)+. 93 3-(3-(Ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazoline-4(3H )-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.41 (d, J = 2.1 Hz, 1H), 8.86 (d, J = 2.1 Hz, 1H), 8.69 (s, 1H), 8.43 (d, J = 8.6 Hz, 1H), 8.16 (s, 1H), 8.06 (s, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.96 (dd, J = 8.3, 1.5 Hz, 1H), 7.75 (t, J = 8.1 Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H), 3.44-3.61 (m, 2H), 1.19 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 544.05 (MH )+. 94 4-(5-(Ethylsulfonyl)-6-(4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)pyridin-3-yl)benzonitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.44 (d, J = 2.1 Hz, 1H), 8.89 (d, J = 2.1 Hz, 1H), 8.69 (s, 1H), 8.43 (d, J = 8.3 Hz, 1H), 8.20 (d, J = 8.3 Hz, 2H), 8.16 (s, 1H), 8.09 (d, J = 8.6 Hz, 2H), 7.95-7.97 (m, 1H), 3.44-3.60 (m , 2H), 1.19 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 485.05 (MH)+. 95 3-(3-(Ethylsulfonyl)-5-(4-methoxyphenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 2.1 Hz, 1H), 8.72 (d, J = 2.1 Hz, 1H), 8.68 (s, 1H), 8.42 (d, J = 8.3 Hz, 1H), 8.15 (s, 1H), 7.92-7.97 (m, 3H), 7.15-7.17 (m, 2H), 3.85 (s, 3H), 3.41-3.57 (m, 2H), 1.18 (t, J = 7.3 Hz, 3H; ESI MS (m/z) 494.00 (MH)+. 96 3-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.1 Hz, 1H), 8.81 (d, J = 2.1 Hz, 1H), 8.69 (s, 1H), 8.43 (d, J = 7.9 Hz, 1H), 8.15 (s, 1H), 8.02 (dt, J = 9.1, 2.4 Hz, 2H), 7.96 (dd, J = 8.4, 1.7 Hz, 1H), 7.68 (dt, J = 8.9, 2.3 Hz , 2H), 3.42-3.59 (m, 2H), 1.18 (t, J = 7.3 Hz, 3H) 97 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.76 (d, J = 2.2 Hz, 1H), 8.55 (s, 1H), 8.44 (dd, J = 8.4, 1.6 Hz, 1H), 8.36 (d, J = 8.3 Hz, 1H), 8.02 (dd, J = 6.6, 2.0 Hz, 2H), 7.69 (dd, J = 6.7, 2.1 Hz , 2H), 3.52 (q, J = 7.4 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 494.0(MH)+. 98 2-(3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.00 (dd, J = 4.7, 1.7 Hz, 1H), 8.75 (s, 1H), 8.59 (dd, J = 7.9, 1.5 Hz, 1H), 8.52 (s , 1H), 8.41 (dd, J = 8.3, 1.8 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 7.96 (dd, J = 7.9, 4.6 Hz, 1H), 3.38 (q, J = 7.3 Hz, 2H), 1.13 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 383.9 (MH)+. 99 2-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.50 (d, J = 1.5 Hz, 1H), 8.93 (d, J = 2.4 Hz, 1H), 8.81 (s, 1H), 8.53 (s, 1H), 8.44 (dd, J = 8.3, 1.8 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 3.54 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 452.0 (MH)+. 100 3-(3-(Ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazoline-4(3H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.43 (d, J = 2.4 Hz, 1H), 8.88 (d, J = 2.1 Hz, 1H), 8.70 (s, 1H), 8.43 (d, J = 8.3 Hz, 1H), 8.21 (d, J = 8.3 Hz, 2H), 8.16 (s, 1H), 7.96-7.99 (m, 3H), 3.45-3.58 (m, 2H), 1.19 (t, J = 7.3 Hz , 3H); ESI MS (m/z) 527.75 (MH)+. 101 3-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl )Quazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.36-9.38 (m, 1H), 8.80-8.82 (m, 1H), 8.68-8.71 (m, 1H), 8.42 (t, J = 8.3 Hz, 1H) , 8.16 (s, 1H), 8.08 (dt, J = 9.4, 2.5 Hz, 2H), 7.96 (dd, J = 8.6, 1.5 Hz, 1H), 7.52 (d, J = 8.6 Hz, 2H), 6.7- 7.0 (m, 1H), 3.42-3.59 (m, 2H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 576.15 (MH)+. 102 2-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl )Phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 2.4 Hz, 1H), 8.75 (d, J = 2.1 Hz, 2H), 8.60 (s, 1H), 8.51 (d, J = 8.3 Hz, 1H), 8.27 (dd, J = 8.6, 1.5 Hz, 1H), 8.05-8.08 (m, 2H), 7.51 (d, J = 8.6 Hz, 2H), 6.74-7.00 (m, 1H), 3.49 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 575.7 (MH)+. 103 2-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 2.4 Hz, 1H), 8.75-8.78 (m, 2H), 8.54 (s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz , 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.07 (dd, J = 6.7, 2.1 Hz, 2H), 7.51 (d, J = 8.9 Hz, 2H), 6.74-7.00 (m, 1H) , 3.50 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 576.05 (MH)+ 104 2-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 2.4 Hz, 1H), 8.78 (s, 1H), 8.76 (d, J = 2.1 Hz, 1H), 8.54 (s, 1H), 8.43 (dd, J = 8.3, 1.8 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.10 (dt, J = 9.4, 2.5 Hz, 2H), 7.60 (d, J = 8.3 Hz, 2H ), 3.50 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 544.0 (MH)+. 105 2-(3-(Ethylsulfonyl)-6-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.66 (d, J = 8.3 Hz, 1H), 8.54 (t, J = 4.1 Hz, 2H), 8.43 (dd, J = 8.3 , 1.8 Hz, 1H), 8.30-8.36 (m, 3H), 7.55 (d, J = 7.9 Hz, 2H), 3.43 (q, J = 7.3 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H ); ESI MS (m/z) 543.9 (MH)+. 106 3-(5-(4-Bromophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.3 Hz, 1H), 8.82 (d, J = 2.2 Hz, 1H), 8.70 (s, 1H), 8.43-8.46 (m, 1H) ), 8.17 (d, J = 3.9 Hz, 1H), 7.96-7.99 (m, 3H), 7.82-7.84 (m, 2H), 3.46-3.57 (m, 2H), 1.20 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 538.00, 540.00 [(MH)+ Br79, 81]. 107 3-(3-(Ethylsulfonyl)-5-(3-fluoro-4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazole Lin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.43 (d, J = 2.2 Hz, 1H), 8.89 (d, J = 2.2 Hz, 1H), 8.71 (s, 1H), 8.44 (d, J = 8.3 Hz, 1H), 8.28 (dd, J = 11.5, 2.2 Hz, 1H), 8.17 (s, 1H), 7.98 (d, J = 8.6 Hz, 2H), 7.84 (t, J = 7.8 Hz, 1H), 3.47-3.59 (m, 2H), 1.21 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 562.05 (MH)+. 108 3-(3-(Ethylsulfonyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quine Oxazolin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8.70 (s, 1H), 8.44 (d, J = 8.3 Hz, 1H), 8.17 (s, 1H), 7.96-8.02 (m, 3H), 7.31 (dd, J = 6.8, 2.0 Hz, 2H), 4.91 (q, J = 8.9 Hz, 2H), 3.45-3.58 (m, 2H), 1.20 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 558.10 (MH)+. 109 3-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.24 (t, J = 2.2 Hz, 2H), 8.88 (d, J = 2.2 Hz, 1H), 8.69-8.73 (m, 2H), 3.39-3.54 (m , 2H), 1.05-1.22 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 462.80, 464.80 [(MH)+ Br79, 81]. 110 3-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidine-4( 3H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.37-9.38 (m, 1H), 9.24 (t, J = 2.0 Hz, 1H), 8.69-8.82 (m, 3H), 7.99-8.03 (m, 2H) , 7.67-7.69 (m, 2H), 3.51 (ddd, J = 34.1, 14.1, 7.4 Hz, 2H), 1.20 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 495.0 (MH)+ . 111 3-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidine-4( 3H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.2 Hz, 1H), 9.24 (d, J = 1.7 Hz, 1H), 8.80 (d, J = 2.4 Hz, 1H), 8.78 ( s, 1H), 8.70 (d, J = 1.5 Hz, 1H), 8.03-8.07 (m, 2H), 7.44-7.48 (m, 2H), 3.41-3.60 (m, 2H), 1.19 (q, J = 7.7 Hz, 3H); ESI MS (m/z) 479.0 (MH)+. 112 3-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl )Pyrido[3,2-d]pyrimidin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 2.4 Hz, 1H), 9.25 (d, J = 1.7 Hz, 1H), 8.86 (dd, J = 19.0, 2.3 Hz, 1H), 8.79 (s, 1H), 8.71 (t, J = 1.0 Hz, 1H), 8.07-8.10 (m, 2H), 7.53 (d, J = 8.6 Hz, 2H), 6.87 (tt, J = 51.9, 3.0 Hz , 1H), 3.43-3.61 (m, 2H), 1.21 (q, J = 7.7 Hz, 3H); ESI MS (m/z) 577.0 (MH)+. 113 3-(3-(Ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2- d)Pyrimidine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.40-9.42 (m, 1H), 9.22-9.24 (m, 1H), 8.87 (d, J = 2.2 Hz, 1H), 8.76-8.77 (m, 1H) , 8.65-8.71 (m, 1H), 7.99-8.10 (m, 2H), 7.68-7.77 (m, 1H), 7.54-7.58 (m, 1H), 3.44-3.62 (m, 2H), 1.21(q, J = 7.7 Hz, 3H); ESI MS (m/z) 545.05 (MH)+. 114 2-(3-(Ethylsulfonyl)-5-(4-(perfluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 2.4 Hz, 1H), 8.77 (t, J = 2.3 Hz, 2H), 8.54 (s, 1H), 8.42 (dd, J = 8.4 , 1.7 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.09-8.12 (m, 2H), 7.60 (d, J = 8.6 Hz, 2H), 3.50 (q, J = 7.2 Hz, 2H ), 1.17 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 594.10 (MH)+ 115 2-(5-(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 8.82 (d, J = 2.2 Hz, 1H), 8.78 (s, 1H), 8.53 (s, 1H), 8.43 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.6 Hz, 1H), 7.84 (dd, J = 8.8, 2.2 Hz, 2H), 7.43-7.48 (m, 1H), 3.51 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 495.90 (MH)+. 116 2-(5-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 8.84 (d, J = 2.4 Hz, 1H), 8.77 (d, J = 0.5 Hz, 1H), 8.53 ( s, 1H), 8.42 (dd, J = 8.3, 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.12 (d, J = 2.0 Hz, 2H), 7.79 (t, J = 1.8 Hz, 1H), 3.51 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 527.85 (MH)+. 117 2-(3-(Ethylsulfonyl)-5-(4-(perfluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -Thione 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.4 Hz, 1H), 9.13 (s, 1H), 8.97 (s, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.47 (dd, J = 8.3, 1.8 Hz, 1H), 8.39 (d, J = 8.3 Hz, 1H), 8.13 (dd, J = 6.7, 2.1 Hz, 2H), 7.60 (d, J = 8.9 Hz, 2H ), 3.46-3.60 (m, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 610.05 (MH)+ 118 2-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-thione 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 2.4 Hz, 1H), 9.13 (s, 1H), 8.97 (s, 1H), 8.80 (d, J = 2.4 Hz, 1H), 8.47 (dd, J = 8.3, 1.8 Hz, 1H), 8.39 (d, J = 8.3 Hz, 1H), 8.09 (d, J = 8.6 Hz, 2H), 7.51 (d, J = 8.6 Hz, 2H), 6.73-6.99 (m, 1H), 3.46-3.60 (m, 2H), 1.15 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 591..90 (MH)+ 119 2-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 2.4 Hz, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 0.6 Hz, 1H), 8.54 ( s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.34-8.36 (m, 2H), 8.27 (d, J = 7.8 Hz, 1H), 7.91 (d, J = 7.8 Hz, 1H ), 7.83 (t, J = 7.7 Hz, 1H), 3.52 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 527.95 (MH)+. 120 2-(3-(Ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.4 Hz, 1H), 8.79 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 0.5 Hz, 1H), 8.54 ( s, 1H), 8.42 (dd, J = 8.6, 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.05 (s, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.74 (t, J = 8.1 Hz, 1H), 7.56 (d, J = 8.3 Hz, 1H), 3.51 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.5 Hz, 3H). ESI MS (m/z) 544.00 (MH)+. 121 4-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)benzonitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.4 Hz, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.78 (s, 1H), 8.54 (s, 1H), 8.43 (dd, J = 8.3, 1.7 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.19 (dd, J = 6.6, 2.0 Hz, 2H), 8.08 (dd, J = 6.6, 2.0 Hz , 2H), 3.51 (q, J = 7.3 Hz, 2H), 1.15-1.19 (m, 3H) ESI MS (m/z) 484.95 (MH)+. 122 2-(3-(Ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.4 Hz, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 0.5 Hz, 1H), 8.54 ( s, 1H), 8.43 (dd, J = 8.2, 1.6 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.20 (d, J = 8.1 Hz, 2H), 7.96 (d, J = 8.3 Hz, 2H), 3.51 (q, J = 7.3 Hz, 2H), 1.16-1.19 (m, 3H) ESI MS (m/z) 527.95 (MH)+. 123 2-(5-(3,4-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 2.2 Hz, 1H), 8.77-8.78 (m, 2H), 8.54 (s, 1H), 8.43 (dd, J = 8.3, 2.0 Hz , 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.19 (ddd, J = 11.7, 7.8, 2.2 Hz, 1H), 7.84-7.87 (m, 1H), 7.65-7.72 (m, 1H), 3.50 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 495.75 (MH)+. 124 2-(5-Cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.75 (d, J = 2.4 Hz, 1H), 8.72 (s, 1H), 8.51 (s, 1H), 8.40 (d, J = 9.8 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 8.16 (d, J = 2.4 Hz, 1H), 3.35-3.41 (m, 2H), 2.24-2.32 (m, 1H), 1.15-1.20 (m, 2H) , 1.11 (t, J = 7.3 Hz, 3H), 0.99-1.02 (m, 2H) ESI MS (m/z) 423.95 (MH)+. 125 1-(4-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)phenyl )Cyclopropane-1-carbonitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 2.4 Hz, 1H), 8.75 (s, 1H), 8.70 (d, J = 2.2 Hz, 1H), 8.51 (s, 1H), 8.40 (dd, J = 8.4, 1.8 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 7.96 (dd, J = 6.6, 2.0 Hz, 2H), 7.52 (dd, J = 6.6, 2.0 Hz , 2H), 3.46 (t, J = 7.5 Hz, 2H), 1.82 (dd, J = 7.7, 4.8 Hz, 2H), 1.60 (dd, J = 8.2, 5.3 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 524.95 (MH)+. 126 2-(5-(4-(Difluoromethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 2.2 Hz, 2H), 8.54 (s, 1H), 8.42 (dd, J = 8.4 , 1.8 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.11 (d, J = 8.3 Hz, 2H), 7.79 (d, J = 8.1 Hz, 2H), 7.15 (t, J = 55.8 Hz, 1H), 3.51 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 509.95 (MH)+. 127 2-(5-(Ethylsulfonyl)-6'-fluoro-[3,3'-dipyridine]-6-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 8.84 (dd, J = 8.7, 2.6 Hz, 2H), 8.78 (d, J = 0.5 Hz, 1H), 8.60 (td, J = 8.2, 2.4 Hz, 1H), 8.54 (s, 1H), 8.42 (dd, J = 8.4, 1.8 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 7.44 (dd , J = 8.6, 2.2 Hz, 1H), 3.50 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 478.95 (MH)+. 128 2-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -Thione 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (dd, J = 6.4, 2.1 Hz, 1H), 9.13 (s, 1H), 8.97 (s, 1H), 8.81 (d, J = 2.1 Hz, 1H ), 8.47 (dd, J = 8.3, 1.5 Hz, 1H), 8.39 (d, J = 8.3 Hz, 1H), 8.09-8.13 (m, 2H), 7.60 (d, J = 7.9 Hz, 2H), 3.44 -3.61 (m, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 560 (MH)+ 129 2-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.17 (s, 1H), 8.77 (s, 1H), 8.53 (s, 1H), 8.41 (d, J = 8.9 Hz, 1H), 8.31 (d, J = 8.9 Hz, 1H), 3.44-3.52 (m, 2H), 2.64 (s, 3H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 475.55, 477.65 [(MH)+ Br79, 81] 130 2-(3-(Ethylsulfonyl)-5-(4-(methylthio)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.29-9.30 (m, 1H), 8.77 (s, 1H), 8.70 (d, J = 2.2 Hz, 1H), 8.54 (s, 1H), 8.42 (dd , J = 8.3, 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 7.89-7.92 (m, 2H), 7.46 (dd, J = 6.7, 1.8 Hz, 2H), 3.49 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 505.75 (MH)+. 131 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 2.1 Hz, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.55 (s, 1H), 8.41 (dd, J = 8.6 , 1.8 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 8.02 (dd, J = 8.6, 5.5 Hz, 2H), 7.44 (t, J = 8.7 Hz, 2H), 3.47-3.52 (m , 2H), 2.66 (s, 3H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 492.10 (MH)+ 132 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-thione 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (dd, J = 7.0, 2.4 Hz, 1H), 9.13 (s, 1H), 8.97 (s, 1H), 8.77-8.79 (m, 1H), 8.43 -8.48 (m, 1H), 8.39 (d, J = 8.3 Hz, 1H), 7.99-8.03 (m, 2H), 7.66 (dd, J = 6.7, 1.8 Hz, 2H), 3.44-3.62 (m, 2H ), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 509.80 (MH)+ 133 2-(5-(3,4-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.2 Hz, 1H), 8.81 (d, J = 2.1 Hz, 1H), 8.77 (s, 1H), 8.53 (s, 1H), 8.42 (d, J = 6.8 Hz, 1H), 8.33-8.35 (m, 2H), 7.98 (dd, J = 8.3, 2.2 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 3.51 (d , J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 527.90 (MH)+. 134 2-(5-(3-chloro-5-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.2 Hz, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.79 (d, J = 0.5 Hz, 1H), 8.55 ( s, 1H), 8.44 (dd, J = 8.3, 1.5 Hz, 1H), 8.36 (d, J = 8.1 Hz, 1H), 8.03 (t, J = 1.6 Hz, 1H), 7.96 (dt, J = 9.6 , 2.0 Hz, 1H), 7.65 (dt, J = 8.6, 2.0 Hz, 1H), 3.53 (q, J = 7.3 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H) ESI MS (m/z ) 511.85 (MH)+. 135 2-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-4-methyl-7- (Trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 2.2 Hz, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.58 (s, 1H), 8.33-8.45 (m, 2H ), 8.08 (dd, J = 6.6, 2.2 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H), 6.75-7.01 (m, 1H), 3.52 (q, J = 7.5 Hz, 2H), 2.68 (s, 3H), 1.20 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 590.10 (MH)+ 136 2-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine -1(2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 2.4 Hz, 1H), 8.74 (d, J = 2.4 Hz, 1H), 8.56 (s, 1H), 8.40-8.43 (m, 1H ), 8.32 (d, J = 8.3 Hz, 1H), 8.09 (dd, J = 6.7, 2.1 Hz, 2H), 7.60 (d, J = 7.9 Hz, 2H), 3.50 (q, J = 7.5 Hz, 2H ), 2.66 (s, 3H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 557.75 (MH)+ 137 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-thione 1H-NMR (400 MHz, DMSO-d6) δ 9.32-9.34 (m, 1H), 9.14 (s, 1H), 8.99 (s, 1H), 8.79 (d, J = 2.4 Hz, 1H), 8.48 (dd , J = 8.3, 1.7 Hz, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.05-8.09 (m, 2H), 7.43-7.48 (m, 2H), 3.46-3.63 (m, 3H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 493.90 (MH)+ 138 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)nicotinonitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.47 (d, J = 2.2 Hz, 1H), 9.14 (d, J = 2.0 Hz, 1H), 8.80 (d, J = 0.7 Hz, 1H), 8.52 ( s, 1H), 8.43 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 3.48 (q, J = 7.4 Hz, 2H), 1.15 (t = 7.3 Hz, 3H); ESI MS (m/z) 408.70 (MH)+ 139 2-(5-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 8.83 (d, J = 2.4 Hz, 1H), 8.58 (s, 1H), 8.43 (dd, J = 8.7 , 1.8 Hz, 1H), 8.34 (d, J = 8.6 Hz, 1H), 8.13 (d, J = 1.7 Hz, 2H), 7.81 (t, J = 1.8 Hz, 1H), 3.54 (q, J = 7.1 Hz, 2H), 2.68 (s, 3H), 1.19 (t = 7.3 Hz, 3H); ); ESI MS (m/z) 541.75, 543.75 [(MH)+ Cl35 140 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (t, J = 2.1 Hz, 1H), 8.74 (t, J = 2.1 Hz, 1H), 8.57 (s, 1H), 8.33-8.45 (m, 2H ), 8.00-8.02 (m, 2H), 7.62-7.69 (m, 2H), 3.54 (q, J = 7.1 Hz, 2H), 2.68 (s, 3H), 1.19 (t = 7.3 Hz, 3H); ESI MS (m/z) 507.70 (MH)+ 141 2-(5-(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.2 Hz, 1H), 8.81 (d, J = 2.2 Hz, 1H), 8.59 (d, J = 9.0 Hz, 1H), 8.33- 8.45 (m, 2H), 7.82-7.87 (m, 2H), 7.46 (tt, J = 9.3, 2.3 Hz, 1H), 3.51-3.58 (m, 2H), 2.68 (s, 3H), 1.19 (q, J = 7.3 Hz, 3H); ESI MS (m/z) 510.10 (MH)+ 142 2-(5-(4-chloro-3-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.4 Hz, 1H), 8.80 (d, J = 2.6 Hz, 1H), 8.77 (s, 1H), 8.53 (s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.16 (dd, J = 10.6, 2.1 Hz, 1H), 7.87 (dd, J = 8.6, 2.0 Hz , 1H), 7.82 (t, J = 7.9 Hz, 1H), 3.50 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 511.65 (MH) +. 143 2-(5-(2-Chloro-5-(trifluoromethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.15 (d, J = 2.2 Hz, 1H), 8.79 (d, J = 0.5 Hz, 1H), 8.73 (d, J = 2.2 Hz, 1H), 8.55 ( d, J = 1.0 Hz, 1H), 8.43 (dd, J = 8.3, 1.5 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.19 (t, J = 1.0 Hz, 1H), 7.92- 7.97 (m, 2H), 3.47 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 561.90 (MH)+. 144 3-chloro-5-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)benzene Acetonitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 2.2 Hz, 1H), 8.91 (d, J = 2.4 Hz, 1H), 8.78 (s, 1H), 8.54 (t, J = 1.6 Hz, 2H), 8.49 (t, J = 1.8 Hz, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.21 (dd, J = 1.8 , 1.3 Hz, 1H), 3.51 (q, J = 7.4 Hz, 2H), 1.18 (t, J = 7.2 Hz, 3H) ESI MS (m/z) 518.70 (MH)+. 145 2-(3-(Ethylsulfonyl)-5-(2-fluoro-5-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.22 (t, J = 1.8 Hz, 1H), 8.79 (s, 1H), 8.75 (q, J = 1.1 Hz, 1H), 8.54 (s, 1H), 8.43 (dd, J = 8.2, 1.8 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.00-8.02 (m, 1H), 7.62-7.64 (m, 2H), 3.48 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 561.75(MH)+. 146 2-(5-(4-chloro-2-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.19 (q, J = 1.3 Hz, 1H), 8.79 (s, 1H), 8.71 (q, J = 1.1 Hz, 1H), 8.54 (s, 1H), 8.43 (dd, J = 8.4, 1.6 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 7.92 (t, J = 8.4 Hz, 1H), 7.73 (dd, J = 10.6, 2.1 Hz, 1H) ), 7.55 (dd, J = 8.3, 2.4 Hz, 1H), 3.47 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 511.90 (MH) +. 147 2-(5-(4-Bromophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.74 (d, J = 2.2 Hz, 1H), 8.54 (s, 1H), 8.41-8.43 (m, 1H), 8.34 (d, J = 8.3 Hz, 1H), 7.92-7.94 (m, 2H), 7.80 (dd, J = 6.7, 2.1 Hz, 2H), 3.50 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 539.90(MH)+. 148 2-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2 -Ethyl methyl propionate 1H-NMR (400 MHz, DMSO-d6) δ 8.73 (s, 1H), 8.59 (d, J = 2.8 Hz, 1H), 8.51 (s, 1H), 8.40 (dd, J = 8.3, 1.8 Hz, 1H ), 8.32 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 2.8 Hz, 1H), 4.22 (q, J = 7.0 Hz, 2H), 3.39 (q, J = 7.3 Hz, 2H), 1.67 (d, J = 14.7 Hz, 6H), 1.20 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 514.05 (MH)+. 149 2-(4-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)phenoxy Yl)-2,2-difluoro-N,N-dimethylacetamide 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 2.1 Hz, 1H), 8.78 (s, 1H), 8.74 (d, J = 2.1 Hz, 1H), 8.54 (s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.05 (dt, J = 9.4, 2.5 Hz, 2H), 7.51 (d, J = 8.6 Hz, 2H ), 3.46-3.52 (m, 2H), 3.26 (d, J = 8.3 Hz, 3H), 2.98 (s, 3H), 1.13-1.18 (m, 4H) ESI MS (m/z) 597.05 (MH)+ . 150 2-(3-(Ethylsulfonyl)-5-(3,3,3-trifluoropropyl-1-en-2-yl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.14 (d, J = 2.4 Hz, 1H), 8.78 (s, 1H), 8.53-8.55 (m, 2H), 8.43 (dd, J = 8.3, 1.8 Hz , 1H), 8.34 (d, J = 8.3 Hz, 1H), 6.62 (t, J = 1.5 Hz, 1H), 6.50 (d, J = 1.2 Hz, 1H), 3.44-3.53 (m, 2H), 1.10 -1.19 (m, 3H) ESI MS (m/z) 477.95 (MH)+. 151 2-(3-(Ethylsulfonyl)-5-(4-(2,2,3,3,3-pentafluoropropoxy)phenyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.54 (s, 1H), 8.42 (dd, J = 8.3, 1.8 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 7.97 (dd, J = 6.9, 2.0 Hz, 2H), 7.29 (d, J = 8.9 Hz, 2H ), 4.97 (t, J = 13.3 Hz, 2H), 3.49 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 608.00 (MH)+. 152 2-(5-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-3-(ethylsulfonyl)pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 2.4 Hz, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.79 (d, J = 0.5 Hz, 1H), 8.54 ( s, 1H), 8.43 (dd, J = 8.6, 2.0 Hz, 1H), 8.35 (d, J = 8.6 Hz, 1H), 7.79 (dd, J = 8.1, 1.0 Hz, 1H), 7.59 (dd, J = 8.1, 1.0 Hz, 1H), 7.44 (t, J = 8.1 Hz, 1H), 3.46-3.51 (m, 3H), 1.22 (s, 0H), 1.17 (t, J = 7.5 Hz, 4H) ESI MS (m/z) 539.80 (MH)+. 153 2-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)acetonitrile 1H-NMR (400 MHz, DMSO-d6) δ 8.81 (d, J = 3.1 Hz, 1H), 8.74 (s, 1H), 8.51 (s, 1H), 8.41 (dd, J = 8.3, 1.8 Hz, 1H ), 8.32 (d, J = 8.3 Hz, 1H), 8.21 (d, J = 2.8 Hz, 1H), 5.52 (s, 2H), 3.36-3.44 (m, 2H), 1.11 (dt, J = 23.8, 7.2 Hz, 3H) ESI MS (m/z) 438.70 (MH)+. 154 2-(3-(Ethylsulfonyl)-5-(1,1,2,3,3,3-hexafluoropropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalein Oxazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 2.4 Hz, 1H), 8.78 (s, 1H), 8.52 (s, 1H), 8.50 (d, J = 2.8 Hz, 1H), 8.43 (dd, J = 8.3, 1.8 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 6.63 (dq, J = 41.3, 6.1 Hz, 1H), 3.46-3.53 (m, 2H), 1.15 (q, J = 7.3 Hz, 3H) ESI MS (m/z) 549.75 (MH)+. 155 2-(3-(Ethylsulfonyl)-5-(4-hydroxyphenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.94 (s, 1H), 9.22 (d, J = 2.4 Hz, 1H), 8.76 (s, 1H), 8.61 (d, J = 2.4 Hz, 1H), 8.53 (s, 1H), 8.41 (dd, J = 8.4, 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 8.6 Hz, 2H), 6.95-6.97 (m , 2H), 3.47 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 475.75 (MH)+. 156 2-(3-(Ethylsulfonyl)-5-hydroxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 8.70 (s, 1H), 8.50 (s, 1H), 8.45 (d, J = 2.8 Hz, 1H), 8.39 (d, J = 8.3 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 2.8 Hz, 1H), 3.37 (q, J = 6.8 Hz, 2H), 1.06-1.13 (m, 4H ) ESI MS (m/z) 399.95 (MH)+. 157 2-(5-(2-chloro-4-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 2.1 Hz, 1H), 8.79 (s, 1H), 8.63 (d, J = 2.4 Hz, 1H), 8.54 (s, 1H), 8.43 (dd, J = 8.4, 1.7 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 7.82 (dd, J = 8.6, 6.1 Hz, 1H), 7.74 (dd, J = 8.9, 2.8 Hz , 1H), 7.47 (td, J = 8.5, 2.5 Hz, 1H), 3.47 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 511.95 ( MH)+. 158 2-(3-(Ethylsulfonyl)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.31-9.35 (m, 1H), 8.78 (d, J = 2.0 Hz, 2H), 8.54 (s, 1H), 8.42 (dd, J = 8.3, 1.7 Hz , 1H), 8.34 (d, J = 8.3 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.90 (d, J = 2.0 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H ), 7.48 (d, J = 8.3 Hz, 1H), 6.86 (tt, J = 51.8, 3.0 Hz, 1H), 3.51 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H ) ESI MS (m/z) 576.05 (MH)+. 159 5'-(Ethylsulfonyl)-6'-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)-[2,3'-dipyridine]-5 -Formonitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.71 (d, J = 2.2 Hz, 1H), 9.26 (q, J = 1.0 Hz, 1H), 9.19 (d, J = 2.4 Hz, 1H), 8.78 ( d, J = 8.6 Hz, 1H), 8.57-8.60 (m, 2H), 8.53 (d, J = 8.8 Hz, 1H), 8.42-8.45 (m, 1H), 8.35 (d, J = 8.3 Hz, 1H ), 3.44-3.52 (m, 2H), 1.11-1.18 (m, 3H) ESI MS (m/z) 486.05 (MH)+. 160 2-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)pyrimidine-5-methyl Nitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.85 (d, J = 2.2 Hz, 1H), 9.55 (d, J = 5.4 Hz, 2H), 9.33 (d, J = 2.2 Hz, 1H), 8.81 ( s, 1H), 8.54 (s, 1H), 8.44 (dd, J = 8.4, 1.8 Hz, 1H), 8.36 (d, J = 8.3 Hz, 1H), 3.50 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 487.00 (MH)+. 161 2-(3-(Ethylsulfonyl)-5-(2,2,2-trifluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.81 (d, J = 3.1 Hz, 1H), 8.73 (s, 1H), 8.51 (s, 1H), 8.40 (dd, J = 8.2, 1.9 Hz, 1H ), 8.32 (d, J = 8.3 Hz, 1H), 8.20 (d, J = 3.1 Hz, 1H), 5.16 (q, J = 8.8 Hz, 2H), 3.41 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 481.95 (MH)+ 162 2-(3-(Ethylsulfonyl)-5-(2,2,3,3,3-pentafluoropropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.80 (d, J = 3.1 Hz, 1H), 8.73 (s, 1H), 8.51 (s, 1H), 8.39-8.42 (m, 1H), 8.32 (d , J = 8.3 Hz, 1H), 8.22 (d, J = 3.1 Hz, 1H), 5.26 (t, J = 13.8 Hz, 2H), 3.41 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 531.95 (MH)+ 163 2-(3-(Ethylsulfonyl)-5-(3-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 2.4 Hz, 1H), 8.77 (d, J = 2.2 Hz, 2H), 8.54 (s, 1H), 8.42 (dd, J = 8.6 , 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 7.91 (dt, J = 10.2, 2.1 Hz, 1H), 7.82 (dq, J = 7.8, 0.8 Hz, 1H), 7.64 (td , J = 8.0, 6.2 Hz, 1H), 7.37-7.42 (m, 1H), 3.51 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 478.05 (MH)+. 164 2-(3-(Ethylsulfonyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 2.2 Hz, 1H), 8.78 (d, J = 2.4 Hz, 2H), 8.54 (s, 1H), 8.43 (dd, J = 8.2 , 1.6 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 7.36 (s, 1H), 4.08 (s, 3H), 3.48 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 532.00 (MH)+. 165 2-(3-(Ethylsulfonyl)-5-(pyrimidin-5-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 2.2 Hz, 1H), 9.40 (s, 2H), 9.33 (s, 1H), 8.95 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 0.5 Hz, 1H), 8.54 (s, 1H), 8.43 (dd, J = 8.2, 1.6 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 3.50 (q, J = 7.4 Hz, 2H), 1.18 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 462.00 (MH)+. 166 2-(3-(Ethylsulfonyl)-5-methylpyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.81 (d, J = 1.5 Hz, 1H), 8.73 (s, 1H), 8.51 (s, 1H), 8.39-8.41 (m, 2H), 8.32 (d , J = 8.6 Hz, 1H), 3.36 (q, J = 7.3 Hz, 2H), 2.53 (s, 3H), 1.06-1.13 (t, 3H) ESI MS (m/z) 397.95 (MH)+. 167 2-(3-(Ethylsulfonyl)-5-((methylthio)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.72 (d, J = 2.8 Hz, 2H), 8.51 (s, 1H), 8.40 (d, J = 8.3 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 8.12 (d, J = 2.8 Hz, 1H), 5.62 (s, 2H), 3.34-3.42 (m, 2H), 2.23-2.27 (m, 3H), 1.13 (t, J = 7.3 Hz , 3H), 1.06 (s, 0H) ESI MS (m/z) 460.00 (MH)+. 168 2-(5-(Cyclopropylmethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.71 (s, 1H), 8.66 (d, J = 2.8 Hz, 1H), 8.50 (s, 1H), 8.40 (dd, J = 8.3, 1.8 Hz, 1H ), 8.31 (d, J = 8.3 Hz, 1H), 7.97 (d, J = 3.1 Hz, 1H), 4.14 (d, J = 7.0 Hz, 2H), 3.35-3.42 (m, 2H), 1.26-1.33 (m, 1H), 1.12 (t, J = 7.5 Hz, 3H), 0.61-0.65 (m, 2H), 0.41 (td, J = 5.3, 3.9 Hz, 2H) ESI MS (m/z) 454.00 (MH )+. 169 3-(5-Bromo-3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.66 (d, J = 2.1 Hz, 1H), 8.58 (d, J = 8.3 Hz, 2H), 8.54 (dd, J = 8.6, 1.8 Hz, 1H), 8.41 (d, J = 2.1 Hz, 1H), 3.10 (q, J = 7.3 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 432.85 (MH)+. 170 3-(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 2.4 Hz, 1H), 8.94 (d, J = 2.2 Hz, 1H), 8.60 (d, J = 8.1 Hz, 2H), 8.55 ( dd, J = 8.6, 2.0 Hz, 1H), 3.47 (q, J = 7.4 Hz, 2H), 1.13 (t, J = 7.4 Hz, 3H) ESI MS (m/z) 464.85 (MH)+. 171 2-(5-((Dimethyl((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.50 (s, 1H), 8.44 (d, J = 2.7 Hz, 1H), 8.39 (dd, J = 8.4, 1.8 Hz, 1H ), 8.31 (d, J = 8.3 Hz, 1H), 7.88 (d, J = 2.7 Hz, 1H), 3.41-3.46 (m, 6H), 3.36 (q, J = 7.2 Hz, 2H), 1.12 (t , J = 7.5 Hz, 3H) ESI MS (m/z) 474.95 (MH)+. 172 2-(3-(Ethylsulfonyl)-5-((methylsulfonyl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.86 (d, J = 2.9 Hz, 1H), 8.73 (d, J = 0.5 Hz, 1H), 8.51 (s, 1H), 8.40 (dd, J = 8.3 , 1.5 Hz, 1H), 8.35 (d, J = 2.9 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 5.71 (s, 2H), 3.40 (q, J = 7.3 Hz, 2H), 3.17 (s, 3H), 1.11-1.16 (t, 3H) ESI MS (m/z) 491.70 (MH)+. 173 2-(4-(Ethylsulfonyl)-6-(3-(trifluoromethyl)phenyl)pyridazin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 19.6 Hz, 1H), 8.89 (d, J = 0.6 Hz, 1H), 8.58-8.71 (m, 3H), 8.48 (dd, J = 8.3, 1.5 Hz, 1H), 8.39 (d, J = 8.3 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.92 (t, J = 7.8 Hz, 1H), 3.75 (q, J = 7.2 Hz, 2H), 1.22 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 528.85 (MH)+ 174 2-(3-(Ethylsulfonyl)-5-(oxetan-3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.68-9.02 (m, 1H), 8.59-8.62 (m, 1H), 8.52 (s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H) , 8.33 (d, J = 8.3 Hz, 1H), 7.87-7.98 (m, 1H), 5.64-5.69 (m, 1H), 4.90-5.04 (m, 2H), 4.68 (dd, J = 7.8, 4.4 Hz , 2H), 3.42 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 456.05 (MH)+ 175 2-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2 -Methylpropionamide 1H-NMR (400 MHz, DMSO-d6) δ 10.60 (s, 1H), 9.27 (d, J = 2.7 Hz, 1H), 9.02 (d, J = 2.4 Hz, 1H), 8.73 (s, 1H), 8.51 (s, 1H), 8.40 (dd, J = 8.4, 1.8 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 5.91 (s, 1H), 3.35 (q, J = 7.4 Hz, 2H ), 1.40 (s, 6H), 1.13 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 485.05 (MH)+. 176 2-(3-(Ethylsulfonyl)-6-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.79 (d, J = 0.5 Hz, 1H), 8.61-8.66 (m, 1H), 8.51-8.54 (m, 2H), 8.43 (dd, J = 8.4, 1.8 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.29 (dt, J = 9.5, 2.5 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 6.84 (tt, J = 51.8, 2.9 Hz, 1H), 3.43 (q, J = 7.4 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 576.00 (MH)+. 177 2-(5-((Diethyl((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.50 (s, 1H), 8.45 (d, J = 2.7 Hz, 1H), 8.39 (dd, J = 8.3, 1.7 Hz, 1H ), 8.30 (d, J = 8.3 Hz, 1H), 7.92 (d, J = 2.7 Hz, 1H), 3.51 (q, J = 7.4 Hz, 4H), 3.35 (t, J = 7.3 Hz, 2H), 1.32 (t, J = 7.3 Hz, 6H), 1.11 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 502.80 (MH)+. 178 2-(5'-(Ethylsulfonyl)-4-(trifluoromethyl)-[2,3'-dipyridine]-6'-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.75 (d, J = 2.4 Hz, 1H), 9.24 (d, J = 2.2 Hz, 1H), 9.09 (d, J = 5.1 Hz, 1H), 8.79 ( d, J = 0.5 Hz, 1H), 8.76 (s, 1H), 8.56 (d, J = 10.0 Hz, 1H), 8.43 (dd, J = 8.3, 1.5 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 7.95 (dd, J = 5.0, 0.9 Hz, 1H), 3.49 (q, J = 7.3 Hz, 2H), 1.14-1.19 (m, 3H) ESI MS (m/z) 528.80 (MH) +. 179 2-(5'-(Ethylsulfonyl)-5-(trifluoromethyl)-[2,3'-dipyridine]-6'-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.72 (d, J = 2.2 Hz, 1H), 9.20-9.22 (m, 2H), 8.80 (s, 1H), 8.59 (d, J = 8.3 Hz, 1H) ), 8.54 (s, 1H), 8.50 (dd, J = 8.6, 2.2 Hz, 1H), 8.43 (dd, J = 8.4, 1.8 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 3.49 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 528.95 (MH)+. 180 2-(5-(3-(benzyloxy)cyclobutoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.73 (s, 1H), 8.61 (dd, J = 7.1, 2.9 Hz, 1H), 8.52 (s, 1H), 8.40-8.43 (m, 1H), 8.33 (d, J = 8.3 Hz, 1H), 7.88 (dd, J = 12.5, 2.9 Hz, 1H), 7.31-7.38 (m, 5H), 4.85-5.24 (m, 1H), 4.46 (s, 2H), 3.85-4.35(m, 1H), 3.4 (m, 2H), 2.9 (m, 1H), 2.45 -2.65(m, 2H) 2.06 (m, 1H), 1.15 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 560.10 (MH)+ 181 2-(5-(3-chloro-4-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 2.4 Hz, 1H), 8.77-8.79 (m, 2H), 8.53 (d, J = 1.0 Hz, 1H), 8.42 (dd, J = 8.4, 1.8 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.30 (dd, J = 7.0, 2.3 Hz, 1H), 8.01 (qd, J = 4.4, 2.4 Hz, 1H), 7.65 (t, J = 8.9 Hz, 1H), 3.50 (q, J = 7.4 Hz, 2H), 1.15-1.19 (t, 3H) ESI MS (m/z) 512.05 (MH)+. 182 3-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]tri Oxazin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 2.4 Hz, 1H), 8.84 (d, J = 2.2 Hz, 1H), 8.60-8.62 (m, 2H), 8.56 (dd, J = 8.7, 1.8 Hz, 1H), 8.05-8.10 (m, 2H), 7.43-7.49 (m, 2H), 3.51 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H) ;ESI MS (m/z) 478.95 (MH)+. 183 2-(3-(Ethylsulfonyl)-5-(2-methoxypyrimidin-5-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.4 Hz, 1H), 9.20 (s, 2H), 8.86 (d, J = 2.4 Hz, 1H), 8.77 (d, J = 0.7 Hz, 1H), 8.53 (s, 1H), 8.42 (dd, J = 8.3, 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 4.01 (s, 3H), 3.48 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 492.05 (MH)+. 184 2-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)acetonitrile 1H-NMR (400 MHz, DMSO-d6) δ 8.98 (d, J = 2.2 Hz, 1H), 8.76 (d, J = 0.5 Hz, 1H), 8.58 (d, J = 2.2 Hz, 1H), 8.52 ( s, 1H), 8.42 (dd, J = 8.3, 1.7 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 4.38 (s, 2H), 3.36-3.43 (m, 2H), 1.13 (t , J = 7.3 Hz, 3H) ESI MS (m/z) 423 (MH)+. 185 2-(5-Bromo-3-(ethylthio)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.75 (d, J = 0.5 Hz, 1H), 8.55 (d, J = 2.0 Hz, 1H), 8.52 (s, 1H), 8.40 (dd, J = 8.2 , 1.6 Hz, 1H), 8.29-8.32 (m, 2H), 3.06 (q, J = 7.3 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 429.85 (MH) +. 186 3-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1 ,2,3)triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 2.2 Hz, 1H), 8.88 (d, J = 2.4 Hz, 1H), 8.60-8.63 (m, 2H), 8.55-8.57 (m , 1H), 8.14 (d, J = 8.8 Hz, 2H), 7.62 (d, J = 8.1 Hz, 2H), 3.51 (q, J = 7.5 Hz, 2H), 1.16 (t, J = 7.5 Hz, 3H ); ESI MS (m/z) 545.00 (MH)+. 187 3-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl )Benzo[d][1,2,3]triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 2.2 Hz, 1H), 8.88 (d, J = 2.2 Hz, 1H), 8.61 (dd, J = 5.1, 3.4 Hz, 2H), 8.56 (dd, J = 8.7, 1.8 Hz, 1H), 8.11 (dt, J = 9.3, 2.6 Hz, 2H), 7.52 (d, J = 8.8 Hz, 2H), 6.73-7.00 (m, 1H), 3.51 (q, J = 7.4 Hz, 2H), 1.16 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 577.00 (MH)+ 188 3-(3-(ethylthio)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine- 4(3H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.80 (d, J = 2.2 Hz, 1H), 8.58-8.61 (m, 2H), 8.55 (dd, J = 8.7, 2.1 Hz, 1H), 8.32 (d , J = 2.2 Hz, 1H), 7.96-7.99 (m, 2H), 7.39-7.43 (m, 2H), 3.15 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ;ESI MS (m/z) 447.00 (MH)+ 189 3-(5-(4-chlorophenyl)-3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine- 4(3H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.81 (d, J = 2.2 Hz, 1H), 8.60 (d, J = 10.8 Hz, 2H), 8.55 (dd, J = 8.6, 2.0 Hz, 1H), 8.34 (d, J = 2.2 Hz, 1H), 7.95 (dd, J = 6.6, 2.0 Hz, 2H), 7.64 (dd, J = 6.6, 2.2 Hz, 2H), 3.16 (q, J = 7.3 Hz, 2H) ), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 463.00 (MH)+ 190 2-(5-(2-Bromo-1,1,2,2-tetrafluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Oxazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.17 (d, J = 2.7 Hz, 1H), 8.78 (d, J = 0.5 Hz, 1H), 8.59 (d, J = 2.7 Hz, 1H), 8.52 ( s, 1H), 8.43 (dd, J = 8.3, 1.7 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 3.51 (q, J = 7.4 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 579.90 (MH)+. 191 3-(3-(ethylthio)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2 ,3)Triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.82 (d, J = 2.2 Hz, 1H), 8.59-8.62 (m, 2H), 8.55 (dd, J = 8.6, 2.0 Hz, 1H), 8.36 (d , J = 2.2 Hz, 1H), 8.03-8.06 (m, 2H), 7.56-7.58 (m, 2H), 3.16 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.3 Hz, 3H) ;ESI MS (m/z) 513.00 (MH)+ 192 3-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3] three Oxazin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.41 (d, J = 2.1 Hz, 1H), 8.87 (d, J = 2.1 Hz, 1H), 8.60-8.62 (m, 2H), 8.56 (dd, J = 8.6, 1.8 Hz, 1H), 8.05 (dd, J = 6.6, 2.0 Hz, 2H), 7.68 (dd, J = 6.7, 2.1 Hz, 2H), 3.51 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 494.94 (MH)+ 193 3-(5-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2, 3) Triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.46 (d, J = 2.4 Hz, 1H), 8.96 (d, J = 2.4 Hz, 1H), 8.60-8.62 (m, 2H), 8.56 (dd, J = 8.6, 1.8 Hz, 1H), 8.16 (d, J = 1.8 Hz, 2H), 7.82 (t, J = 1.8 Hz, 1H), 3.53 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 528.85 (MH)+ 194 3-(5-(3,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2, 3) Triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.46 (d, J = 2.2 Hz, 1H), 8.94 (d, J = 2.2 Hz, 1H), 8.61 (dd, J = 5.3, 3.3 Hz, 2H), 8.56 (dd, J = 8.8, 1.7 Hz, 1H), 7.85-7.90 (m, 2H), 7.47 (tt, J = 9.3, 2.3 Hz, 1H), 3.53 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 496.90 (MH)+ 195 3-(5-(3-chloro-5-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2 ,3)Triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.46 (d, J = 2.2 Hz, 1H), 8.95 (d, J = 2.2 Hz, 1H), 8.60-8.62 (m, 2H), 8.56 (dd, J = 8.6, 1.7 Hz, 1H), 8.05 (d, J = 1.7 Hz, 1H), 7.99 (dt, J = 9.5, 1.8 Hz, 1H), 7.65 (dt, J = 8.6, 2.1 Hz, 1H), 3.53 (q, J = 7.2 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 512.90 (MH)+ 196 3-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1, 2,3]Triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.48 (d, J = 2.2 Hz, 1H), 8.98 (d, J = 2.4 Hz, 1H), 8.61-8.63 (m, 2H), 8.56 (dd, J = 8.6, 2.0 Hz, 1H), 8.39 (s, 1H), 8.31 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.85 (t, J = 7.8 Hz, 1H ), 3.53 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 528.95 (MH)+ 197 2-(5-((4,4-Difluorobut-3-en-1-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.71 (s, 1H), 8.67 (d, J = 2.9 Hz, 1H), 8.50 (s, 1H), 8.40 (dd, J = 8.4, 1.8 Hz, 1H ), 8.31 (d, J = 8.3 Hz, 1H), 8.00 (d, J = 2.9 Hz, 1H), 4.67 (dtd, J = 26.8, 7.8, 2.5 Hz, 1H), 4.32 (t, J = 6.2 Hz , 2H), 3.40 (q, J = 7.4 Hz, 2H), 2.52 (s, 1H), 2.45 (s, 1H), 1.12 (t, J = 7.5 Hz, 3H), ESI MS (m/z) 490 (MH)+ 198 2-(3-(ethylthio)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Oxazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.71 (d, J = 2.1 Hz, 1H), 8.54 (s, 1H), 8.41 (dd, J = 8.3, 1.5 Hz, 1H ), 8.32 (d, J = 8.3 Hz, 1H), 8.25 (d, J = 2.1 Hz, 1H), 7.96-7.99 (m, 2H), 7.46 (d, J = 8.6 Hz, 2H), 6.72-6.99 (m, 1H), 3.12 (q, J = 7.3 Hz, 2H), 1.18 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 544.05 (MH)+ 199 2-(3-(Ethylsulfonyl)-5-(1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.20 (d, J = 2.1 Hz, 1H), 8.78 (s, 1H), 8.67 (d, J = 2.1 Hz, 1H), 8.54 (d, J = 0.9 Hz, 1H), 8.43 (dd, J = 8.3, 1.8 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 6.83 (d, J = 1.8 Hz, 1H), 4.01 (s, 3H), 3.49 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 464.05 (MH)+ 200 2-(3-(Ethylsulfonyl)-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.21 (d, J = 2.2 Hz, 1H), 8.75 (s, 1H), 8.63 (d, J = 2.2 Hz, 1H), 8.56 (s, 1H), 8.52 (s, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.33 (d, J = 8.1 Hz, 1H), 8.22 (s, 1H), 3.92 (s, 3H), 3.43 (q, J = 7.6 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 464.00 (MH)+ 201 2-(3-(Ethylsulfonyl)-5-(3-fluoro-5-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.41 (d, J = 2.2 Hz, 1H), 8.90 (d, J = 2.2 Hz, 1H), 8.78 (s, 1H), 8.54 (s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.25-8.28 (m, 2H), 7.88 (d, J = 8.6 Hz, 1H), 3.52 (q , J = 7.4 Hz, 2H), 1.18 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 546.00 (MH)+ 202 1-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane-1- Formonitrile 1H-NMR (400 MHz, DMSO-d6) δ 8.93 (d, J = 2.4 Hz, 1H), 8.75 (d, J = 0.5 Hz, 1H), 8.51 (s, 1H), 8.40-8.42 (m, 2H ), 8.33 (d, J = 8.3 Hz, 1H), 3.44 (q, J = 7.4 Hz, 2H), 1.95-1.99 (m, 2H), 1.88-1.93 (m, 2H), 1.12-1.16 (t, J = 7.4 Hz, 3H); ESI MS (m/z) 449.05(MH)+ 203 2-(3-(Ethylsulfonyl)-5-(4-(methylsulfonyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 2.4 Hz, 1H), 8.83 (d, J = 2.1 Hz, 1H), 8.79 (s, 1H), 8.54 (d, J = 0.9 Hz, 1H), 8.43 (dd, J = 8.4, 1.7 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.23-8.26 (m, 2H), 8.11-8.14 (m, 2H), 3.46 -3.54 (m, 2H), 3.35 (s, 3H), 1.18 (t, J = 7.5 Hz, 3H); ESI MS (m/z) 537.95(MH)+ 204 2-(3-(Ethylthio)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.67-8.69 (m, 1H), 8.54 (d, J = 1.2 Hz, 1H), 8.41 (dd, J = 8.4, 1.8 Hz , 1H), 8.31-8.33 (m, 1H), 8.21 (d, J = 2.2 Hz, 1H), 7.91-7.98 (m, 2H), 7.36-7.42 (m, 2H), 3.11 (q, J = 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 446.05 (MH)+ 205 (5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) ethyl phosphonate 1H-NMR (400 MHz, DMSO-d6) δ 8.91 (q, J = 1.3 Hz, 1H), 8.76 (s, 1H), 8.52 (s, 1H), 8.40-8.43 (m, 2H), 8.33 (d , J = 8.3 Hz, 1H), 4.18-4.28 (m, 2H), 3.43 (q, J = 7.3 Hz, 2H), 2.08-2.18 (m, 2H), 1.29 (t, J = 7.1 Hz, 3H) , 1.12-1.22 (m, 6H) ESI MS (m/z) 520 (MH)+ 206 2-(5-(Dimethylphosphoryl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (dd, J = 5.4, 2.0 Hz, 1H), 8.83 (dd, J = 10.0, 2.0 Hz, 1H), 8.78 (d, J = 0.5 Hz, 1H ), 8.53 (s, 1H), 8.43 (dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 3.46 (q, J = 7.4 Hz, 2H), 1.90 (s , 3H), 1.87 (s, 3H), 1.15 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 460 (MH)+ 207 2-(3-(Ethylsulfonylimino)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.23 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.69 (d, J = 2.1 Hz, 1H), 8.52 (s, 1H), 8.40 (dd, J = 8.3, 1.8 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 8.01-8.04 (m, 2H), 7.51 (d, J = 8.9 Hz, 2H), 6.86 (tt , J = 52.0, 2.9 Hz, 1H), 4.61 (d, J = 38.8 Hz, 1H), 3.27 (q, J = 6.7 Hz, 2H), 1.12 (t, J = 7.3 Hz, 3H) ESI MS (m /z) 575.10 (MH)+ 208 2-(3-(Ethylsulfonyl)-5-((S-methylsulfonylimino)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 8.85 (dd, J = 7.1, 2.9 Hz, 1H), 8.73 (s, 1H), 8.51 (s, 1H), 8.40 (dd, J = 8.3, 1.5 Hz , 1H), 8.30-8.33 (m, 2H), 5.54 (d, J = 12.2 Hz, 1H), 5.45 (d, J = 12.0 Hz, 1H), 4.09 (s, 1H), 3.36-3.42 (q, J = 7.2 Hz, 2H), 3.02 (s, 3H), 1.08-1.18 (t, J = 7.3 HZ, 3H) ESI MS (m/z) 490.90 (MH)+ 209 2-(3-(Ethylsulfonylimino)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.20 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.52 (s, 1H), 8.40 (dd, J = 8.3, 1.8 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 7.95-8.00 (m, 2H), 7.41-7.47 (m, 2H), 4.60 (d, J = 41.9 Hz, 1H), 3.28 (q, J = 7.3 Hz, 2H), 1.12 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 477.10 (MH)+ 210 2-(3-(Ethylsulfonyl)-5-(1,1,2,2-tetrafluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.10 (d, J = 2.4 Hz, 1H), 8.78 (d, J = 0.6 Hz, 1H), 8.53 (d, J = 2.4 Hz, 2H), 8.43 ( dd, J = 8.3, 1.5 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 6.98 (tt, J = 51.6, 3.0 Hz, 1H), 3.49 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 500.00 (MH)+ 211 2-(3-(Ethylsulfonyl)-5-(3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 2.4 Hz, 1H), 8.80 (d, J = 2.4 Hz, 2H), 8.55 (s, 1H), 8.43 (dd, J = 8.3 , 1.7 Hz, 1H), 8.35 (d, J = 8.1 Hz, 1H), 6.94 (s, 1H), 3.50 (q, J = 7.4 Hz, 2H), 2.55 (s, 3H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 532.00 (MH)+ 212 3-(3-(Ethylsulfonyl)-5-hydroxypyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 11.63 (s, 1H), 8.56-8.59 (m, 2H), 8.52-8.54 (m, 2H), 7.89 (d, J = 2.8 Hz, 1H), 3.34 (q, J = 7.3 Hz, 2H), 1.11 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 401.00 (MH)+ 213 3-(3-(Ethylthio)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 8.9 Hz, 2H), 8.53 (td, J = 4.6, 1.5 Hz, 2H), 8.19 (dd, J = 8.1, 1.4 Hz, 1H ), 7.70 (dd, J = 8.1, 4.7 Hz, 1H), 3.02 (q, J = 7.2 Hz, 2H), 1.15 (t, J = 7.1 Hz, 3H); ESI MS (m/z) 352.95 (MH )+ 214 3-(3-(Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.10 (dd, J = 4.9, 1.7 Hz, 1H), 8.71 (dd, J = 8.1, 1.7 Hz, 1H), 8.59-8.61 (m, 2H), 8.54 -8.56 (m, 1H), 8.07 (dd, J = 7.9, 4.8 Hz, 1H), 3.38 (q, J = 7.4 Hz, 2H), 1.14 (t, J = 7.4 Hz, 3H); ESI MS (m /z) 384.95 (MH)+ 215 3-(5-((Diethyl((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl) Benzo[d][1,2,3]triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.57 (dd, J = 5.3, 3.3 Hz, 2H), 8.51-8.54 (m, 2H), 7.98 (d, J = 2.7 Hz, 1H), 3.55 (q , J = 7.3 Hz, 4H), 3.34 (q, J = 7.3 Hz, 2H), 1.32-1.37 (m, 6H), 1.12 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 504.00 (MH)+ 216 2-(3-(Ethylsulfonyl)-5-(ethylthio)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.87 (d, J = 2.1 Hz, 1H), 8.74 (s, 1H), 8.51 (d, J = 0.9 Hz, 1H), 8.40 (dd, J = 8.3 , 1.5 Hz, 1H), 8.32 (q, J = 2.8 Hz, 2H), 3.42 (q, J = 7.4 Hz, 2H), 3.27 (q, J = 7.3 Hz, 2H), 1.33 (t, J = 7.3 Hz, 3H), 1.13 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 443.95 (MH)+ 217 2-(5-(4-Fluorophenyl)-3-(N-methylethylsulfonylimino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.22 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.53 (s, 2H), 8.41 (d, J = 8.3 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 7.99 (dd, J = 8.8, 5.4 Hz, 2H), 7.44 (t, J = 8.8 Hz, 2H), 3.35-3.44 (m, 2H), 2.43 (s , 3H), 1.09-1.14 (m, 3H) ESI MS (m/z) 491.10 (MH)+ 218 (5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) tert-butyl carbamate 1H-NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 8.87 (d, J = 2.4 Hz, 1H), 8.72 (d, J = 0.5 Hz, 1H), 8.68 (d, J = 2.4 Hz, 1H), 8.51 (s, 1H), 8.40 (dd, J = 8.3, 1.5 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 3.35 (q, J = 7.3 Hz, 2H), 1.52 (s, 9H), 1.12 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 499.00 (MH)+ 219 2-(5-((Ethyl(methyl)((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.50 (s, 1H), 8.45 (d, J = 2.7 Hz, 1H), 8.38-8.40 (m, 1H), 8.31 (d , J = 8.6 Hz, 1H), 7.90 (d, J = 2.7 Hz, 1H), 3.52-3.58 (m, 2H), 3.34-3.38 (m, 5H), 1.36 (t, J = 7.3 Hz, 3H) , 1.12 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 488.95 (MH)+ 220 3-(5-((Ethyl(isopropyl)((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-6-(tri Fluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.53-8.60 (m, 4H), 8.03 (d, J = 2.7 Hz, 1H), 3.74-3.81 (m, 1H), 3.55 (dd, J = 15.5, 7.2 Hz, 2H), 3.33-3.35 (m, 2H), 1.44 (d, J = 6.6 Hz, 3H), 1.39 (d, J = 6.6 Hz, 3H), 1.35 (t, J = 7.3 Hz, 3H) , 1.12 (t, J = 7.2 hz, 3H); ESI MS (m/z) 518.05 (MH)+ 221 5-(Ethylsulfonyl)-6-(4-oxo-6-(trifluoromethyl)benzo[d][1,2,3]triazine-3(4H)-yl)pyridine- Dimethyl 3-sulfamate 1H-NMR (400 MHz, DMSO-d6) δ 9.16 (d, J = 2.7 Hz, 1H), 8.67-8.72 (m, 1H), 8.61 (d, J = 8.8 Hz, 2H), 8.56 (dd, J = 8.4, 2.1 Hz, 1H), 3.47 (q, J = 7.3 Hz, 2H), 3.06 (s, 6H), 1.14 (t, J = 7.3 Hz, 3H); ESI MS (m/z) 507.95 (MH )+ 222 2-((5-(Ethylsulfonyl)-6-(4-oxo-6-(trifluoromethyl)benzo[d][1,2,3]triazine-3(4H)- (Yl)pyridin-3-yl)oxy)acetonitrile 1H-NMR (400 MHz, DMSO-d6) δ 8.90 (d, J = 2.9 Hz, 1H), 8.58-8.60 (m, 2H), 8.54 (dd, J = 8.6, 2.0 Hz, 1H), 8.33 (d , J = 2.9 Hz, 1H), 5.54 (s, 2H), 3.42 (q, J = 7.4 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 439.95 (MH) + 223 3-(3-(Ethylsulfonyl)-5-(2,2,2-trifluoroethoxy)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1 ,2,3)triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.90 (d, J = 2.8 Hz, 1H), 8.58-8.60 (m, 2H), 8.54 (dd, J = 8.7, 2.0 Hz, 1H), 8.33 (d , J = 2.8 Hz, 1H), 5.19 (q, J = 8.7 Hz, 2H), 3.43 (q, J = 7.3 Hz, 2H), 1.13 (t, J = 7.3 Hz, 3H) ESI MS (m/z ) 482.95 (MH)+ 224 3-(5-(Cyclopropylmethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3] Triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.75 (d, J = 2.9 Hz, 1H), 8.57-8.59 (m, 2H), 8.53 (dd, J = 8.8, 1.7 Hz, 1H), 8.09 (d , J = 2.9 Hz, 1H), 4.17 (d, J = 7.1 Hz, 2H), 3.39 (q, J = 7.5 Hz, 2H), 1.28-1.34 (m, 1H), 1.12 (t, J = 7.5 Hz , 3H), 0.62-0.67 (m, 2H), 0.40-0.43 (m, 2H) ESI MS (m/z) 454.95 (MH)+ 225 3-(3-(Ethylsulfonyl)-5-(methoxymethoxy)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3] Triazine-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.81 (t, J = 2.8 Hz, 1H), 8.58-8.60 (m, 2H), 8.54 (dd, J = 8.6, 1.8 Hz, 1H), 8.23 (dd , J = 11.8, 2.9 Hz, 1H), 5.53 (s, 2H), 3.47 (d, J = 7.9 Hz, 3H), 3.39 (q, J = 7.2 Hz, 2H), 1.13 (t, J = 7.2 Hz , 3H) ESI MS (m/z) 444.95 (MH)+ 226 3-(5-(Difluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3] three Oxazin-4(3H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.03 (d, J = 2.7 Hz, 1H), 8.59-8.62 (m, 2H), 8.54-8.57 (m, 1H), 8.50 (d, J = 2.7 Hz , 1H), 7.63 (t, J = 72.3 Hz, 1H), 3.46 (q, J = 7.3 Hz, 2H), 1.14 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 450.95 (MH) + 227 2-((5-(Ethylsulfonyl)-6-(4-oxo-6-(trifluoromethyl)benzo[d][1,2,3]triazine-3(4H)- (Yl)pyridin-3-yl)oxy)-2-methylpropanamide 1H-NMR (400 MHz, DMSO-d6) δ 10.69 (s, 1H), 9.37 (d, J = 2.4 Hz, 1H), 9.10 (d, J = 2.4 Hz, 1H), 8.53-8.60 (m, 3H ), 5.95 (s, 1H), 3.35 (q, J = 7.3 Hz, 2H), 1.41 (s, 6H), 1.14 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 486.00 (MH) + 228 2-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-2-methyl Propionitrile 1H-NMR (400 MHz, DMSO-d6) δ 9.19 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.60 (d, J = 2.4 Hz, 1H), 8.52 (s, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 3.45 (q, J = 7.3 Hz, 2H), 1.88 (s, 6H), 1.15 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 451.00 (MH)+ 229 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl dimethyl sulfamate 1H-NMR (400 MHz, DMSO-d6) δ 9.07 (d, J = 2.7 Hz, 1H), 8.78 (s, 1H), 8.53 (d, J = 2.7 Hz, 2H), 8.43 (d, J = 8.3 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 3.47 (q, J = 7.3 Hz, 2H), 3.04 (s, 6H), 1.14 (t, J = 7.3 Hz, 3H) ESI MS ( m/z) 506.95 (MH)+ 230 2-(5-Amino-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.66 (s, 1H), 8.49 (d, J = 0.9 Hz, 1H), 8.37 (dd, J = 8.4, 1.7 Hz, 1H), 8.29 (d, J = 8.3 Hz, 1H), 8.12-8.14 (m, 1H), 7.57 (d, J = 2.8 Hz, 1H), 6.31 (s, 2H), 3.21-3.29 (q, J = 7.3 Hz, 2H), 1.09 (t, J = 7.6 Hz, 3H) ESI MS (m/z) 399.00 (MH)+ 231 2-(5-Chloro-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 9.11 (d, J = 2.4 Hz, 1H), 8.76 (d, J = 0.5 Hz, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.52 ( d, J = 1.2 Hz, 1H), 8.42 (dd, J = 8.3, 1.5 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 3.46 (q, J = 7.4 Hz, 2H), 1.14 ( t, J = 7.3 Hz, 3H) ESI MS (m/z) 418.05(MH)+ 232 2-(3-(Ethylsulfonyl)-6-(1H-1,2,4-triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 1H-NMR (400 MHz, DMSO-d6) δ 9.44 (s, 1H), 8.80-8.82 (m, 2H), 8.54 (d, J = 0.9 Hz, 1H), 8.44 (dd, J = 7.9, 1.8 Hz , 2H), 8.33-8.37 (m, 2H), 3.41-3.46 (q, 7.5 Hz, 2H), 1.15 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 450.95 (MH)+ 233 2-(3-(Ethylsulfonyl)-5-((4-oxoanion-1,4l6-xanthene-4-yl subunit) amino)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.71 (d, J = 0.7 Hz, 1H), 8.53 (d, J = 2.7 Hz, 1H), 8.50 (s, 1H), 8.39 (dd, J = 8.3 , 1.5 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 7.94 (d, J = 2.7 Hz, 1H), 4.14 (td, J = 8.6, 3.8 Hz, 2H), 3.99-4.05 (m , 2H), 3.68-3.72 (m, 2H), 3.57-3.63 (m, 2H), 3.33-3.40 (q, 2H), 1.12 (t, J = 7.3 Hz, 3H) ESI MS (m/z) 517.05 (MH)+ 234 2-(6-Bromo-3-(ethylthio)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.86 (q, J = 0.8 Hz, 1H), 8.76 (d, J = 8.9 Hz, 1H), 8.54 (s, 1H), 8.41 (dd, J = 8.4 , 2.0 Hz, 1H), 8.31 (d, J = 8.6 Hz, 1H), 7.71-7.75 (m, 1H), 7.64-7.68 (m, 1H), 2.74 (q, J = 7.3 Hz, 2H), 1.05 (t, J = 24.7, 7.1 Hz, 3H) ESI MS (m/z) 468.90 (MH)+ 235 2-(5-(Difluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.94 (d, J = 2.7 Hz, 1H), 8.76 (s, 1H), 8.52 (s, 1H), 8.42 (dd, J = 8.2, 1.6 Hz, 1H ), 8.37 (d, J = 2.9 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 7.60 (t, J = 72.5 Hz, 1H), 3.44 (q, J = 7.4 Hz, 2H), 1.14 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 450.00(MH)+ 236 1-cyano-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) Cyclopropane-1-formamide 1H-NMR (400 MHz, DMSO-d6) δ 10.80 (s, 1H), 9.16 (d, J = 2.4 Hz, 1H), 8.79 (d, J = 2.8 Hz, 1H), 8.74 (s, 1H), 8.52 (s, 1H), 8.41 (dd, J = 8.3, 1.8 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 3.37 (q, J = 7.3 Hz, 2H), 1.79 (d, J = 4.3 Hz, 4H), 1.13 (t, J = 7.5 Hz, 3H) ESI MS (m/z) 492.00(MH)+ 237 2-(3-(Ethylsulfonyl)-6-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 1H-NMR (400 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.76 (d, J = 8.6 Hz, 1H), 8.55 (s, 1H), 8.42-8.44 (m, 1H), 8.35 (d , J = 8.6 Hz, 2H), 6.92 (s, 1H), 3.47 (q, J = 7.4 Hz, 2H), 2.60 (s, 3H), 1.17 (t, J = 7.5 Hz, 3H) ESI MS (m /z) 532.00 (MH)+ *Use the compound name generated by Chemdraw Professional 18.1

The following compounds (Table 2) are obtained by using suitable starting materials and following the similar methods described in Schemes 1-9 or Examples 1-16. Table-2 Serial number Compound name Serial number Compound name 238 2-(3-(Ethylsulfonyl)-5-((2,2,2-trifluoroethyl)thio)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 337 2-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-((trifluoromethyl)sulfonyl)phthalazine-1(2H)-one 239 2-(3,5-bis(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 338 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-((trifluoromethyl)sulfonyl)phthalazine-1(2H)- ketone 240 2-(5-((1,1-Difluoroethyl)thio)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H )-ketone 339 1-(5-(Ethylsulfonyl)-6-(1-oxo-7-((trifluoromethyl)sulfonyl)phthalazine-2(1H)-yl)pyridin-3-yl) Cyclopropane-1-carbonitrile 241 2-(5-(Ethylsulfonylimino)-3-(ethylsulfonylimino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 340 7-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8 (7H)-ketone 242 2-(5-((1,1-Difluoroethyl)sulfonyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 341 7-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl )Pyrido[2,3-d]pyridazine-8(7H)-one 243 2-(5-(4-(Dimethylphosphoryl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H )-ketone 342 7-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3- d)Pyridazine-8(7H)-one 244 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropanecarboxamide 343 2-(5-(Ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine- 3-yl)acetonitrile 245 2-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2 -Methylpropionitrile 344 1-(5-(Ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine- 3-yl)cyclopropane-1-carbonitrile 246 2-(3-(Ethylsulfonyl)-5-isopropoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 345 7-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8( 7H)-ketone 247 2-(3-(Ethylsulfonyl)-5-((1,1,1-trifluoro-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7-(tris Fluoromethyl)phthalazine-1(2H)-one 346 2-(3-(Ethylsulfonyl)-5-(ethylthio)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 248 2-(3-(Ethylsulfonyl)-5-(trifluoromethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 347 2-(3-(Ethylsulfonyl)-5-((2-(trifluoromethyl)cyclopropyl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-ketone 249 2-(3-(Ethylsulfonyl)-5-(1-oxyanion-4,5-dihydro-3H-1l6-isothiazol-1-yl)pyridin-2-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-one 348 2-(3-(Ethylsulfonyl)-5-(3-methoxyazetidine-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 250 2-(3-(Ethylsulfonyl)-5-((3-hydroxy-1-oxytetrahydro-1l6-thiophen-1-yl subunit) amino)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 349 2-(3-(Ethylsulfonyl)-5-((1-methylazacyclobutan-3-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-ketone 251 2-(3-(Ethylsulfonyl)-5-((4-oxoanion-1,4l6-xanthene-4-yl subunit) amino)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 350 2-(3-(Ethylsulfonyl)-5-(1H-1,2,4-triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 252 4-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)benzenesulfonyl fluoride 351 2-(3-(Ethylsulfonyl)-5-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 253 2-(5-(4-(Dimethylphosphoryl)phenyl)-3-(ethylsulfonylimino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 352 2-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)pyridin-2-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-one 254 5'-(Ethylsulfonyl)-6'-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)-[3,3'-dipyridine]-6 -Sulfonyl fluoride 353 2-(3-(Ethylsulfonyl)-5-(4-(2-hydroxy-2-methylpropyl)-1H-1,2,3-triazol-1-yl)pyridine-2- Base)-7-(trifluoromethyl)phthalazine-1(2H)-one 255 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3-sulfonyl fluoride 354 2-(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Oxazine-1(2H)-one 256 2-(5-(4-(1,1-Difluoroethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 355 2-(3-(Ethylsulfonyl)-5-(3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 257 2-(3-(Ethylsulfonyl)-5-(1-(trifluoromethyl)cyclopropyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 356 2-(5-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Base) phthalazine-1(2H)-one 258 2-(3-(Ethylsulfonyl)-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one 357 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(2,2,2-trifluoroethoxy)phthalazine-1(2H )-ketone 259 2-(3-(Ethylsulfonyl)-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 358 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(2,2,3,3,3-pentafluoropropoxy)phthalazine -1(2H)-ketone 260 2-(3-(Ethylsulfonyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 359 1-(3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyrimidine- 7-yl)cyclopropane-1-carbonitrile 261 2-(3-(Ethylsulfonyl)-5-(1-isobutyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 360 2-(3-(Ethylsulfonyl)-6-methylimidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 262 2-(3-(Ethylsulfonyl)-5-(3-methoxy-1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one 361 2-(6-(Ethylsulfonyl)-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 263 2-(1'-(Difluoromethyl)-5-(ethylsulfonyl)-6'-oxo-1',6'-dihydro-[3,3'-dipyridine]-6- Yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 362 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[2,1-b]thiazole-2-methan Nitrile 264 2-(3-(Ethylsulfonyl)-5-isopropylpyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 363 1-(3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyrimidine- 6-yl)cyclopropane-1-carbonitrile 265 2-(5-(3,5-Dimethylisoxazol-4-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 364 1-(3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyrazolo[1,5-a]pyridine -5-yl)cyclopropane-1-carbonitrile 266 2-(3-(Ethylsulfonyl)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-4-methyl-7- (Trifluoromethyl)phthalazine-1(2H)-one 365 2-(2-(Ethylsulfonyl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 267 2-(3-(Ethylsulfonylimino)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one 366 2-(3-(Ethylsulfonyl)-1-methyl-6-(trifluoromethoxy)-1H-indol-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 268 4-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)phenylsulfur fluoride 367 2-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)-1H-pyrrolo[2,3-b ]Pyridin-1-yl)acetonitrile 269 2-(3-(Ethylsulfonylimino)-5-((1,1,1-trifluoro-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7- (Trifluoromethyl)phthalazine-1(2H)-one 368 2-(5-(Ethylsulfonyl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 270 2-((5-(Ethylsulfonylimino)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy) -2-Methylpropionitrile 369 2-(7-Cyclopropyl-2-(ethylsulfonyl)imidazo[1,2-a]pyrimidin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 271 2-(3-(Ethylsulfinyl)-5-((methylsulfinyl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 370 2-(3-(Ethylsulfonyl)imidazo[1,2-a]pyrazin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 272 2-(3-(Ethylsulfonyl)-5-(2,2,3,3-tetrafluoropropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 371 2-(3-(Ethylsulfonyl)imidazo[1,2-b]pyridazin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 273 2-(3-(Ethylsulfonyl)-5-(1,1,2-trifluoro-2-(trifluoromethoxy)ethoxy)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one 372 2-(5-(Bromodifluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 274 2-(3-(Ethylsulfonyl)-5-(2,2,3,4,4,4-hexafluorobutoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalein Oxazine-1(2H)-one 373 2-(3-(Ethylsulfonyl)-5-(pyridin-3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 275 2-(3-(Ethylsulfonyl)-5-(2,2,3,3,3-pentafluoropropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-ketone 374 2-(3-(Ethylsulfonyl)-5-(pyridin-2-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 276 2-(5-(2,2-Difluoro-2-(trifluoromethoxy)ethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one 375 2-(5-((5-Bromopyridin-2-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H )-ketone 277 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-2,2- Difluorocyclopropane-1-formamide 376 2-(3-(Ethylsulfonyl)-5-(pyrimidin-2-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 278 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-2,2- Dimethylcyclopropane-1-formamide 377 2-(3-(Ethylsulfonyl)-5-((1-methyl-1H-pyrazol-3-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-ketone 279 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-fluoro Propane-1-formamide 378 2-(5-(3,3-Difluorocyclobutoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 280 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methyl Cyclopropane-1-formamide 379 2-(5-(2,2-Difluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 281 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-N-methyl Cyclobutane carboxamide 380 2-(5-((1,3-Difluoropropan-2-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-ketone 282 1-cyano-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) Cyclopropane-1-formamide 381 2-(3-(Ethylsulfonyl)-5-(neopentyloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 283 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-3,3- Dimethylcyclobutane-1-formamide 382 1-(((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)methyl Base) cyclopropane-1-carbonitrile 284 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-3,3- Difluorocyclobutane-1-carboxamide 383 2-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)propionitrile 285 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclobutane amine 384 2-(3-(Ethylsulfonyl)-5-((1-fluoro-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one 286 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methyl Cyclobutane-1-formamide 385 2-(3-(Ethylsulfonyl)-5-methoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 287 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-3-methyl Cyclobutane-1-formamide 386 2-(3-(Ethylsulfonyl)-5-(2-fluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 288 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-3-oxo Cyclobutane-1-formamide 387 2-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2 -(Methylthio)acetonitrile 289 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopentanemethan amine 388 2-(5-((2,2-Difluorocyclopropyl)methoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 290 1-cyano-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) Cyclopentane-1-formamide 389 4-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)butyronitrile 291 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methyl Cyclopentane-1-formamide 390 2-(5-(Cyclobutylmethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 292 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclohexanemethyl amine 391 2-(5-(2,2-Difluoropropoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 293 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-4-methyl Cyclohexane-1-formamide 392 2-(3-(Ethylsulfonyl)-5-(1-fluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 294 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-4,4- Difluorocyclohexane-1-methanamide 393 2-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-N ,N-Dimethyl-2-(methylthio)acetamide 295 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)azetidine -3-formamide 394 2-Ethyl-2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl ) Oxygen) Butyronitrile 296 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methyl Azetidine-3-formamide 395 2-(3-(Ethylsulfonyl)-5-isobutoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 297 1-Ethyl-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazin-2(1H)-yl)pyridin-3-yl) Azetidine-3-formamide 396 2-(3-(Ethylsulfonyl)-5-(2,2,2-trifluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -ketone 298 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxetane e-3-formamide 397 2-(5-(2-Bromo-1,1-difluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 299 3-ethyl-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazin-2(1H)-yl)pyridin-3-yl) Oxetane e-3-formamide 398 2-(5-((3-Cyclopropylisoxazol-5-yl)methoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Oxazine-1(2H)-one 300 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methyl Pyrrolidine-3-formamide 399 2-(3-(Ethylsulfonyl)-5-(3-methoxycyclobutoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 301 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)tetrahydrofuran-3-methyl Amide 400 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl difluoromethanesulfonate 302 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)piperidine-4- Formamide 401 3-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)cyclobutane Alkane-1-carbonitrile 303 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methyl Pyridine-4-methamide 402 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl fluoromethanesulfonate 304 1-Ethyl-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazin-2(1H)-yl)pyridin-3-yl) Pyridine-4-methamide 403 3-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-3 -Methyl butyronitrile 305 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)tetrahydro-2H- Pyran-4-formamide 404 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl triflate 306 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-4-fluorotetra Hydrogen-2H-pyran-4-methylamide 405 2-(3-(Ethylsulfonyl)-5-((1-methoxy-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one 307 2-(7-Bromo-3-(ethylsulfonyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 406 2-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-N ,N,2-Trimethylpropionamide 308 2-(3-(Ethylsulfonyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 407 2-(3-(Ethylsulfonyl)-5-((3-methyloxetan-3-yl)methoxy)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one 309 2-(3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine- 7-base) acetonitrile 408 (E)-2-(3-(Ethylsulfonyl)-5-(2-(methylimino)propoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-ketone 310 3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine-7-methyl Nitrile 409 2-(3-(Ethylsulfonyl)-5-((trimethylsilyl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 311 2-(3-(Ethylsulfonyl)-7-methoxyimidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 410 2-(3-(Ethylsulfonyl)-5-(2-oxypropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 312 2-(3-(Ethylsulfonyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 411 2-(3-(Ethylsulfonyl)-5-((2-methyl-3-oxobutan-2-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one 313 1-(3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine- 7-yl)cyclopropane-1-carbonitrile 412 2-(5-(allyloxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 314 2-(3-(Ethylsulfonyl)-7-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one 413 2-(3-(Ethylsulfonyl)-5-propoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 315 2-(6-Bromo-3-(ethylsulfonyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 414 2-(5-Ethoxy-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 316 2-(3-(Ethylsulfonyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 415 2-(3-(Ethylsulfonyl)-5-(methoxymethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 317 3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine-6-methyl Nitrile 416 2-(5-Cyclobutyl-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 318 2-(3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine- 6-base) acetonitrile 417 2-(5-(2,2-Difluorocyclopropyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one 319 2-(3-(Ethylsulfonyl)-7-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-ketone 418 2-(3-(Ethylsulfonyl)-5-(2-methyloxetan-2-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-ketone 320 2-(3-(Ethylsulfonyl)-7-(methylamino)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H )-ketone 419 2-(3-(Ethylsulfonyl)-5-(3-methylthietane-3-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 321 7-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-2-(trifluoromethyl )Pyrido[2,3-d]pyridazine-8(7H)-one 420 2-(5-(1,1-Dioxanethioetanyl-2-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one 322 7-(3-(Ethylsulfonyl)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-2-(trifluoromethyl )Pyrido[2,3-d]pyridazine-8(7H)-one 421 6-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)nicotinonitrile 323 7-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3- d)Pyridazine-8(7H)-one 422 2-(3-(Ethylsulfonyl)-5-(thietanyl-3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H )-ketone 324 7-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-8 (7H)-ketone 423 2-(5-((1,1-Dioxanethioetanyl-3-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one 325 5-(Ethylsulfonyl)-6-(8-oxo-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)nicotinonitrile 424 2-(5-((1,1-dioxanylthietanyl-3-yl)methyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one 326 2-(5-(Ethylsulfonyl)-6-(8-oxo-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine- 3-yl)acetonitrile 425 7-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-8( 7H)-ketone 327 1-(5-(Ethylsulfonyl)-6-(8-oxo-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine- 3-yl)cyclopropane-1-carbonitrile 426 2-(3-(N-Methylethylsulfonylimino)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one 328 2-((5-(Ethylsulfonyl)-6-(8-oxo-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine -3-yl)oxy)-2-methylpropionitrile 427 2-(3-(N-Methylethylsulfonylimino)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one 329 7-(5-(Difluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-8 (7H)-ketone 428 N-(Ethyl((oxo)(2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)-5-(4-(1,1,2, 2-Tetrafluoroethoxy)phenyl)pyridin-3-yl)-16-sulfinyl)cyanamide 330 2-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-(perfluoroethyl)phthalazin-1(2H)-one 429 2-(3-(N-ethylethylsulfonylimino)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one 331 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(perfluoroethyl)phthalazine-1(2H)-one 430 2-(6-Bromo-3-(ethylsulfonylimino)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- ketone 332 2-(3-(Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(perfluoroethyl) )Phthalazine-1(2H)-one 431 2-(6-Bromo-3-(N-methylethylsulfonylimino)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone 333 5-(Ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H)-yl)nicotinonitrile 432 1-(3-(Ethylsulfonylimino)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a] (Pyridin-6-yl) cyclopropane-1-carbonitrile 334 2-(5-(Ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H)-yl)pyridin-3-yl)acetonitrile 433 3-(Ethylsulfonylimino)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine-6 -Formonitrile 335 1-(5-(Ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane-1- Formonitrile 434 2-(6-(Cyclopropylamino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one 336 5-(Ethylsulfonyl)-6-(1-oxo-7-((trifluoromethyl)sulfonyl)phthalazine-2(1H)-yl)nicotinonitrile 435 N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-2-yl)cyclopropanecarboxamide *Use the compound name generated by Chemdraw Professional 18.1

As described herein, the compound of general formula (I) shows extremely high insecticidal activity, which is effective against many pests that attack important crops. The following tests will evaluate the activity of the compounds of the invention: biological examples :

Example A: Helicoverpa armigera

Using the food incorporation method, the required amount of test compound is weighed and dissolved in a test tube containing a solvent solution. The test tube was vortexed at 2000 rpm for 90 minutes for proper mixing, and then diluted with water to the desired experimental concentration. When the temperature in the bioassay container reaches about 50 ^o C, the semi-synthetic diet is added to the specific solution. Stir the food and solution thoroughly to mix well, and then cool for 30 minutes. Cut the solidified diet evenly into several pieces, and then place these pieces into the cells of the bioassay tray. A single third-instar hungry larva is released into these cells of the bioassay tray, and each tray is covered with a lid. Keep the bioassay tray ^{under laboratory conditions with a temperature of 25 o} C and a relative humidity of 70%. The dead, dying and alive larvae observed were recorded 96 hours after the larvae were released. The mortality was calculated by adding the dead and dying larvae, and the results were compared with an untreated control group. According to records, the compound 10 15 26 38 72 89 94 96 101 102 103 115 116 119 123 125 127 128 134 137 144 146 152 158 160 201 204 207 209 210 and 217 can cause more than 70% mortality.

Example B: Spodoptera litura

Using the food incorporation method, the required amount of test compound is weighed and dissolved in a test tube containing a solvent solution. The test tube was vortexed at 2000 rpm for 90 minutes for proper mixing. When the temperature in the bioassay container reaches about 50 ^o C, the semi-synthetic diet is added to the specific solution. Stir the food and solution thoroughly to mix well, and then cool for 30 minutes. Cut the solidified diet evenly into several pieces, and then place these pieces into the cells of the bioassay tray. A single third-instar hungry larva is released into these cells of the bioassay tray, and each tray is covered with a lid. Keep the bioassay tray ^{under laboratory conditions with a temperature of 25 o} C and a relative humidity of 70%. The dead, dying and alive larvae observed were recorded 96 hours after the larvae were released. The mortality was calculated by adding the dead and dying larvae, and the results were compared with an untreated control group. According to records, compounds 15 17 87 89 103 104 116 118 119 120 124 125 128 131 132 134 137 151 152 158 163 182 190 198 201 202 204 207 209 210 217 and 234 can cause more than 70% mortality.

Example C: Plutella xylostella

Using the blade dipping method, weigh and dissolve the required amount of compound in a test tube containing a solvent solution, place it on a stirrer with a rotation speed of 2000 rpm for 90 minutes to mix properly, and then dilute it with 0.01% Triton-X solution. The required experimental concentration. The cabbage leaves were immersed in the solution for 10 seconds, shaded and dried for 20 minutes, and then transferred to the bioassay tray. A single second instar larva is released into these cells of the bioassay tray, and each tray is covered with a lid. Keep the bioassay tray ^{under laboratory conditions with a temperature of 25 o} C and a relative humidity of 70%. The dead, dying and alive larvae observed were recorded 72 hours after the larvae were released. The mortality was calculated by adding the dead and dying larvae, and the results were compared with an untreated control group. According to records, the compound with a concentration of 300ppm 1 2 3 4 6 8 9 10 11 14 15 16 17 18 22 23 24 25 26 27 28 29 34 37 38 41 47 52 53 55 56 57 58 59 60 62 66 67 69 71 72 74 76 77 80 85 87 88 89 90 91 92 94 96 97 98 99 100 101 102 103 104 105 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 127 128 130 131 132 134 135 137 140 141 143 144 145 147 151 152 154 157 158 159 160 161 162 163 164 165 171 175 177 178 179 181 185 186 187 190 191 193 194 198 201 202 203 204 207 209 210 213 215 216 217 218 226 228 231 232 234 and 235 Cause more than 70% mortality.

Example D: Bemisia tabaci

Using the blade dipping method, weigh and dissolve the required amount of compound in a test tube containing a solvent solution, place it on a stirrer with a rotation speed of 2000 rpm for 90 minutes to mix properly, and then dilute it with 0.01% Triton-X solution. The required experimental concentration. Soak the cotton leaves in the solution for 10 seconds, cool and dry for 20 minutes, then store the leaves in a glass cell, and immerse the petioles in water. Release a known number of vigorous emerging adults and store them in a ^{plant growth room at a temperature of 25 o} C and a relative humidity of 70%. The dead, dying and alive larvae observed were recorded 72 hours after the insects were released. The mortality was calculated by adding the dead and dying larvae, and the results were compared with an untreated control group. According to records, compounds 4 and 18 at a concentration of 300 ppm can cause more than 70% mortality.

Example E: Myzus persicae

Using the blade dipping method, weigh and dissolve the required amount of test compound in a test tube containing a solvent solution, place it on a stirrer at 2000 rpm for 90 minutes to mix properly, and then dilute it with 0.01% Triton-X solution to The required experimental concentration. Soak the pepper leaves in the solution for 10 seconds, cool and dry for 20 minutes, and then place the leaves backside up in the cells of the bioassay tray containing 4 ml of 1% agar solution. Release a known number of third instar nymphs and store them in a ^{plant growth room at a temperature of 25 o} C and a relative humidity of 70%. The dead, dying and alive larvae observed were recorded 72 hours after the insects were released. The mortality was calculated by adding the dead and dying larvae, and the results were compared with an untreated control group. According to records, compounds 24 35 36 40 124 171 200 202 209 and 219 at a concentration of 300 ppm can cause more than 70% mortality.

Example F: Brown planthopper

The seedling immersion method is used for screening, the required amount of compound is weighed and dissolved in a test tube containing a solvent solution, placed on a stirrer with a rotation speed of 2000 rpm for 90 minutes for proper mixing, and then diluted with a 0.01% Triton-X solution To the required experimental concentration. The rice seedlings were immersed in the solution for 10 seconds, and dried for 20 minutes in a cool shade, and then the seedlings were stored in a glass test tube, the roots were immersed in water, and the test tube was placed in a glass container. Release a known number of third instar nymphs and store them in a ^{plant growth room at a temperature of 25 o} C and a relative humidity of 75%. The dead, dying and alive larvae observed were recorded 72 hours after the insects were released. The mortality was calculated by adding the dead and dying larvae, and the results were compared with an untreated control group. According to records, compound 6 at a concentration of 300 ppm can cause more than 70% mortality.

After describing the present invention with reference to certain preferred embodiments, those skilled in the art should be familiar with other technical parameters. For those skilled in the art, many modifications to materials and methods can be implemented without departing from the scope of the present invention.

no

no

Claims (16)

A compound of formula (I),

Formula (I) wherein, R ^{1 is} selected from C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -Haloalkenyl, C ₃ -C ₈ -cycloalkyl and C ₃ -C ₈ -cycloalkyl-C ₁ -C ₆ -alkyl; Y is independently selected from O and/or NR ^y ; R ^y Selected from hydrogen, cyano, C ₁ -C ₄ -alkyl, C ₂ -C ₄ -alkenyl, C ₂ -C ₄ -alkynyl, C ₁ -C ₄ -haloalkyl, C ₂ -C _{4 -halo} Alkenyl, C ₃ -C ₅ -cycloalkyl and C ₃ -C ₅ -cycloalkyl-C ₁ -C ₃ -alkyl; Q represents a 5- to 10-membered heterocyclic ring system, which may optionally be substituted by one Or multiple R ² groups; R ^{2 is} selected from hydrogen, halogen, cyano, nitro, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, C ₁ -C ₆ -cyanoalkyl, OR ⁴ , NR ⁵ R ⁶ , CR ⁴ =NR ⁵ , C(=O)R ⁸ , S(O) _0-2 R ⁷ , SCN, S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , P(=O)(OR”) ₂ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclic group; Wherein each R ² may be optionally substituted by one or more R ^2a groups; R ^{2a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C _2- C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , CR ⁴ =NR ⁵ , C(=O)R ⁸ , S(O) _0-2 R ⁷ , SCN, S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , Si( R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; or two R ^2a substituents and the atoms to which they are connected or other options Atoms from C, N, O, S, and optionally including 1 to 3 rings selected from C(=O), C(=S), S(O) _0-2 and Si(R”) ₂ The members together can form a 3 to 7 membered ring, which itself can be optionally substituted by one or more R ^2aa groups; R ^{2aa is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ^6. CR ⁴ =NR ⁵ , C(=O)R ⁸ , S(O) _0-2 R ⁷ , S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; A ₁ and A ₂ independently represent N or CR ^A ; R ^{A is} selected from hydrogen, halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₃ -C ₈ - cycloalkyl, oR "and N (R") _2; wherein each R ^a groups may optionally be substituted with one or more R ^a radicals; R ^{a 'is} selected from halo, cyano Group, C ₃ -C ₈ -cycloalkyl, OR” and N(R”) ₂ ; Z represents O or S; G ₁ , G ₂ , G ₃ and G ₄ independently represent N or CR ³ ; where in the ring There are no more than two Ns present in E; R ^{3 is} selected from hydrogen, halogen, cyano, nitro, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynes Group, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , CR ⁴ =NR ⁵ , C(=O ) R ⁸ , S(O) _0-2 R ⁷ , SCN, S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , P(=O)( OR”) ₂ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclic group; wherein each R ³ group can be any Is optionally substituted with one or more R ^3a groups; R ^{3a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , CR ⁴ =NR ⁵ , C(=O)R ⁸ , S(O) _0-2 R ⁷ , S(O) _0-1 R ⁹ =NR ¹⁰ , N=S(O) _0-1 (R ⁹ ) ₂ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl group, C ₇ -C ₁₄ -aralkyl group and C ₃ -C ₁₀ -heterocyclic group; R ^{4 is} selected from hydrogen, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -Cycloalkyl, S(O) _0-2 R ⁷ , Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocycle Group; wherein each R ⁴ group may be optionally ^{substituted by R 4a} group; R ^{4a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C _2- C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR", NR'R", S(O) _{0- 2} R', C(=O)R', Si(R”) ₃ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; R ⁵ Selected from hydrogen, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl , C ₃ -C ₈ -Cycloalkyl, OR ⁴ , NR'R”, S(O) _0-2 R ⁷ , C(=O)R ⁸ , Si(R”) ₃ , C ₆ -C _10- Aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; wherein each R ⁵⁴ group may be optionally ^{substituted by R 5a} ; R ^{5a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -Cycloalkyl, OR", NR'R", S(O) _0-2 R', C(=O)R', Si(R") ₃ , C ₆ -C ₁₀ -aryl, C _7- C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; R ^{6 is} selected from hydrogen, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₁ -C ₆ -cycloalkyl and C(=O)R ⁸ ; R ^{7 is} selected from C ₁ -C ₆ -alkyl , C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, NR ⁵ R ⁶ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; wherein each R ⁷ group may optionally Substituted by one or more R ^7a groups; R ^{7a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C _1- C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR", NR'R", S(O) _0-2 R', C(=O) R', C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; R ^{8 is} selected from hydrogen, C ₁ -C ₆ -alkyl, C _2- C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR ⁴ , NR ⁵ R ⁶ , N=S(O) _0-1 (R ⁹ ) ₂ , C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl, and C ₃ -C ₁₀ -heterocyclic group; each of them R ⁸ may be optionally substituted with one or more R ^8a groups; R ^{8a is} selected from halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C _6- Alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, OR", NR'R", S(O) _0-2 R' , C(=O)R', C ₆ -C ₁₀ -aryl, C ₇ -C ₁₄ -aralkyl and C ₃ -C ₁₀ -heterocyclyl; R ^{9 is} selected from C ₁ -C ₆ -alkyl , C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl and C (=O) R ⁸ ; R ^{10 is} selected from hydrogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl, C ₂ -C ₆ -alkynyl, C ₁ -C ₆ -haloalkane Group, C ₂ -C ₆ -haloalkenyl, C ₃ -C ₈ -cycloalkyl, Si(R”) ₃ , S(O) _0-2 R ⁷ and C(=O)R ⁸ ; or two The R ⁹ substituents and the atoms to which they are attached or other atoms selected from C, N, O, and optionally including C(=O) substituents together can form a 4- to 7-membered ring, which itself may optionally be Substituted by one or more halogen, cyano, C ₁ -C ₆ -alkyl, C ₁ -C ₆ -haloalkyl or C ₁ -C ₆ -alkoxy groups; or R ⁹ and R ¹⁰ substituents and The atoms to which they are attached or other atoms selected from C, N, O, and optionally including C(=O) substituents together can form a 4- to 7-membered ring, which itself may optionally be substituted by one or more halogens. , Cyano, C ₁ -C ₆ -alkane Group, C ₁ -C ₆ -haloalkyl or C ₁ -C ₆ -alkoxy group; R'is selected from hydrogen, halogen, cyano, C ₁ -C ₆ -alkyl, C ₂ -C _6- Alkenyl, C ₂ -C ₆ -alkynyl, C ₃ -C ₈ -cycloalkyl, OR”, N(R”) ₂ , S(O) _0-2 R”, C(=O)R”, C(=O)OR” and C(=O)N(R”) ₂ ; R” is selected from hydrogen, C ₁ -C ₆ -alkyl, C ₂ -C ₆ -alkenyl and C ₂ -C _6- alkynyl, and C ₃ -C ₈ - cycloalkyl; wherein each R "group may optionally be substituted by halogen; each R ¹ to ^{R 10, R A, R 2a} , R 2aa, R 3a, R 4a , R ^5a , R ^7a and R ^8a may optionally be selected from X, CN, R', OR", SR', N(R') ₂ , COOR" and CON(R') ₂ Group substitution; "n" is an integer from 0 to 2; or its agriculturally acceptable salts, isomers/structural isomers, stereoisomers, diastereomers, enantiomers, Tautomers, polymorphs, metal complexes, N-oxides or S-oxides. The compound of formula (I) as described in claim 1, wherein Q is selected from Q1 to Q14:

; Among them, # represents the connection point with the DE ring,

Represents the point of attachment to the -S(Y) _n R ¹ group, and the Q ring may be optionally substituted by one or more R ² groups; wherein each aliphatic group may be optionally substituted by one or more R ^{The 2a} group is substituted, and ^{the cyclic group of R 2} may be optionally substituted with one or more R ^2b groups; "n" is an integer from 0 to 2. The compound of formula (I) as described in claim 1, wherein the DE ring is selected from formulas DE-a to DE-c;

Wherein G ₁ , G ₂ , G ₃ and G ₄ independently represent N or CR ³ ; A ₁ and A ₂ independently represent N or CR ^A ; where # represents the connection point with the Q ring. The compound of formula (I) as described in claim 1, wherein the DE ring is selected from formulas DE1 to DE16;

Wherein # denotes the point of attachment of the Q ring, and the ring may DE optionally substituted with one or more substituents R ³ and R ^A groups. The compound of formula (I) according to claim 1, wherein the compound of formula (I) is selected from 2-(3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl )Phthalazine-1(2H)-one; 2-(3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5 -Bromo-3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-bromo-3-(ethylsulfonyl) )Pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-chloro-3-(ethylsulfonyl)pyridin-2-yl)-6 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,5-dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,5-difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl) -6-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylthio)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoro Methyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-6-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(1H-1,2,4-triazol-1-yl)pyridin-2-yl)-6-( Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(5-methyl-3-(trifluoromethyl)-1H-pyrazole- 1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(3-(trifluoro) (Methyl)-1H-pyrazol-1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) -6-(3-(Trifluoromethyl)-1H-1,2,4-triazol-1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H) -Ketone; 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(Ethylthio)-6'-fluoro-[3,3'-dipyridine]-6-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(Ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H) -Ketone; 2-(5-(Ethylsulfonyl)-6'-fluoro-[3,3'-dipyridine]-6-yl)-6-(trifluoromethyl)phthalazine-1( 2H)-one; 7-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8( 7H )-Ketone; 7-(3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(6-Chloro-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8 (7H)-ketone; 7-(3-(ethylsulfonyl)-5-(3-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoro Methyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)- 3-(Trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4-(trifluoromethoxy) (Phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl) )-5-(4-Fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8( 7H)-one; 7-(3-(ethylsulfonyl)-6-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d ]Pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoro Methyl)pyrido[2,3-d]pyridazine-8(7H)-one; 4-(5-(ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl) )Pyrido[2,3-d]pyridazine-7(8H)-yl)pyridin-3-yl)benzonitrile; 7-(3-(ethylsulfonyl)-6-(4-(tri Fluoromethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethyl) Sulfonyl)-5-phenylpyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(5-(3 ,5-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)- Ketone; 7-(5-(3,5-Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d ]Pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl )-3-(Trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-6-(3-(trifluoro (Methyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(6-(3,5- two Chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 3- (3-(Ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)pyridine- 2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylthio)-5-(trifluoromethyl)pyridin-2-yl)- 6-(Trifluoromethyl)quinazolin-4(3H)-one; 7-(3-(ethylsulfonyl)-6-(3-methyl-1H-1,2,4-triazole) -1-yl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl) )-6-(3-Fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8( 7H)-one; 4-(5-(ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H) -Yl)pyridin-2-yl)benzonitrile; 7-(3-(ethylsulfonyl)-6-(4-fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl )-3-(Trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 3-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl )-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-6 -(Trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(3,5-dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)- 6-(Trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-6- (Trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-phenylpyridin-2-yl)-6-(trifluoromethyl)quine Oxazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(4-methoxyphenyl)pyridin-2-yl)-6-(trifluoromethyl)quine Oxazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl) Yl)quinazolin-4(3H)-one; 7-(3-(ethylsulfonyl)-6-phenylpyridin-2-yl)-3-(trifluoromethyl)pyrido[2, 3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(2-fluoro-4-(trifluoromethoxy)phenyl)pyridine-2 -Yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(5-(2,2-difluorobenzo[d][1 ,3]Dioxol-5-yl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine -8(7H) -Ketone; 7-(6-(3,5-difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3- d]Pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridine- 2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 3-(3-(ethylsulfonyl)-5-(3- (Trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 4-(5-(ethylsulfonyl)-6 -(4-oxo-6-(trifluoromethyl)quinazolin-3(4H)-yl)pyridin-3-yl)benzonitrile; 3-(3-(ethylsulfonyl)-5 -(4-(Trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(3,5- Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(4-chloro Phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl) )-5-(3-(Trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethyl) Sulfonyl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(3-chloro-4-(trifluoromethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)quinazoline- 4(3H)-one; 3-(3-(ethylsulfonyl)-5-(2-fluoro-4-(trifluoromethoxy)phenyl)pyridin-2-yl)-6-( Trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(4-fluoro-3-(trifluoromethyl)phenyl)pyridine- 2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(2-fluoro-5-(trifluoro) Methoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 2-(3-(ethylsulfonyl)-5-(4 -Fluoro-3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonate) Yl)-5-(4-fluoro-3-methoxyphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-( 2,4-Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-( Ethylsulfonyl)-5-(4-fluoro-3-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-( 5-(4-chlorophenyl)-3-(ethyl Sulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridine- 2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(4-fluorophenyl)pyridin-2-yl )-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-pyrazole- 1-yl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6-(4-(trifluoro) Methoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylsulfonyl)-5-(4- (1,1,2,2-Tetrafluoroethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)quinazolin-4(3H)-one; 2-(6-( 4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2-chloro -4-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-5-(3,4,5-trifluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-( Ethylsulfonyl)-5-(4-fluoro-2-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-( 6-Chloro-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) -6-(4-Fluoro-2-methylphenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-(2-chloro -4-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-6-(3,4,5-trifluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-bromo -3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(5-(3,5-dichlorophenyl) -3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5 -(4-Fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-( 4-(Trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 2-(3-(ethylsulfonyl) -5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6- (4-Fluorophenyl)pyridine-2 -Yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl) -7-(Trifluoromethyl)phthalazine-1(2H)-one; 3-(5-(3,5-difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl) -7-(Trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridine- 2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 4-(5-(ethylsulfonyl)-6-(4-oxo-7-(trifluoro) Methyl)quinazolin-3(4H)-yl)pyridin-3-yl)benzonitrile; 3-(3-(ethylsulfonyl)-5-(4-methoxyphenyl)pyridine- 2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridine-2- Yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl) -7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone; 2-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 3-(3-(Ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazoline-4( 3H)-one; 3-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7- (Trifluoromethyl)quinazolin-4(3H)-one; 2-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy) Phenyl)pyridin-2-yl)-6-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(1,1 ,2,2-Tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) )-5-(4-(Trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-6-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(5- (4-Bromophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)quinazolin-4(3H)-one; 3-(3-(ethyl) Sulfonyl)-5-(3-fluoro-4-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)quinazoline-4(3H)- Ketone; 3-(3-(Ethylsulfonyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl ) Quinazolin-4(3H)-one; 3 -(5-Bromo-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4(3H)-one; 3- (5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidine-4(3H) -Ketone; 3-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidine -4(3H)-ketone; 3-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl) -7-(Trifluoromethyl)pyrido[3,2-d]pyrimidin-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(3-(trifluoromethoxy) (Yl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4(3H)-one; 2-(3-(ethylsulfonyl) -5-(4-(perfluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,5 -Difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,5 -Dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) (Phenyl)-5-(4-(perfluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-thione; 2-(3- (Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-thione; 2-(3-(ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl Yl)phthalazine-1(2H)-one; 4-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl) )Pyridin-3-yl)benzonitrile; 2-(3-(ethylsulfonyl)-5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; 2-(5-(3,4-difluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone; 1-(4-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine- 3-yl)phenyl)cyclopropane-1-carbonitrile; 2-(5-(4-(difluoromethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7 -(Trifluoro Methyl)phthalazine-1(2H)-one; 2-(5-(ethylsulfonyl)-6'-fluoro-[3,3'-dipyridyl]-6-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-thione; 2-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-4-methyl-7-( Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(methylthio)phenyl)pyridin-2-yl)-7- (Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-4-methyl- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-thione; 2-(5-(3,4-dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7- (Trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3-chloro-5-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy) Phenyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4 -(Trifluoromethoxy)phenyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfon) Aceto)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-thione; 5-(ethylsulfonyl)-6 -(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)nicotinonitrile; 2-(5-(3,5-dichlorophenyl)-3-(ethylsulfon) (Pyridine-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-chlorophenyl)-3-(ethyl Sulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3,5-difluorophenyl) -3-(Ethylsulfonyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-chloro- 3-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2-chloro -5-(trifluoromethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 3-chloro -5-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)benzonitrile; 2-(3-(Ethylsulfonyl)-5 -(2-Fluoro-5-(trifluoromethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-( 4-chloro-2-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 2-(5- (4-Bromophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-((5-(ethyl Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2-methylpropionate; 2-(4-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)phenoxy Yl)-2,2-difluoro-N,N-dimethylacetamide; 2-(3-(ethylsulfonyl)-5-(3,3,3-trifluoropropyl-1- En-2-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-( 2,2,3,3,3-Pentafluoropropoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-( 2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl Yl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)- Yl)pyridin-3-yl)oxy)acetonitrile; 2-(3-(ethylsulfonyl)-5-(1,1,2,3,3,3-hexafluoropropoxy)pyridine-2- Yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-hydroxyphenyl)pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-hydroxypyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(5-(2-chloro-4-fluorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridine-2- Group)-7-(trifluoromethyl)phthalazine-1(2H)-one; 5'-(ethylsulfonyl)-6'-(1-oxo-7-(trifluoromethyl)phthalein Azin-2(1H)-yl)-[2,3'-dipyridine]-5-carbonitrile; 2-(5-(ethylsulfonyl)-6-(1-oxo-7-(three Fluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)pyrimidine-5-carbonitrile; 2-(3-(ethylsulfonyl)-5-(2,2,2-tri Fluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2,2, 3,3,3-pentafluoropropoxy) Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-fluorophenyl)pyridine-2 -Yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-3-(trifluoromethyl) )-1H-pyrazol-5-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5 -(Pyrimidine-5-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-methyl Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((methylthio)methoxy) Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(cyclopropylmethoxy)-3-(ethylsulfonyl)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(5-bromo-3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl) Yl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(5-bromo-3-(ethylsulfonyl)pyridin-2-yl)-6-( Trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-(5-((dimethyl((oxo)-l6-sulfinyl)) Amino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)- 5-((Methylsulfonyl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(4-(ethylsulfonyl) )-6-(3-(trifluoromethyl)phenyl)pyridazin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-5-(oxetan-3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 2-((5 -(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2-methylpropionyl Amine; 2-(3-(Ethylsulfonyl)-6-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; 2-(5-((diethyl((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5'-(ethylsulfonyl)-4-(trifluoromethyl)-[2,3 '-Dipyridine]-6'-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5'-(ethylsulfonyl)-5-(trifluoromethyl) Yl)-[2,3'-dipyridyl]-6'-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3-(benzyloxy) Cyclobutoxy)-3-( Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(3-chloro-4-fluorophenyl)-3- (Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylsulfonyl)-5-(4- Fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-(3-(ethylsulfon) Amino)-5-(2-methoxypyrimidin-5-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 2-(5-(ethyl Sulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)acetonitrile; 2-(5-bromo-3-( Ethylthio)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylsulfonyl)-5-(4-(trifluoro) Methoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(3-( Ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d] [1,2,3]Triazine-4(3H)-one; 3-(3-(ethylthio)-5-(4-fluorophenyl)pyridin-2-yl)-6-(trifluoromethyl Yl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(5-(4-chlorophenyl)-3-(ethylthio)pyridin-2-yl) -6-(Trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-(5-(2-bromo-1,1,2,2-tetra Fluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylthio) -5-(4-(Trifluoromethoxy)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H) -Ketone; 3-(5-(4-chlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2, 3] Triazine-4(3H)-one; 3-(5-(3,5-dichlorophenyl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl Yl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(5-(3,5-difluorophenyl)-3-(ethylsulfonyl)pyridine -2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(5-(3-chloro-5-fluorobenzene) Yl)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 3 -(3-(Ethylsulfonyl)-5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2 ,3] Triazine-4(3H)-one; 2 -(5-((4,4-Difluorobut-3-en-1-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(3-(ethylthio)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-1H-pyrazol-5-yl)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-1H-pyrazole-4) -Yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-fluoro-5 -(Trifluoromethyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 1-(5-(ethylsulfonyl)-6- (1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropane-1-carbonitrile; 2-(3-(ethylsulfonyl) -5-(4-(Methylsulfonyl)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylthio) )-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; (5-(ethylsulfonyl)-6-( 1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl) ethyl phosphonate; 2-(5-(dimethylphosphoryl)- 3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonylimino)-5 -(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-( 3-(Ethylsulfonyl)-5-((S-methylsulfonylimino)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -Ketone; 2-(3-(ethylsulfonylimino)-5-(4-fluorophenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(3-(Ethylsulfonyl)-5-(1,1,2,2-tetrafluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine- 1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine-2- Yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(3-(ethylsulfonyl)-5-hydroxypyridin-2-yl)-6-(trifluoromethyl) Yl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(3-(ethylthio)pyridin-2-yl)-6-(trifluoromethyl)benzene And [d][1,2,3]triazine-4(3H)-one; 3-(3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo [d][1,2 ,3] Triazine-4(3H)-one; 3-(5-((diethyl((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridine- 2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-(3-(ethylsulfonyl)-5- (Ethylthio)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-fluorophenyl)-3-(N-methyl) Ethylsulfonylimino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; (5-(ethylsulfonylimino)-6-(1-oxygen) Tert-butyl -7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)carbamate; 2-(5-((ethyl(methyl)((oxo) -l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3-(5- ((Ethyl(isopropyl)((oxo)-l6-sulfinyl)amino)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzene And [d][1,2,3]triazine-4(3H)-one; 5-(ethylsulfonyl)-6-(4-oxo-6-(trifluoromethyl)benzo[ d][1,2,3]triazine-3(4H)-yl)pyridin-3-yl dimethylsulfamate; 2-((5-(ethylsulfonyl)-6-(4- Oxo-6-(trifluoromethyl)benzo[d][1,2,3]triazine-3(4H)-yl)pyridin-3-yl)oxy)acetonitrile; 3-(3-(ethyl) Sulfonyl)-5-(2,2,2-trifluoroethoxy)pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine -4(3H)-one; 3-(5-(cyclopropylmethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-6-(trifluoromethyl)benzo[d ][1,2,3]triazine-4(3H)-one; 3-(3-(ethylsulfonyl)-5-(methoxymethoxy)pyridin-2-yl)-6- (Trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 3-(5-(difluoromethoxy)-3-(ethylsulfonyl) Pyridin-2-yl)-6-(trifluoromethyl)benzo[d][1,2,3]triazine-4(3H)-one; 2-((5-(ethylsulfonyl) -6-(4-oxo-6-(trifluoromethyl)benzo[d][1,2,3]triazine-3(4H)-yl)pyridin-3-yl)oxy)-2- Methylpropionamide; 2-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl )-2-Methylpropionitrile; 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl Dimethyl sulfamate; 2-(5-amino-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2- (5- Chloro-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-6 -(1H-1,2,4-triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-5-((4-oxoanion-1,4l6-xanthene-4-yl subunit) amino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-one; 2-(6-bromo-3-(ethylthio)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H )-Ketone; 2-(5-(difluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one ; 1-cyano-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl ) Cyclopropane-1-carboxamide; 2-(3-(ethylsulfonyl)-6-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine -2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((2,2,2-trifluoroethane) (Yl)thio)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3,5-bis(ethylsulfonyl)pyridin-2-yl) )-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-((1,1-difluoroethyl)thio)-3-(ethylsulfonyl)pyridine -2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(ethylsulfonylimino)-3-(ethylsulfonyl)pyridine- 2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-((1,1-difluoroethyl)sulfonyl)-3-(ethylsulfon (Dimethyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(4-(dimethylphosphoryl)phenyl)-3- (Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; N-(5-(ethylsulfonyl)-6-(1- Oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopropanecarboxamide; 2-((5-(ethylsulfonyl)-6-( 1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-2-methylpropionitrile; 2-(3-(ethylsulfonyl) )-5-isopropoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(( 1,1,1-Trifluoro-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-( 3-(Ethylsulfonyl)-5-(trifluoromethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-( Ethyl sulfonate Aceto)-5-(1-oxyanion-4,5-dihydro-3H-1l6-isothiazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1 (2H)-ketone; 2-(3-(ethylsulfonyl)-5-((3-hydroxy-1-oxytetrahydro-1l6-thiophen-1-yl subunit) amino)pyridin-2-yl )-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((4-oxoanion-1,4l6-xanthene -4-yl subunit)amino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 4-(5-(ethylsulfonyl)-6-( 1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)benzenesulfonyl fluoride; 2-(5-(4-(dimethylphosphoryl) Phenyl)-3-(ethylsulfonylimino)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 5'-(ethylsulfonylimino) -6'-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)-[3,3'-dipyridine]-6-sulfonyl fluoride; 5-(ethyl Sulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3-sulfonyl fluoride; 2-(5-(4-(1, 1-Difluoroethyl)phenyl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3- (Ethylsulfonyl)-5-(1-(trifluoromethyl)cyclopropyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2- (3-(Ethylsulfonyl)-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoro Methyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazole-5- Yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-isobutyl-1H -Pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3 -Methoxy-1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(1'- (Difluoromethyl)-5-(ethylsulfonyl)-6'-oxo-1',6'-dihydro-[3,3'-dipyridine]-6-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-isopropylpyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-one; 2-(5-(3,5-dimethylisoxazol-4-yl)-3-(ethylsulfonyl)pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-(1,1,2,2-tetrafluoroethoxy) )Phenyl)pyridin-2-yl)-4-methyl-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonylimino)-5 -(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 4-( 5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)phenylsulfur fluoride; 2- (3-(Ethylsulfonylimino)-5-((1,1,1-trifluoro-2-methylpropan-2-yl)oxy)pyridin-2-yl)-7-(tri Fluoromethyl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonylimino)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2 (1H)-yl)pyridin-3-yl)oxy)-2-methylpropionitrile; 2-(3-(ethylsulfonyl)-5-((methylsulfinyl)methoxy) Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2,2,3,3-tetra Fluoropropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1,1, 2-Trifluoro-2-(trifluoromethoxy)ethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-5-(2,2,3,4,4,4-hexafluorobutoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(3-(Ethylsulfonyl)-5-(2,2,3,3,3-pentafluoropropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(5-(2,2-difluoro-2-(trifluoromethoxy)ethoxy)-3-(ethylsulfonyl)pyridin-2-yl )-7-(trifluoromethyl)phthalazine-1(2H)-one; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalein) (Azin-2(1H)-yl)pyridin-3-yl)-2,2-difluorocyclopropane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxygen) Substitution-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-2,2-dimethylcyclopropane-1-carboxamide; N-(5-(ethyl Sulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-fluorocyclopropane-1-carboxamide ; N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methyl Cyclopropane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine -3-yl)-N-methyl ring Butanecarboxamide; 1-cyano-N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl) Pyridin-3-yl) cyclopropane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H )-Yl)pyridin-3-yl)-3,3-dimethylcyclobutane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7 -(Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-3,3-difluorocyclobutane-1-carboxamide; N-(5-(ethylsulfonamide) Yl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclobutanecarboxamide; N-(5-(ethyl) Sulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methylcyclobutane-1-methyl Amine; N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-3- Methylcyclobutane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl) )Pyridin-3-yl)-3-oxocyclobutane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl) )Phthalazine-2(1H)-yl)pyridin-3-yl)cyclopentanecarboxamide; 1-cyano-N-(5-(ethylsulfonyl)-6-(1-oxo- 7-(Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclopentane-1-carboxamide; N-(5-(ethylsulfonyl)-6-( 1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methylcyclopentane-1-carboxamide; N-(5-( Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)cyclohexanecarboxamide; N-(5 -(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-4-methylcyclohexane- 1-Formamide; N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl )-4,4-Difluorocyclohexane-1-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine- 2(1H)-yl)pyridin-3-yl)azetidine-3-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(three Fluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1-methylazetidine-3-carboxamide; 1-ethyl-N-(5-(ethyl) Sulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)azetidine-3-methanamide; N -(5-(Ethylsulfonyl)-6-(1- Oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxetane e-3-formamide; 3-ethyl-N-(5- (Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxetane e-3-methyl Amide; N-(5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-1 -Methylpyrrolidine-3-methanamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl) )Pyridin-3-yl)tetrahydrofuran-3-carboxamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H )-Yl)pyridin-3-yl)piperidine-4-methamide; N-(5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine -2(1H)-yl)pyridin-3-yl)-1-methylpiperidine-4-carboxamide; 1-ethyl-N-(5-(ethylsulfonyl)-6-(1 -Oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)piperidine-4-methamide; N-(5-(ethylsulfonyl)- 6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)tetrahydro-2H-pyran-4-carboxamide; N-(5 -(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)-4-fluorotetrahydro-2H- Pyran-4-carboxamide; 2-(7-bromo-3-(ethylsulfonyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(3-(ethylsulfonyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl) Fluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H) -Yl)imidazo[1,2-a]pyridin-7-yl)acetonitrile; 3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2 (1H)-yl)imidazo[1,2-a]pyridine-7-carbonitrile; 2-(3-(ethylsulfonyl)-7-methoxyimidazo[1,2-a]pyridine -2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)imidazo[1,2-a]pyridin-2-yl )-7-(trifluoromethyl)phthalazine-1(2H)-one; 1-(3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalein Azin-2(1H)-yl)imidazo[1,2-a]pyridin-7-yl)cyclopropane-1-carbonitrile; 2-(3-(ethylsulfonyl)-7-(2, 2,2-Trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-bromo- 3-(Ethylsulfonyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl) Sulfonyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 3- (Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine-6-carbonitrile; 2-(3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine- 6-yl)acetonitrile; 2-(3-(ethylsulfonyl)-7-(1-methylcyclopropyl)imidazo[1,2-a]pyridin-2-yl)-7-(tris Fluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-7-(methylamino)imidazo[1,2-a]pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 7-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy) )Phenyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl) -5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine -8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)-2-(trifluoromethyl )Pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-2 -(Trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 5-(ethylsulfonyl)-6-(8-oxo-2-(trifluoromethyl) Yl)pyrido[2,3-d]pyridazine-7(8H)-yl)nicotinonitrile; 2-(5-(ethylsulfonyl)-6-(8-oxo-2-(trifluoro Methyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridin-3-yl)acetonitrile; 1-(5-(ethylsulfonyl)-6-(8-oxo) -2-(Trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridin-3-yl)cyclopropane-1-carbonitrile; 2-((5-(ethyl Sulfonyl)-6-(8-oxo-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridin-3-yl)oxy)- 2-methylpropionitrile; 7-(5-(difluoromethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3 -d]Pyridazine-8(7H)-one; 2-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-(perfluoroethyl)phthalein Azin-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(perfluoroethyl)phthalazine- 1(2H)-ketone; 2-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)- 7-(perfluoroethyl)phthalazine-1(2H)-one; 5-(ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H) )-Yl)nicotinonitrile; 2-(5-(ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H)-yl)pyridine-3- Yl)acetonitrile; 1-(5-(ethylsulfonyl)-6-(1-oxo-7-(perfluoroethyl)phthalazine-2(1H)-yl)pyridin-3-yl) ring Propane-1-carbonitrile; 5-(ethylsulfonyl)-6-(1-oxo-7-((trifluoromethyl)sulfonyl)phthalazine-2(1H)-yl)nicotinonitrile ; 2-(3-(Ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-7-((trifluoromethyl)sulfonyl)phthalazine-1(2H)- Ketone; 2-(3-(Ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-((trifluoromethyl)sulfonyl)phthalazine-1(2H )-Ketone; 1-(5-(ethylsulfonyl)-6-(1-oxo-7-((trifluoromethyl)sulfonyl)phthalazine-2(1H)-yl)pyridine- 3-yl)cyclopropane-1-carbonitrile; 7-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-3-(trifluoromethyl)pyridine And [2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl)-5-(4-(1,1,2,2-tetrafluoroethoxy) )Phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 7-(3-(ethylsulfonyl) -5-(4-(Trifluoromethoxy)phenyl)pyridin-2-yl)-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 2-(5-(Ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H)-yl)pyridine- 3-yl)acetonitrile; 1-(5-(ethylsulfonyl)-6-(8-oxo-3-(trifluoromethyl)pyrido[2,3-d]pyridazine-7(8H )-Yl)pyridin-3-yl)cyclopropane-1-carbonitrile; 7-(3-(ethylsulfonyl)-5-(trifluoromethyl)pyridin-2-yl)-3-(tris Fluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 2-(3-(ethylsulfonyl)-5-(ethylthio)pyridin-2-yl)- 7-(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((2-(trifluoromethyl)cyclopropyl)methoxy )Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-methoxy azacyclo Butane-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-((1 -Methyl azacyclic ring Butane-3-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-( 1H-1,2,4-triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) Yl)-5-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 2-(3 -(Ethylsulfonyl)-5-(3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl) )Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-(2-hydroxy-2-methylpropyl)-1H-1,2,3- Triazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3- (Trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfon) Amino)-5-(3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-one; 2-(5-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)-7-(2 ,2,2-Trifluoroethoxy)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(4-fluorophenyl)pyridin-2-yl)- 7-(2,2,3,3,3-pentafluoropropoxy)phthalazine-1(2H)-one; 1-(3-(ethylsulfonyl)-2-(1-oxo- 7-(Trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyrimidin-7-yl)cyclopropane-1-carbonitrile; 2-(3-(ethylsulfon) (Acidyl)-6-methylimidazo[1,2-a]pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(6-(ethyl) Sulfonyl)-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 5- (Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[2,1-b]thiazole-2-carbonitrile; 1-(3-(Ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyrimidine- 6-yl)cyclopropane-1-carbonitrile; 1-(3-(ethylsulfonyl)-2-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl )Pyrazolo[1,5-a]pyridin-5-yl)cyclopropane-1-carbonitrile; 2-(2-(ethylsulfonyl)-7-methylpyrazolo[1,5- a] pyridine Pyridin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-1-methyl-6-(trifluoromethoxy) Yl)-1H-indol-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(ethylsulfonyl)-6-(1-oxygen) Substituted-7-(trifluoromethyl)phthalazine-2(1H)-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)acetonitrile; 2-(5-(ethylsulfonyl) Yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(7- Cyclopropyl-2-(ethylsulfonyl)imidazo[1,2-a]pyrimidin-3-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-( 3-(Ethylsulfonyl)imidazo[1,2-a]pyrazin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-( Ethylsulfonyl)imidazo[1,2-b]pyridazin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(bromodifluoro) Methoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) )-5-(pyridin-3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) -5-(pyridin-2-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-((5-bromopyridine-2) -Yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) Aceto)-5-(pyrimidin-2-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) Yl)-5-((1-methyl-1H-pyrazol-3-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2- (5-(3,3-Difluorocyclobutoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2,2-Difluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one ; 2-(5-((1,3-Difluoropropan-2-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine -1(2H)-one; 2-(3-(ethylsulfonyl)-5-(neopentyloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-one; 1-(((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3- Oxy)methyl)cyclopropane-1-carbonitrile; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2( 1H) -Yl)pyridin-3-yl)oxy)propionitrile; 2-(3-(ethylsulfonyl)-5-((1-fluoro-2-methylpropan-2-yl)oxy)pyridine -2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-methoxypyridin-2-yl)-7 -(Trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2-fluoroethoxy)pyridin-2-yl)-7-( Trifluoromethyl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2( 1H)-yl)pyridin-3-yl)oxy)-2-(methylthio)acetonitrile; 2-(5-((2,2-difluorocyclopropyl)methoxy)-3-(ethyl Sulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 4-((5-(ethylsulfonyl)-6-(1-oxo) -7-(Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)butyronitrile; 2-(5-(cyclobutylmethoxy)-3-(ethylsulfonyl) )Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2,2-difluoropropoxy)-3-(ethylsulfonyl) Yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(1-fluoroethoxy) Pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-( Trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-N,N-dimethyl-2-(methylthio)acetamide; 2-ethyl-2- ((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)butyronitrile; 2 -(3-(Ethylsulfonyl)-5-isobutoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethyl Sulfonyl)-5-(2,2,2-trifluoroethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5 -(2-Bromo-1,1-difluoroethoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one ; 2-(5-((3-cyclopropylisoxazol-5-yl)methoxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl) Phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(3-methoxycyclobutoxy)pyridin-2-yl)-7-(trifluoromethyl )Phthalazine-1(2H)-one; 5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3 -Difluoromethanesulfonate; 3-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine -3-yl)oxy) ring Butane-1-carbonitrile; 5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl fluoride Methanesulfonate; 3-((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl )Oxy)-3-methylbutyronitrile; 5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridine-3 -Yl trifluoromethanesulfonate; 2-(3-(ethylsulfonyl)-5-((1-methoxy-2-methylpropan-2-yl)oxy)pyridin-2-yl )-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-((5-(ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl) Phthalazine-2(1H)-yl)pyridin-3-yl)oxy)-N,N,2-trimethylpropionamide; 2-(3-(ethylsulfonyl)-5-((3 -Methyloxetan-3-yl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; (E)-2-(3 -(Ethylsulfonyl)-5-(2-(methylimino)propoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2 -(3-(Ethylsulfonyl)-5-((trimethylsilyl)methoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(Ethylsulfonyl)-5-(2-oxypropoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2- (3-(Ethylsulfonyl)-5-((2-methyl-3-oxobutan-2-yl)oxy)pyridin-2-yl)-7-(trifluoromethyl)phthalein Azin-1(2H)-one; 2-(5-(allyloxy)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1( 2H)-one; 2-(3-(ethylsulfonyl)-5-propoxypyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2- (5-Ethoxy-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) (Phenyl)-5-(methoxymethoxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-cyclobutyl-3- (Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-(2,2-difluorocyclopropyl)-3 -(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl)-5-(2 -Methyloxetan-2-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(3-(ethylsulfonyl) -5-(3-Methylthietane-3-yl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 2-(5-( 1,1-Dioxon Subgroup thietane-2-yl)-3-(ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazin-1(2H)-one; 6 ((5-(Ethylsulfonyl)-6-(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-3-yl)oxy)nicotinonitrile; 2 -(3-(Ethylsulfonyl)-5-(thietanyl-3-yloxy)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H) -Ketone; 2-(5-((1,1-dioxanylthietane-3-yl)oxy)-3-(ethylsulfonyl)pyridin-2-yl)-7- (Trifluoromethyl)phthalazine-1(2H)-one; 2-(5-((1,1-dioxanion thietane-3-yl)methyl)-3-(ethyl Sulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 7-(3-(ethylsulfonyl)-5-(trifluoromethyl) )Pyridin-2-yl)-2-(trifluoromethyl)pyrido[2,3-d]pyridazine-8(7H)-one; 2-(3-(N-methylethylsulfonamide) Amino)-5-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)- Ketone; 2-(3-(N-methylethylsulfonylimino)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl) -7-(Trifluoromethyl)phthalazine-1(2H)-one; N-(ethyl((oxo)(2-(1-oxo-7-(trifluoromethyl)phthalazine-2) (1H)-yl)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-3-yl)-16-sulfinyl)cyanamide; 2-( 3-(N-Ethylethylsulfonylimino)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyridin-2-yl)-7-(three Fluoromethyl)phthalazine-1(2H)-one; 2-(6-bromo-3-(ethylsulfonylimino)imidazo[1,2-a]pyridin-2-yl)-7- (Trifluoromethyl)phthalazine-1(2H)-one; 2-(6-bromo-3-(N-methylethylsulfonylimino)imidazo[1,2-a]pyridine-2 -Yl)-7-(trifluoromethyl)phthalazine-1(2H)-one; 1-(3-(ethylsulfonylimino)-2-(1-oxo-7-(trifluoro (Methyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridin-6-yl)cyclopropane-1-carbonitrile; 3-(ethylsulfonylimino)-2- (1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)imidazo[1,2-a]pyridine-6-carbonitrile; 2-(6-(cyclopropylamino )-3-(Ethylsulfonyl)pyridin-2-yl)-7-(trifluoromethyl)phthalazine-1(2H)-one and N-(5-(ethylsulfonyl)-6 -(1-oxo-7-(trifluoromethyl)phthalazine-2(1H)-yl)pyridin-2-yl)cyclopropanecarboxamide. A composition for controlling or preventing insects and/or mite pests, which comprises a biologically effective amount of a compound of formula (I) or an agronomically acceptable salt, isomer/structural isomer, stereoisomer, non-pair Enantiomers, enantiomers, tautomers, polymorphs, metal complexes or N-oxides and at least one other ingredient selected from surfactants and adjuvants. The composition according to claim 6, wherein the composition further comprises at least one selected suicide fungicide, insecticide, nematicide, acaricide, biological pesticide, herbicide, plant growth regulator, antibiotic, fertilizer Or a biologically active compatible compound of nutrients. The composition according to claim 6, wherein the biologically effective amount of the compound of formula (I) ranges from 0.1% to 99% of the total weight of the composition, preferably from 5% to 50% of the total weight of the composition. A combination comprising a biologically effective amount of the compound according to claim 1 and at least one selected suicide fungicide, insecticide, nematicide, acaricide, biocide, herbicide, plant growth regulator, antibiotic , Fertilizer and nutrient bioactive compatible compound. A method for combating insects and mites, which comprises using a biologically effective amount of the compound of formula (I) or its salt, metal complex, N-oxide, isomer as described in claim 1 or 6 or 9 , Polymorphs, compositions or combinations that come into contact with insects and mites, their habitats, breeding grounds, food, plants, seeds, soil, areas where invertebrate pests grow or may grow, or materials that wish to be protected from pests or infestations , Plants, seeds, soil, surfaces or spaces to protect them from pests or infestation. A method for protecting crops from insects and mites infestation or infestation, which comprises using a biologically effective amount of the compound or its salt, metal complex, N-oxide, isomer as described in claim 1 or 6 or 9 , Polymorphs, compositions or combinations contact crops. The method according to claim 10 or 11, wherein the method comprises applying an effective dose of the compound of formula (I) to agricultural or horticultural crops in an amount of 1 g to 5000 g/ha. A method for protecting seeds, plants and plant parts from soil insects, and protecting seedling roots and shoots from soil and foliar insects, which includes applying such methods as claim 1 or 6 or 9 before sowing and/or after germination The compound of formula (I) or its salt, metal complex, N-oxide, isomer, polymorph, composition or combination contact seed. A method for protecting seeds, plants and plant parts from soil insects, and protecting seedling roots and shoots from soil and foliar insects, which includes applying such methods as claim 1 or 6 or 9 before sowing and/or after germination The compound of formula (I) or its salt, metal complex, N-oxide, isomer, polymorph, composition or combination contact seed. A method for protecting seeds, plants and plant parts from soil insects, and protecting seedling roots and shoots from soil and foliar insects, which includes applying such methods as claim 1 or 6 or 9 before sowing and/or after germination The compound of formula (I) or its salt, metal complex, N-oxide, isomer, polymorph, composition or combination contact seed. A method for protecting seeds, plants and plant parts from soil insects, and protecting seedling roots and shoots from soil and foliar insects, which includes applying such methods as claim 1 or 6 or 9 before sowing and/or after germination The compound of formula (I) or its salt, metal complex, N-oxide, isomer, polymorph, composition or combination contact seed.